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Chapter I – Introduction 
1. Epigenetics and bromodomains 
 
In the middle of the 20th century, in times of war and the rise of the superpowers, an 
exciting race for the discovery of the chemical composition of our inheritable 
information thrilled the scientific communities. As a key event in 1944 Avery et al. 
published evidence that DNA contains the genetic information of bacteria.[1] The 
Hershey–Chase experiments[2] in 1952 supported the DNA-hypothesis and shortly 
later the DNA‘s double helix structure was resolved by Crick and Watson. Prior to that, 
due to their greater structural complexity, proteins were favored by most researchers 
as the carriers of genetic information. In a special edition issued in 1979 for the 35th 
birthday of Avery’s publication, the president of the Rockefeller University states in his 
foreword: 
 
„Furthermore, the chemical studies of Phoebus A. T. Levene [on 
nucleic acids with the proposal of circular tetranucleotides; added by 
Popp] pointed to a monotonous homogeneity of structure, manifestly 
inconsistent with the specificity (today we would say informational 
capacity) of nucleic acids. No wonder that most biologists of the era 
spoke vaguely of ‚nucleoproteins‘ as the most likely composition of 
genes.“[3] 
 
Also from today’s point of view, that uncertainty does not seem so unjustified (again?). 
Undoubtly our genetic information is stored on the DNA. However, the clear and simple 
concept with exclusively the DNA carrying our inheritable information has been 
shattered. For example so called ‚nucleoproteins‘ like histones do not only „store“ the 
DNA, but also direct gene transcription etc. and are finely tuned. Over the recent 
decades the research field of epigenetics revealed new mechanisms and further 
hereditary processes that do not involve alteration of the DNA sequence. Arthur Riggs 
and colleagues defined epigenetics as “the study of mitotically and/or meiotically 
inheritable changes in gene function that cannot be explained by changes in DNA 
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sequence”.[4] There are three major types of epigenetic modifications: Methylation of 
the bases that make up the DNA double strand; nucleosome positioning; and 
modifications of the histones around which the DNA is wrapped. An overview on these 
mechanisms will be given in the following pages. Other regulatory mechanisms like 
microRNA expression etc. seem to be downstream results of these three principles.[5] 
 
 
1.1 DNA methylation 
 
The term DNA methylation almost exclusively describes the methylation of cytosine to 
5-methylcytosine in CpG dinucleotides[5] (Figure 1.1). This process occurs seldom but 
with large impact in regions of the DNA that are called CpG islands.[6] Those CpG 
islands are regions with > 200 bases, a content of cytosine and guanine > 50 %, a CpG 
frequency > 0.6, and often contain gene promotors.[5-6] If CpG island methylation 
occurs, that is generally associated with long-term gene silencing[5]. The process of 
DNA methylation is essential for X-chromosome inactivation and genomic imprinting: 
Hypermethylation of one of the two parent alleles enables monoallelic expression.[7]  
 
 
Figure 1.1. The CpG dinucleotide of one DNA strand forming hydrogen bonds (blue) to the 
corresponding base pairs of the other DNA strand. Cytosine has been methylated at position 5 (red). 
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1.2 Nucleosome positioning 
 
The nucleosome is the repetitive unit of the chromatin and contains most of the DNA 
(Figure 1.2). It consists of approximately 166 base pairs of the DNA backbone, which 
is wrapped twice around one histone octamer and an additional H1 histone protein. 
The octamer is formed of two of each of the histone proteins H2A, H2B, H3, and H4. 
The histone proteins are positively charged at cellular pH through protonation of basic 
amino acid side chains. This is essential for the attraction of the negatively charged 
phosphate-sugar backbone of the DNA. The nucleosomes are connected via linker 
DNA, which is approximately 20 base pairs long.[8] Obviously packaging the genetic 
information tightly within nucleosomes itself affects gene transcription. The DNA and 
transcription start sites are shielded from transcription factors and activators, and the 
elongation of transcripts by polymerases is inhibited.[5] Nucleosome positioning has 
also been linked to DNA methylation.[9]  
 
 
Figure 1.2. Three nucloeosomes with connecting linker DNA. 
 
 
1.3 Histone post-translational modifications 
 
The posttranslational modification of histones is a process known since the 1960s[10], 
but more and more means of modification are found and we are just beginning to 
understand these processes.[11] This chapter is only intended to give a concise and 
very simplified overview on some of these complex and tightly cross-linked processes: 
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One of the modifications involved is the multiple or single methylation of lysine and 
arginine amino acids of the side chains of the histones. In 2004 two groups 
simultanoeusly showed that the methylation of arginine is antagonized via the 
conversion into citrulline.[12] Since then demethylases are known that selectively 
demethylate tri-, di-, and monomethylated lysine moieties.[13] Processes like 
ubiquitinylation, histone tail clipping, and histone-phosphorylation have also been 
described.[11] Histone-phosphorylation is mediated by histone kinases, which are able 
to phosphorylate the hydroxyl group of the side chain of serines, threonines and 
tyrosines using ATP[14] (1 & 2, Scheme 1.1). As a result the net charge of the histone 
is reduced, faciliating the detachment of the negatively charged DNA double strand. 
The heterochromatin decoils to euchromatin, is accessible by DNA-, RNA-
polymerases, and transcription factors and gene transcription is activated[15]. This 
process is reversed by phosphatases.[11] 
 
 
Scheme 1.1. Simplified depiction of reactions influencing chromatin structure and gene transcription. 
 
Another major and very dynamic process influencing the net charge of histones is 
histone-acetylation (3 & 4, Scheme 1.1). The degree of acetylation is increased by 
histone acetyltransferases (HATs) and decreased by histone deacetylases (HDACs). 
HATs catalyse the transfer of an acetyl group from cofactor acetyl CoA to the ε-amino 
group of basic lysine side chains.[11] As one possible result, the acetylated lysine is no 
longer positively charged, resulting in reduced interaction with the negatively charged 
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DNA backbone and fostering the formation of euchromatin. Obviously aberrant 
degrees of histone acetylation and thus gene activation are associated with various 
diseases such as cancer. Accordingly, HDACs have been recognized as possible drug 
targets[16], and EMA and the FDA have approved several successful HDAC inhibitors 
for cancer therapy[17]. However, due to their pleitotropic anticancer effects, these drugs 
didn’t provide a much deeper understanding of the underlying biological mechanisms, 
possibly limiting their optimal use.[15b, 18] 
 
 
1.4 The histone acetyltransferases p300/CBP and the bromodomains of CBP and 
p300  
 
Depending on their occurance, HATs are grouped into A-type HATs (nucleus) and B-
type HATs (cytoplasm). Type-A HATs are further subdivided into at least five families, 
one of them being p300/CBP.[19] Actually CBP (CREB (cAMP responsive element 
binding protein) binding protein (CREBBP)) and p300 (adenovirus E1A-associated 
300-kD protein) are two different acetyltransferase enzymes occuring in man and most 
eukaryotes[20], but because of the very high sequence homology, the two enzymes are 
often embraced as p300/CBP.[20-21]  These are described as „key enzymes in higher 
eukaryotes“[20] and acetylate lysines (K  Kac) of all histone core proteins using their 
HAT-domain.[22] p300/CBP also catalyses the acetylation of non-histone proteins such 
as transcription factors, in total 100 proteins.[20, 23] Apart from their HAT domain, the 
p300/CBP proteins contain further domains for the interaction with more than 400 
proteins[20, 24], enabling them to act as transcriptional co-activators for RNA polymerase 
II and others.[25] Likewise CBP/p300 is involved in many signaling pathways such as 
the cAMP pathway, Notch- and NFκB-signalling.[20] Another domain of p300/CBP is 
able to recognize ε–N-acetylated lysine moieties, for example on tumor supressor 
protein p53.[26] Recognition of these ε–N-acetylated lysine motifs of histones is a key 
step in the reading process of epigenetic marks and is exclusively accomplished by 
domains named bromodomains.[27]  
61 different bromodomains are known on 46 nuclear proteins like methyl transferases, 
transcriptional coactivators and regulators, ATP-dependent chromatin-remodeling 
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complexes, helicases, and the HATs.[27b] For most of the bromodomains and the 
corresponding specific Kac the binding affinities were determined and found to be in 
the order of µM.[22b] Bromodomains are clustered into eight families, but all share one 
conserved fold, which consists of a left-handed bundle of four α helices (αZ, αA, αB, αC) 
(Figure 1.3). These helices are linked by ZA and BC loops of varying length and amino 
acid sequence, lining the Kac binding site and influencing the binding specificity.[27b] 
 
 
Figure 1.3.* (1) The bromodomain families and availability of structural information. CBP (CREBBP) 
and p300 (EP300) belong to familiy III. (2) General structure of bromodomains for the example of 
BRD4(1): The four conserved α helices and the variable ZA and BC loops.  
* Cutout from figure 1 of: Histone recognition and large-scale structural analysis of the human bromodomain family[27b]. Further 
modified by addition of numbers 1 & 2. Under public license; Creative Commons Attribution License (CC BY); Elsevier.  
 
Owen et al. demonstrated in 2000 with a co-crystallization that the Gcn5p 
bromodomain recognizes Kac via hydrogen bonds from Asn407.[28] Meanwhile 
corresponding interaction has been confirmed for further bromodomains including the 
CBP bromodomain and its Asn1168 (located on the BC loop).[29] At the same time a 
few, but essential water molecules remain at a shallow depression at the end of the 
bromodomain’s binding pocket (Figure 1.4) and mediate further hydrogen bonds.[28-29]  
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Figure 1.4.* Electrostatic surface potential of the p300 (EP300) and CBP (CREBBP) bromodomains 
based on crystal structures.  Positive charge is blue, negative charge is red. The binding pockets for 
Kac are surrounded by green circles. 
* Cutout from figure 2 of: Histone recognition and large-scale structural analysis of the human bromodomain family[27b]. Further 
modified by circles around the binding sites. Under public license; Creative Commons Attribution License (CC BY); Elsevier. 
 
Data indicates that recognition of ε–N-acetylated lysine by p300/CBPs‘ bromodomains 
leads to positive feedback and further acetylation via the HAT domain.[30] CBP is 
essential for regulation of hematopoietic stem cell (HSC) self-renewal[31], and 
chromosomal translocations of CBP or p300 with MOZ or MLL have been observed in 
acute myeloid leukemia.[32] Besides leucemias[33] CBP and p300 have also been linked 
to carcinomas[34] and the Rubinstein-Taybi syndrome, with patients suffering from 
broad thumbs, cranio-facial and cardiac abnormalities, as well as mental retardation 
and cancer predisposition.[35] Consequently academia and the pharmaceutical industry 
extended their research to HATs and bromodomains for the elucidation of biological 
mechanisms and the development of novel drugs. 
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Chapter II – Project and strategy 
2.1 Aim of this thesis 
 
„Selective small molecule inhibitors (chemical probes) have a major 
impact on our understanding of human biology and for the validation of 
novel disease associated targets for the development of new treatment 
therapies. However, the development and characterization of chemical 
probes is a cost intensive multidisciplinary process requiring significant 
efforts in medicinal chemistry, structural biochemistry, screening and cell 
biology that can rarely be accomplished by an isolated laboratory‘[36]‘.  
… to combine expertise and resources in different areas of chemical 
biology we formed a large multinational group involving academic 
research laboratories and also currently 8 large pharmaceutical 
companies. This consortium was established based on the Structural 
Genomics Consortium (SGC) open access model, which distributes and 
publishes reagents promptly and without constrains imposed by 
intellectual property.“[37]  
 
Following this approach to a more efficient research model, the SGC has managed to 
develop a number of impressive probes for protein kinases[38] and more recently a 
comprehensive set of probes for the bromodomains[15b]. The effort to develop 
bromodomain inhibitors first focused on bromodomains of the BET family,[15b] which 
were predicted[39] and proven to be easily druggable[40]. The probe coverage for other 
bromodomain families has also been expanding rapidly, and more and more 
publications and patent applications have been filed concerning the various 
bromodomains.[41]  
Friendship and cooperation between Prof. Franz Bracher’s medicinal chemistry group 
and Prof. Stefan Knapp’s groups at the SGC at the University of Oxford has developed 
into a fruitful tradition. This tradition yielded the potent and selective kinase inhibitor 
KH-CB19[38b] and gave further insight into the inhibition of bromodomains of the BET 
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family through benzodiazepines and benzotriazepines[42]. With the general research 
focus shifting towards bromodomains outside the BET family, our research cooperation 
followed: Based on the screening of a commercial substance library and some custom 
made compounds, the SGC developed the potent and to some extent selective 
benzoxazepine-type inhibitor I-CBP112 for the CBP and p300 bromodomains (Figure 
2.1).[43]  
 
 
Figure 2.1. CBP/p300 bromodomain inhibitor I-CBP112. 
 
Some of this compound’s moieties were assumed not to be fully optimized and aim of 
this thesis was the further refinement of this inhibitor: Especially the residual activity 
towards the BET family remained an issue of this probe. Selectivity is essential to 
clearly understand and prove the biological mechanisms of epigenetics, which may be 
difficult enough with CBP and p300, due to the promiscuity of these proteins described 
above. This residual activity towards the BET family could not be completely eradicated 
by other inhibitors, which were published during the course of this thesis. These were 
based on different scaffolds such as dihydroquinoxalinone[44], acetylbenzene[45], or 
benzimidazole[46]. However, an 34-fold selectivity of benzimidazole compound CBP30 
over BRD4(1) was published by Hay et al. from the SGC in 2014.[46] Inhibition of 
CBP/p300 by this compound leads to suppression of the human Th17 responses, 
making it an interesting compound for use against ankylosing spondylitis or psoriatic 
arthritis.[47] Meanwhile the alternative inhibitor I-CBP112 has been provided as a 
research tool and has become commercially available.[43] I-CBP112 was proven to be 
effective against mouse and human leukemic cell lines in vitro and in vivo. Synergistic 
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effects were shown with standard therapeutics (doxorubicin) or with BET-inhibitors, 
and I-CBP112 may be an interesting candidate for clinical evaluation.[48]  
Obviously bromodomains and their inhibition is currently a hot topic, which may yield 
an understanding of and cure for horrible diseases. Accordingly competition is great 
and the pace is quick. The preparation of a large number of inhibitors will be necessary 
to find those that are most suitable for therapy. It is not yet clear, whether the selective 
or the unselective ones will be more interesting for clinical approaches. The aim of this 
thesis was to further investigate I-CBP112-type inhibitors, to learn more about the 
SAR, and to be able to functionalize this molecule for different purposes.  
 
 
2.2 Strategy of synthesis: Published syntheses and innovative approaches 
2.2.1 Preparation of the 2,3,4,5-tetrahydro-1,4-benzoxazepine scaffold with 
methyl ether at C-9 and first compounds 
 
The 1,4-benzoxazepine element is reported as a scaffold of various substances with 
anti-inflammatory[49], anti-thrombotic[50], anti-tumor[51], and anti-amyloid-beta plaque 
activity[52]. Accordingly, various synthetic strategies have been published. The 
favoured scaffold for this thesis seemed readily available following an established 
approach to a 2,3,4,5-tetrahydro-1,4-benzoxazepine backbone[51b, 51c], but starting with 
5-bromo-2-hydroxy-3-methoxybenzaldehyde 5 instead of 5-bromo-2-
hydroxybenzaldehyde (Scheme 2.1). Preliminary data from the SGC suggested that 
the voluminous C-9 ether moiety of lead structure I-CBP112 was pointing towards the 
solvent and away from the protein, so this moiety did not seem vital for the compound’s 
activity. Thus the intention was to test first variations of the 2,3,4,5-tetrahydro-1,4-
benzoxazepine scaffold on the simplified backbone 9 (Scheme 2.1) bearing a methoxy 
moiety at C-9. This intermediate was planned as a versatile building block that would 
allow flexible introduction of different moieties at C-7 via cross coupling and various N-
functionalizations at N-4 in any order. This flexibility would be important to then 
optimize the moieties at C-7 and N-4. 
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Scheme 2.1. Planned synthesis of the simplified 2,3,4,5-tetrahydro-1,4-benzoxazepine scaffold. 
 
Since the initial investigations conducted by the SGC on purchased 2,3,4,5-tetrahydro-
1,4-benzoxazepines had already revealed that only very small residues on N-4 were 
tolerated, further modifications of the hitherto most promising acyl group should be 
performed without increasing the size of the group too much. We mainly aimed at the 
introduction of more polar groups of similar size, to enable further hydrogen bonds 
mediated through the conserved water molecules at the end of the binding pocket. 
Attempts to replace these essential water molecules were fruitless so far as they form 
a network of hydrogen bonds mediating Kac binding. For moieties at C-7 it was planned 
to test all kinds of groups, since the purchased molecules mainly comprised chloro- 
and methoxyphenyl substituents. 
 
 
2.2.2 Preparation of 2,3,4,5-tetrahydro-1,4-benzothiazepine analogues 
 
In order to investigate whether the 2,3,4,5-tetrahydro-1,4-benzothiazepine ring could 
act as a a more selective scaffold, benzothiazepine analogues bearing promising 
moieties at both C-7 and N-4 and a methoxy group at C-9 were planned. Starting with 
bromination of 2-amino-3-methoxybenzoic acid (10, Scheme 2.2),[53] a number of 
standard reactions should be adapted to lead to a versatile 1,4-benzothiazepine 
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building block 15. Those reactions include a standard multistep reaction for the 
preparation of thiols from anilines: Diazotation, reaction with potassium ethyl xanthate, 
and alkaline hydrolysis[54] to obtain novel mercaptobenzoic acid 12. The acid-catalyzed 
conversion of other mercaptobenzoic acids into the corresponding methyl esters is 
described for the synthesis of benzothiophenes.[54b] Subsequent thioetherification of 
differently substituted methyl mercaptobenzoates with 2-chloroethylamine and base-
mediated lactamization is also described.[55] It was planned to obtain 
benzothiazepinone 14 via 13 in the same manner. Reduction of the lactam function[55] 
would provide the versatile 1,4-benzothiazepine intermediate 15.  
 
 
Scheme 2.2. Planned synthesis of the 2,3,4,5-tetrahydro-1,4-benzothiazepine scaffold. 
 
 
2.2.3 Preparation of 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine analogues 
 
The oxygen at position 1 of the 1,4-benzoxazepine scaffold is capable to act as a 
hydrogen bond acceptor. The secondary amine at N-1 of the 2,3,4,5-tetrahydro-1H-
1,4-benzodiazepine scaffold is capable to act as hydrogen bond acceptor and donor, 
making this structure particularly interesting. The 1,4-benzodiazepine scaffold has 
been intensively studied over many decades now, and has been designated a 
“privileged scaffold” in drug development.[56]  Depending on the degree of unsaturation 
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of the diazepine ring and the substitution pattern of the two rings, compounds with a 
broad spectrum of pharmacological activities have been designed.[56a] Consequently, 
a large number of approaches towards the 1,4-benzodiazepine ring system have been 
published[56b, 57]. Most of the sophisticated syntheses of the 2,3,4,5-tetrahydro-1H-1,4-
benzodiazepine ring system, including aziridine ring opening reactions[58], 
aminoalkylstannane-based routes[59], Pd-catalyzed cyclizations[60], metal-catalyzed 
hydrogen-transfer reactions[61], chlorosilane-promoted cyclizations of N,O-acetals[57] 
were unattractive for our purposes, since these protocols necessarily included the 
introduction of undesired alkyl or aryl residues at either N-1, N-4, C-2 or C-3. Thus, for 
the preparation of analogues for our purposes, we initially pursued a classical, short, 
and very drastic approach[62] via activation of the anthranilic acid 2-amino-5-bromo-3-
methoxybenzoic acid (11, Scheme 2.3) with triphosgene to the isatoic acid anhydride 
16. Conversion with glycine and reduction of the obtained dilactam 17 was expected 
to yield the 1,4-benzodiazepine 18 as useful intermediate. Thanks to the higher 
nucleophilicity of N-4 (secondary aliphatic amine) compared to N-1 (secondary 
aromatic amine), selective functionalization of N-4 in presence of the unsubstitited N-
1 was expected to be feasible.[62e] 
 
 
Scheme 2.3. Planned synthesis of the 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine scaffold. 
 
However, the rection conditions for the reduction of the dilactam are extremely harsh 
(lengthy refluxing with BH3 or LiAlH4 in THF) and not compatible with all functional 
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groups. Even debromination at C-7 is observed and reported in literature[51c]. It was 
decided to test this classical approach for our purposes, but we kept two alternative 
and innovative ideas in mind and soon strived to develop a novel and mild approach 
to 2,3,4,5-tetrahydro-1H-1,4-benzodiazepines.  
One of these ideas was a two step approach: The first step being a SN2-reaction of 
reactive N-nosylaziridine[63] and 2-aminobenzyl alcohol (19 & 20, Scheme 2.4), with 
the aniline’s nitrogen acting as nucleophile, resulting in intermediate 21. This idea was 
inspired by a publication on the use of N-tosylaziridines for the one-pot synthesis of 
tosylated 1,4-benzodiazepin-5-ones.[64] Following this published synthesis was not an 
option, because the tosyl protected 1,2,3,4-tetrahydro-1,4-benzodiazepin-5H-5-one 
that is obtained was expected to be difficuilt to reduce. Furthermore, cleavage of the 
tosyl group is performed under reductive conditions and can also be very problematic. 
The aziridine idea was adopted, but the N-nosylaziridine was chosen, because the 
nosyl protecting group is cleaved very smoothly using thiophenol or thioglycolic acid[65]. 
We also decided to implement a second reaction step: Fukuyama amine synthesis[65] 
with the acidic sulfonamide function acting as nucleophile under Mitsunobu 
conditions[66] should lead to fused compound 22. Recently the use of N-tosylates and 
Mitsunobu conditions has been published for the synthesis of 2,3,4,5-tetrahydro-1H-
1,4-benzodiazepines.[50] However this synthesis is lengthy and also results in di-tosyl-
protected compounds. 
 
 
Scheme 2.4. Proposed alternative route I to the 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine scaffold. 
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The other idea for a novel, mild, and short approach to 2,3,4,5-tetrahydro-1H-1,4-
benzodiazepines also involved Fukuyama amine synthesis[65]: N-(2,2-dimethoxyethyl)-
2-nitrobenzenesulfonamide[67] was expected to react with a N-Boc protected 
2-aminobenzyl alcohol (23, Scheme 2.5) under Mitsunobu conditions to give 
compound 24. The intermolecular alkylation of anilines using dimethyl acetals of 
aldehydes in a triethylsilane – trifluoroacetic acid mixture had been described as giving 
good yields.[68] To obtain compound 22, an attempt should be made to use this acidic 
mixture for Boc-cleavage, intramolecular imine formation, and reduction in a one-pot 
reaction. Again the nosyl group could finally be cleaved smoothly with thiophenol[65]  to 
obtain intermediate 18.  
 
 
Scheme 2.5. Proposed alternative route II to the 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine scaffold. 
 
Both novel approaches would offer one cunning feature: The resulting 2,3,4,5-1H-
tetrahydro-1,4-benzodiazepines would have a protecting group on the more 
nucleophilic nitrogen (N-4), thus leaving the possibility of functionalizing the less 
nucleophilic aniline (N-1) prior to deprotection of the more reactive amine. 
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2.2.4 Preparation of a versatile 2,3,4,5-tetrahydro-1,4-benzoxazepine scaffold 
with ester function at C-9 
 
The hitherto used „simplified“ 2,3,4,5-tetrahydro-1,4-benzoxazepine scaffold should 
also be refined at C-9 to introduce further moieties. We decided to embed a carbonyl 
function and replace I-CBP112’s ether function with an amide bond. Of course, this 
new carbonyl function would also allow introduction of a large number of other 
functional groups following reactions such as Curtius-rearrangment, Schmidt reaction, 
amide reduction after transamidiation, etc. Synthesis of this backbone was planned 
exactly as for the simplified scaffold (Scheme 2.1), but required synthesis of the 
intermediate methyl 5-bromo-3-formyl-2-hydroxybenzoate (bearing an ester group) 
beforehand (27, Scheme 2.6). Inexpensive 5-bromosalicylic acid (25) had been 
described to undergo Duff formylation and subsequent esterification in large scale and 
good yields[69] and was selected as starting point.  
 
 
Scheme 2.6. Known preparation of the educt for the synthesis of 2,3,4,5-tetrahydro-1,4-benzoxazepines 
with ester function at C-9. 
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Chapter III - Highlighted methods for the 
characterization of the compounds 
 
Almost all compounds synthesized for the inhibition of the CBP/p300 bromodomains 
were screened by differential scanning fluorimetry (DSF, chapter 3.1) for an 
approximate determination of their potency. The potency of one inhibitor was 
determined by Alphascreen assay, which gives an IC50 value (chapter 3.2). Following 
the hints obtained through these screenings, the compounds were further optimized. 
Final compounds which proved more optimized and interesting were further 
characterized. ITC (isothermal titration calorimetry, chapter 3.3) was conducted for 
determination of the Kd of one inhibitor. A Co-crystallization was analyzed for this 
advanced compound for the exact determination of its binding mode (chapter 3.4), and 
the effectiveness of a final compound in living cells was proven via a FRAP assay 
(chapter 3.5). All these experiments were conducted at the SGC at the University of 
Oxford, under supervision of Stefan Knapp, Oleg Fedorov, Catherine Rogers, Cynthia 
Tallant Blanco and co-workers. Thanks to these and Franz Bracher, I was able to visit 
the SGC and assist in some of the assays. Moreover all synthesized and novel 
compounds were routinely tested in our group for cytotoxicity by the MTT assay 
(chapter 3.6), and for antibacterial and antifungal activity by agar diffusion test (chapter 
3.7). These assays were mainly conducted by Martina Stadler. 
 
 
3.1 Differential scanning fluorimetry (DSF) 
 
Differential scanning fluorimetry is a fast and inexpensive method for the determination 
of relative binding affinities of small compounds to purified proteins. The melting 
temperature (Tm) of a protein in a solution with a potential inhibitor / ligand is observed 
and compared to the Tm in a solution of pure protein. Generally proteins are most stable 
at moderate temperatures, and susceptible to low temperatures and freezing. Likewise 
at high temperatures proteins denature, they unfold and lose their function. The state 
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of equilibrium, with equal concentrations of folded and unfolded protein is defined as 
the melting temperature (Tm) of proteins (although the process of unfolding is not 
reversible for many proteins). A potent ligand stabilizes the protein and conserves its 
folded state. In a solution with protein and ligand this generally results in an elevated 
melting temperature (Tm), compared to a solution with protein only.[70]  
The DSF assay can be run as a high throughput method using devices, which were 
originally designed for PCR.[71] The increase of a protein’s melting temperature is 
detected by gradual heating of mixtures of protein, ligand candidates, and a suitable 
fluoresecent dye from room temperature to high temperatures. For example SYPRO® 
orange is a suitable dye as it is highly fluorescent in a hydrophobic environment, while 
its fluorescence is quenched in aqueous media. Furthermore, its high excitation 
wavelength of 492 nm is favorable as it reduces the chance of undesired quenching 
through other small molecules. For DSF analysis the fluorescence signal is plotted 
against the rising temperature. Starting at ambient temperature very little fluorescence 
is noticed. As the temperature rises and protein denatures and unfolds, the protein‘s 
internal hydrophobic sites are exposed. As a result the fluorescent dye can bind to 
those sites and the fluorescence signal rapidly increases to a maximum. Fluorescence 
later decreases again, as hydrophobic sites are removed through protein aggregation 
or precipitation.[70]  
The Tm of the protein in the solution with the potential ligand can be derived from this 
plot. Subtraction of the Tm of the pure protein in the reference solution gives ∆ Tm ("Tm 
shift"). Generally the larger ∆ Tm, the higher the ligand affinity. However, the magnitude 
of ∆ Tm also depends on the specific protein, the ligand concentration, and various 
potential modes of binding.[70] Accordingly the magnitude of ∆ Tm allows only a 
comparison of potencies of compounds with similar physicochemical properties and 
only within the same specific protein (and at best the same batch of protein). 
 
 
3.2 Alphascreen 
 
Another sophisticated approach to the characterisation of inhibitors is the Alphascreen 
assay. This assay is useful for the investigation of protein protein interactions and 
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inhibition thereof. Interference of these interactions allows the determination of the IC50 
values of inhibitors. Advantages of this assay are a high sensitivity, high specificity, 
and simple protocols without washing steps. Consequently Alphascreens on microtiter 
plates have become a tool in high throughput screening.[72] 
ALPHA is an abbreviation for „amplified luminescent proximity homogeneous assay“. 
Its core elements are „donor“ and „acceptor“ polystyrene beads. Each of these beads 
can bind to the analyte protein in a specific, non-covalent way. Through this interaction 
with the beads, the protein recruits donor and acceptor beads to its surface and 
mediates their proximity. The donor bead contains a photosensitizing agent 
(phthalocyanine), that - under excitation at 680 nm - generates excited singlet oxygen 
from ambient oxygen at a very high rate, thus amplifying the excitation signal. The 
acceptor bead typically contains three polycyclic dyes: Thioxene, anthracene and 
rubrene. If the acceptor bead is within proximity (maximum of 200 nm) of the excitated 
donor bead, the created singlet oxygen excites the thioxene dye on the acceptor bead. 
This energy is there converted into light energy, and transferred via anthracene to 
rubrene. Rubrene finally emits light with a wavelenght of 520 – 620 nm, which can be 
quantified. Because of the short half life of the singlet oxygen, a dark background, and 
low bead concentrations, the signal to noise ratio is excellent in this assay.[72] 
For the determination of the IC50 value of a CBP/p300 bromodomain inhibitor, the 
donor bead is coated with streptavadin, the acceptor bead with Ni2+-chelators. The 
following non-covalent bindings result in the signal cascade described above: 
Streptavadin firmly binds to added biotinylated peptides, and these contain acetylated 
lysines. The studied target bromodomain (CBP, p300, etc.) then binds to acetylated 
lysine and remains in proximity to the donor bead. The bromodomain itsself contains 
a polyhistidine-tag, whose histidine moieties bind to the acceptor bead via Ni2+-
complexes. Donor and acceptor beads are thus immobilized and luminescence will be 
observed, when the donor is excited. This signal cascade and thus the detection of 
luminescence can be interrupted by the inhibition of binding of the bromodomain to 
acetylated lysine. Depending on the bromodomain inhibitor concentration and potency, 
the donor bead will not be recruited into the proximity of the acceptor bead and no or 
very little luminescence will be observed. The IC50 value can be derived from a 
corresponding plot.[73] 
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3.3 Isothermal titration calorimetry (ITC) 
 
The dissociation constant (Kd) of a ligand from a protein is an important characteristic 
of an inhibitor. The smaller the value, the stronger the binding. Unlike ∆ Tm obtained 
from DSF, Kd values may be used to compare the potency of inhibitors across 
substance classes and different proteins. Kd values of protein inhibitors can be 
determined accurately using a technique called ITC. The enthalpy change upon 
binding of the ligand to the protein is measured, thus dissecting ΔG (free energy of 
binding) into contributions from ΔH (free enthalpy change) and ΔS (entropy change) 
and allowing calculation of ΔG and ΔS. This is the major advantage over DSF and has 
contributed to the elucidation of relationships between thermodynamics, structure and 
function.[74]  For this titration two adiabatic cells are simultaneously heated very slowly 
(< 0.1 °C/h). The reference cell contains buffer solution, the sample cell protein 
solution. Ligand is titrated into the sample cell. This results in temperature effects that 
are recognised and lead to adaption of the heating rate for the sample cell and an 
electronic signal. Initially, due to the surplus of protein, most of the ligand binds upon 
release, giving a value for ΔH. As titration goes on, more and more binding sites are 
occupied and ligands remain unbound, although binding sites are still available. This 
point gives a good estimate of Kd. Obviously this titration also allows conclusions on 
the stochiometry of the binding[74] (Figure 3.1).  
 
Figure 3.1. Typical graph of an ITC experiment. The top panel depicts the relative power applied to the 
sample cell compared to the reference cell in order to maintain the same temperature in both cells. The 
bottom panel shows the integrals from the peaks of the top panel with a line of best fit, necessary to 
derive ΔH, Kd and the binding stoichiometry. 
Chapter III – Highlighted methods 
 
21 
 
3.4 Co-crystallization 
 
Differential scanning fluorimetry, isothermal titration calorimetry and Alphascreen data 
give a comprehensive picture of a compound’s potency and selectivity. However, this 
data contains no information on the binding modes and binding sites. To explain the 
potency and to undoubtly describe the binding modes, it is necessary to obtain co-
crystallizations of inhibitors with the corresponding bromodomain. Furthermore, co-
crystallizations may reveal new potential interaction sites and thus give hints for the 
introduction of new moieties or for the derivatization of present functional groups. 
 
 
3.5 FRAP  
 
The experiments described so far allow a good characterization of an inhibitor’s 
potency and selectivity. However, these experiments are mainly conducted in vitro on 
the purified protein. To go a step further and to prove efficacy in living cells, the FRAP 
(fluorescence recovery after photobleaching) assay has been established. FRAP has 
been developed since the 1970s, and allows studies of protein protein interactions and 
protein mobility in living cells.[75] Novel techniques for protein labeling and fluorescence 
microscopy turned this assay into a powerful tool in the field of epigenetics.[75-76] Figure 
3.2 depicts the course of a typical FRAP experiment with a confocal microscope: 
 
 
Figure 3.2*. Typical course of a FRAP experiment: A cell with good fluroescence signal arising from 
excitation of the fluorescence tagged target protein is focused (1st photograph from left). The 
fluorescence dye of the tagged target protein is then photobleached within a small area (2nd photograph). 
Afterwards the rate of recovery of the fluorescence signal through protein migration is measured (3rd 
photograph and so on). 
* Cutout from figure 5 of: Munc18-1 protein molecules move between membrane molecular depots distinct from vesicle docking 
sites.[77] Under public license; Creative Commons Attribution License (CC BY). 
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FRAP can be employed to study the interaction and binding of a bromodomain to 
chromatin. The bromodomain must be tagged with a fluorescent dye such as green 
fluorescent protein (GFP). First all GFP tagged bromodomains are photobleached 
within a small area of the nucleus with a high-intensity laser pulse. Then the rate of 
recovery of the fluorescence signal in that area is measured. The duration of recovery 
is obviously dependant on the rate of migration of GFP tagged bromodomains into the 
bleached area and thus the bromodomain mobility. Bromodomain mobility itsself is 
influenced by the binding to Kac of the chromatin. This binding again is also dependant 
on the degree of lysine acetylation. To obtain a firm binding of the bromodomains to 
the chromatin and consequently clearer results, the HDAC inhibitor suberoylanilide 
hydroxamic acid (SAHA) is added in experiments, resulting in increased global 
acetylation. The presence of potent inhibitors of the bromodomain’s Kac binding site 
will release the GFP tagged bromodomains from the chromatin and result in rapid 
migration and recovery of the fluorescence signal.[75-76, 78]   
For our purposes, the FRAP assay was performed with human osteosarcoma cells 
(U2OS). This assay may still be an in vitro assay on isolated cells, but proof of cell 
permeability and intracellular compound efficacy is essential for potential drug 
candidates.[76]  
 
 
3.6 MTT assay 
 
All synthesised and novel compounds were also tested for cell toxicity using the 
standard MTT assay, following the protocol of Mosmann.[79] This well established 
assay is suitable to differentiate between living and dead cells. It allows the 
determination of a substance’s cytotoxicity via measurement of cellular metabolic 
activity. Advantages of this assay are a high precision, a protocol without washing 
steps and a high throughput using multiwell scanning spectrophotometers.  
The assay is based on the conversion of the water soluble, yellow 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT, 28, Scheme 3.1) to an 
insolube dark blue formazan dye (29). This reduction is catalysed in the cytosol of 
living, metabolically active cells and requires nicotinamide adenine dinucleotide 
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(NADH) or nicotinamide adenine dinucleotide phosphate (NADPH) as reductive 
agents. After incubation of lymphoma cells with MTT, the insoluble formazan dye is 
redissolved and photometrically quantified. The amount of formazan dye correlates 
with the number of living cells. For our purposes human leucemia cells (HL-60) are 
used, and the nonionic detergent Triton X-100 is applied for positive control. The assay 
is performed with several suitable dilutions of a stock solution of the test compound. 
When plotting the dilutions against the percentage of living cells, a sigmoidal curve is 
obtained, from which the IC50 of the substance can be derived. The IC50 of cisplatin is 
around 5 µM. For this thesis IC50 values were only exactly determined when smaller 
than 50 µM. 
 
 
Scheme 3.1. Water soluble MTT is reduced into the insoluble formazan dye. 
 
 
3.7 Agar diffusion test 
 
Not linked to the main topic of this thesis, but as part of a routine screening of our 
group, novel substances were tested for antibacterial and antifungal activity against 
eight model microorganisms, namely Escherichia coli and Pseudomonas marginalis 
for Gram-negative bacteria, and Staphylococcus equorum and Streptococcus 
entericus for Gram-positive bacteria. Furthermore Yarrowia lipolytica and Candida 
glabrata for yeasts, as well as the fungi Aspergillus niger and Hyphopichia burtonii. For 
the agar diffusion test, these organisms are seeded on appropriate agar plates. Tiny 
platelets containing either the synthesized compounds or tetracycline as reference for 
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antibacterial potency and clotrimazole as reference for antifungal potency are added 
to the plate (Figure 3.3).  
 
 
Figure 3.3. Reference substances tetracyline (left-hand) and clotrimazole (right-hand). 
 
After incubation circular growth inhibition is measured around the reference plateletes 
and the diameter of growth inhibition is compared to the diameter of colony free areas 
arround the plateletes with the synthesized compounds. This test allows just a rough 
estimate of the antibacterial and antifungal potency of novel compounds, but is well 
enough to detect possible new lead structures.  
 
 
3.8 High-temperature NMR  
 
Recently scale-up experiments for the preparation of a kinase inhibitor with 2,3,4,5-
tetrahydro-1,4-benzoxazepine scaffold were published. This mTOR inhibitor bears an 
amide function at N-4, and two rotational isomers were observed in 1H and 13C NMR 
spectra. Two separate signals for the isomeric protons (and carbon atoms) and thus a 
double set of signals were found. This mTOR inhibitor was characterized at room 
temperature and the ratio of the two isomers could be deducted from comparison of 
their integrals[51c], although this ratio may be different in other solvents or the cellular 
medium. This well-known phenomenon[80] is caused by a hindered rotation about the 
amide bond. It was observed in all synthesized CBP inhibitors of this work, which bear 
an amide, thioamide, carbamate, or thiourea function at N-4, for example in amide 30 
(Scheme 3.2).  
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Scheme 3.2. The two rotational isomers of synthesized compound 30. 
 
For some of these compounds NMR spectra were recorded at a high temperature of 
100 °C (in DMSO-d6) or 110 °C (in C2D2Cl4). At these temperatures sufficient energy 
is available to smoothly overcome the energy barrier between the two isomers and a 
coalescence of the NMR signals was observed. The 1H NMR spectra of 30 in C2D2Cl4 
at room temperature and at 110 °C can be compared in Figure 3.4.  
 
 
Figure 3.4. 1H NMR spectra of amide 30 at room temperature (top panel) and 110 °C (bottom panel). 
 
For thioamide 31 the energy barrier was particularly high, with the signals from the 
methylene groups between 4.0 and 5.5 ppm not even coalescing at 110 °C (Figure 
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3.5). The carbon-nitrogen bond in thioamides shows an increased double bond 
character compared to amides.[81] Although energy barriers differ from solvent to 
solvent, generally higher energy barriers for signal coalescence for thioamides (81 – 
103 kJ/mol) than for amides (66 – 88 kJ/mol) are described in literature.[82]  
 
 
 
Figure 3.5. 1H NMR spectra of thioamide 31 at room temperature (top panel) and 110 °C (bottom 
panel). 
 
In 2014 Opatz et al. described two very stable rotational isomers of a 
tetrahydroisoquinoline derivative with formamide function: They could even be 
chromatographically separated and equilibrium was restored very slowly at 20 °C. 
Even at 150 °C no signs of the onset of coalescence of the formyl proton resonances 
were found. The energy barrier for the transformation of these isomers was found to 
be approximately 90 kJ/mol.[83] Rotational isomers are also important in medicinal 
chemistry. Only one of the two conformers may bind to the target and ΔG will be smaller 
for the inhibitor-protein complex, since conversion of the inactive into the active isomer 
requires energy and entropy is lost by forcing the molecule into one conformation. In 
the course of the development of HIV-1 integrase inhibitor L-870810, approximately 
21 kJ/mol are reported for overcoming of the rotational barrier of a corresponding 
amide bond. The conformation of the inactive form was favoured and the net difference 
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between inactive and active form was + 7.1 kJ/mol only, however a 29-fold increase in 
the potency (by IC50) was accomplished through rigidification (lactamization) of model 
compounds.[84] CBP inhibitors with rigid or swiftly rotatable binding elements like 
CBP30[85] do not pay a comparable energy penalty and the occurance of rotameric 
isomers may be a limitation of the 2,3,4,5-tetrahydro-1,4-benzoxazepine scaffold. 
However I-CBP112 is already a potent lead structure with high affinity and its scaffold 
is certainly worth further refinement without giving up its 2,3,4,5-tetrahydro-1,4-
benzoxazepine scaffold and without adapting rigid scaffolds known from many other 
bromodomain inhibitors. 
 
 
 
Chapter IV – Synthesis, results & discussion 
 
28 
 
Chapter IV – Synthesis, results & discussion 
4.1 The 2,3,4,5-tetrahydro-1,4-benzoxazepine scaffold with methyl ether at C-9 
4.1.1 Synthesis of the 2,3,4,5-tetrahydro-1,4-benzoxazepine scaffold with methyl 
ether at C-9 
 
Preparation of scaffold 9 was accomplished as planned, following the established 
approach to the 2,3,4,5-tetrahydro-1,4-benzoxazepine backbone[51b, 51c], but starting 
with 5-bromo-2-hydroxy-3-methoxybenzaldehyde (5, Scheme 4.1) instead of 5-bromo-
2-hydroxybenzaldehyde. Reductive amination of 5-bromo-2-hydroxy-3-
methoxybenzaldehyde (5) with 2-aminoethanol and NaBH4 in THF/MeOH gave 
secondary amine 6 in 93 % yield. After Boc-protection of the amino group, ring closure 
of phenol 7 to the benzoxazepine 8 was performed in 91 % yield using the Mitsunobu 
reagents DIAD and triphenylphosphine. Acidic N-deprotection gave an almost 
quantitative yield of the 1,4-benzoxazepine 9. The central building block 9 could thus 
be synthesized within few steps in large scale. This was important, because plenty 
variations were planned.  
 
Scheme 4.1. Synthesis of the 2,3,4,5-tetrahydro-1,4-benzoxazepine scaffold with methyl ether at C-9. 
Reagents and conditions: (a) 2-aminoethanol, NaBH4, THF, MeOH, rt, 93 %; (b) di-tert-butyl 
dicarbonate, NaHCO3 solution, EtOAc, rt, 69 %; (c) PPh3, DIAD, DCM, rt, 91 %; (d) HCl, 1,4-dioxane, 
MeOH, reflux, 94 %. 
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4.1.2 Preparation of compounds for the optimization of the substituent at C-7  
 
First, for the assessment of the best moiety at C-7 precursor 32 was prepared by 
N-acylation (Scheme 4.2). The cyclopropanecarboxamide moiety was selected as it 
was among the most promising residues in the set of purchased, prescreened 
compounds. 
 
 
Scheme 4.2. Preparation of intermediate 32. Reagents and conditions: (a) cyclopropanecarbonyl 
chloride, DIPEA, DCM, 0 °C - rt, 71 %. 
 
Suzuki cross-coupling[51b] of aryl bromide 32 with various boronic acids and boronic 
acid pinacol esters under Pd(dppf)Cl2 catalysis gave the biaryls 30, and 33 - 46 
(Scheme 4.3).  
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Scheme 4.3. Preparation of compounds from intermediate 32. Reagents and conditions: (a) various 
boronic acidsa or boronic pinacol esterb, Pd(dppf)Cl2 x DCM, DIPEA, H2O/1,4-dioxane, 95 °C, 31 – 94 %. 
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Additionally, the aromatic aldehyde 37 and the nitrophenyl compound 30 were also 
used as intermediates for further modifications (Scheme 4.4). The aromatic aldehyde 
37 was reduced to the benzyl alcohol 47 using NaBH4 with 97 % yield, and converted 
quantitatively with O-methylhydroxylamine into the O-methyloxime 48. A reductive 
amination with 4-aminobenzoic acid and NaCNBH3 gave the N-aryl compound 49 in 
good yield. The nitrophenyl compound 30 was reduced in a transfer hydrogenation to 
the corresponding aniline 50 using Raney-nickel and hydrazine in 38 % yield. This 
aniline was further functionalized with mediocre yields into the sulfonamide 51 using 
ethanesulfonyl chloride and the urea derivative 52 using ethyl isocyanate. 
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Scheme 4.4. Preparation of 2,3,4,5-tetrahydro-1,4-benzoxazepine inhibitors with different moieties at 
C-7. Reagents and conditions: (a) NaBH4, DCM, MeOH, rt, 97 %; (b) O-methylhydroxylamine, K2CO3, 
EtOH, rt, 99 %; (c) 4-aminobenzoic acid, NaCNBH3, DCM, MeOH, rt, 80 %; (d) Raney-nickel, N2H4, 
EtOH, reflux, 38 %; (e) ethanesulfonyl chloride, DMAP, pyridine, 0 °C - rt, 60 %; (f) ethyl isocyanate, 
DIPEA, DCM, rt, 47 %. 
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We also strived for two compounds that were not accessible with boronic acids: 
Aminopyrimidine 53 and aminothiazole 54. Both compounds could be synthesized in 
several steps starting with Stille cross-coupling and different aqueous workups. Stille 
cross-coupling of 32 with tributyl(1-ethoxyvinyl)tin under Pd(PPh3)2Cl2 catalysis 
(Scheme 4.5) followed by acidic workup[86] gave the methyl ketone 55 in 67 % yield. 
This was further converted into the aminopyrimidine 53 in 57 %, using Bredereck's 
reagent and guanidinium carbonate[87]. The same Stille coupling of 32 with tributyl(1-
ethoxyvinyl)tin, but with neutral aqueous workup gave an unstable enolether in 71 % 
yield. After purification by flash column chromatography, this intermediate was treated 
with NBS giving a bromoacetyl intermediate. Aqueous workup allowed cyclization with 
thiourea[88] and conversion into the aminothiazole 54 (20 % yield over three steps). 
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Scheme 4.5. Preparation of 2,3,4,5-tetrahydro-1,4-benzoxazepine inhibitors with different moieties at 
C-7. Reagents and conditions: (a) (i) Pd(PPh3)2Cl2, tributyl(1-ethoxyvinyl)tin, 1,4-dioxane, 140 °C, 
(ii) 2.7 M HClaq, rt, 67 %; (b) Bredereck's reagent, DMF, 160 °C, then guanidinium carbonate, K2CO3, 
DMF, 160 °C, 57 %; (c) (i) Pd(PPh3)2Cl2, tributyl(1-ethoxyvinyl)tin, 1,4-dioxane, 140 °C, (ii) NBS, THF, 
H2O, 0 °C - rt; (iii) thiourea, DMF, rt, 20 % overall yield. 
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4.1.3 Preparation of compounds for the optimization of the residue at N-4  
 
Next, we turned to derivatisations of N-4. This evaluation of the best moiety at the 
nitrogen at position 4 was performed with a 2,3,4,5-tetrahydro-1,4-benzoxazepine 
scaffold bearing a 3-chloro-4-methoxyphenyl substituent at C-7, since at that time this 
substitution pattern looked most promising. Intermediate 9 (Scheme 4.2) was 
subjected to a Suzuki cross-coupling reaction[51b] with 3-chloro-4-
methoxyphenylboronic acid to give biaryl 56 in 48 % yield (Scheme 4.6). Treatment of 
the secondary amine 56 with acyl chlorides or carboxylic acid anhydrides gave the 
amides 57, 58, carbamate 59, and urea 60. EDC as coupling reagent and appropriate 
carboxylic acids were used to obtain amides 61 and 62. (Thio)ureas 63 and 64 were 
accessible through iso(thio)cyanates, and glycolic acid amide 65 was obtained in 
acceptable yield through transamidation with neat ethyl glycolate. Finally, Lawesson's 
reagent was used to convert carboxamide 57 into the corresponding thioamide 31. We 
thus obtained a neat set of compounds with very small residues at N-4, and several 
functional groups that had not been tried for CBP inhibition before. The DSF values 
obtained from the screening of purchased compounds suggested that no groups much 
larger than a propionyl or a cyclopropanecarboxamide moiety do fit into the end of the 
bromodomain binding pocket. Other larger residues may simply be too bulky to fit into 
the pocket, or the substitution of the conserved water molecules at the pocket’s end 
(see Figure 4.8 in Chapter 4.4.5.4), which form essential hydrogen bonds for the 
recognition of the N-acyl function, is energetically not favoured. The residues in our 
systematic investigation ranged from very polar (59, 63, 64, 65) to less polar (31, 57, 
58, 61, 62). Some of them offered the option for creating additional hydrogen bonds to 
the conserved water molecules in the pocket, but would not be protonated under 
physiological conditions, thus avoiding an unfavored hydration shell. 
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Scheme 4.6. Functionalizations at N-4. Reagents and conditions: (a) 3-chloro-4-methoxyphenylboronic 
acid, Pd(dppf)Cl2 x DCM, DIPEA, H2O/1,4-dioxane, 95 °C, 48 %; (b) propionyl chloride, DIPEA, DCM, 
0 °C - rt, 40 %; (c) trifluoroacetic anhydride, DIPEA, DMAP, DCM, 0 °C - rt, 92 %; (d) methyl 
chloroformate, DIPEA, DCM, 0 °C - rt, 94 %; (e) N,N-dimethylcarbamoyl chloride, DIPEA, DCM, 0 °C 
- rt, 74 %; (f) 3,3,3-trifluoropropionic acid, DMAP, EDC x HCl, DCM, 0 °C - rt, 94 %; (g) (±)-2-
fluoropropionic acid, DMAP, EDC x HCl, 0 °C - rt, 81 %; (h) NaH, THF, then methyl isothiocyanate, rt, 
69 %; (i) (trimethylsilyl)isocyanate, DCM, then HCl in 1,4-dioxane, rt, 87 %; (j) ethyl glycolate, 60 °C, 
51 %; (k) Lawesson's reagent, THF, rt, 96 %. 
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4.1.4 Screening results of compounds from chapters 4.1.2 and 4.1.3  
 
Most of the compounds from these batches were analysed by DSF, the only exception 
being aminobenzoic acid 49 (Scheme 4.4), which had been prepared by reductive 
amination from aromatic aldehyde 37. We were hoping to install a ionic interaction 
between aminobenzoic acid moiety in 49 and remote arginine 1112 or to form at least 
a hydrogen bond. 49 was analysed by Alphascreen and the determined value of 
5.2 µM was disappointing (compare: 170 nM for I-CBP112), so this derivatization was 
not further considered. The results of the DSF screening of the variations at C-7 are 
displayed in Table 4.1. All compounds were screened for binding to CBP and 
exemplarily to BRD4(1), to estimate selectivity over the BET-family. Only a few 
substances were also tested on p300, since it was not expected to achieve notable 
selectivity between CBP and p300.  
Most of the heteroaromatic variations at C-7 (33, 34, 36, 53, 54) gave only very poorly 
active compounds. Only electron-rich isoxazole 35 gave a good result. Upon 
replacement of the phenyl moiety at C-7 by an acetyl moiety (55) potency was 
completely lost. While potency decreased for some compounds bearing electron-
deficient phenyl moieties at C-7 (37, 38), the electron-deficient nitrophenyl 
compound 30 still showed mediocre activity. The electron-rich aminophenyl derivatives 
39 and 50 showed similar potency, whereas modifications of the amino group 
(sulfonamide 51, urea 52) led to increased potency. The sulfonamide and the urea 
moiety were introduced as they are flexible hydrogen bond acceptors and donors, but 
the outcome of these modifications was not very satisfactory. Regarding the 
compounds with electron-rich phenyl moiety, 40 with a 3,5-dimethoxyphenyl group was 
the most potent compound in this series, while related compounds 41, 42, 43, 44, and 
47 still showed acceptable to good potency on CBP. O-Methyl benzaldoxime 48 gave 
the second best result. 
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Table 4.1. DSF results for compounds with different moieties at C-7 (n = 3). Continued on the next 
page. 
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Continutation of Table 4.1. DSF results for compounds with different moieties at C-7 (n = 3). 
 
Regarding variations at N-4, we aimed at using the network of essential, conserved 
water molecules at the end of the pocket for the formation of new hydrogen bonds 
between CBP and the new, more or less polar moieties at N-4 of the inhibitor. The 
outcome is shown in Table 4.2. It is noteworthy that the polar and small ureas 60 and 
64 were the only N4-derivatives (except for the sulfonamides, chapter 4.3.3), for which 
no rotameric isomers were observed in the NMR spectra, hence their poor 
performance in the DSF screening was particularly disappointing. Due to its capability 
to act as hydrogen bond acceptor and donator, one of the most promising candidates 
was the polar, glycolic amide 65. However this compound was totally inactive. Thiourea 
63, and thioamide 31 showed poor activity, too. The greater van der Waals radius of 
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sulfur (1.80 Å) compared to oxygen (1.52 Å) and hence steric repulsion could account 
for inactivity of 31, but with 63 being somewhat potent, another explanation is more 
likely: The double bond character of the carbon-nitrogen bond is increased in 
thioamides[81], and the sulfur in thioamides is a weaker hydrogen bond acceptor than 
the oxygen of amides.[89] Residual potency of thiourea 63 could result from hydrogen 
bond donor activity of the NH-group. The introduction of sulfur was not only devastating 
for the affinity to CBP, but potency to BRD4(1) was not reduced to the same extent (at 
least for 63). We had accepted to sacrifice some potency for increased selectivity, but 
in this case selectivity even decreased. With the thioanalogs and the quite polar 
moieties having failed, we now aimed at the introduction of less polar, fluorinated 
residues (compounds 58, 61, 62). The SGC had found that the propionyl moiety at N-
4 did fit into the binding pocket, while replacement with an acetyl moiety or a 
considerably larger moiety than propionyl results in complete inactivity. The 
trifluoroacetyl moiety of compound 58 is estimated of similar size than the propionyl 
moiety, but of different geometry and polarization.[90] The trifluoropropionyl moiety of 
61 was hoped to fit better into the binding pocket than the propionyl moiety, without 
being repelled by the conserved, essential water molecules. Monofluorination in α-
position of an amide can also affect amide conformation. This effect is particularly 
strong in amides formed from primary amines, but dipole−dipole interaction between 
the C−F and C=O bonds should also occur in amides formed from secondary 
amines.[91] With the conformation of the amide being important for CBP binding, we 
were hoping for improved binding of compound 62. The existence and significance of 
fluorine-hydrogen bonds are still under discussion.[91] In this case all three fluorinated 
compounds were inactive. Finally, we found that still the propionyl residue (57) is most 
favourable with regard to potency and selectivity, and only the cyclopropanoyl (44) and 
the more polar methyl carbamate (59) are nearly as active. 
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Table 4.2. DSF results for compounds with different N-acyl residues (n = 3). 
 
Having further explored these two edges of the molecule, we next turned to the 
backbone itself through substitution of the oxygen at position 1 by nitrogen or sulfur. 
We were hoping that the benzothiazepine would act as potent and more selective 
scaffold. A secondary amine at position 1 of the 2,3,4,5-tetrahydro-1H-1,4-
benzodiazepine scaffold could act as hydrogen bond acceptor and donor. Alternatively 
additional residues could be introduced by N-alkylation at this amino group.  
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4.2 The 2,3,4,5-tetrahydro-1,4-benzothiazepine scaffold 
4.2.1 Synthesis of the 2,3,4,5-tetrahydro-1,4-benzothiazepine scaffold and 
compounds 
 
The preparation of the 2,3,4,5-tetrahydro-1,4-benzothiazepine scaffold generally went 
as planned, but consisted of a few labour-intensive reactions. Following quantitative 
and regioselective bromination[53] of anthranilic acid 10, conversion[54] of anthranilic 
acid 11 into mercaptobenzoic acid 12 was accomplished (Scheme 4.7). In this 
multistep reaction, first a diazonium group was generated from the aniline using sodium 
nitrite and aqueous hydrogen chloride and a temperature of 0 °C. Then at higher 
temperatures, nucleophilic substitution took place employing ethyl xanthate, and giving 
the S-arylxanthogenate. Finally alkaline hydrolysis gave thiol 12 with a yield of 62 %. 
Subsequent acidic esterification[54b] to 13 was accomplished with a satisfactory yield of 
72 %. The next alkylation/transamidation reaction did not work as smoothly as 
described for methyl 2-mercapto-5-methoxy benzoate[55a]: The mere mixing of methyl 
5-bromo-2-mercapto-3-methoxybenzoate, 2-chloroethylamine hydrochloride, and 
sodium methoxide in DMF at 0 °C and the stirring of this mixture overnight at room 
temperature, did not simply give benzothiazepinone 14. Only S-alkylation was 
accomplished, but the lactamization had not taken place. To force lactamization, a 
different procedure[92] was adopted after aqueous workup. tBuOK was added to the 
crude aminoester and the mixture in THF was heated to 45 °C. Benzothiazepinone 14 
was now obtained in 63 % yield. Lactam 14 was reduced with BH3-THF, and the crude 
1,4-benzothiazepine was directly acylated at N-4. To get a broader set of compounds, 
we used both cyclopropanecarbonyl chloride and propionyl chloride for the amidation 
and thus obtained the two intermediates 66 and 68. Suzuki cross coupling[51b] was then 
applied and three exemplary 7-aryl-2,3,4,5-tetrahydro-1,4-benzothiazepines (67, 69, 
70) were synthesized. The acyl chlorides and boronic acids used would undoubtly give 
potent inhibitors with the 1,4-benzoxazepine scaffold. 
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Scheme 4.7. Reagents and conditions: (a) Br2, CHCl3, 0 °C – rt, 99 %; (b) (i) NaNO2, HCl, H2O, 0 °C, 
(ii) KOAc, potassium ethyl xanthate, H2O, 90 °C, (iii) NaOH, NaHSO3, 85 °C, 62 %; (c) MeOH, H2SO4, 
reflux, 72 %; (d) (i) 2-chloroethylamine, NaOMe, DMF, 0 °C - rt, (ii) tBuOK, THF, 0 °C - 45 °C, 63 %; 
(e) BH3-THF, -30 °C - reflux; (f) propionyl chloride, DIPEA, DCM, 0 °C - rt, 49 %; 
(g) 3,4-dimethoxyphenylboronic acid, Pd(dppf)Cl2 x DCM, DIPEA, H2O/1,4-dioxane, 95 °C, 59 %; 
(h) cyclopropanecarbonyl chloride, DIPEA, DCM, 0 °C - rt, 45 %; (i) 3,4-dimethoxyphenylboronic acid or 
3-chloro-4-methoxyphenylboronic acid, Pd(dppf)Cl2 x DCM, DIPEA, H2O/1,4-dioxane, 95 °C, 85 % and 
70 %. 
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4.2.2. Screening results  
 
The prepared compounds were screened with DSF. The obtained Tm shifts can best 
be compared with those of benzoxazepine compounds 40 and 44 (Table 4.3). However 
the obtained Tm shifts are disappointing. Moreover selectivity over BRD4(1) remained 
unchanged at best. Consequently, this scaffold was discarded. 
 
 
Table 4.3. DSF results for 2,3,4,5-tetrahydro-1,4-benzothiazepine compounds (n = 3). 
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4.3 The 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine scaffold 
4.3.1 Classic route via isatoic acid anhydride  
 
To get an access to the desired benzodiazepine analogues, compound 18 was 
regarded as a suitable intermediate. But the initial attempt to obtain the 2,3,4,5-
tetrahydro-1H-1,4-benzodiazepine 18 following classical approaches via the isatoic 
acid anhydride 16 was soon discarded (Scheme 4.8). Bromination of commercially 
available compound 10 was accomplished according to literature[53] in almost 
quantitative yield and as required earlier for the synthesis of the 1,4-benzothiazepines. 
The next steps were conducted as described in literature for similar compounds.[62] 
Activation of 11 with triphosgene to isatoic acid anhydride 16 and subsequent ring 
transformation with glycine worked well under the harsh conditions described. 
However, any attempts to reduce compound 17 by refluxing with BH3-THF resulted in 
exclusive reduction of the carbonyl group at position 2 and thus conversion into 
vinylogous urea 71. The same occured with LiAlH4, and even harsher conditions didn’t 
result in a completer reduction. Instead debromination at C-7 was observed and this 
reductive dehalogenation is a known problem with this reducing agent.[51c] To 
circumvent this debromination problem, of course we could have performed the Suzuki 
reaction with a suitable boronic acid first. But this had led to another problem: Only aryl 
residues bearing groups that are inert to these reducing agents and the drastic 
conditions had been applicable then. Thus we now aimed at a novel route to 
compound 18.  
 
Chapter IV – Synthesis, results & discussion 
 
46 
 
 
Scheme 4.8. Discarded synthesis of the 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine scaffold. Reagents 
and conditions: (a) Br2, CHCl3, 0 °C – rt, 99 %; (b) triphosgene, DIPEA, THF, reflux, 79 %; (c) glycine, 
AcOH, DMF, reflux, 72 %; (d) BH3-THF, reflux, 73 %. 
 
 
4.3.2 Novel route via N-nosylaziridine 
 
This route was pursued by Edgar Uhl in his master thesis under my supervision. Since 
details of this approach and compound descriptions are given in his thesis and because 
this approach did not yield the target scaffold, just a short summary is given here: 
Experiments were conducted with two different 2-aminobenzyl alcohols. Commercial 
2-aminobenzyl alcohol (72) (Figure 4.1) was used for model experiments and known 
(2-amino-5-bromo-3-methoxyphenyl)methanol (20)[53] as educt for the actual scaffold. 
1-[(2-NitrophenyI)sulfonyl]aziridine (“N-nosylaziridine”) was smoothly synthesized 
according to literature from 2-aminoethanol and 2-nitrobenzene-1-sulfonyl chloride in 
three steps.[93] For the Fukuyama type[65] Mitsunobu reaction[66] following upon the N-
alkylation of the aminobenzyl alcohol, initially diisopropyl azodicarboxylate (DIAD) 
along with triphenylphosphine were used. Later di-tert-butyl azodicarboxylate 
(DTBAD)[94] and (cyanomethylene)trimethylphosphorane (CMMP)[95] were also tested. 
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Figure 4.1. Common educts and reagents of the route via N-nosylaziridine. 
 
Initial experiments showed that mixing of equimolar amounts of N-noslaziridine and 
aminobenzyl alcohol, aimed at nosylaminoethylation of the aniline, gave several side 
products and a very poor yield. The conducted experiments suggested that for a proper 
conversion, either a four-fold excess of the 2-aminobenzyl alcohol should be used 
(Scheme 4.9, a) or the alcohol function of the 2-aminobenzyl alcohol should be 
TBDMS-protected (Scheme 4.9, b). This would mean either low efficiency due to 
wasting large amounts of aminobenzyl alcohol or two additional synthetic steps 
(protection/deprotection of the alcohol).  
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Scheme 4.9. Innovative but unaccomplished route with N-nosylaziridine. Reagents and conditions: (a) 
N-nosylaziridine, DMF, rt, 46 % (21) / 94 % (73); (b) tert-butyldimethylsilyl chloride, imidazole, DMF, rt, 
15 % (74) / 95 % (75); (c) N-nosylaziridine, rt, 93 %; (d) tetrabutylammonium fluoride, THF, rt, 91 %. 
 
These problems were tolerable, but the next reaction posed new problems, that could 
not be overcome: Ring closure under Mitsunobu conditions was not observed, 
although many different reaction conditions (different orders of addition, various 
concentrations, molar ratios, and temperatures) and reagents (DIAD, DTBAD, CMMP) 
were applied. Only two byproducts could be isolated among many others: These 
suggested that reaction of the alcohol group with the Mitsunobu reagents may be 
favoured (Figure 4.2; left side: product from experiment with DIAD; right side: product 
from experiment with CMMP). DTBAD was then employed to facilitate workup but use 
of this sterically more hindered reagent resulted in no reaction at all. Consequently this 
approach was discarded as well. 
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Figure 4.2. Left side: Product obtained by conversion of 2-aminobenzyl alcohol 72 with DIAD under 
Mitsunobu conditions; right side: product obtained from conversion of 2-aminobenzyl alcohol 72 with 
CMMP under Mitsunobu conditions. 
 
 
4.3.3 A new approach to monoprotected 1,4-benzodiazepines via a one-pot N-
deprotection/reductive cyclization procedure 
 
With the previous innovative approach towards 2,3,4,5-tetrahydro-1H-1,4-
benzodiazepines having failed, we focussed on an alternative route using N-(2,2-
dimethoxyethyl)-2-nitrobenzenesulfonamide[67] (Figure 4.3) as an alternative building 
block for introduction of C-2, C-3, and N-4 of the attempted 1,4-benzodiazepine 
scaffold. Initial experiments for this approach were also conducted under my auspices 
by Edgar Uhl for his master thesis. His experiments with model educt 72 yielded 
compounds 78, 79, 80, 81, and 95. Moreover he applied his findings on (2-amino-5-
bromo-3-methoxyphenyl)methanol (20) and prepared and characterized intermediates 
23, 24, and 22. For a completer picture of the story, his compounds are also shown in 
this chapter and the spectral data is displayed in the experimental section. They are 
also found in our joint paper “A new approach to monoprotected 1,4-benzodiazepines 
via a one-pot N-deprotection/reductive cyclization procedure”[96] or Uhl’s master thesis. 
 
 
Figure 4.3. N-(2,2-dimethoxyethyl)-2-nitrobenzenesulfonamide 
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Again first model experiments were conducted with unsubstituted 2-aminobenzyl 
alcohol. It was attempted to perform a Fukuyama-type[65] Mitsunobu[66] reaction of N-
(2,2-dimethoxyethyl)-2-nitrobenzenesulfonamide with unprotected 2-aminobenzyl 
alcohol (72), but an inseparable mixture of products was obtained. So the amino 
function of 72 was protected with the Boc group in almost quantitative yield[97] (Scheme 
4.10). Using this intermediate 78 and after inspiration from an ultrasound-assisted 
protocol[98] Mitsunobu reaction proceeded well to give the desired product 79 in 50% 
yield.  
 
 
Scheme 4.10. Innovative approach to 2,3,4,5-tetrahydro-1H-1,4-benzodiazepines using N-(2,2-
dimethoxyethyl)-2-nitrobenzenesulfonamide, part I. Reagents and conditions: (a) di-tert-butyl 
dicarbonate, THF, 40 °C, 99 %; (b) PPh3, DIAD, N-(2,2-dimethoxyethyl)-2-nitrobenzenesulfonamide, 
THF, rt, 50 %. 
 
Having reversed the reaction order from the previous nosylaziridine approach and thus 
having accomplished the Mitsunobu reaction as first crucial step, we could now deal 
with the ring closure. Obviously a cyclization reaction with reductive amination protocol 
involving acetal and N-1 required cleavage of the N-Boc group first. For the 
construction of an annulated azepine, a lengthy three step deprotection/reductive 
amination protocol (N-deprotection with TFA, acetal hydrolysis with aqueous acid and 
spontaneous formation of a cyclic imine, reduction of the imine) has been described.[99] 
We considered to develop a one-pot procedure for N- deprotection and ring closure by 
reductive amination. This idea was boosted by the outcome of a preliminary experiment 
for acidic cleavage of the Boc protective group of 79. Using a standard mixture of 
trifluoroacetic acid and methylene chloride, a poor yield below 50 % was obtained.  
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Because Boc cleavage inevitably requires a strong acid, we chose one of the few 
reducing agents, which is stable under acidic conditions: triethylsilane. In fact the 
organosilane-trifluoroacetic acid couple has been shown to be suitable for the direct 
reductive amination of acetals in intermolecular reactions.[68, 100] And truely, treatment 
of intermediate 79 with 2.5 equivalents of triethylsilane in a trifluoroacetic acid-
dichloromethane mixture at ambient temperature gave the desired N-nosyl 2,3,4,5-
tetrahydro-1H-1,4-benzodiazepine 80 (Scheme 4.11) in 93 % yield (overall yield over 
3 steps: 46 %).  
To prove feasibility of this approach for the synthesis of unsubstituted 2,3,4,5-
tetrahydro-1H-1,4-benzodiazepines, cleavage of the Nosyl protective group from N-4 
of 80 remained the last challenge. This was accompished under standard conditions[65] 
with thiophenol and potassium carbonate and gave 81 (isolated as the hydrochloride). 
 
 
Scheme 4.11. Innovative approach to 2,3,4,5-tetrahydro-1H-1,4-benzodiazepines using N-(2,2-
dimethoxyethyl)-2-nitrobenzenesulfonamide, part II. Reagents and conditions: (a) TFA, Et3SiH, DCM, rt, 
93 %; (b) (i) thiophenol, K2CO3, MeCN, 50 °C; (ii) 4 M HCl in 1,4-dioxane, MeOH, -18 °C, 61 %. 
 
The smooth benzodiazepine formation from 79 to 80 and the lack of by-products was 
finally a great relief. Specifically no by-products from a conceivable Pomeranz-Fritsch-
type cyclization[101] were found (Scheme 4.12). This was considered as a possible 
competing reaction, with an acid-triggered electrophilic attack of a cationic species 
arising from protonation of the acetal moiety at C-3 giving an 8-
aminodihydroisoquinoline 82.  
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Scheme 4.12. Pomeranz-Fritsch-type cyclization as conceivable competing reaction. 
 
General applicability of this approach was attempted for altogether five different 
2-aminobenzyl alcohols. All of them were successfully converted within three steps 
from the 2-aminobenzyl alcohol into the monoprotected 2,3,4,5-tetrahydro-1H-1,4-
benzodiazepine, which is a versatile building block for further reactions. The educts, 
the obtained monoprotected 2,3,4,5-tetrahydro-1H-1,4-benzodiazepines, the yields 
over the three steps, and the compound numbers of the corresponding intermediates 
are shown in Scheme 4.13. 
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Scheme 4.13. Educts, synthesized monoprotected 2,3,4,5-tetrahdyro-1H-1,4-benzodiazepines with 
total yields, and intermediate numbers; *Commercially available; a prepared from 2-amino-3-
methoxybenzoic acid by bromination and reduction according to literature[53]; b prepared from 2-amino-
3-methoxybenzoic acid by reduction according to literature[102].  
 
Chapter IV – Synthesis, results & discussion 
 
54 
 
With the one-pot N-deprotection/reductive cyclization procedure going so smoothly, we 
wondered whether an additional reductive amination reaction with the obtained 
monoprotected 1,4-benzodiazepine was feasible within the same one-pot reaction. An 
experiment was conducted to benzylate 80 at N-1 in a one-pot reaction, starting with 
79 by the known protocol and simply adding benzaldehyde and additional triethylsilane 
after completed formation of 80. N-alkylations using 4-formylimidazole and 
triethylsilane-trifluoroacetic acid have been described in literature.[103] However, the 
desired 1-benzyl-4-nosyl-benzodiazepine 95 was obtained in 11 % only (Scheme 4.14) 
and 68 % of non-benzylated compound 80 was found in the mixture. At this point it 
was decided not to make any further experiments and not to answer the question, 
whether this extended protocol is simply not suitable for the introduction of larger 
residues at N-1 or whether it could work better with acetals. 
 
 
Scheme 4.14. Further one-pot functionalization at N-1 following upon the first reductive amination. 
Reagents and conditions: (a) TFA, Et3SiH, DCM, rt; then benzaldehyde, TFA, Et3SiH, DCM, rt, 11 % of 
95 and 68 % of 80. 
 
Instead another idea aroused our interest: The behaviour of the cyclic acetal-type 
formaldehyde trimer 1,3,5-trioxane in a triethylsilane/trifluoroacetic acid/aniline 
mixture. As mentioned[68] and demonstrated, acetals undergo reductive aminations 
aided by the triethylsilane/trifluoroacetic acid mixture. We were keen to learn, whether 
the combination of triethylsilane, 1,3,5-trioxane, and trifluoroacetic acid (TTT) was 
applicable for the N-methylation of anilines. Upon a number of preliminary experiments 
we managed to develop and publish this novel TTT system for the chemoselective N-
methylation of aromatic amines. The development of this method is described in detail 
in Chapter V. This TTT system could also be applied effectively for the one-pot 
methylation at N-1 following the conversion of 85 into 86 (Scheme 4.15). This was 
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accomplished by treating 85 as described above with the mixture of triethylsilane, 
trifluoroacetic acid, and dichloromethane for 24 hours. After confirmation of the 
conversion to 86 via TLC, 1,3,5-trioxane and additional triethylsilane was added and 
the 1-methyl-4-nosyl-1,4-benzodiazepine 96 obtained in 79 % yield. 
 
 
Scheme 4.15. Further one-pot functionalization at N-1 following upon the ring closure by reductive 
amination. Reagents and conditions: (a) TFA, Et3SiH, DCM, rt; then 1,3,5-trioxane, TFA, Et3SiH, DCM, 
rt, 79 %. 
 
 
4.3.4 Synthesis of a 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine analogue of the 
CBP inhibitors 
 
Finally we could now synthesize a 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine 
compound for comparison with the 2,3,4,5-tetrahydro-1,4-benzoxazepine inhibitors. 
The oxygen at position 1 of the 2,3,4,5-tetrahydro-1,4-benzoxazepine scaffold is only 
capable to act as hydrogen bond acceptor. A secondary amine at N-1 is capable to act 
as both hydrogen bond acceptor and donor, making this structure particularly 
interesting. Compound 22 was subjected to a standard Suzuki coupling protocol[51b] 
with the meanwhile most interesting boronic acid, 3,5-dimethoxyphenylboronic acid, to 
obtain compound 97 (Scheme 4.16). We decided to conduct the Suzuki coupling prior 
to Nosyl deprotection to facilitate workup and to avoid losses with the very polar, 
deprotected and uncoupled 1,4-benzodiazepine 18. The Nosyl group was then cleaved 
under standard conditions (K2CO3 in thiophenol) and replaced by an acyl function to 
obtain compound 98. Chemoselective introduction of the propionyl residue at N-4 (and 
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not at the aromatic amino group N-1)[62d, 62e] proved not to be a problem due to the 
significantly higher nucleophilicity of the secondary aliphatic amino group compared to 
the aromatic amino group. Thus compound 99 was obtained. 
 
 
 
Scheme 4.16. Preparation of a CBP inhibitor with 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine scaffold. 
Reagents and conditions: (a) 3,5-dimethoxyphenylboronic acid, Pd(dppf)Cl2 * DCM, DIPEA, H2O, 
1,4-dioxane, 95 °C, 68 %; (b) K2CO3, thiophenol, MeCN, 50 °C, 75 %; (c) propionyl chloride, DIPEA, 
DCM, 0 °C - rt, 56 %. 
 
 
4.3.5 Screening results 
 
The screening results for the 1,4-benzodiazepine 99 were rather disappointing. For 
CBP a Tm shift of 4.8 °C and an IC50 of 1.8 µM was measured. For BRD4(1), IC50 was 
around 25 µM, at least indicating selectivity to some extent. Obviously no additional 
interaction with the protein through a hydrogen bond was introduced, and consequently 
no further effort was made on the synthesis of benzodiazepine-type CBP inhibitors. 
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4.4 The 2,3,4,5-tetrahydro-1,4-benzoxazepine scaffold with ester function at C-9 
4.4.1 Synthesis of the 2,3,4,5-tetrahydro-1,4-benzoxazepine scaffold with ester 
function at C-9 
 
The findings so far suggested that a very potent CBP/p300 inhibitor had the following 
structural elements: A 2,3,4,5-tetrahydro-1,4-benzoxazepine scaffold with a 
3,5-dimethoxyphenyl substituent at position 7, and a propionyl residue at N-4. A 
3,4-dimethoxyphenyl moiety was also considered as it is present in I-CBP112. Having 
this in mind we could follow the planned route to a new 2,3,4,5-tetrahydro-1,4-
benzoxazepine scaffold with a versatile methyl ester function at C-9 (Chapter 2.2.4). 
An ester function was considered as it could allow an additional hydrogen bond 
compared to I-CBP112’s ether function. Furthermore a methyl ester function seemed 
very suitable as it could easily be converted into the carboxylic acid and subsequently 
into various amides. Theoretically also an aromatic amine function could be introduced 
at C-9 by Schmidt reaction or Hofmann rearrangement or an urea or carbamate could 
be introduced by Curtius rearrangement. Moreover, starting from the neutral, 
uncharged methyl ester, the introduction of acidic and basic (and thus charged) 
functions seemed swiftly accomplishable. One of the main objectives was the 
introduction of a basic amino function comparable to that of I-CBP112. Finally reactions 
and workups were expected to be far less troublesome with a methyl ester than with 
the free carboxylic acid. 
This approach was successful: 5-bromosalicylic acid underwent Duff formylation and 
subsequent esterification as described[69] in good yields (Scheme 4.17). Thus 
intermediate 27 was available at large scale and we could apply the same protocols 
as used before for the synthesis of the 2,3,4,5-tetrahydro-1,4-benzoxazepine scaffold 
with methyl ether at C-9: Reductive amination of aromatic aldehyde 27 with 
2-aminoethanol, and following N-Boc protection were accomplished with good yields 
and gave phenol 101. Intramolecular Mitsunobu ring closure reaction of 101 to the 
2,3,4,5-tetrahydro-1,4-benzoxazepine 102, and acidic N-Boc deprotection and 
N-acylation with propionyl chloride followed. These four steps with an overall yield of 
33 % gave the N-propionylbenzoxazepine intermediate 103. Using 103, we 
synthesized two intermediates for two different batches of compounds by a standard 
Suzuki cross-coupling protocol[51b], namely intermediate 104 for one batch of 
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compounds bearing the 3,5-dimethoxyphenyl substituent at C-7, and 105 for the other 
batch with 3,4-dimethoxyphenyl substituent.  
   
 
Scheme 4.17. Preparation of the 2,3,4,5-tetrahydro-1,4-benzoxazepine scaffold with ester function at 
C-9. Reagents and conditions: (a) (i) urotropine, TFA, 90 °C, (ii) HCl, rt, 76 % (b) H2SO4, MeOH, reflux, 
50 %; (c) 2-aminoethanol, NaBH4, MeOH, THF, rt, 93 %; (d) di-tert-butyl dicarbonate, EtOAc, NaHCO3 
solution, rt, 56 %; (e) PPh3, DIAD, THF, 0 °C - rt, 85 %; (f) (i) HCl, 1,4-dioxane, rt, (ii) propionyl chloride, 
DIPEA, DCM, 0 °C - rt, 74 %; (g) 3,5-/3,4-dimethoxyphenylboronic acid, Pd(dppf)Cl2 x DCM, DIPEA, 
H2O,1,4-dioxane, 95 °C, 72 % / 80 %; 
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4.4.2 Preparation of compounds with 2,3,4,5-tetrahydro-1,4-benzoxazepine 
scaffold and different functional groups at C-9 
 
Compounds 104 and 106 bearing an ester group at C-9 were interesting candidates 
for CBP/p300 inhibition. In contrast to I-CBP112, which is positively charged at 
physiological pH due to its amino group in the side chain at C-9,  these can neither be 
protonated nor deprotonated under physiological pH and will thus be uncharged. 
Furthermore the ester (and later amide) function may form an additional hydrogen bond 
and possibly require more space than I-CBP112's ether function. Esters 104 and 105 
smoothly underwent alkaline hydrolysis into the corresponding carboxylic acids 106 
and 107 (Scheme 4.18). The effects of a negative charge at position 9 resulting from 
deprotonation of the carboxylic acids at physiological pH were of interest, too. 
Furthermore EDC-mediated amidation of these carboxylic acids with 1-(2-
aminoethyl)piperidine gave the amides 108 and 109 in moderate yields. Those were 
bearing a basic, tertiary amine in a similar position than I-CBP112. At the same time, 
introduction of a stereocenter was avoided with the diamine building block employed 
here. 
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Scheme 4.18. Preparation of two batches of compounds with either 3,5- or 3,4-dimethoxyphenyl moiety 
at C-7. Reagents and conditions: (a) NaOH, MeOH, THF, 70 °C, 93 % / 87 %; (b) (i) 1-(2-
aminoethyl)piperidine, EDC, DMAP, DIPEA, DCM, 0 °C - rt, 31 %, (ii, 109 only) HCl, 1,4-dioxane, rt, 
43 %; 
 
 
4.4.3 Screening results 
 
A DSF screening of these compounds 104 – 109 demonstrated good binding to CBP 
and no Tm shift for BRD4(1), which was an excellent result (Table 4.4). Merely the 
potency (by Tm shift) was not on the same level as that of I-CBP112 (CBP: 7.8 ±0.5 
°C, BRD4(1) 2.1 ±0.4 °C). For our compounds there seemed little difference between 
a neutral, a basic, and an acidic residue at C-9. Despite the assumption that  the C-9 
moiety – like that of I-CBP112[29a] - is rather directed towards the solvent than towards 
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the binding pocket of the bromodomain, this was still surprising. Although the difference 
found between the 3,5- and 3,4-dimethoxyphenyl substitution pattern was not huge, 
the 3,5-pattern was slightly superior. The introduction of a residue containing a 
carbonyl group at C-9 was recognized as an extremely promising structure variation, 
especially regarding subtype selectivity. 
 
 
Table 4.4. DSF results for compounds with different functional groups at C-9 (n = 3). 
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4.4.4 Preparation of further compounds with 2,3,4,5-tetrahydro-1,4-
benzoxazepine scaffold and amide function at C-9 
 
A number of further compounds were synthesized after the preliminary screening of 
104 – 109 had indicated interesting selectivity over BRD4(1). The next challenge was 
to increase potency to a level comparable with I-CBP112. With the compounds with 
3,5-dimethoxyphenyl substitution pattern being slightly more potent, compound 106 
was selected as new lead structure. Compounds 110 and 111 representing open-chain 
aminoalkyl amides were synthesized from carboxylic acid 106 using the amidation 
reagent EDC (Scheme 4.19). Likewise chiral compounds 112 and 113 were 
synthesized using both (S)- and (R)-configured 3-amino-1-Boc-piperidine as building 
blocks, and subsequent, acidic N-Boc-deprotection. Finally these secondary amines 
were N-methylated using formaldehyde and NaCNBH3[104] yielding 
N-methylpiperidines 114 and 115, to obtain compounds for direct comparison with 
I-CBP112. 
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Scheme 4.19. (a) N,N-dimethylethylenediamine, EDC, DMAP, DIPEA, DCM, 0 °C - rt, 69 %; (b) N,N-
diethylethylenediamine, EDC, DMAP, DIPEA, DCM, 0 °C - rt, 46 %; (c) (i) (S)-3-amino-1-Boc-piperidine, 
EDC, DMAP, DIPEA, DCM, 0 °C - rt; (ii) HCl, 1,4-dioxane, rt, 31 %; (d) (i) (R)-3-amino-1-Boc-piperidine, 
EDC, DMAP, DIPEA, DCM, 0 °C - rt; (ii) HCl, 1,4-dioxane, rt, 55 %; (e) formaldehyde solution, NaCNBH3, 
AcOH, MeCN, rt, 35 % and 36 %. 
 
 
4.4.5 Biological evaluation 
4.4.5.1 DSF 
 
Compounds 112 – 115 showed a potency at CBP (by DSF, Table 4.5) that was 
comparable to that of I-CBP112[48] (CBP: 7.8 ±0.5 °C, BRD4(1) 2.1 ±0.4 °C). At the 
same time, the Tm shift for BRD4(1) was extremely low. Configuration of the stereo 
center did not seem to cause any effect. Also, no decisive difference was observed 
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between the tertiary amines 114 and 115 and the secondary amines 112 and 113. The 
compounds 110 and 111 were far less potent. 
 
 
Table 4.5. DSF results for compounds with different decoration at C-9 (n = 3). 
 
 
It was decided to further characterize this novel type of inhibitors on the basis of 
compounds 112 and 114, which had shown both promising activity on CBP and 
exciting selectivity in this screening. First of all a comprehensive DSF screening 
against 48 bromodomains was done with these two compounds. The Tm shifts of 114 
with most of the bromodomains is depicted in Figure 4.3 and shows impressive 
selectivity. The corresponding table with the specific Tm shifts for each protein with 112 
and 114 is shown in Table 4.6. Tm shifts of I-CBP112 and bromodomains of the BET 
family are shown in Table 4.7 for comparison. 
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Figure 4.3.* Tm shifts of 114 and bromodomains of all families. Tm shifts with bromodomains without 
dots were not measured. 
* Cutout from figure 1 of: Histone recognition and large-scale structural analysis of the human bromodomain family[27b]. Further 
modified by removing dots at the bromodomains and placing new dots and a new key. Under public license; Creative Commons 
Attribution License (CC BY); Elsevier.  
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Bromodomain 114 112 Bromodomain 114 112 
ASH1L 0.09 -0.28 FALZ -0.03 -0.39 
ATAD2 -0.21 -0.02 GCN5L2 -0.97 -0.47 
BAZ1A -0.51 0.25 ATAD2B -0.26 0.31 
BAZ1B -0.18 -0.42 SP140L 0.0 -0.48 
BAZ2A 0.50 0.41 MLL -1.24 0.53 
BAZ2B 0.05 0.28 PB1(1) -0.91 0.92 
BRD1 -0.15 -0.88 PB1(2) -0.09 -0.53 
BRD2(1) 0.43 0.49 PB1(3) 0.35 0.65 
BRD2(2) 0.67 0.54 PB1(4) 0.09 0.14 
BRD3(1) -0.35 0.26 PB1(5) 0.07 0.59 
BRD3(2) 0.05 0.28 PB1(6) -0.4 0.09 
BRD4(1) 0.76 1.31 PCAF -0.32 0.62 
BRD4(2) 0.42 0.09 PHIP(2) -1.17 -2.72 
BRD7 0.86 1.19 SMARCA2 0.23 -0.05 
BRD9 -0.89 1.04 SMARCA4 0.04 0.08 
BRDT(1) -0.44 0.21 SP140 -0.42 -0.44 
BRDT(2) 0.32 0.58 TAF1(1) -0.28 0.27 
BRPF1A 0.53 0.67 TAF1(2) -0.21 0.28 
BRPF1B 0.20 -0.67 TAF1L(1) 0.15 -0.58 
BRPF3 0.11 -0.86 TAF1L(2) -0.65 -0.36 
BRWD3(2) 1.09 0.24 TIF1-bromo 0.41 -0.12 
CECR2 1.08 0.94 TIF1-phd-bromo -0.19 0.49 
CBP 7.47 7.81 TRIM28 -0.81 0.10 
EP300 8.45 8.27 WDR9(2) -0.92 1.16 
Table 4.6. Tm shifts of different bromodomains with 114 and 112 in °C. 
 
 
Bromodomain I-CBP112 
BRD1 0.43 ± 0.35 
BRD2(1) 1.35 ± 0.48 
BRD2(2) 0.87 ± 0.28 
BRD3(1) 1.55 ± 0.44 
BRD3(2) 0.94 ± 0.25 
BRD4(1) 2.09 ± 0.41 
BRD4(2) 0.58 ± 0.20 
CBP 7.77 ± 0.53 
EP300 8.69 ± 0.28 
Table 4.7. Tm shifts of I-CBP112 with BET-bromodomains in °C.[105]  
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4.4.5.2 ITC 
 
The dissociation constant Kd of an inhibitor can be determined by isothermal titration 
calorimetry (ITC). This constant is essential for the characterization of an inhibitor. For 
the established inhibitor I-CBP112, this value is 151 ± 6 nM for CBP and 5.6 µM for 
BRD4(1), which differs by factor 37.[48] A Kd of 134 ± 10 nM was found for 114 and 
CBP, the titration is displayed in Figure 4.4 (left-hand panel). The Kd for BRD4(1) was 
determined as 5.02 µM for BRD4(1) by our cooperation partner (right-hand panel), but 
the determination is not very reliable for such high values. Although 114 is slightly more 
potent on CBP than I-CBP112 by ITC, the obtained Kd values for CBP and BRD4(1) 
differ by a factor of 37 as well, and this data cannot be used to prove the increased 
selectivity found by DSF.  
 
 
Figure 4.4. Diagram of the ITC experiment of 114. The titration with CBP is on the left-hand side, the 
titration with BRD4(1) on the right-hand side. 
 
An binding ratio of CBP and 114 of 1 to 1 can clearly be seen in the titration curve. ΔGo 
can be calculated using the Gibbs-equation: 
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∆𝐺° =  ∆𝐻° − 𝑇∆𝑆° =  −𝑅𝑇 ln 𝐾 
∆𝐺° =  −7.8 𝑘𝑐𝑎𝑙/𝑚𝑜𝑙 − (288.15𝐾 𝑥 0.0044
𝑘𝑐𝑎𝑙
𝑚𝑜𝑙 𝐾
) 
∆𝐺° =  − 9.1 𝑘𝑐𝑎𝑙/𝑚𝑜𝑙 
 
With ΔHo being - 7.8 kcal/mol and TΔSo being 1.3 kcal/mol, the enthalpy’s influence on 
the binding is larger than entropy’s impact. Looking at CBP inhibitors with different 
scaffolds, CBP30 is certainly the most interesting. This 5-isoxazolyl-benzimidazole 
compound was published in 2015 and is currently the most potent inhibitor of CBP. 
CBP30 has been reported to inhibit the production of proinflammatory cytokines in 
human cells and patient blood samples. Furthermore it is very well characterized, with 
a Kd of 26 nM of CBP and 890 nM for BRD4(1), which means 34 fold selectivity.[47] It 
may be difficuilt to develop a more potent inhibitor, but an inhibitor with a different 
scaffold and a Kd in the µM order for BRD4(1) is a valuable alternative. 
 
 
4.4.5.3 FRAP assay 
 
To prove efficacy of this compound class in living cells a FRAP experiment was 
conducted. The results obtained with compound 112 (named E57682a in the 
experiment) are displayed in Figure 4.5. The diagram on the left-hand side displays 
the results of five experiments (x-axis), in which the half-recovery times of the 
fluorescence signal (y-axis) of GFP-tagged CBP under different conditions is 
displayed. The recovery of the intensity as a function of time is shown on the right-
hand side. The first experiment was done with the GFP-tagged wild type CBP 
bromodomain. Half-recovery time of the fluorescence signal was approximately 1 s. In 
the next experiment the histone deacetylase inhibitor SAHA was added. This caused 
global hyperacetylation and increased immobilization of the CBP bromodomain at the 
chromatin. This reduced migration into the bleached area and half-recovery time 
increaded to about 2.5 s. Repeating this experiment, but with CBP inhibitor 112 added, 
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the binding of the GFP-CBP construct to the chromatin was inhibited, CBP migration 
enabled, and the initial half-recovery time of approximately 1 s was restored. To prove 
that this effect is due to specific inibition of the bromodomain – Kac interaction, two 
further experiments were conducted using a mutant form of the GFP-tagged CBP 
bromodomain. Here asparagine 1168 is replaced by phenylalanine. Asparagine 1168 
is vital for the CBP’s function as it forms a hydrogen bond to the oxygen of the amide 
function of N-acetyllysine. Using this mutant, Kac – bromodomain binding is impossible. 
The similar half-recovery times obtained with this mutant GFP-tagged CBP 
bromodomain with and without SAHA addition, proves the concept of delayed CBP 
migration due to chromatin binding. Summing the results of this FRAP assay up, 112 
is an active inhibitor of the CBP bromodomain in living, human cells. 
 
 
 
 
Figure 4.5. Graphs of the results of the FRAP experiment with 112. 
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4.4.5.4 Co-crystallization 
 
A co-crystallization of compound 114 and CBP was obtained by our partners at the 
SGC (Figure 4.6). The 1,4-benzoxazepine core lies in a central position along the 
entrance to the deep Kac binding pocket, while the N-propanoyl moiety immerges into 
this binding pocket. Accordingly, this benzoxazepine inhibitor and putatively analogous 
molecules are competitive inhibitors, replacing acetylated lysine residues from the Kac-
binding site. 
 
                                  
Figure 4.6. Compound 114 (left side) and co-crystallization (right side) of 114 (gold) with CBP (grey). 
Central 1,4-benzoxazepine core and N-propanoyl moiety are highlighted by an orange circle. Oxygen 
atoms are coloured red and nitrogen atoms blue.  
 
Going more into detail and having a closer look at the Kac binding pocket (Figure 4.7), 
it is clear that the N-propanoyl residue acts as an N-acetyllysine (Kac) mimic. A 
hydrogen bond (Figure 4.7, arrow a) is formed between the amide's carbonyl function 
at N-4 and the NH2 group of asparagine (N1168, green). The amide group at C-9 also 
interacts through a water-mediated hydrogen bond (Figure 4.7, arrow b) with this amino 
acid - here with the oxygen atom of the carboxamide side-chain. Conserved water 
molecules are found at the deepest point of the pocket (Figure 4.7, arrow c). These 
water molecules mediate binding to the N-acetylated lysine moiety of target proteins 
and are also typical for bromodomain – inhibitor co-crystallizations.  
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Figure 4.7. Kac binding site with a hydrogen bonds (yellow dotted lines) from asparagine 1168 (green; 
a, b) and a conserved water molecule (red dot) at the deepest point of the pocket (c). 
 
Indeed one of the conserved water molecules mediates a further hydrogen bond 
(Figure 4.8) between the N-propanoyl residue and tyrosine (Y1125, turquoise), which 
is a typical interaction between bromodomains and Kac or Kac mimics.  
 
 
Figure 4.8. Kac binding site with water mediated hydrogen bond between the Kac-mimetic N-propanoyl 
residue of inhibitor 114 and tyrosine 1125. 
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Moreover the electron rich aromatic moiety at C-7 (Figure 4.9) binds to positively 
charged arginine (R1173, blue) via π-cation interaction.  
 
 
Figure 4.9. Interaction of the electron rich aromatic system at C-7 and arginine 1173. 
 
These interactions are summed up in Figure 4.10. Most of these interactions have also 
been found for I-CBP112[29a], however the water mediated interaction between the 
novel acyl group at C-9 and asparagine 1168 is an additional interaction, which might 
contribute positively to both affinity and selectivity of our new chemotype of CBP 
inhibitors. 
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Figure 4.10. Interactions of 114 (gold) and CBP (black). Conserved water molecules are coloured green. 
 
 
4.5 Results from MTT assay and agar diffusion test  
 
The novel compounds synthesized for the preparation of CBP inhibitors and for the 
development of the 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine synthesis were tested 
for cell cytotoxicity (MTT assay) and antibacterial and antifungal activity as part of 
routine measurements. Most of the compounds were not particularly cytotoxic and had 
a IC50 value > 50 µM. This was also the case for the most interesting inhibitors 106 - 
115. This is an important result, because CBP inhibitors are potential drug candidates. 
Compounds with IC50 values < 50 µM are displayed in Table 4.8. Not included are 
compounds from the master thesis of Edgar Uhl, which were neither particulary 
effective.  
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No. IC50 (µM) No. IC50 (µM) No. IC50 (µM) 
34 33 44 30 63 34 
37 32 45 44 64 37 
39 28 46 13 65 34 
40 14 47 28 67 18 
41 37 48 8 69 36 
42 40 51 14 102 45 
43 10 60 40 104 40 
Table 4.8. Compounds with IC50 values < 50 µM. Reference drug cisplatin shows an IC50 value of 5 µM. 
 
Regarding the agar diffusion test, no exciting results were found. Only a few 
intermediates showed minor antibacterial or antifungal activity. These are listed in 
Table 4.9. 
 
Table 4.9. Microbiologically active substances. Shown is the quotient of the diameter of growth inhibition 
of synthesized compound and reference substance (clotrimazole or tetracycline). 
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12 - - 0.3 0.4 - - - - 
100 - - - - 0.5 0.4 - - 
102  - - - - 0.4 0.4 - - 
103  - - - - 0.4 0.4 - - 
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Chapter V - N-Methylation of aromatic amines and N-
heterocycles under acidic conditions with the TTT 
(1,3,5-trioxane – triethylsilane – trifluoroacetic acid) 
system  
5.1 Introduction 
 
As described in chapter 4.3.3, the reductive alkylation of anilines with aldehydes[100a]  
and especially acetals[68, 100a] was thoroughly examined as it was essential for the 
preparation of the 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine scaffold (Scheme 5.1, 85 
-> 86). This inspired us to investigate an extension of this methodology and examine 
the cyclic acetal-type formaldehyde trimer 1,3,5-trioxane for the purpose of reductive 
N-methylations, which had not been desribed at that time. The later application of this 
methodology in a one-pot N-methylation following the intramolecular ring closure 
reaction of an (at the beginning of the reaction Boc-protected) aniline and a dimethyl 
acetal group (in 85) under reductive and acidic conditions is mentioned in chapter 4.3.3 
and again displayed in Scheme 5.1: 
 
 
Scheme 5.1. Addition of 1,3,5-trioxane and additional Et3SiH to the reaction mixture results in 
methylation of the aniline. Reagents and conditions: (a) (i) TFA, Et3SiH, DCM, rt; (ii) 1,3,5-trioxane, TFA, 
Et3SiH, DCM, rt, 79 %. 
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It was decided to examine the potential of a mixture of 1,3,5-trioxane, trifluoroacetic 
acid, and triethylsilane ("TTT system") for reductive N-methylation of further anilines, 
but also aliphatic amines and N-heterocycles.  
Certainly numerous protocols for N-methylations are already available, but one distinct 
advantage of 1,3,5-trioxane (and also trifluoroacetic acid and triethylsilane) is its 
formidable solubility in organic solvents[106]. Reagents typically employed for N-
methylations under mild conditions are paraformaldehyde or aqueous solutions of 
formaldehyde. However the polymeric formaldehyde paraformaldehyde is not readily 
soluble in many solvents, and the aqueous formaldehyde solution obviously does not 
allow working under anhydrous conditions. Along with formaldehyde or 
paraformaldehyde, reducing agents like formic acid (Eschweiler-Clarke reaction[107]) 
and complex hydrides (sodium borohydride[108], sodium cyanoborohydride[104] in 
combination with Lewis acids[109]) are typically employed. Due to the high 
nucleophilicity of primary and secondary amines, most N-methylation protocols applied 
on primary amines give the N,N-dimethylated products directly. However, N-
monomethylated products are accessible in two steps: The aliphatic nitrogen of 
tryptamine derivatives for example is N-monomethylated via reduction of N-formyl 
derivatives[110] or alkyl carbamates with lithium aluminum hydride[111]. Another 
publication explicitely describes the N-methylation reaction according to the 
formaldehyde/NaBH4/ZnCl2 protocol to be slower for aromatic amines[112], which is not 
surprising as these are less nucleophilic than aliphatic amines. Consequently for many 
aromatic substrates like anilines, pyrroles, azoles, and annulated analogues harsher 
protocols are used: Either methyl halides or dimethyl sulfate are applied directly on the 
amide anions or on the substrate in the presence of acid scavengers. These protocols 
often result in good yields, but volatility and toxicity of the methylation agents are an 
issue.[113] Furthermore, under the described alkaline conditions overalkylation to the 
quarternary ammonium salts or C-alkylations at acidic postitions may occur.[114] The 
less toxic dimethyl carbonate may be used as an alternative, but C-methylations[113] 
and N-methoxycarbonylations[115] are also reported for this agent.  
The stability of the reducing agent triethylsilane in strongly acidic media may be an 
advantage and may allow simple protocols. Furthermore, the triethylsilane-
trifluoroacetic acid mixture was demonstrated to be compatible with a large number of 
functional and protective groups.[116],[68] We were keen to learn about the scope and 
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limitations of N-methylations with the TTT system and how this protocol would integrate 
into the existing set of protocols. 
 
 
5.2 Scope and limitations 
 
We started with two simple experiments employing the TTT system on the aromatic 
amine 1,2,3,4-tetrahydroquinoline (116) and its regioisomer 1,2,3,4-
tetrahydroisoquinoline (117) as a secondary aliphatic amine. We found that the 
aromatic amine did undergo N-methylation readily with 64 % yield and without any by-
products, while the aliphatic amine did not react at all (Scheme 5.2). This indicated an 
interesting (and to the best of our knowledge unprecedented) selectivity of the TTT 
system for aromatic amines and reaction conditions were optimized. Best results were 
obtained with 3 equivalents of 1,3,5-trioxane and 10 equivalents of  triethylsilane in a 
1:2 trifluoroacetic acid-dichloromethane mixture. The mixtures were stirred under 
nitrogen atmosphere at room temperature for either 24 h, or  in the case of incomplete 
conversion (tlc control) for 48 h. 
 
 
Scheme 5.2. Initial experiments indicate selectivity for aromatic amines. Reagents and conditions: (a) 
1,3,5-trioxane, Et3SiH, TFA, CH2Cl2, rt. 
 
The TTT system was applied to a number of further substances, and the obtained 
compounds, compound numbers, reaction times, and yields are depicted in Figure 5.1. 
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Figure 5.1. Products obtained from N-methylation with the TTT system, in parentheses reaction times 
and yields. Introduced methyl groups are labeled "CH3". 
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The secondary aromatic amines diphenylamine, N-benzylaniline, and tetracaine were 
converted with good yields and without any by-products into the corresponding 
N-methylated compounds 120, 121, and 122. Not surprisingly, from the primary 
aromatic amine ethyl 4-aminobenzoate, two compounds were obtained, 
N-monomethylated aniline 123, and mainly N,N-dimethylated aniline 124. 
4-Nitroaniline was quantitatively alkylated to N,N-dimethylaniline 125  without reduction 
of the nitro group. Sterically more hindered and electron poorer 2,4,6-trichloroaniline 
seemed a particular challenge, since the previous N,N-dimethylation was 
accomplished with only 54 % yield by refluxing with dimethyl sulfate in toluene. The 
TTT system gave 126 with a yield of 93 % under mild conditions. Likewise heterocyclic 
substrates phenoxazine and phenothiazine were converted in excellent yields, and 
N-methylcarbazole 129 was prepared with 61 %. 1-Oxo-1,2,3,4-tetrahydrocarbazole 
was converted into the N-methylated product 130 in 29 % yield only, the remainder 
being educt. This seems disappointing at first glance, but earlier attempts made in our 
group with the classical reagents sodium hydride and iodomethane only yielded the 
2,2,9-trimethyl derivative.[114] The conversion of 1,2,3,4-tetrahydro-β-carboline was 
particularly exciting, because an aliphatic and an aromatic amine is present. But apart 
from the educt only one compound was found in the reaction mixture. It was shown to 
bear a methyl group at N-9 only, and thus compound 131 was isolated with 67 % yield. 
Likewise tryptamine gave derivative 132 with a methyl group at N-1 exclusively in 33 
%. The aliphatic amino side chain was not affected and the remaining percentage was 
educt. This conversion was also interesting, because neither reduction to the indoline 
134, nor a Pictet-Spengler-type cyclization to tetrahydro-β-carboline 135 was observed 
(Scheme 5.3). The reduction to indolines is reported for several indoles in TFA/TES 
mixtures without or with small portions of dichloromethane,[117] and Pictet-Spengler-
type cyclization is demonstrated for related arylethylamines, when treated with 1,3,5-
trioxane and acid[118]. 
 
 
Scheme 5.3. Conceivable side products of the application of the TTT system on tryptamine. 
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As shown, no conversion of the aliphatic amino group of three substances was 
observed with the TTT mixture. We assume that the aliphatic, basic amino function is 
fully protonated under the acidic reaction conditions, and is thus protected from the 
electrophilic attack of a reactive, cationic intermediate generated from 1,3,5-trioxane. 
Accordingly this newly developed TTT protocol is complementary to existing protocols 
such as the standard reductive N-methylation protocol with aqueous formaldehyde and 
sodium cyanoborohydride, which allows conversion of 1,2,3,4-tetrahydro-β-carboline 
into 2-methyl-1,2,3,4-tetrahydro-β-carboline[119], and of tryptamine into N’,N’-
dimethyltryptamine[110]. 
 
The TTT system was also tested for a one-pot acidic deprotection/N-methylation on a 
substrate other than 1,4-benzodiazepine precursor 85. It is a standard procedure to 
deprotect N-Boc with a mixture of trifluoroacetic acid and dichloromethane. Moreover 
the triethylsilane employed within the TTT system, is known as a beneficial scavenger 
for tert-butyl cations in deprotections of tert-butyl esters and tert-butoxycarbonyl 
residues[117a, 120], so the TTT system seemed an excellent candidate for general one-
pot acidic deprotection/N-methylation reactions. N-Boc-carbazole[121] (136) was 
selected and converted into N-methylcarbazole (129) with 49 % yield (Scheme 5.4).  
 
 
Scheme 5.4. One-pot acidic deprotection/N-methylation. Reagents and conditions: (a) 1,3,5-trioxane, 
Et3SiH, TFA, CH2Cl2, 49 %. 
 
Of course, not all conversions were successful. Apart from the aliphatic amines, a 
number of further compounds showed no N-methylation with the TTT system. Acridone 
(137), harmane (138), 1-oxo-1,2,3,4-tetrahydro-β-carboline[122] (139), and lactam 
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substrate 140[123] neither showed conversion (Figure 5.2). We assume that the 
nucleophilicity of the nitrogen atom is eradicated by a conjugated protonated carbonyl 
group in acridone (137) and lactam (140) or a conjugated, protonated pyridine ring 
(138). Likewise nucleophilicity may be eliminated for the basic heteroarenes 
theophylline (141), benzimidazole (142), 2-chlorobenzimidazole (143), 4-iodopyrazole 
(144), and benzotriazole (145). The attempt to extend the scope of this approach to 
the N-ethylation of aromatic amines by replacing 1,3,5-trioxane with paraldehyde 
(2,4,6-trimethyl-1,3,5-trioxane), the cyclic trimer of acetaldehyde, failed. The 
application of the corresponding PTT system on diphenylamine resulted in a strongly 
exothermal reaction with a darkening of the solution within seconds and finally an 
inseperable mixture of products. Cooling to 0 °C did only slow this process down. 
 
 
Figure 5.2. Substances inert to the TTT system. 
 
In conclusion we worked out a new protocol for the selective N-methylation of aromatic 
amines and N-heterocycles (indoles and annulated analogues, phenoxazine, 
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phenothiazine), that was published in Synthesis in 2015.[124] This method is highly 
chemoselective and inert to the normally more reactive/nucleophilic aliphatic amines. 
As demonstrated with tryptamine and 1,2,3,4-tetrahydro-β-carboline, this protocol is 
complementary to the known standard protocols, as merely the less nucleophilic 
nitrogen is methylated. The yields obtained ranged from 29 – 99 % and were highest 
for those educts, that were expected to be less reactive. The reaction protocol is 
simple, and the conditions are mild and compatible with many functional groups such 
as esters and nitro groups. No side reactions such as C-alkylation, or overalkylation to 
quarternary ammonium salts were observed. Moreover, this protocol can be combined 
with other reactions, such as acidic deprotections or intramolecular reductive 
aminations. 
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Chapter VI - Summary  
 
Based on the screening of a commercial library and some custom made compounds, 
the SGC had developed the 1,4-benzoxazepine type CBP/p300 inhibitor I-CBP112 
(Figure 6.1). This inhibitor is very potent and to some extent selective, but several 
edges, especially the 2,3,4,5-tetrahyro-1,4-benzoxazepine scaffold, the acyl moiety at 
N-4, the C-7-, and the C-9 moiety were not fully explored. Initially, the objective of this 
thesis was the further refinement of these moieties of this inhibitor. Difficulties in the 
preparation of some compounds for inhibitor refinement prompted us to extend the 
topic of this thesis to the development of a novel and mild approach to 2,3,4,5-
tetrahydro-1H-1,4-benzodiazepines. Moreover this approach finally inspired us to 
develop a new preparative protocol for the chemoselective N-methylation of aromatic 
amines.  
 
 
Figure 6.1. CBP/p300 bromodomain inhibitor I-CBP112 and Tm shifts. 
 
Since co-crystallizations indicated that I-CBP112’s bulky ether moiety at C-9 does not 
interact with CBP, we conducted first experiments on a simplified scaffold. Thanks to 
standard protocols[51b, 51c] a new 2,3,4,5-tetrahydro-1,4-benzoxazepine scaffold 9 with 
a methyl ether group at C-9 (Scheme 6.1) could be prepared on a large scale. An 
appropriate number of novel compounds could then be synthesized to obtain a clearer 
picture of promising substituents at C-7 and N-4. For variations at C-7 secondary 
amine 9 was first converted into intermediate 32, bearing a promising acyl moiety at 
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N-4. Subsequently, palladium-catalyzed cross-coupling reactions were performed to 
introduce aryl and heteroaryl residues at C-7. Introduction of residues at C-7 bearing 
a positive or negative charge at physiological pH diminished the affinity to both 
bromodomains. Generally electron-rich phenyl substituents at C-7 were more potent, 
although this was not the case for all compounds. Finally, compound 40 with 3,5-
dimethoxyphenyl moiety was the most promising in this series. For most compounds, 
affinity was only determined for CBP and not p300, since it was not expected to obtain 
selectivity for one of the two. However selectivity over the BET family was important 
and thus affinity towards BRD4(1) was determined, too. 
 
 
Scheme 6.1. In the process of optimizing residues at C-7, compound 40 showed the best activity in the 
DSF screening. 
 
The optimization of the moiety at N-4 was conducted simultaneously. Converting 
bromoaryl scaffold 9 into the biaryl 56 allowed the introduction of eleven different 
moieties at N-4 to give a library with small, functional groups such as thioamides, 
carbamates, and (thio)ureas, which had not been tested for CBP inhibition before 
(Scheme 6.2). The most potent inhibitor in this series was the N-propionylamide 57. 
Despite thorough examinations of the moieties at C-7 or N-4, no improvement of 
potency or selectivity over I-CBP112 could be obtained so far.  
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Scheme 6.2. DSF screening of eleven compounds with different, small moieties at N-4 revealed that 
the I-CBP112’s N-propionyl residue is still the best.  
 
We next turned to the 2,3,4,5-tetrahydro-1,4-benzoxazepine scaffold itself and aimed 
at the replacement of oxygen by sulfur (2,3,4,5-tetrahydro-1,4-benzothiazepine) or 
nitrogen (2,3,4,5-tetrahydro-1H-1,4-benzodiazepine). The preparation of the novel 
2,3,4,5-tetrahydro-1,4-benzothiazepine scaffold 15 went as planned and described for 
similar compounds with satisfactory yields. Following bromination, the anthranilic acid 
11 was converted into the mercaptobenzoic acid 12 (Scheme 6.3). Its methyl ester 13 
was S-alkylated with 2-chloroethylamine and intramolecular amide formation gave 
lactam 14. Reduction of 14 gave the secondary amine 15, which was then converted 
into three novel structure analogues (e.g. compound 70) of the 2,3,4,5-tetrahydro-1,4-
benzoxazepine inhibitors. However, these new compounds were neither potent nor 
selective inhibitors of CBP. 
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Scheme 6.3. Preparation of the 2,3,4,5-tetrahydro-1,4-benzothiazepine scaffold and exemplarily the 
synthesis of the 2,3,4,5-tetrahydro-1,4-benzothiazepine analogue 70. 
 
Likewise the 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine 99 showed poor potency, not 
even slightly matching the efforts required to accomplish its synthesis. A classical, 
drastic approach to 2,3,4,5-tetrahydro-1H-1,4-benzodiazepines via an isatoic acid 
anhydride[62] failed at the last step, and prompted us to experiment with N-
nosylaziridine[63]. Having learned to supress side reactions and raise yields, the last 
intramolecular ring closure reaction, a Fukuyama-type[65] Mitsunobu[66] reaction could 
not be accomplished. Fortunately this failed synthesis gave inspiration for another 
approach: The desired compound was finally synthesized using the newly developed 
approach to monoprotected 2,3,4,5-tetrahydro-1H-1,4-benzodiazepines via a one-pot 
N-deprotection/reductive cyclization procedure (Scheme 6.4). This approach begins 
with the N-Boc protection of a 2-aminobenzylalcohol A. A Fukuyama amine 
synthesis[65] with obtained N-Boc protected compounds of type B and N-(2,2-
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dimethoxy-ethyl)-2-nitrobenzenesulfonamide[67] under Mitsunobu conditions[66] is then 
conducted. The one-pot N-deprotection/reductive cyclization procedure of compounds 
with structure C with triethylsilane, trifluoroacetic acid, and dichloromethane directly 
gives a protected 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine D (e.g. compound 22), 
which can be easily deprotected with thiophenol to obtain compounds of type E. 
 
Scheme 6.4. Novel, mild approach to various 2,3,4,5-tetrahydro-1H-1,4-benzodiazepine scaffolds and 
CBP inhibitor 99. 
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The general applicability of this approach was demonstrated for five differently 
substituted 2,3,4,5-tetrahydro-1H-1,4-benzodiazepines and was published by us in 
Tetrahedron in 2016.[96] The preparation is accomplished under mild conditions (mild 
reagents and temperature never >50 °C), consists of few steps and results in 
substances with a monoprotected aliphatic amine at position 4. This is advantageous, 
because it allows facile and selective conversion of the less nucleophilic nitrogen at 
position 1. As demonstrated, this conversion of N-1 may even be conducted in a one-
pot reaction along with the described ring closure step. Given the importance of the 
1,4-benzodiazepine scaffold,[56] we are confident that this approach will be of value for 
the community. 
 
Having analyzed the moieties at C-7 (3,5-dimethoxyphenyl substituent best), and N-4 
(propionyl best), and having found the 1,4-benzoxazepine scaffold to be the most 
suitable backbone, we turned to the ether function at C-9. This edge of the molecule 
had only been poorly explored by the SGC so far. No moieties other than an ether 
function with neutral or basic residues had been tested. Starting with Duff formylation 
of 5-bromosalicylic acid and subsequent esterification, we combined a number of 
known protocols[51b, 51c, 69]  to develop an efficient five-step synthesis of the new 2,3,4,5-
tetrahydro-1,4-benzoxazepine scaffold 102 with methyl ester group at C-9 (Scheme 
6.5). Due to the numerous effects reported for 1,4-benzoxazepines (anti-
inflammatory[49], anti-thrombotic[50], anti-tumor[51], and anti-amyloid-beta plaque 
activity[52]), particularly versatile intermediate 102, which can be smoothly prepared in 
large scale, may be of interest for other researchers, too. Three further reactions with 
high yields (N-Boc deprotection, N-acylation, Suzuki cross-coupling) gave the methyl 
esters 104 and 105, which were interesting as potential inhibitors and suitable 
intermediates for further syntheses. 
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Scheme 6.5. Preparation of the 2,3,4,5-tetrahydro-1,4-benzoxazepine scaffold with methyl ester at C-9. 
 
Preparing several compounds using methyl esters 104 and 105 as educts, we found a 
slight superiority of the 3,5-dimethoxyphenyl substitution pattern over the 3,4-
dimethoxyphenyl substitution pattern at C-7 for this scaffold. The uncharged, neutral 
methyl esters 104 and 105 were converted into the corresponding carboxylic acids and 
further into amides with protonable, basic amino moieties, thus giving negatively or 
positively charged side-chains at physiological pH. DSF results for CBP were similar 
for the three chemotypes (neutral, basic, acidic) with the charge seeming irrelevant. 
However, DSF screening revealed absolute selectivity over BRD4(1) for five (of six) 
compounds with carbonyl function at C-9. Further compounds were synthesized and 
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the introduction of an amide function at C-9 and a stereocenter yielded compounds 
that were comparable in potency with I-CBP112, but showed no affinity to BRD4(1) 
(112 - 115; Table 6.1). The configuration of the stereocenter itself was irrelevant. 
 
 
Table 6.1. Compounds 112 – 115 are of similar potency as I-CBP112, but show no affinity towards 
BRD4(1). 
 
With absolute selectivity over BRD4(1) being a great result, compounds 112 and 114 
were selected as lead structures and screened against a broad panel of 48 
bromodomains. The Tm shifts of 114 were <1.3 °C with all bromodomains except CBP 
and p300 (Figure 6.2). This confirmed selectivity over other bromodomains, most 
importantly over the BET-family. 
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Figure 6.2. Comprehensive DSF screening with 114. The few bromodomains without red or blue dots 
were not tested. 
 
The Kd of 114 was determined as 134 nM for CBP, which is slightly lower than that of 
I-CBP112 (151 nM). This may results from an additional water-mediated hydrogen 
bond that is revealed through a co-crystallization of CBP with competitive inhibitor 114. 
Moreover a FRAP experiment with 112 demonstrated activity of this more selective 
generation of 1,4-benzoxazepine-type inhibitors in living, human cells. At the same 
time no general cytotoxic effects were found for 112, 114, and similar compounds in 
human leukemia cells (HL-60). This is essential when 114 shall be considered as a 
more selective alternative to preclinical drug candidate I-CBP112. Furthermore due to 
114’s greater selectivity compared to I-CBP112, 114 may serve as valuable, specific 
chemical probe for the further elucidation of the exact role of the bromodomains CBP 
and p300 in human cells. 
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In the course of this thesis we also developed a new protocol for the chemoselective, 
reductive N-methylation of aromatic amines and N-heterocycles. The protocol uses the 
new TTT-system (1,3,5-trioxane, trimethylsilane, trifluoroacetic acid, Scheme 6.6.) and 
was published in Synthesis in 2015.[124]  
 
 
Scheme 6.6. The TTT-system. 
 
It is a very mild protocol, conducted at room temperature and compatible with many 
functional groups sensitive to reduction, such as nitro groups or esters. No side 
reactions such as C-alkylation or overalkylation to quarternary ammonium salts, for 
which harsher protocols are known, were observed. We demonstrated that this 
protocol can be combined with other reactions, such as acidic deprotections or 
intramolecular reductive aminations. Yields ranged from 29-99 %, depending on the 
educt and this is the actual highlight of this protocol: The order of reactivity was 
reversed: Generally more reactive aliphatic amines are not N-methylated at all under 
our reaction conditions, and those aromatic amines are N-methylated with best yields, 
that are expected to be least nucleophilic. A selection of particularly interesting 
N-methylated products are shown in Figure 6.3. Unreactive nitrogens were 
N-methylated in excellent yields to anilines 120, 125, 126 and N-methyl phenoxazine 
127, while yield was worse for slightly more nucleophilic N-benzylaniline. Products 131 
and 132 confirmed inertness of aliphatic amines and proved this protocol to be 
complementary to standard procedures, with which exclusively the more nucleophilic, 
aliphatic amine is N-methylated. 
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Figure 6.3. Highlighted products of the new N-methylation protocol. Reaction times and yields in 
parentheses.  
 
As a final conclusion we could further enhance the CBP/p300 inhibitor I-CBP112, 
although retrospectively I-CBP112 was already pretty optimized. However, 
introduction of the amide function at C-9 resulted in further selectivity over the BET-
family (demonstrated by DSF), while slightly improving potency. It will be interesting to 
see, whether this selectivity yields benefits, and whether inhibitor 114 can replace 
I-CBP112 in case its residual affinity towards the BET-family should be problematic. 
This enhancement of I-CBP112 could be beneficial for the elucidation of the functions 
of CBP and p300 and possibly lead to novel therapeutic approaches. Furthermore two 
novel, valuable synthetic protocols were worked out and published during this thesis. 
Both protocols use mild reagents, temperatures from room temperature to a maximum 
of 50 °C, and are outstanding with regard to chemoselectivity: They allow conversion 
of a generally more unreactive aniline in the presence of an aliphatic amine. For the 
newly developed N-methylation protocol of aromatic amines and N-heterocycles, this 
is achieved due to the mere inertness of aliphatic amines in the TTT system. The newly 
published, short and mild approach towards 2,3,4,5-tetrahydro-1H-1,4-
benzodiazepines gives a product with nosyl-protected, aliphatic amine, allowing 
conversion of the aromatic amine prior to deprotection. Although we initially aimed at 
achieving selectivity in a pharmacological context, the scope of this thesis was soon 
successfully extended to the accomplishment of selectivity in purely chemical contexts.
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Chapter VII - Experimental Section.  
7.1 Procedures conducted by our cooperation partners at the University of 
Oxford 
 
Protein expression 
 
cDNA encoding human bromodomains were cloned, expressed and purified as 
described by Filippakopoulos et al. in 2010.[125] 
  
Thermal shift assay  
 
Thermal melting experiments were carried out using an Mx3005p Real Time PCR 
machine (Stratagene). Proteins were buffered in 10 mM HEPES pH 7.5, 500 mM NaCl 
and assayed in a 96-well plate at a final concentration of 2 μM in 20 μL volume. 
Compounds were added at a final concentration of 10 μM. SYPRO Orange (Molecular 
Probes) was added as a fluorescence probe at a dilution of 1:1000. Excitation and 
emission filters for the SYPRO-Orange dye were set to 465 nm and 590 nm, 
respectively. The temperature was raised with a step of 3 °C per minute from 25 °C to 
96 °C and fluorescence readings were taken at each interval.[125]  
 
Isothermal titration calorimetry (ITC) 
 
Experiments were carried out on a VP-ITC microcalorimeter (MicroCal™). All 
experiments were performed at 15 °C in 50 mM HEPES pH 7.5, 150 mM NaCl. The 
titrations were conducted using an initial injection of 2 µl followed by 34 identical 
injections of 8 µl. The dilution heats were measured on separate experiments and were 
subtracted from the titration data. Thermodynamic parameters were calculated using 
∆G = ∆H - T∆S = -rtlnKB, where ∆G, ∆H and ∆S are the changes in free energy, 
Chapter VII – Experimental Section 
 
96 
 
enthalpy and entropy of binding respectively. In all cases a single binding site model 
was employed. 
 
Alphascreen assay 
 
Assays were performed as described previously[126] with minor modifications from the 
manufacturer’s protocol (PerkinElmer, USA). All reagents were diluted in 25 mM 
HEPES, 100 mM NaCl, 0.1 % BSA, pH 7.4 supplemented with 0.05 % CHAPS and 
allowed to equilibrate to room temperature prior to addition to plates. A 11-point 1:2.5 
serial dilution of the ligands was prepared over the range of 5000 – 0 μM and 0.1 µL 
transferred to low-volume 384-well plates filled with 5 uL of the assay buffer 
(ProxiPlateTM-384 Plus, PerkinElmer, USA), followed by 7 uL of biotinylated peptide 
H-ALREIRRYQK(ac) STELLIRKLK(biotin)-OH and His-tagged protein to achieve final 
assay concentrations of 50 nM. Plates were sealed and incubated for a further 30 
minutes, before the addition of 8 μl of the mixture of streptavidin-coated donor beads 
(12.5 μg/ml) and nickel chelate acceptor beads (12.5 μg/ml) under low light conditions. 
Plates were foil-sealed to protect from light, incubated at room temperature for 60 
minutes and read on a PHERAstar FS plate reader (BMG Labtech, Germany) using 
an Alphascreen 680 excitation/570 emission filter set. IC50 values were calculated in 
Prism 5 (GraphPad Software, USA) after normalization against corresponding DMSO 
controls and are given as the final concentration of compound in the 20 μl reaction 
volume. 
 
Protein crystallization 
 
Aliquots of the purified proteins were set up for crystallization using a mosquito® 
crystallization robot (TTP Labtech). Coarse screens were typically setup onto Greiner 
3-well plates using three different drop ratios of precipitant to protein per condition 
(100+50 nL, 75+75 nL and 50+100 nL). All crystallizations were carried out using the 
sitting drop vapour diffusion method at 4°C. CBP crystals with 114 (2 mM final 
concentration) were grown by mixing 200 nL of the protein (8.6 mg/ml) with 100 μL of 
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reservoir solution containing 0.10 M MgCl2, 0.1 M MES pH 6.0, 20 % PEG 6K and 
10 % ethylene glycol.  
 
 
Fluorescence recovery after photobleaching (FRAP) 
FRAP studies were performed essentially as described.[76] In brief, U2OS cells were 
transfected (Fugene HD; Roche) with mammalian over-expression constructs a 
triplicated CBP bromodomain harbouring a nuclear localization sequence. The imaging 
system consisted of a Zeiss LSM 710 laser-scanning and control system (Zeiss) 
coupled to an inverted Zeiss Axio Observer.Z1 microscope equipped with a high-
numerical-aperture (N. A. 1.3) 40 x oil immersion objective (Zeiss). Samples were 
placed in an incubator chamber in order to maintaining temperature and humidity. 
FRAP and GFP fluorescence imaging were both carried out with an argon-ion laser 
(488 nm) and with a PMT detector set to detect fluorescence between 500-550 nm. 
Once an initial scan had been taken, a region of interest corresponding to 
approximately 50 % of the entire GFP positive nucleus was empirically selected for 
bleaching. A time lapse series was then taken to record GFP recovery using 1% of the 
power used for bleaching. The image datasets and fluorescence recovery data were 
exported from ZEN 2009, the microscope control software, into Origin to determine the 
average half-time for full recovery for 10-20 cells per treatment point. Data were 
analysed using one-way ANOVA with Dunnetts’s multiple comparisons test. 
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7.2 General procedures for biological characterization conducted by Martina 
Stadler in the Bracher laboratory of the LMU 
 
MTT assay 
 
The MTT assay was conducted with HL-60 cells. First the number of cells per mL was 
determined with a hematocyte cell counter (Fuchs-Rosenthal). Then the cell 
suspension was diluted with medium to 9 x 105 cells mL-1 on a Petri dish. 99 µL of this 
cell suspension were filled into each well of a 96-well plate and incubated at 37 °C for 
24 h. 10 mM stock solutions were prepared from the synthesized compounds in DMSO. 
These were diluted with DMSO six times 1 : 2. For negative control 1 µL of DMSO was 
added to the 99 µL cell medium in the wells. For positive control 1 µL of Triton® X-100 
solution with a final concentration of 1 µg/mL was added. Of each dilution of the stock 
solution 1 µL was added to a well with 99 µL cell culture. The 99-well plate was 
incubated at 37 °C with 5 % CO2 for 24 h. Then 10 µL MTT solution (5 mg MTT in 
1.0 mL PBS) was added to each well and further incubated for two hours. Then 190 µL 
DMSO were added and the plate shaked for one hour. Photometric quantification was 
conducted at a wavelength of 570 nm with an ELISA reader (SLT Spectra, Crailsheim). 
Statistical analysis and calculation of IC50 values was done with Prism 4 Software 
(GraphPad, USA).  
 
Agar diffusion test 
 
Solutions with 1 % (m/V) compound in DMSO were prepared. Of these solutions 3.0 µL 
were given on a test platelete (diameter 6 mm, Macherey-Nagel), equivalent to 30 µg 
substance. The same was done for clotrimazole and tetracycline. Blind control was 
conducted with mere DMSO. The test platelets were then dried for 24 hours at room 
temperature. Microorganisms were obtained from Deutsche Sammlung von 
Mikroorganismen und Zellkulturen GmbH (DSMZ) in Braunschweig and cultivated 
according to recommendations in liquid culture. For the agar diffusion test, different 
agars were required. For Candida glabrata (DSM number: 11226), Hyphopichia 
burtonii (DSM number: 70663), Yarrowia lipolytica (DSM number: 1345), Escherichia 
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coli (DSM number: 426) and Pseudomonas marginalis (DSM number: 7527) all-culture 
agar (AC-agar) of Sigma Aldrich was used. 35.2 g AC-agar and 20 g agar were 
suspended in 1.0 L water and treated by autoclave. For Staphylococcus equorum 
(DSM number: 20675) and Streptococcus entericus (DSM number: 14446) an agar is 
likewise prepared from 10.0 g caseinpeptone, 5.0 g yeast extract, 5.0 g glucose and 
5.0 g sodium chloride in 1.0 L water. For Aspergillus niger (DSM number: 1988) 32 g 
potato dextrose agar and 20 g agar in 1.0 L water were used. After treatment in the 
autoclave 15 mL of the warm, liquid agar was filled into Petri dishes under aseptic 
conditions and cooled to 8 °C for one hour. The germs were then brought onto the 
different agars using cotton swabs. The platelets containing the substances, the 
reference, and the blind control were put onto the agar. The agar plates were incubated 
for 36 h at 32 °C (bacteria) or 28 °C (yeasts). Then the diameters of growth inhibiton 
were measured manually. 
 
 
7.3 General procedures for compound preparation and chemical 
characterization conducted in the Bracher laboratory of the LMU 
  
Melting points were determined with a Büchi Melting Point B-540 and are uncorrected. 
1H and 13C NMR spectra were recorded either with Avance III HD 400 MHz Bruker 
BioSpin or Avance III HD 500 MHz Bruker BioSpin spectrometers. Chemical shifts (δ) 
are given in ppm relative to TMS or residual undeuterated solvent, and coupling 
constants (J) are given in hertz (Hz). Splitting patterns are abbreviated as follows: s = 
singlet; d = doublet; t = triplet; q = quartet; dd = doublet of doublet; m = multiplet, br s 
= broad singlet. If no temperature is given, measurements were performed at ambient 
temperature, but some NMR spectra were recorded at elevated temperature to 
suppress the appearance of double peaks arising from the rotameric isomers. Those 
occurred in the NMR spectra of almost all CBP inhibitors and arise from the 
(thio-)amide bond of the aliphatic nitrogen (N-4) of the seven-membered ring. EI mass 
spectra were recorded at an ionization energy of 70 eV either with a JMS GCmate II 
Jeol or a JEOL JMS-700 MStation. ESI-Mass spectra were recorded on a Thermo 
Finnigan LTQ FT at 4 kV. Purification by flash column chromatography (FCC) was 
performed using Silica Gel 60 from Merck KGaA. For microwave experiments a CEM 
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Discover was used with power set to 300 W. Optical rotations were determined with a 
Perkin Elmer 241 polarimeter. HPLC purity analysis was individually performed on an 
Agilent 1100 Series apparatus with a G1311A QuatPump, and a G1329A ALS 
autosampler, and a G1316A ColComp column oven, and Agilent ChemStation Rev. 
B04.02 as software. A G1315A DAD detector was set to 210 nm for detection. Injection 
volume was 5 or 10 µL of a dilution of 100 µg/mL (sample in mobile phase). Column 
temperature was 50 °C, flow either 0.3 mL/min, or 0.8 mL/min or 1.0 mL/min. Different 
solvent mixtures were used as mobile phase, from 50 % to 25 % water and from 50 % 
to 75 % acetonitrile respectively. The water used for preparation of the mobile phase 
contained 1 % THF. The following columns were used: Kinetex 2.6 u PFP, 100 A, 
(100 x 2.10 mm), Agilent Poroshell 120, PFP 2.7 µm, (3.0 x 100 mm), Varian Pursuit 
UPS 2.4 Diphenyl (50 x 2.0 mm), and Agilent Poroshell 120, EC-C18 2.7 µm, (3.0 x 
100 mm). All tested substances showed a purity > 95.0 %. The key to the different 
methods is shown on the next page. 
Chapter VII – Experimental Section 
 
101 
 
Methods for the determination of purity by HPLC 
 
Method 1: Agilent Poroshell 120, EC-C18 2.7 µm, (3.0 x 100 mm); flow: 1 mL/min; 
a) MeCN – water with 0,1 % NaOH: 75 - 25; 
b) MeCN – water with 0,1 % NaOH: 55 - 45; 
c) MeCN – water with 0,1 % NaOH: 70 - 30; 
d) MeCN – water: 70 - 30; 
Method 2: Kinetex 2.6 u PFP, 100 A, (100 x 2.10 mm); flow: 0.3 mL/min; 
a) MeCN – water: 50 - 50; 
b) MeCN – water with 0,1 % NaOH: 50 - 50; 
Method 3: Agilent Poroshell 120, PFP 2.7 µm, (3.0 x 100 mm); flow: 1 mL/min; 
a) MeCN – water: 70 - 30; 
b) MeCN – water: 50 - 50; 
Method 4: Agilent Poroshell 120, EC-C18 2.7 µm, (3,0 x 100 mm); flow: 0.8 mL/min; 
a) MeCN – water: 55 - 45; 
Method 5: Varian Pursuit UPS 2.4 Diphenyl (50 x 2.0 mm); flow: 0.3 mL/min; 
a) MeCN – water: 55 – 45; 
Method 6: Agilent Poroshell 120, EC-C18 2,7 µm, (3,0 x 100 mm); flow: 0.8 mL/min; 
a) MeCN – water: 80 - 20; 
b) MeCN – water with 0,1 % NaOH: 75 - 25;  
Method 7: Agilent Poroshell 120, EC-C18 2,7 µm, (3,0 x 100 mm); flow: 1 mL/min; 
a) MeCN – water: 75 - 25;  
b) MeCN – water: 80 - 20; 
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Standard synthetic protocols  
 
Standard protocol 1 (N-acylation of 2,3,4,5-tetrahydro-1,4-benzoxazepines and 
2,3,4,5-tetrahydro-1,4-benzothiazepines): The educt (0.50 mmol) was dissolved in 
1.0 mL DCM and 1.5 mmol DIPEA was added at 0 °C. 1.3 mmol acyl chloride was 
added, the mixture warmed to rt and stirred for 1.5 h. Then 50 mL 2 M NaOH was 
added and the mixture was extracted with DCM (3 x 50 mL) three times. The combined 
organic layers were dried over MgSO4, concentrated in vacuo and purified by FCC with 
EtOAc and hexanes. 
Standard protocol 2 (Suzuki cross-coupling of 7-bromo-2,3,4,5-tetrahydro-1,4-
benzoxazepines and 7-bromo-2,3,4,5-tetrahydro-1,4-benzothiazepines with boronic 
acids and boronic acid pinacol esters): To 0.30 mmol bromoarene, 0.36 mmol boronic 
acid or boronic acid pinacol ester and 0.03 mmol [1.1′-
bis(diphenylphosphino)ferrocene]dichloropalladium(II) were added. A mixture of 0.50 
mL water, 2.0 mL 1,4-dioxane and 1.2 mmol DIPEA was added under nitrogen 
atmosphere, and the mixture heated under vigorous stirring to 95 °C for 3.5 h. To this 
solution was added 20 mL of either water or 0.5 M NaOH for compounds with basic 
moieties or 0.5 M HCl for compounds with acidic moieties. The mixture was extracted 
with DCM (3 x 20 mL) three times and the combined organic layers were dried over 
MgSO4, and concentrated in vacuo, and purified by FCC with EtOAc and hexanes. 
Standard protocol 3 (conversion of the carboxylic acids 106 and 107 to 
carboxamides): 0.29 mmol carboxylic acid and 0.35 mmol EDC-HCl were dissolved in 
3.0 mL DCM and cooled to 0 °C. Then 0.29 mmol DIPEA, 0.35 mmol of the required 
primary amine, and 2 mg DMAP were added. The solution was stirred at rt for 16 h. To 
this mixture was added 50 mL 1 M NaOH was added and the mixture was extracted 
with EtOAc (3 x 50 mL) three times. The combined organic layers were dried over 
MgSO4, concentrated in vacuo, and purified by FCC. 
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7.4 Description of compounds 
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4-Bromo-2-{[(2-hydroxyethyl)amino]methyl} 
-6-methoxyphenol (6) 
 
 
MF: C10H14BrNO3        MW: 276.13 g/mol 
To a solution of 9.9 g (43 mmol) 5-bromo-3-methoxysalicylaldehyde in 200 mL THF 
and 20 mL MeOH, 3.3 g (54 mmol) 2-aminoethanol were added and the mixture was 
stirred for 25 min. Over 1.5 h three equal portions of 1.5 g (40 mmol) NaBH4 were 
added and the mixture stirred for 16 h. The solvent was evaporated under reduced 
pressure, and the residue dissolved in 100 mL EtOAc. Upon addition of 200 mL water, 
the product partially precipitated as white solid and was collected by filtration. This 
mixture was extracted with EtOAc (3 x 200 mL) three times. The combined organic 
layers were dried over MgSO4 and concentrated in vacuo. FCC of precipitate and 
concentrate of organic phases with EtOAc and MeOH (4:1, Rf 0.3) gave 11 g (40 mmol, 
93 %) of 6 as a white solid.  
mp: 153 - 154 °C.  
1H-NMR (400 MHz, DMSO-d6): δ = 6.96 (d, J = 2.2 Hz, 1H, 5-H), 6.88 (d, J = 2.2 Hz, 
1H, 3-H), 3.80 (s, 2H, 2-CH2), 3.75 (s, 3H, OCH3), 3.46 (t, J = 5.7 Hz, 2H, CH2OH), 
2.54 (t, J = 5.7 Hz, 2H, CH2NH).  
13C NMR (101 MHz, DMSO-d6): δ = 148.3 (C-6), 145.9 (C-1), 126.3 (C-2), 122.7 (C-
3), 113.5 (C-5), 108.8 (C-4), 59.7 (CH2OH), 55.8 (OCH3), 50.2 (CH2NH), 49.5 (2-CH2).  
IR (KBr): ṽ (cm-1) = 3178, 2949, 2936, 2880, 2830, 1618, 1556, 1483, 1443, 1321, 
1246, 1087, 967, 828, 762. 
MS (EI+): m/z (%) = 108 (32), 215 (100), 217 (88), 244 (50), 246 (52), 275 (14) [M]+•, 
277 (15). 
HRMS (EI+): m/z calcd for C10H1479BrNO3 275.0157, found 275.0157. 
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tert-Butyl (5-bromo-2-hydroxy-3-methoxybenzyl)(2-hydroxyethyl)carbamate (7) 
 
 
MF: C15H22BrNO5        MW: 376.25 g/mol  
To a suspension of 11 g (40 mmol) 6 in 100 mL EtOAc and 58 mL saturated NaHCO3 
solution, 12 g (53 mmol) di-tert-butyl dicarbonate were added and the mixture was 
stirred for 16 h. The suspension turned into a clear two phase system and the organic 
layer was separated. The aqueous phase was extracted with EtOAc (3 x 60 mL) three 
times, and the combined organic layers were dried over MgSO4 and concentrated in 
vacuo. FCC with EtOAc and hexanes (3:2, Rf 0.5) gave 11 g (28 mmol, 69 %) of 7 as 
a white solid.  
mp: 95 - 96 °C.  
1H NMR (70 °C, 400 MHz, DMSO-d6): δ = 8.75 (s, 1H, 2’-OH), 7.01 (d, J = 2.3 Hz, 1H, 
4’-H), 6.81 (d, J = 2.3 Hz, 1H, 6’-H), 4.53 – 4.32 (m, 3H, 1’-CH2, CH2OH), 3.81 (s, 3H, 
OCH3), 3.53 – 3.43 (m, 2H, CH2OH), 3.32 – 3.19 (m, 2H, NCH2), 1.40 (s, 9H, (CH3)3).  
13C NMR (70 °C, 101 MHz, DMSO-d6): δ = 154.9 (C-1), 148.3 (C-3’), 143.3 (C-2’), 
127.1 (C-1’), 122.3 (C-6’), 113.5 (C-4’), 109.4 (C-5’), 78.6 (C(CH3)3), 58.9 (CH2OH), 
56.1 (OCH3), 49.0 (NCH2), 45.2 (1’-CH2), 27.7 ((CH3)3).  
IR (KBr): ṽ (cm-1) = 3447, 3200, 2975, 2943, 1669, 1460, 1415, 1233, 1163, 1055, 955, 
830. 
MS (EI+): m/z (%) = 244 (100), 246 (91), 319 (15), 321 (10), 375 (8) [M]+•. 
HRMS (EI+): m/z calcd for C15H2279BrNO5 375.0681, found 375.0685. 
Purity (HPLC): 98 % (210 nm; method 5a). 
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tert-Butyl 7-bromo-9-methoxy-2,3-dihydro-1,4-benzoxazepine-4(5H)-carboxylate 
(8) 
 
 
MF: C15H20BrNO4        MW: 358.23 g/mol  
To a solution of 9.7 g (26 mmol) 7 and 11 g (42 mmol) triphenylphosphine in 260 mL 
DCM, 8.7 mL (40 mmol) DIAD were added and the mixture was stirred for 16 h. Then 
100 mL water was added and the mixture was extracted with EtOAc (3 x 100 mL) three 
times. The combined organic layers were dried over MgSO4 and concentrated in 
vacuo. FCC with EtOAc and hexanes (1:4, Rf 0.3) gave 8.6 g (24 mmol, 91 %) of 8 as 
a white solid.  
mp: 96 - 97 °C.  
1H NMR (70 °C, 400 MHz, DMSO-d6): δ = 7.09 (d, J = 2.3 Hz, 1H, 8-H), 6.98 (d, J = 
2.3 Hz, 1H, 6-H), 4.38 (s, 2H, 5-H), 4.05 – 3.93 (m, 2H, 2-H), 3.78 (s, 3H, OCH3), 3.74 
– 3.67 (m, 2H, 3-H), 1.35 (s, 9H, C(CH3)).  
13C NMR (70 °C, 101 MHz, DMSO-d6): δ = 154.6 (C=O), 152.8 (C-9), 148.2 (C-9a), 
134.9 (C-5a), 124.4 (C-6), 116.0 (C-8), 114.7 (C-7), 79.8 (C(CH3)), 72.3 (C-2), 56.9 
(OCH3), 49.9 (C-3), 49.3 (C-5), 28.5 (C(CH3)).  
IR (KBr): ṽ (cm-1) = 3432, 2975, 2933, 2867, 2839, 1686, 1578, 1486, 1455, 1399, 
1297, 1188, 1082, 1023, 834, 721. 
MS (EI+): m/z (%) = 134 (41), 214 (62), 216 (54), 257 (100), 259 (80), 300 (84), 302 
(88), 357 (59) [M]+•. 
HRMS (EI+): m/z calcd for C15H2079BrNO4 357.0576, found 357.0575. 
Purity (HPLC): > 99 % (210 nm; method 5a). 
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7-Bromo-9-methoxy-2,3,4,5-tetrahydro-1,4-benzoxazepine (9) 
 
  
MF: C10H12BrNO2        MW: 258.12 g/mol  
To a suspension of 10 g (28 mmol) 8 in 120 mL MeOH was added a mixture of 80 mL 
36 % HCl and 120 mL 1,4-dioxane. The mixture was refluxed for 2 h and then 
concentrated in vacuo. Then 200 mL saturated Na2CO3 solution was carefully added 
and the mixture was extracted with DCM (3 x 200 mL) three times. The combined 
organic layers were dried over MgSO4 and concentrated in vacuo to give 6.7 g (26 
mmol, 94 %) of 9 as a white solid.  
mp: 119 - 120 °C.  
1H NMR (400 MHz, DMSO-d6): δ = 7.05 (d, J = 2.4 Hz, 1H, 8-H), 6.98 (d, J = 2.4 Hz, 
1H, 6-H), 3.93 – 3.83 (m, 2H, 2-H), 3.75 (s, 3H, OCH3), 3.73 (s, 2H, 5-H), 3.06 – 2.94 
(m, 2H, 3-H).  
13C NMR (126 MHz, DMSO-d6): δ = 153.1 (C-9), 149.0 (C-9a), 140.0 (C-5a), 124.1 (C-
6), 115.2 (C-8), 115.1 (C-7), 75.8 (C-2), 56.9 (OCH3), 52.9 (C-5), 52.8 (C-3).  
IR (KBr): ṽ (cm-1) = 3433, 3324, 3085, 2978, 2951, 2930, 2904, 1736, 1690, 1590, 
1574, 1485, 1289, 1266, 1205, 1079, 985, 834. 
MS (EI+): m/z (%) = 134 (30), 214 (38), 216 (32), 257 (100) [M]+•.  
HRMS (EI+): m/z calcd for C10H1279BrNO2 257.0051, found 257.0052. 
Purity (HPLC): > 99 % (210 nm; method 5a). 
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5-Bromo-2-mercapto-3-methoxybenzoic acid (12) 
 
 
MF: C8H5O2BrS        MW: 263.11 g/mol  
A suspension of 9.6 g (30 mmol) 4-bromo-2-carboxy-6-methoxybenzenaminium 
bromide[54], 2.4 g (60 mmol) NaOH, and 2.1 g (30 mmol) NaNO2 in 60 mL water was 
added over 0.5 h to a mixture of 20 mL conc. HCl with ice and the temperature was 
kept at 0 °C by the addition of ice. After 0.5 h at 0 °C, potassium acetate was used to 
adjust to neutral pH. The resulting yellow solution was added to a stirred solution of 23 
g (140 mmol) of potassium ethyl xanthate in 40 mL water at 90 °C. After 0.5 h at 90 °C 
the solution was cooled to 0 °C. Conc. HCl was added until acidic pH. The resulting 
precipitate was collected by filtration and dissolved in 100 mL 10 % NaOH. The solution 
was heated to 85 °C for 2 h. Then 3.1 g (30 mmol) NaHSO3 were added and 85 °C 
were maintained for 0.25 h. The solution was filtrated, cooled to 0 °C, and acidified 
with conc. HCl. The precipitate was separated by filtration and dissolved in 300 mL of 
a mixture of EtOAc and THF (1:1). This organic layer was washed with 100 mL 
saturated NaCl solution twice, dried over MgSO4 and concentrated in vacuo. 
Purification by FCC with DCM with 4 % EtOH and 5 % AcOH (Rf 0.2) gave 4.9 g (19 
mmol, 62 %) of 12 as a white solid.  
mp: 208 – 209 °C.  
1H NMR (400 MHz, CD2Cl2): δ = 7.90 (d, J = 2.0 Hz, 6-H), 7.20 (d, J = 2.0 Hz, 4-H), 
5.28 (br s, 1H, SH), 3.96 (s, 3 H, OCH3).  
13C NMR (101 MHz, CD2Cl2): δ = 169.2 (C=O), 155.3 (C-3), 129.0 (C-2), 127.1 (C-6), 
127.0 (C-1), 118.0 (C-4), 117.3 (C-5), 57.4 (OCH3).  
IR (KBr): ṽ (cm-1) = 3445, 3066, 3007, 2973, 2941, 2855, 2622, 1695, 1449, 1316, 
1255, 1058, 856. 
MS (EI+): m/z (%) = 109 (17), 186 (20), 188 (20), 216 (30), 218 (29), 244 (100) [M]+•, 
246 (91), 262 (39), 264 (35). 
Chapter VII – Experimental Section 
 
109 
 
HRMS (EI+): m/z calcd for C8H5O279BrS 243.9193, found 243.9195. 
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Methyl 5-bromo-2-mercapto-3-methoxybenzoate (13) 
 
 
MF: C9H9O3BrS        MW: 277.13 g/mol  
A solution of 3.0 g (12 mmol) 12 in 25 mL anhydrous MeOH and 1.0 mL 96 % sulfuric 
acid was refluxed under N2 for 12 h and then concentrated in vacuo. Ice was added 
and the mixture was extracted with EtOAc (3 x 100 mL) three times. After drying over 
MgSO4 and concentration in vacuo, FCC with hexanes and EtOAc (9:1, Rf 0.4) gave 
2.3 g (8.6 mmol, 72 %) of 13 as a yellow solid.  
mp: 60 - 61 °C.  
1H NMR (500 MHz, DMSO-d6): δ = 7.69 – 7.65 (m, 1H, 6-H), 7.45 – 7.42 (m, 1H, 4-H), 
5.42 – 5.39 (m, 1H, SH), 3.95 (s, 3H, 5-OCH3), 3.85 (s, 3H, O=COCH3).  
13C NMR (126 MHz, DMSO-d6): δ = 165.2 (C=O), 154.8 (C-3), 127.7 (C-2), 126.3 (C-
1), 125.1 (C-6), 117.3 (C-4), 116.7 (C-5), 57.3 (5-OCH3), 52.6 (O=COCH3).  
IR (KBr): ṽ (cm-1) = 3435, 2971, 2951, 2939, 1715, 1448, 1427, 1315, 1258, 1059, 838, 
777, 624. 
MS (EI+): m/z (%) = 276 (100) [M]+•, 277 (11), 278 (97), 279 (11). 
HRMS (EI+): m/z calcd for C9H9O379BrS 275.9456, found 275.9452. 
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7-Bromo-9-methoxy-3,4-dihydro-1,4-benzothiazepin-5(2H)-one (14) 
 
 
MF: C10H10BrNO2S        MW: 286.96 g/mol  
To a solution of 2.3 g (8.3 mmol) 13 and 1.0 g (9.0 mmol) 2-chloroethylamine 
hydrochloride in 17 mL anhydrous DMF at 0 °C under N2, 1.0 g (19 mmol) NaOMe was 
added and the mixture stirred for 12 h. Water was added, the pH adjusted with 2 M 
NaOH to 12 and the mixture extracted with DCM three times. The combined organic 
layers were dried over MgSO4 and concentrated in vacuo. The residue was dissolved 
in 60 mL anhydrous THF and cooled to 0 °C. 7.2 g (64 mmol) t-BuOK was added and 
the mixture stirred at 45 °C for 1 h. Saturated ammonium chloride solution was added 
and the mixture extracted with EtOAc three times. The combined organic layers were 
dried over MgSO4 and concentrated in vacuo. FCC with DCM with 4 % MeOH (Rf 0.3) 
gave 1.5 g (5.2 mmol, 63 %) of 14 as a yellow solid.  
mp: 185 - 186 °C.  
1H NMR (400 MHz, CD2Cl2): δ = 7.33 (d, J = 2.0 Hz, 1H, 6-H), 7.16 (d, J = 2.0 Hz, 1H, 
8-H), 7.02 (br s, 1H, NH), 3.87 (s, 3H, OCH3), 3.32 – 3.26 (m, 2H, 3-H), 3.10 – 3.05 
(m, 2H, 2-H).  
13C NMR (101 MHz, CD2Cl2): δ = 170.9 (C-5), 160.3 (C-9), 144.1 (C-5a), 124.4 (C-6), 
123.7 (C-7), 117.1 (C-8), 116.9 (C-9a), 57.0 (OCH3), 40.2 (C-3), 37.4 (C-2).  
IR (KBr): ṽ (cm-1) = 3290, 3189, 3075, 2939, 1661, 1559, 1423, 1379, 1253, 1049, 888, 
834, 809, 645, 609. 
MS (ESI+): m/z (%) = 210 (13), 288 (98) [M + H]+, 290 (100). 
HRMS (ESI+): m/z calcd for [C10H1179BrNO2S]+ 287.9694, found 287.9688. 
Purity (HPLC): > 99 % (210 nm; method 5a). 
  
Chapter VII – Experimental Section 
 
112 
 
6-bromo-8-methoxy-3,1-benzoxazine-2,4(1H)-dione (16) 
 
 
MF: C9H6BrNO4        MW: 272,05 g/mol 
4.5 g (14 mmol) 11 was suspended in 240 mL anhydrous THF under nitrogen 
atmosphere. After addition of 2.4 mL DIPEA (25 mmol) a solution was obtained, which 
was refluxed. A solution of 1.8 g (6.1 mmol) triphosgene in 30 mL anhydrous THF was 
added and the mixture was refluxed for 0.5 h. The mixture was then cooled to rt, and 
300 mL saturated NaHCO3 solution was added. The mixture was extracted with DCM 
(3 x 300 mL) three times and the combined organic layers were concentrated in vacuo. 
The obtained precipitate was washed with DCM to obtain 3.0 g (11 mmol, 79 %) of 16 
as a white solid. 
mp: 208 °C (decomposition). 
1H NMR (400 MHz, DMSO-d6): δ = 11.45 (s, 1H, NH), 7.58 – 7.51 (m, 2H, 5-H, 7-H), 
3.91 (s, 3H, OCH3). 
13C NMR (101 MHz, DMSO-d6): δ = 158.8 (C-4), 147.3 (C-8), 146.5, 131.3, 121.2 (C-
5/C-7), 120.0 (C-5/C-7), 114.6, 112.3, 56.9 (OCH3). 
IR (KBr): ṽ (cm-1) = 3391, 3197, 3074, 2946, 1789, 1721, 1502, 1336, 1251, 1001. 
MS (ESI-): m/z (%) = 226 (21), 228 (21), 270 (87) [M - H]-, 272 (100). 
HRMS (ESI-): m/z calcd for C9H5Br79NO4 269.9407, found 269.9403. 
Purity (HPLC): > 99 % (210 nm; method 5).  
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7-bromo-9-methoxy-3,4-dihydro-1H-1,4-benzodiazepine-2,5-dione (17) 
 
  
MF: C10H9BrN2O3        MW: 285,10 g/mol 
0.20 g (0.74 mmol) 16 and 0.11 g (1.5 mmol) glycine were suspended in 1 mL 
anhydrous DMF and 1 mL glacial acetic acid. This mixture was refluxed for 18 h. The 
mixture was then cooled to room temperature and 50 mL saturated NaHCO3 solution 
was added. The mixture was extracted with EtOAc (3 x 50 mL) three times and the 
combined organic layers were dried over MgSO4. After concentration in vacuo, the 
obtained solid was washed with DCM to give 0.15 g (0.53 mmol, 72 %) of 17 as a white 
solid. 
mp: 243 – 244 °C. 
1H NMR (400 MHz, CD2Cl2): δ = 7.85 (br s, 1H, NH), 7.63 (d, J = 2.1 Hz, 1H, 6-H), 7.19 
(d, J = 2.1 Hz, 1H, 8-H), 6.77 (br s, 1H, NH), 3.91 (s, 3H, OCH3), 3.81 (d, J = 0.7 Hz, 
1H, 3-H), 3.80 (d, J = 0.7 Hz, 1H, 3-H). 
13C NMR (126 MHz, CD2Cl2): δ = 170.2 (C-2), 167.7 (C-5), 149.7 (C-9), 126.5 
(C-5a/C-7), 126.1 (C-9a), 125.5 (C-6), 117.6 (C-5a/C-7), 117.2 (C-8), 57.1 (OCH3), 
45.4 (C-3). 
IR (KBr): ṽ (cm-1) = 3218, 3081, 2918, 1689, 1624, 1482, 1457, 1370, 1244, 1056. 
MS (ESI-): m/z (%) = 283 (91) [M - H]-, 285 (100). 
HRMS (ESI-): m/z calcd for C10H8Br79N2O3 282.9724, found 282.9719. 
Purity (HPLC): > 99 % (210 nm; method 5). 
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tert-Butyl [4-bromo-2-(hydroxymethyl)-6-methoxyphenyl]carbamatea (23) 
 
 
MF: C13H18BrNO4        MW: 332.19 g/mol 
To a solution of 2.3 g (11 mmol) di-tert-butyl dicarbonate in 20 mL anhydrous THF 
under N2 atmosphere, 2.3 g (9.9 mmol) (2-amino-5-bromo-3-
methoxyphenyl)methanol[127] was added and the resulting solution was stirred at 40 °C 
for 2 d. The solvent was evaporated under reduced pressure and FCC with EtOAc and 
hexanes (1:5, Rf 0.2) gave 1.6 g (4.8 mmol, 48 %) of 23 as a white solid. 
mp: 135 - 137 °C. 
1H NMR (500 MHz, CDCl3) δ = 7.20 (d, J = 2.1 Hz, 1H, 3-H), 6.89 (d, J = 2.1 Hz, 1H, 
5-H), 6.19 (br s, 1H, NH), 4.42 (s, 2H, CH2), 3.77 (s, 3H, OCH3), 1.44 (s, 9H, C(CH3)3). 
13C NMR (rt, 126 MHz, CDCl3) δ = 155.8 (C=O), 153.6 (C-6), 139.3 (C-2), 125.8 (C-3), 
123.5 (C-1), 119.9 (C-4), 113.7 (C-5), 81.6 (C(CH3)3), 61.8 (CH2), 56.2 (OCH3), 28.3 
(C(CH3)3). 
IR (KBr): ṽ (cm-1) = 3462, 3327, 3009, 2981, 2944, 1695, 1509, 1275, 1164, 1043. 
MS (EI+): m/z (%) = 185 (40), 187 (38), 213 (53), 215 (60), 231 (100), 233 (81), 257 
(25), 259 (24), 275 (12), 277 (15), 331 (15) [M]+•. 
HRMS (EI+): m/z calcd for C13H1879BrNO4 331.0419, found 331.0431. 
Purity (HPLC): 95 % (210 nm; method 1b).  
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tert-Butyl [4-bromo-2-({[N-(2,2-dimethoxyethyl)-2-
nitrophenyl]sulfonylamino}methyl)-6-methoxyphenyl]carbamatea (24) 
 
 
MF: C23H30BrN3O4S       MW: 604.47 g/mol 
To a vigorously stirred solution of 0.55 g (2.1 mmol) triphenylphosphine in 2.0 mL 
anhydrous THF under N2 atmosphere, 0.33 mL (1.7 mmol) DIAD was added. When a 
homogenous white precipitate formed, 0.48 g (1.7 mmol) N-(2,2-dimethoxyethyl)-2-
nitrobenzenesulfonamide[67] was added and the reaction mixture was treated in an 
ultrasonic bath. After 10 min 0.50 g (1.5 mmol) 23 was added and the suspension was 
sonicated until a clear solution was obtained. The solvent was evaporated under 
reduced pressure and FCC with EtOAc and hexanes (1:2, Rf 0.4) followed by a second 
FCC with pure CH2Cl2 gave 0.46 g (0.76 mmol, 36 %) of 24 as a colorless oil. 
1H NMR (500 MHz, CD2Cl2) δ = 7.93 (dd, J = 7.9, 1.3 Hz, 1H, Ar-HNosyl), 7.76 – 7.57 
(m, 3H, Ar-HNosyl), 7.02 – 6.95 (m, 1H, 3-H), 6.92 (d, J = 2.1 Hz, 1H, 5-H), 6.26 (br s, 
1H, NH), 4.62 (s, 2H, 2-CH2-N), 4.35 (t, J = 5.2 Hz, 1H, CH(OCH3)2), 3.80 (s, 3H, 6-
OCH3), 3.35 (d, J = 5.2 Hz, 2H, N-CH2-CH), 3.27 (s, 6H, CH(OCH3)2), 1.47 (s, 9H, 
C(CH3)3).  
13C NMR (126 MHz, CDCl3) δ = 154.9 (C-6), 154.3 (C=O), 148.3 (quart. CNosyl), 135.7 
(C-2), 134.3 (CHNosyl), 134.0 (quart. CNosyl), 132.2 (CHNosyl), 131.3 (CHNosyl), 124.7 (C-
1), 124.7 (CHNosyl), 123.4 (C-3), 120.3 (C-4), 114.1 (C-5), 104.2 (CH(OCH3)2), 81.1 
(C(CH3)3), 56.7 (6-OCH3), 55.3 (CH(OCH3)2), 50.4 (N-CH2-CH), 49.1 (2-CH2-N), 28.5 
(C(CH3)3). 
IR (film): ṽ (cm-1) = 3095, 2936, 2837, 1720, 1544, 1368, 1161, 1070, 779. 
MS (EI+): m/z (%) = 385 (20), 387 (26), 503 (93), 505 (100), 603 (65) [M]+•. 
HRMS (EI+): m/z calcd for C23H3079BrN3O4S 603.0886, found 603.0881. 
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7-Bromo-9-methoxy-4-[(2-nitrophenyl)sulfonyl]-2,3,4,5-tetrahydro-1H-1,4-
benzodiazepinea (25) 
 
 
MF: C16H16BrN3O5S       MW: 442.28 g/mol 
To a solution of 0.85 g (1.4 mmol) 24 in 3.4 mL CH2Cl2 under N2 atmosphere, 1.7 mL 
trifluoroacetic acid and 0.56 mL (3.5 mmol) triethylsilane were added in rapid 
succession. After 48 h 2 M NaOH was added and the mixture extracted three times 
with CH2Cl2. The combined organic layers were dried over MgSO4 and concentrated 
in vacuo. FCC with EtOAc and hexanes (1:1, Rf 0.4) gave 0.51 g (1.2 mmol, 86 %) of 
25 as a yellow solid. 
mp: 68 – 69 °C. 
1H NMR (500 MHz, CD2Cl2) δ = 7.89 (dd, J = 7.8, 1.5 Hz, 1H, Ar-HNosyl), 7.71 – 7.57 
(m, 3H, Ar-HNosyl), 6.97 (d, J = 2.1 Hz, 1H, 6-H), 6.88 (d, J = 2.1 Hz, 1H, 8-H), 4.70 (br 
s, NH), 4.39 (s, 2H, 5-H), 3.80 (s, 3H, OCH3), 3.64 – 3.59 (m, 2H, 3-H), 3.25 – 3.20 (m, 
2H, 2-H). 
13C NMR (126 MHz, CD2Cl2) δ = 150.2 (C-9), 148.4 (quart. CNosyl), 138.9 (C-9a), 134.0 
(CHNosyl), 133.3 (quart. CNosyl), 132.0 (CHNosyl), 130.9 (CHNosyl), 129.1 (C-5a), 124.7 (C-
6), 124.3 (CHNosyl), 113.5 (C-8), 111.7 (C-7), 56.5 (OCH3), 52.0 (C-5), 51.9 (C-3), 48.2 
(C-2). 
IR (KBr): ṽ (cm-1) = 3420, 3092, 2936, 1629, 1542, 1488, 1372, 1341, 1162, 1029. 
MS (EI+): m/z (%) = 169 (100), 181 (90), 441 (25) [M]+•. 
HRMS (EI+): m/z calcd for C16H1679BrN3O5S 440.9994, found 440.9998. 
Purity (HPLC): 90 % (210 nm; method 1b).  
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1-Cyclopropyl-1-[9-methoxy-7-(4-methyl-3-nitrophenyl)-2,3-dihydro-1,4-
benzoxazepin-4(5H)-yl]methanone (30) 
 
  
MF: C21H22N2O5        MW: 382.42 g/mol  
Standard protocol 2 with 0.80 g (2.5 mmol) 32 and 0.51 g (2.8 mmol) 4-methyl-3-
nitrophenylboronic acid. FCC with DCM with 1 % MeOH (Rf 0.3) gave 0.56 g (1.5 
mmol, 60 %) of 30 as a yellow solid.  
mp: 141 - 142 °C.  
1H NMR (110 °C, 400 MHz, C2D2Cl4): δ = 8.04 (d, J = 2.0 Hz, 1H, 2’’-H), 7.63 (dd, J = 
8.0, 2.0 Hz, 1H, 6’’-H), 7.35 (d, J = 8.0 Hz, 1H, 5’’-H), 7.06 – 7.00 (m, 2H, 6’-H, 8’-H), 
4.73 (s, 2H, 5’-H), 4.22 – 4.13 (m, 2H, 2’-H), 4.04 – 3.97 (m, 2H, 3’-H), 3.89 (s, 3H, 
OCH3), 2.58 (s, 3H, 4’’-CH3), 1.80 – 1.68 (m, 1H, CH-CH2), 0.95 – 0.87 (m, 2H, CH-
CH2), 0.78 – 0.68 (m, 2H, CH-CH2).  
13C NMR (110 °C, 101 MHz, C2D2Cl4): δ = 172.2 (C-1), 152.2 (C-9‘), 149.9 (C-3‘‘), 
149.1 (C-9a‘), 139.7 (C-1‘‘), 133.9 (C-7‘), 132.8 (C-5‘‘), 132.5 (C-5a‘), 131.6 (C-4‘‘), 
130.7 (C-6‘‘), 122.3 (C-2‘‘), 120.0 (C-6‘), 112.2 (C-8‘), 72.2 (C-2‘), 56.9 (OCH3), 49.7 
(C-5‘), 49.4 (C-3‘), 19.1 (4’’-CH3), 11.6 (CH-CH2), 7.0 (CH-CH2).  
IR (KBr): ṽ (cm-1) = 3439, 3057, 2987, 2926, 2875, 2345, 1634, 1620, 1589, 1528, 
1504, 1481, 1469, 1345, 1203, 1183, 1089, 826, 732. 
MS (ESI+): m/z (%) = 383 (100) [M + H]+, 405 (29), 765 (15), 787 (14). 
HRMS (ESI+): m/z calcd for [C21H23N2O5]+ 383.1607, found 383.1600. 
Purity (HPLC): 99 % (210 nm; method 2a). 
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1-[7-(3-Chloro-4-methoxyphenyl)-9-methoxy-2,3-dihydro-1,4-benzoxazepin-
4(5H)-yl]propane-1-thione (31) 
 
  
MF: C20H22ClNO3S        MW: 391.91 g/mol  
A solution of 0.052 g (0.13 mmol) 57 and 0.073 g (0.18 mmol) Lawesson’s reagent in 
1.0 mL anhydrous THF was stirred at rt for 72 h. To this solution was added 20 mL 
water and this mixture extracted with DCM (3 x 20 mL) three times. The combined 
organic layers were dried over MgSO4 and concentrated in vacuo. FCC with EtOAc 
and hexanes (3:1, Rf 0.7) gave 0.051 g (0.13 mmol, 96 %) of 31 as a white solid.  
mp: 82 – 83 °C.  
1H NMR (mixture of rotamers, 400 MHz, C2D2Cl4): δ = 7.58 (d, J = 2.3 Hz, 0.5H, 2’’-H), 
7.54 (d, J = 2.3 Hz, 0.5H, 2’’-H), 7.45 (dd, J = 8.6, 2.3 Hz, 0.5H, 6’’-H), 7.40 (dd, J = 
8.5, 2.3 Hz, 0.5H, 6’’-H), 7.25 (d, J = 2.1 Hz, 0.5H, 6’-H), 7.04 – 6.96 (m, 2H, 8’-H, 5’’-
H), 6.92 (d, J = 2.1 Hz, 0.5H, 6’-H), 5.29 (s, 1.0H, 5’-H), 4.86 (s, 1.0H, 5’-H), 4.76 – 
4.67 (m, 1.0H, 3’-H), 4.31 – 4.25 (m, 1.0H, 2’-H), 4.25 – 4.17 (m, 1.0H, 2’-H), 4.17 – 
4.09 (m, 1.0H, 3’-H), 3.93 (s, 3H, 4’’-OCH3), 3.90 (s, 3H, 9’-OCH3), 2.87 (q, J = 7.4 Hz, 
1.0H, 2-H), 2.77 (q, J = 7.4 Hz, 1.0H, 2-H), 1.32 (t, J = 7.4 Hz, 1.5H, 3-H), 1.25 (t, J = 
7.4 Hz, 1.5H, 3-H). 
13C NMR (mixture of rotamers, 101 MHz, C2D2Cl4): δ = 206.4 (C-1), 205.1 (C-1), 154.3 
(C-4‘‘), 154.2 (C-4‘‘), 151.9 (C-9‘), 151.3 (C-9‘), 147.24 (C-9a‘), 147.19 (C-9a‘), 135.4 
(C-7‘), 134.8 (C-7‘), 133.6 (C-1‘‘), 133.5 (C-1‘‘), 129.4 (C-5a‘), 129.0 (C-5a‘), 128.5 (C-
2‘‘), 126.2 (C-6‘‘), 122.5 (C-3‘‘), 122.4 (C-3‘‘), 121.6 (C-6‘), 119.2 (C-6‘), 112.3 (C-5‘‘), 
112.2 (C-5‘‘), 111.1 (C-8‘), 110.4 (C-8‘), 71.5 (C-2‘), 70.8 (C-2‘), 56.4 (C-3‘), 56.3 
(OCH3), 56.3 (OCH3), 56.2 (OCH3), 54.9 (C-5‘), 54.4 (C-3‘), 54.1 (C-5‘), 37.0 (C-2), 
35.9 (C-2), 13.9 (C-3), 13.5 (C-3).  
IR (Film): ṽ (cm-1) = 3384, 2965, 2935, 2839, 1587, 1485, 1441, 1343, 1290, 1256, 
1200, 1063, 1023, 967, 811, 752. 
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MS (EI+): m/z (%) = 131 (85), 169 (87), 181 (71), 219 (60), 281 (38), 331 (30), 391 (4) 
[M]+•. 
HRMS (EI+): m/z calcd for C20H2235ClNO3S 391.1009, found 391.0988. 
Purity (HPLC): 98 % (210 nm; method 1c). 
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1-(7-Bromo-9-methoxy-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl)-1-
(cyclopropyl)methanone (32) 
 
 
MF: C14H16BrNO3        MW: 326.19 g/mol  
Standard protocol 1 with 7.9 g (31 mmol) 9 and 3.6 mL (40 mmol) 
cyclopropanecarbonyl chloride. FCC with EtOAc and hexanes (1:2, Rf 0.1) gave 7.4 g 
(22 mmol, 71 %) of 32 as a white solid.  
mp: 85 - 86 °C.  
1H NMR (mixture of rotamers, 500 MHz, DMSO-d6): δ = 7.29 (d, J = 2.1 Hz, 0.6H, 6’-
H), 7.12 (d, J = 2.1 Hz, 0.6H, 8’-H), 7.08 (d, J = 2.1 Hz, 0.4H, 8’-H), 6.97 (d, J = 2.1 Hz, 
0.4H, 6’-H), 4.77 (s, 1.2H, 5’-H), 4.51 (s, 0.8H, 5’-H), 4.10 – 4.06 (m, 1.6H, 2’-H, 3’-H), 
3.99 – 3.94 (m, 1.2H, 2’-H), 3.87 – 3.81 (m, 1.2H, 3’-H), 3.76 (s, 3H, OCH3), 2.14 – 
2.08 (m, 0.6H, CH-CH2), 1.96 – 1.89 (m, 0.4H, CH-CH2), 0.71 – 0.63 (m, 4H, CH-CH2).  
13C NMR (mixture of rotamers, 126 MHz, DMSO-d6): δ = 173.1 (C-1), 172.6 (C-1), 
153.1 (C-9’), 152.9 (C-9’), 148.3 (C-9a’), 148.2 (C-9a’), 134.9 (C-5a’), 134.7 (C-5a’), 
124.9 (C-6’), 124.0 (C-6’), 116.1 (C-8’), 115.7 (C-8’), 115.5 (C-7’), 115.2 (C-7’), 73.2 
(C-2’), 72.5 (C-2’), 57.0 (OCH3), 51.3 (C-3’), 49.8 (C-5’), 49.0 (C-3’), 48.2 (C-5’), 11.6 
(CH-CH2), 8.4 (CH-CH2), 8.0 (CH-CH2).  
IR (KBr): ṽ (cm-1) = 3424, 3092, 3013, 3002, 2980, 2939, 2870, 1637, 1590, 1573, 
1482, 1412, 1291, 1208, 1082, 1048, 980, 840, 782, 657. 
MS (EI+): m/z (%) = 159 (16), 238 (37), 240 (40), 325 (100) [M]+•. 
HRMS (EI+): m/z calcd for C14H1679BrNO3 325.0314, found 325.0316. 
Purity (HPLC): > 99 % (210 nm; method 5a). 
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1-Cyclopropyl-1-[7-(2,3-dichloropyridin-4-yl)-9-methoxy-2,3-dihydro-1,4-
benzoxazepin-4(5H)-yl]methanone (33) 
 
  
MF: C19H18Cl2N2O3        MW: 393.26 g/mol 
Standard protocol 2 with 0.098 g (0.30 mmol) 32 and 0.069 g (0.36 mmol) 2,3-
dichloropyridine-4-boronic acid. FCC with EtOAc and hexanes (3:1, Rf 0.2) gave 0.091 
g (0.23 mmol, 77 %) of 33 as an orange solid.  
mp: 186 - 187 °C.  
1H NMR (mixture of rotamers, 400 MHz, CD2Cl2): δ = 8.34 – 8.23 (m, 1H, 6‘‘-H), 7.29 
– 7.20 (m, 1H, 5‘‘-H), 7.04 – 6.89 (m, 2H, 6‘-H, 8‘-H), 4.77 (s, 1.2H, 5‘-H), 4.67 (s, 0.8H, 
5‘-H), 4.28 – 4.21 (m, 0.8H, 2‘-H), 4.14 – 4.08 (m, 2H, 2‘-H, 3‘-H), 4.03 – 3.97 (m, 1.2H, 
3‘-H), 3.88 – 3.82 (m, 3H, OCH3), 1.91 – 1.81 (m, 0.6H, CH-CH2), 1.78 – 1.65 (m, 0.4H, 
CH-CH2), 0.89 – 0.82 (m, 2H, CH-CH2), 0.78 – 0.69 (m, 2H, CH-CH2).  
13C NMR (mixture of rotamers, 126 MHz, CD2Cl2): δ = 172.6 (C-1), 172.1 (C-1), 152.0 
(C-9‘), 151.2 (C-9‘), 150.4 (C-2‘‘), 150.4 (C-4‘‘), 149.2 (C-9a‘), 149.1 (C-9a‘), 146.8 (C-
6‘‘), 146.7 (C-6‘‘), 132.7 (C-5a‘), 132.4 (C-5a‘), 132.0 (C-3‘‘), 131.6 (C-3‘‘), 128.6 (C-
7‘), 128.5 (C-7‘), 124.9 (C-5‘‘), 124.7 (C-5‘‘), 122.6 (C-6‘), 121.1 (C-6‘), 113.0 (C-8‘), 
112.5 (C-8‘), 72.6 (C-2‘), 56.4 (OCH3), 51.1 (C-3‘), 50.9 (C-5‘), 48.8 (C-3‘), 48.2 (C-5‘), 
11.4 (CH-CH2), 11.3 (CH-CH2), 7.4 (CH-CH2), 7.2 (CH-CH2).  
IR (KBr): ṽ (cm-1) = 3441, 2993, 2941, 2866, 2841, 1633, 1574, 1490, 1463, 1441, 
1354, 1213, 1089, 1046. 
MS (EI+): m/z (%) = 293 (42), 295 (49), 305 (63), 307 (49), 323 (70), 392 (100) [M]+•, 
393 (36), 394 (67), 395 (16), 396 (12). 
HRMS (EI+): m/z calcd for C19H1835Cl2N2O3 392.0694, found 392.0699. 
Purity (HPLC): 96 % (210 nm; method 1a).        
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1-{5-[4-(Cyclopropanecarbonyl)-9-methoxy-2,3,4,5-tetrahydro-1,4-
benzoxazepin-7-yl]thiophen-2-yl}ethan-1-one (34) 
 
  
MF: C20H21NO4S        MW: 371.45 g/mol 
Standard protocol 2 with 0.098 g (0.30 mmol) 32 and 0.061 g (0.36 mmol) 5-acetyl-2-
thienylboronic acid. FCC with EtOAc and hexanes (2:1, Rf 0.2) gave 0.079 g (0.21 
mmol, 71 %) of 34 as an orange solid.  
mp: 85 - 87 °C.  
1H NMR (110 °C, 400 MHz, C2D2Cl4): δ = 7.58 (d, J = 3.9 Hz, 1H, 3‘-H), 7.20 (d, J = 
3.9 Hz, 1H, 4‘-H), 7.15 – 7.03 (m, 2H, 6‘‘-H, 8‘‘-H), 4.70 (s, 2H, 5‘‘-H), 4.21 – 4.09 (m, 
2H, 2‘‘-H), 4.04 – 3.92 (m, 2H, 3‘‘-H), 3.88 (s, 3H, OCH3), 2.49 (s, 3H, 2-H), 1.81 – 1.64 
(m, 1H, CH-CH2), 0.98 – 0.84 (m, 2H, CH-CH2), 0.79 – 0.64 (m, 2H, CH-CH2).  
13C NMR (110 °C, 101 MHz, C2D2Cl4): δ = 189.7 (C-1), 172.4 (C-1‘‘‘), 152.4 (C-9‘‘), 
151.9 (C-5a), 149.8 (C-9a‘‘), 143.3 (C-2‘), 133.0 (C-3‘), 132.7 (C-7‘‘), 129.1 (C-5a‘‘), 
123.9 (4‘-H), 119.8 (C-6‘‘), 111.8 (C-8‘‘), 72.5 (C-2‘‘), 57.1 (OCH3), 49.8 (C-5‘‘), 49.6 
(C-3‘‘), 26.4 (C-2), 11.8 (CH-CH2), 7.3 (CH-CH2).  
IR (KBr): ṽ (cm-1) = 3427, 2985, 2960, 2938, 1652, 1632, 1441, 1421, 1277, 1209, 
1085, 1051, 991. 
MS (EI+): m/z (%) = 260 (54), 274 (35), 284 (63), 302 (43), 371 (100) [M]+•, 372 (24). 
HRMS (EI+): m/z calcd for C20H21NO4S 371.1191, found 371.1192. 
Purity (HPLC): 95 % (210 nm; method 1c).  
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1-Cyclopropyl-1-[7-(3,5-dimethylisoxazol-4-yl)-9-methoxy-2,3-dihydro-1,4-
benzoxazepin-4(5H)-yl]methanone (35) 
 
  
MF: C19H22N2O4        MW: 342.40 g/mol 
Standard protocol 2 with 0.098 g (0.30 mmol) 32 and 0.080 g (0.36 mmol) 3,5-
dimethylisoxazole-4-boronic acid pinacol ester. FCC with EtOAc and hexanes (3:1, 
Rf 0.2) gave 0.089 g (0.26 mmol, 87 %) of 35 as a white solid.  
mp: 175 - 176 °C.  
1H NMR (110 °C, 400 MHz, C2D2Cl4): δ = 6.74 – 6.66 (m, 2H, 6‘-H, 8‘-H), 4.69 (s, 2H, 
5‘-H), 4.20 – 4.10 (m, 2H, 2‘-H), 4.05 – 3.95 (m, 2H, 3‘-H), 3.84 (s, 3H, OCH3), 2.35 (s, 
3H, (isoxazole-CH3)), 2.21 (s, 3H, (isoxazole-CH3)), 1.80 – 1.64 (m, 1H, CH-CH2), 0.96 
– 0.87 (m, 2H, CH-CH2), 0.76 – 0.66 (m, 2H, CH-CH2).  
13C NMR (110 °C, 101 MHz, C2D2Cl4): δ = 172.4 (C-1), 165.0 (C-3’’/C-5’’), 158.4 (C-
3’’/C-5’’), 152.2 (C-9’), 148.4 (C-9a’), 132.7 (C-5a’), 126.0 (C-7’), 122.4 (C-6’), 116.3 
(C-4’’), 114.7 (C-8’), 72.4 (C-2’), 57.1 (OCH3), 50.1 (C-5’), 49.6 (C-3’), 11.7 (CH-CH2), 
11.4 (isoxazole-CH3), 10.6 (isoxazole -CH3), 7.3 (CH-CH2).  
IR (KBr): ṽ (cm-1) = 3427, 2991, 2969, 2935, 1646, 1585, 1467, 1452, 1415, 1324, 
1257, 1201, 1178, 1104, 990. 
MS (EI+): m/z (%) = 119 (54), 169 (41), 255 (37), 273 (45), 342 (86) [M]+•, 343 (25), 
344 (48). 
HRMS (EI+): m/z calcd for C19H22N2O4 342.1580, found 342.1572. 
Purity (HPLC): > 99 % (210 nm; method 1c).  
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1-[7-(Benzo[b]thiophen-2-yl)-9-methoxy-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-
1-(cyclopropyl)methanone (36) 
 
 
MF: C22H21NO3S        MW: 379.47 g/mol  
Standard protocol 2 with 0.12 g (0.36 mmol) 32 and 0.080 g (0.43 mmol) benzo[b]thien-
2-ylboronic acid. FCC with EtOAc and hexanes (2:1, Rf 0.2) gave 0.13 g (0.34 mmol, 
94 %) of 36 as a white solid.  
mp: 83 - 84 °C.  
1H NMR (100 °C, 400 MHz, DMSO-d6): δ = 7.95 – 7.87 (m, 1H, Ar-H), 7.87 – 7.79 (m, 
1H, 4‘‘-H), 7.79 – 7.70 (m, 1H, 3‘‘-H), 7.43 – 7.25 (m, 4H, 6‘-H, 8‘-H, Ar-H), 4.79 (s, 2H, 
5‘-H), 4.20 – 4.08 (m, 2H, 2‘-H), 4.06 – 3.92 (m, 2H, 3‘-H), 3.89 (s, 3H, OCH3), 2.12 – 
1.95 (m, 1H, CH-CH2), 0.78 – 0.66 (m, 4H, CH-CH2).  
13C NMR (100 °C, 101 MHz, DMSO-d6): δ = 171.4 (C-1), 151.2 (C-9‘), 148.3 (C-9a‘), 
142.5 (C-2‘‘/C-3a‘‘), 140.0 (C-2‘‘/C-3a‘‘), 138.2 (C-7a‘‘), 131.9 (C-5a‘), 128.2 (C-7‘), 
124.1 (aromat. CH), 123.8 (aromat. CH), 122.9 (C-4‘‘), 121.6 (aromat. CH), 119.2 
(C-3‘‘), 119.1 (C-6‘), 110.6 (aromat. CH), 71.2 (C-2‘), 56.1 (OCH3), 48.4 (C-3‘, C-5’), 
10.5 (CH-CH2), 6.3 (CH-CH2).  
IR (KBr): ṽ (cm-1) = 3441, 3004, 2931, 1640, 1583, 1487, 1460, 1434, 1296, 1226, 
1166, 1102, 1048. 
MS (EI+): m/z (%) = 268 (63), 281 (35), 291 (53), 308 (32), 379 (100) [M]+•, 380 (24). 
HRMS (EI+): m/z calcd for C22H21NO3S 379.1242, found 379.1240. 
Purity (HPLC): 97 % (210 nm; method 1a). 
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5-[4-(Cyclopropanecarbonyl)-9-methoxy-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-
yl]-2-methoxybenzaldehyde (37) 
 
  
MF: C22H23NO5        MW: 381.43 g/mol  
Standard protocol 2 with 1.5 g (4.6 mmol) 32 and with 0.96 g (5.4 mmol) 3-formyl-4-
methoxyphenylboronic acid. FCC with EtOAc and hexanes (3:1, Rf 0.2) gave 1.4 g of 
37 as ayellow solid (3.7 mmol, 80 %).  
mp: 152 – 153 °C.  
1H NMR (100 °C, 400 MHz, DMSO-d6): δ = 10.42 (s, 1H, HC=O), 7.97 – 7.88 (m, 2H, 
6-H, 4-H), 7.32 – 7.26 (m, 1H, 3-H), 7.20 (br s, 1H, 6’-H), 7.16 (d, J = 2.2 Hz, 1H, 8’-
H), 4.78 (s, 2H, 5’-H), 4.14 – 4.06 (m, 2H, 2’-H), 4.01 – 3.94 (m, 5H, H’-3, 2-OCH3), 
3.87 (s, 3H, 9’-OCH3), 2.11 – 1.95 (m, 1H, CH-CH2), 0.75 – 0.66 (m, 4H, CH-CH2).  
13C NMR (100 °C, 101 MHz, DMSO-d6): δ = 188.5 (HC=O), 171.4 (C-1’’), 160.4 (C-2), 
151.2 (C-9’), 147.4 (C-9a’), 133.6 (C-4), 133.5 (C-7’), 132.1 (C-5), 131.9 (C-5a’), 125.2 
(C-6), 124.4 (C-1), 119.0 (C-6’), 113.1 (C-3), 111.0 (C-8’), 71.2 (C-2’), 56.1 (9’-OCH3), 
55.9 (2-OCH3), 48.5 (C-5’), 48.4 (C-3’), 10.4 (CH-CH2), 6.3 (CH-CH2).  
IR (KBr): ṽ (cm-1) = 3448, 3080, 3005, 2938, 2864, 1734, 1682, 1638, 1608, 1485, 
1464, 1431, 1390, 1293, 1249, 1206, 1074, 821. 
MS (ESI+): m/z (%) = 382 (100) [M + H]+, 404 (35), 763 (11). 
HRMS (ESI+): m/z calcd for [C22H24NO5]+ 382.1654, found 382.1647. 
Purity (HPLC): 99 % (210 nm; method 1c). 
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4-[4-(Cyclopropanecarbonyl)-9-methoxy-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-
yl]benzonitrile (38) 
 
  
MF: C21H20N2O3        MW: 348.40 g/mol  
Standard protocol 2 with 0.098 g (0.30 mmol) 32 and 0.053 g (0.36 mmol) 4-
cyanophenylboronic acid. FCC with EtOAc and hexanes (2:1, Rf 0.2) gave 0.091 g 
(0.26 mmol, 87 %) of 38 as an orange solid.  
mp: 157 - 158 °C.  
1H NMR (mixture of rotamers, 400 MHz, CD2Cl2): δ = 7.80 – 7.62 (m, 4H, 2-H, 3-H, 5-
H, 6-H), 7.20 – 7.02 (m, 2H, 6‘-H, 8‘-H), 4.78 (s, 1.1H, 5‘-H), 4.68 (s, 0.9H, 5‘-H), 4.26 
– 4.17 (m, 0.9H, 2‘-H), 4.17 – 4.04 (m, 2H, 2‘-H, 3‘-H), 4.04 – 3.96 (m, 1.1H, 3‘-H), 3.92 
– 3.86 (m, 3H, OCH3), 1.95 – 1.83 (m, 0.6H, CH-CH2), 1.75 – 1.65 (m, 0.4H, CH-CH2), 
0.89 – 0.80 (m, 2H, CH-CH2), 0.80 – 0.67 (m, 2H, CH-CH2).  
13C NMR (mixture of rotamers, 126 MHz, CD2Cl2): δ = 172.9 (C-1‘‘), 172.4 (C-1‘‘), 152.8 
(C-9‘), 152.3 (C-9‘), 149.5 (C-9a‘), 149.3 (C-9a‘), 145.4 (C-4), 145.3 (C-4), 135.2 (C-
7‘), 134.8 (C-7‘), 133.4 (C-5a‘), 133.3 (C-5a‘), 133.0 (C-2, C-6), 132.9 (C-2, C-6), 128.0 
(C-3, C-5), 127.9 (C-3, C-5), 121.3 (C-6‘), 119.8 (C-6‘), 119.3 (C-1/CN), 119.2 (C-
1/CN), 111.6 (C-8‘), 111.3 (C-1/CN), 111.1 (C-1/CN), 110.9 (C-8‘), 73.2 (C-2‘), 73.0 
(C-2‘), 56.7 (OCH3), 51.5 (C-3‘), 51.3 (C-5‘), 49.1 (C-3‘), 48.8 (C-5‘), 11.8 (CH-CH2), 
11.6 (CH-CH2), 7.7 (CH-CH2), 7.5 (CH-CH2).  
IR (KBr): ṽ (cm-1) = 3427, 3003, 2986, 2927, 2222, 1644, 1604, 1587, 1486, 1463, 
1330, 1294, 1206, 1177, 1089. 
MS (EI+): m/z (%) = 41 (100), 140 (28), 249 (22), 261 (36), 279 (37), 348 (27) [M]+•.  
HRMS (EI+): m/z calcd for C21H20N2O3 348.1474, found 348.1473. 
Purity (HPLC): > 99 % (210 nm; method 1c). 
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1-Cyclopropyl-1-{7-[4-(dimethylamino)phenyl]-9-methoxy-2,3-dihydro-1,4-
benzoxazepin-4(5H)-yl}methanone (39) 
 
  
MF: C22H26N2O3        MW: 366.46 g/mol  
Standard protocol 2 with 0.30 g (0.92 mmol) 32 and 0.23 g (1.4 mmol) 4-
(dimethylamino)phenylboronic acid. FCC with EtOAc and hexanes (1:2, Rf 0.1) gave 
0.17 g (0.46 mmol, 50 %) of 39 as a white solid.  
mp: 79 - 80 °C.  
1H NMR (mixture of rotamers, 400 MHz, C2D2Cl4): δ = 7.52 – 7.39 (m, 2H, 2’’-H, 6’’-H), 
7.09 – 6.93 (m, 2H, 6’-H, 8’-H), 6.78 (d, J = 8.2 Hz, 2H, 3’’-H, 5’’-H), 4.73 (s, 1.4H, 5’-
H), 4.67 (s, 0.6H, 5’-H), 4.28 – 3.93 (m, 4H), 3.88 (s, 3H, OCH3), 3.03 – 2.93 (m, 6H, 
N(CH3)2), 1.91 – 1.80 (m, 0.7H, CH-CH2), 1.69 – 1.62 (m, 0.3H, CH-CH2), 0.96 – 0.87 
(m, 2H, CH-CH2), 0.81 – 0.69 (m, 2H, CH-CH2).  
13C NMR (mixture of rotamers, 101 MHz, C2D2Cl4): δ = 172.6 (C-1), 172.0 (C-1), 151.6 
(C-9‘), 151.1 (C-9‘), 149.6 (C-4‘‘), 146.6 (C-9a‘), 146.5 (C-9a‘), 136.8 (C-7‘), 136.4 (C-
7‘) , 131.9 (C-5a‘), 131.7 (C-5a‘), 128.1 (C-1‘‘), 127.5 (C-2‘‘, C-6‘‘), 127.4 (C-2‘‘, C-6‘‘), 
119.4 (C-6‘), 118.1 (C-6‘), 112.5 (C-3‘‘, C-5‘‘), 110.2 (C-8‘), 109.5 (C-8‘), 72.4 (C-2‘), 
56.1 (OCH3), 51.0 (C-5‘), 50.9 (C-3‘), 48.6 (C-5‘), 48.4 (C-3‘), 40.4 (N(CH3)2), 11.6 (CH-
CH2), 11.4 (CH-CH2), 7.6 (CH-CH2), 7.4 (CH-CH2).  
IR (KBr): ṽ (cm-1) = 3432, 2923, 2363, 2344, 1638, 1611, 1586, 1527, 1490, 1459, 
1444, 1344, 1207, 1180, 1102, 1045, 816. 
MS (ESI+): m/z (%) = 367 (100) [M + H]+, 389 (37). 
HRMS (ESI+): m/z calcd for [C22H27N2O3]+ 367.2021, found 367.2017. 
Purity (HPLC): 95 % (210 nm; method 2a). 
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1-Cyclopropyl-1-[7-(3,5-dimethoxyphenyl)-9-methoxy-2,3-dihydro-1,4-
benzoxazepin-4(5H)-yl]methanone (40) 
 
  
MF: C22H25NO5        MW: 383.44 g/mol  
Standard protocol 2 with 0.12 g (0.37 mmol) 32 and 0.078 g (0.43 mmol) 3,5-
dimethoxyphenylboronic acid. FCC with EtOAc and hexanes (2:1, Rf 0.4) gave 0.090 
g (0.23 mmol, 62 %) of 40 as a white solid.  
mp: 50 - 51 °C.  
1H NMR (110 °C, 400 MHz, C2D2Cl4) δ = 7.10 – 6.96 (m, 2H, 6‘-H, 8‘-H), 6.66 (d, J = 
2.2 Hz, 2H, 3‘‘-H, 5‘‘-H), 6.44 (t, J = 2.2 Hz, 1H, 4’’-H), 4.72 (s, 2H, 5‘-H), 4.20 – 4.09 
(m, 2H, 2‘-H), 4.04 – 3.95 (m, 2H, 3‘-H), 3.87 (s, 3H, 9‘-OCH3), 3.81 (s, 6H, 3’’-OCH3 
and 5‘‘-OCH3), 1.85 – 1.70 (m, 1H, CH-CH2), 0.99 – 0.85 (m, 2H, CH-CH2), 0.79 – 0.66 
(m, 2H, CH-CH2).  
13C NMR (ambient temperature, mixture of rotamers, 101 MHz, C2D2Cl4) δ = 172.6 (C-
1), 172.1 (C-1), 160.8 (C-3‘‘, C-5‘‘), 151.6 (C-9‘), 151.1 (C-9‘), 147.8 (C-9a‘), 147.7 (C-
9a‘), 142.6 (C-1‘‘), 142.3 (C-1‘‘), 136.5 (C-7‘), 136.0 (C-7‘), 131.9 (C-5a‘), 131.5 (C-
5a‘), 120.4 (C-6‘), 119.1 (C-6‘), 111.0 (C-8‘), 110.4 (C-8‘), 105.5 (C-2‘‘, C-6‘‘), 105.1 
(C-2‘‘, C-6‘‘), 99.1 (C-4‘‘), 98.6 (C-4‘‘), 72.3 (C-2‘), 72.2 (C-2‘), 56.2 (9‘-OCH3), 55.4 
(3‘‘-OCH3, 5‘‘-OCH3), 50.9 (C-3‘, C-5‘), 48.5 (C-3‘), 48.2 (C-5‘), 11.6 (CH-CH2), 11.4 
(CH-CH2), 7.6 (CH-CH2), 7.5 (CH-CH2).  
IR (Film): ṽ (cm-1) = 3475, 3002, 2957, 2934, 2843, 1638, 1581, 1460, 1402, 1275, 
1204, 1154, 1089, 1044, 856, 834, 693. 
MS (EI+): m/z (%) = 159 (42), 296 (53), 383 (100) [M]+•. 
HRMS (EI+): m/z calcd for C22H25NO5 383.1733, found 383.1724. 
Purity (HPLC): 98 % (210 nm; method 3a). 
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1-Cyclopropyl-1-[9-methoxy-7-(4-methoxy-3-methylphenyl)-2,3-dihydro-1,4-
benzoxazepin-4(5H)-yl]methanone (41) 
 
  
MF: C22H25NO4        MW: 367.45 g/mol  
Standard protocol 2 with 0.50 g (1.5 mmol) 32 and 0.28 g (1.7 mmol) 4-methoxy-3-
methylphenylboronic acid. FCC with EtOAc and hexanes (3:2, Rf 0.3) gave 0.38 g (1.0 
mmol, 68 %) of 41 as a pale brown solid.  
mp: 109 - 110 °C.  
1H NMR (110 °C, 400 MHz, C2D2Cl4): δ = 7.32 – 7.27 (m, 2H, 2’’-H, 6’’-H), 7.02 – 6.96 
(m, 2H, 6’-H, 8’-H), 6.87 – 6.82 (m, 1H, 5’’-H), 4.71 (s, 2H, 5’-H), 4.15 – 4.10 (m, 2H, 
2’-H), 4.00 – 3.95 (m, 2H, 3’-H), 3.87 (s, 3H, 9’-OCH3), 3.83 (s, 3H, 4’’-OCH3), 2.26 (s, 
3H, 3‘‘-CH3), 1.81 – 1.69 (m, 1H, CH-CH2), 0.94 – 0.87 (m, 2H, CH-CH2), 0.75 – 0.68 
(m, 2H, CH-CH2).  
13C NMR (ambient temperature, mixture of rotamers, 101 MHz, C2D2Cl4): δ = 172.6 
(C-1), 172.0 (C-1), 157.22 (C-4‘‘), 157.17 (C-4‘‘), 151.6 (C-9‘), 151.1 (C-9‘), 147.0 (C-
9a‘), 146.9 (C-9a‘), 136.6 (C-7‘), 136.2 (C-7‘), 132.4 (C-1‘‘), 132.1 (C-1‘‘), 131.9 (5a‘), 
131.7 (5a‘), 129.2, 129.1, 126.9 (C-3‘‘), 126.8 (C-3‘‘), 125.2 (C-2‘‘/C-6‘‘), 125.1 (C-2‘‘/C-
6‘‘), 120.0 (C-6‘), 118.6 (C-6‘), 110.7 (C-8‘), 110.1 (C-5‘‘), 110.0 (C-8‘), 72.4 (C-2‘), 72.3 
(C-2‘), 56.2 (9’-OCH3), 55.4 (4’’-OCH3), 50.9 (C-3‘, C-5‘), 48.6 (C-3‘), 48.4 (C-5‘), 16.4 
(3‘‘-CH3), 16.3 (3‘‘-CH3), 11.6 (CH-CH2), 11.4 (CH-CH2), 7.6 (CH-CH2), 7.4 (CH-CH2).  
IR (KBr): ṽ (cm-1) = 3448, 3002, 2922, 2836, 1639, 1487, 1464, 1293, 1249, 1207, 
1079, 812, 612. 
MS (EI+): m/z (%) = 256 (76), 270 (46), 280 (64), 298 (50), 367 (100) [M]+•. 
HRMS (EI+): m/z calcd for C22H25NO4 367.1784, found 367.1784. 
Purity (HPLC): 95 % (210 nm; method 2a). 
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1-[7-(Benzo[d][1,3]dioxol-5-yl)-9-methoxy-2,3-dihydro-1,4-benzoxazepin-4(5H)-
yl]-1-(cyclopropyl)methanone (42) 
 
  
MF: C21H21NO5        MW: 367.40 g/mol  
Standard protocol 2 with 0.20 g (0.61 mmol) 32 and 0.11 g (0.67 mmol) 3,4-
(methylenedioxy)phenylboronic acid. FCC with EtOAc and hexanes (3:2, Rf 0.4) gave 
0.21 g (0.58 mmol, 94 %) of 42 as a pale brown solid.  
mp: 127 - 128 °C.  
1H NMR (110 °C, 400 MHz, C2D2Cl4): δ = 7.01 – 6.94 (m, 4H, 6‘-H, 8‘-H, 4‘‘-H, 7‘‘-H), 
6.82 (dd, J = 7.7, 0.8 Hz, 1H, 6‘‘-H), 5.94 (s, 2H, 2‘‘-H), 4.71 (s, 2H, 5‘-H), 4.15 – 4.10 
(m, 2H, 2‘-H), 4.01 – 3.96 (m, 2H, 3‘-H), 3.86 (s, 3H, OCH3), 1.81 – 1.70 (m, 1H, CH-
CH2), 0.95 – 0.87 (m, 2H, CH-CH2), 0.76 – 0.69 (m, 2H, CH-CH2).  
13C NMR (110 °C, 101 MHz, C2D2Cl4): δ = 172.6 (C-1), 152.1 (C-9’), 148.3 (C-1’’), 
148.2 (C-9a’), 147.2 (C-3’’), 136.7 (C-5’’), 135.1 (C-7’), 132.3 (C-5a’), 120.5 (C-4’’/C-
7’’), 120.0 (C-6’), 112.5 (C-4’’/C-7’’), 108.6 (C-6’’), 107.6 (C-8’), 101.2 (C-2’’), 72.5 (C-
2’), 57.0 (OCH3), 50.2 (C-5’), 49.6 (C-3’), 11.9 (CH-CH2), 7.2 (CH-CH2). 
IR (KBr): ṽ (cm-1) = 3447, 3072, 2991, 2929, 2898, 2838, 1628, 1584, 1482, 1419, 
1295, 1243, 1197, 1041, 806, 733. 
MS (EI+): m/z (%) = 112 (11), 178 (23), 247 (40), 256 (40), 280 (33), 367 (100) [M]+•. 
HRMS (EI+): m/z calcd for C21H21NO5 367.1420, found 367.1433. 
Purity (HPLC): 97 % (210 nm; method 2a). 
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1-Cyclopropyl-1-[9-methoxy-7-(4-methoxy-3,5-dimethylphenyl)-2,3-dihydro-1,4-
benzoxazepin-4(5H)-yl]methanone (43) 
 
  
MF: C23H27NO4        MW: 381.47 g/mol  
Standard protocol 2 with 0.20 g (0.61 mmol) 32 and 0.12 g (0.68 mmol) 3,5-dimethyl-
4-methoxyphenylboronic acid. FCC with EtOAc and hexanes (3:2, Rf 0.4) gave 0.071 
g (0.19 mmol, 31 %) of 43 as a pale brown solid.  
mp: 146 – 147 °C.  
1H NMR (110 °C, 400 MHz, C2D2Cl4): δ = 7.16 – 7.12 (m, 2H, 2‘‘-H, 6‘‘-H), 7.02 – 6.97 
(m, 2H, 6‘-H, 8‘-H), 4.71 (s, 2H, 5‘-H), 4.16 – 4.10 (m, 2H, 2‘-H), 4.01 – 3.96 (m, 2H, 
3‘-H), 3.87 (s, 3H, 9‘-OCH3), 3.73 (s, 3H, 4‘‘-OCH3), 2.31 (s, 6H, 3‘‘-CH3, 5‘‘-CH3), 1.81 
– 1.70 (m, 1H, CH-CH2), 0.94 – 0.88 (m, 2H, CH-CH2), 0.75 – 0.68 (m, 2H, CH-CH2).  
13C NMR (110 °C, 101 MHz, C2D2Cl4): δ = 172.6 (C-1), 156.9 (C-4‘‘), 152.0 (C-9‘), 
148.1 (C-9a‘), 136.8 (C-7‘), 135.9 (C-3’‘, C-5’’), 132.2 (C-5a‘), 131.0 (C-1‘‘), 127.4 
(C-2‘‘, C-6‘‘), 120.2 (C-6‘), 112.6 (C-8‘), 72.5 (C-2‘), 59.7 (4‘‘-OCH3), 57.1 (9‘-OCH3), 
50.2 (C-5‘), 49.6 (C-3‘), 16.2 (3‘‘-CH3, 5‘‘-CH3), 11.9 (CH-CH2), 7.2 (CH-CH2).  
IR (KBr): ṽ (cm-1) = 3432, 2997, 2973, 2926, 2875, 1642, 1580, 1479, 1467, 1416, 
1271, 1210, 1091, 1046, 851, 741. 
MS (EI+): m/z (%) = 119 (22), 169 (29), 270 (98), 284 (55), 294 (78), 312 (64), 381 
(100) [M]+•. 
HRMS (EI+): m/z calcd for C23H27NO4 381.1940, found 381.1940.  
Purity (HPLC): 95 % (210 nm; method 2a). 
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1-[7-(3-Chloro-4-methoxyphenyl)-9-methoxy-2,3-dihydro-1,4-benzoxazepin-
4(5H)-yl]-1-(cyclopropyl)methanone (44) 
 
 
MF: C21H22ClNO4        MW: 387.86 g/mol  
Standard protocol 2 with 0.20 g (0.61 mmol) 32 and 0.13 g (0.67 mmol) 3-chloro-4-
methoxyphenylboronic acid. FCC with EtOAc and hexanes (3:2, Rf 0.3) gave 0.16 g 
(0.42 mmol, 69 %) of 44 as a pale brown solid.  
mp: 130 – 131 °C.  
1H NMR (110 °C, 400 MHz, C2D2Cl4): δ = 7.52 (d, J = 2.3 Hz, 1H, 2‘‘-H), 7.36 (dd, J = 
8.5, 2.3 Hz, 1H, 6‘‘-H), 7.00 – 6.93 (m, 3H, 6‘-H, 8‘-H, 5‘‘-H), 4.71 (s, 2H, 5‘-H), 4.16 – 
4.11 (m, 2H, 2‘-H), 4.01 – 3.96 (m, 2H, 3‘-H), 3.89 (s, 3H, 4‘‘-OCH3), 3.87 (s, 3H, 9‘-
OCH3), 1.79 – 1.69 (m, 1H, CH-CH2), 0.94 – 0.88 (m, 2H, CH-CH2), 0.76 – 0.68 (m, 
2H, CH-CH2).  
13C NMR (110 °C, 101 MHz, C2D2Cl4): δ = 172.3 (C-1), 154.9 (C-4‘‘), 152.2 (C-9‘), 
148.5 (C-9a‘), 135.3 (C-7‘), 134.5 (C-1‘‘), 132.5 (C-5a‘), 128.8 (C-2‘‘), 126.2 (C-6‘‘), 
123.6 (C-3‘‘), 120.0 (C-6‘), 113.4 (C-5‘‘), 112.4 (C-8‘), 72.5 (C-2‘), 57.1 (9‘-OCH3), 56.7 
(4‘‘-OCH3), 50.1 (C-5‘), 49.6 (C-3‘), 11.8 (CH-CH2), 7.3 (CH-CH2).  
IR (KBr): ṽ (cm-1) = 3621, 3439, 3087, 3003, 2972, 2929, 2840, 1634, 1587, 1486, 
1463, 1345, 1259, 1183, 1061, 1042, 807, 700. 
MS (ESI+): m/z (%) = 388 (100) [M + H]+, 390 (37). 
HRMS (ESI+): m/z calcd for [C21H2335ClNO4]+ 388.1316, found 388.1317. 
Purity (HPLC): 99 % (210 nm; method 2a). 
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1-Cyclopropyl-1-[7-(3,4-difluorophenyl)-9-methoxy-2,3-dihydro-1,4-
benzoxazepin-4(5H)-yl]methanone (45) 
 
 
MF: C20H19F2NO3        MW: 359.37 g/mol  
Standard protocol 2 with 0.12 g (0.37 mmol) 32 and 0.068 g (0.43 mmol) 3,4-
difluorophenylboronic acid. FCC with EtOAc and hexanes (2:1, Rf 0.4) gave 0.090 g 
(0.25 mmol, 68 %) of 45 as a white solid.  
mp: 136 - 137 °C.  
1H NMR (110 °C, 400 MHz, C2D2Cl4): δ = 7.34 – 7.26 (m, 1H, 2‘‘-H), 7.26 – 7.09 (m, 
2H, 5‘‘-H, 6‘‘-H), 7.04 – 6.91 (m, 2H, 6‘-H, 8‘-H), 4.72 (s, 2H, 5‘-H), 4.22 – 4.10 (m, 2H, 
2‘-H), 4.04 – 3.94 (m, 2H, 3‘-H), 3.88 (s, 3H, OCH3), 1.83 – 1.66 (m, 1H, CH-CH2), 0.95 
– 0.86 (m, 2H, CH-CH2), 0.79 – 0.66 (m, 2H, CH-CH2).  
13C NMR (110 °C, 101 MHz, C2D2Cl4): δ = 172.4 (C-1), 152.3 (C-9‘), 150.6 (dd, 1JCF = 
248.6 Hz, 2JCF =12.8 Hz, C-4’’), 150.0 (dd, 1JCF = 248.9 Hz, 2JCF = 12.6 Hz, C-3’’), 149.0 
(C-9a‘), 137.9 (C-1‘‘), 134.8 (C-7‘), 132.6 (C-5a‘), 122.9 (dd, 3JCF = 5.5, 4JCF = 3.4 Hz, 
C-6’’), 120.2 (C-6‘), 117.5 (d, 2JCF = 17.4 Hz, C-5’’), 115.9 (d, 2JCF = 17.8 Hz, C-2’’), 
112.5 (C-8‘), 72.5 (C-2‘), 57.1 (OCH3), 50.0 (C-5‘), 49.6 (C-3‘), 11.8 (CH-CH2), 7.3 (CH-
CH2).  
IR (Film): ṽ (cm-1) = 3442, 3006, 2956, 2924, 1639, 1584, 1489, 1463, 1272, 1206, 
1161, 1103, 992, 854, 770. 
MS (EI+): m/z (%) = 131 (100), 169 (83), 181 (62), 219 (51), 251 (53), 280 (34), 359 
(6) [M]+•. 
HRMS (EI+): m/z calcd for C20H19F2NO3 359.1333, found 359.1335.  
Purity (HPLC): 99 % (210 nm; method 1c). 
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1-Cyclopropyl-1-[7-(3,4-dichlorophenyl)-9-methoxy-2,3-dihydro-1,4-
benzoxazepin-4(5H)-yl]methanone (46) 
 
  
MF: C20H19F2NO3        MW: 392.28 g/mol  
Standard protocol 2 with 0.098 g (0.30 mmol) 32 and 0.068 g (0.36 mmol) 3,4-
dichlorophenylboronic acid. FCC with EtOAc and hexanes (2:1, Rf 0.4) gave 0.095 g 
(0.24 mmol, 81 %) of 46 as a pale brown solid.  
mp: 115 - 116 °C.  
1H NMR (mixture of rotamers, 500 MHz, CD2Cl2): δ = 7.75 – 7.60 (m, 1H, 2’’-H), 7.59 
– 7.46 (m, 1H, 5’’-H), 7.46 – 7.36 (m, 1H, 6’’-H), 7.17 – 6.96 (m, 2H, 6’-H, 8’-H), 4.77 
(s, 1.2H, 5’-H), 4.66 (s, 0.8H, 5’-H), 4.23 – 4.16 (m, 0.8H, 2‘-H), 4.12 – 4.05 (m, 2H, 2’-
H, 3’-H), 4.01 – 3.95 (m, 1.2H, 3’-H), 3.93 – 3.84 (m, 3H, OCH3), 1.94 – 1.82 (m, 0.6H, 
CH-CH2), 1.74 – 1.68 (m, 0.4H, CH-CH2), 0.89 – 0.82 (m, 2H, CH-CH2), 0.79 – 0.67 
(m, 2H, CH-CH2).  
13C NMR (mixture of rotamers, 101 MHz, CD2Cl2): δ = 172.9 (C-1), 172.4 (C-1), 152.7 
(C-9‘), 152.2 (C-9‘), 149.1 (C-9a‘), 149.0 (C-9a‘), 141.2 (C-1‘‘), 141.1 (C-1‘‘), 134.6 (C-
7‘), 134.3 (C-7‘), 133.4 (C-5a‘), 133.3 (C-5a‘), 133.0 (C-3‘‘), 131.6 (C-4‘‘), 131.4 (C-4‘‘), 
131.1 (C-5‘‘), 131.0 (C-5‘‘), 129.1 (C-2‘‘), 129.0 (C-2‘‘), 126.8 (C-6‘‘), 120.9 (C-6‘), 119.5 
(C-6‘), 111.3 (C-8‘), 110.7 (C-8‘), 73.2 (C-2‘), 72.9 (C-2‘), 56.7 (OCH3), 51.6 (C-3‘), 51.3 
(C-5‘), 49.1 (C-3‘), 48.8 (C-5‘), 11.8 (CH-CH2), 11.6 (CH-CH2), 7.7 (CH-CH2), 7.5 (CH-
CH2).  
IR (KBr): ṽ (cm-1) = 3433, 3061, 3004, 2930, 1638, 1586, 1469, 1421, 1369, 1203, 
1134, 1078, 1044, 852, 819, 737, 679, 530. 
MS (EI+): m/z (%) = 169 (52), 181 (43), 219 (27), 294 (46), 304 (64), 306 (44), 322 
(56), 324 (25), 325 (11), 391 (2) [M]+•. 
HRMS (EI+): m/z calcd for C20H19NO335Cl2 391.0742, found 391.0749. 
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Purity (HPLC): 98 % (210 nm; method 3b). 
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1-Cyclopropyl-1-{7-[3-(hydroxymethyl)-4-methoxyphenyl]-9-methoxy-2,3-
dihydro-1,4-benzoxazepin-4(5H)-yl}methanone (47) 
 
  
MF: C22H25NO5        MW: 383.44 g/mol  
To a suspension of 0.078 g (2.0 mmol) sodium borohydride in a mixture of 7.5 mL DCM 
and 2.5 mL MeOH were added 0.43 g (1.1 mmol) 37 and the mixture was stirred for 2 
h. 20 mL 2 M HCl was added and after 15 min of stirring, the mixture was extracted 
with EtOAc (3 x 20 mL) three times. The combined organic layers were dried over 
MgSO4 and concentrated in vacuo to give 0.42 g (1.9 mmol, 97 %) of 47 as a white 
solid.  
mp: 74 – 75 °C.  
1H-NMR (mixture of rotamers, 500 MHz, CDCl3): δ = 7.52 – 7.39 (m, 2H, 2’’-H, 6’’-H), 
7.14 – 6.87 (m, 3H, 6’-H, 8’-H, 5’’-H), 4.82 – 4.66 (m, 4H, 5’-H, CH2OH), 4.29 – 4.21 
(m, 0.7H, 2’-H), 4.19 – 4.00 (m, 3.3H, 2’-H, 3’-H), 3.95 – 3.86 (m, 6H, OCH3), 2.35 (br 
s, 1H, OH), 1.92 – 1.85 (m, 0.7H, CH-CH2), 1.73 – 1.67 (m, 0.3H, CH-CH2), 1.01 – 
0.90 (m, 2H, CH-CH2), 0.82 – 0.69 (m, 2H, CH-CH2).  
13C-NMR (mixture of rotamers, 101 MHz, CDCl3): δ = 172.8 (C-1), 172.1 (C-1), 157.0 
(C-4’’), 156.9 (C-4’’), 152.0 (C-9’), 151.3 (C-9’), 147.5 (C-9a’), 147.1 (C-9a’), 136.7 (C-
7’), 136.4 (C-7’), 133.2 (C-1’’), 132.4 (C-5a’), 132.0 (C-5a’), 129.5 (C-3’’), 129.3 (C-3’’), 
127.43 (C-2’’, C-6’’), 127.39 (C-2’’/C-6’’), 127.30 (C-2’’/C-6’’), 120.5 (C-6’), 118.9 (C-
6’), 110.8 (C-5’’), 110.5 (C-8’), 110.5 (C-5’’), 110.1 (C-8’), 72.81 (C-2’), 72.75 (C-2’), 
62.1 (3’’-CH2OH), 62.0 (CH2OH), 56.3 (OCH3), 56.2 (OCH3), 55.5 (OCH3), 51.2 (C-5’), 
51.2 (C-3’), 48.9 (C-3’), 48.6 (C-5’), 11.6 (CH-CH2), 11.5 (CH-CH2), 7.7 (CH-CH2), 7.5 
(CH-CH2).  
IR (KBr): ṽ (cm-1) = 3406, 3002, 2933, 2865, 2836, 1637, 1486, 1464, 1368, 1344, 
1292, 1244, 1044, 813. 
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MS (ESI+): m/z (%) = 298 (3), 366 (7), 384 (100) [M + H]+, 406 (25). 
HRMS (ESI+): m/z calcd for [C22H26NO5]+ 384.1811, found 384.1806. 
Purity (HPLC): > 99 % (210 nm; method 2a). 
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5-[4-(Cyclopropanecarbonyl)-9-methoxy-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-
yl]-2-methoxybenzaldehyde O-methyl oxime (48) 
 
  
MF: C23H26N2O5        MW: 410.47 g/mol  
To a suspension of 0.15 g (0.39 mmol) 37 in 6 mL EtOH were added 0.13 g (1.5 mmol) 
O-methylhydroxylamine hydrochloride and 0.21 g (1.5 mmol) K2CO3. After 12 h the 
mixture was concentrated in vacuo, treated with 40 mL EtOAc and 40 mL saturated 
NaCl solution, and extracted with EtOAc (3 x 40 mL) three times. The combined 
organic layers were dried over MgSO4 and concentrated in vacuo. FCC with DCM with 
2 % MeOH (Rf 0.3) gave 0.16 g (0.39 mmol, 99 %) of 48 as a white solid. 
mp: 78 – 79 °C.  
1H-NMR (mixture of rotamers, 500 MHz, CD2Cl2): δ = 8.45 (s, 1H, N=CH), 7.95 (d, J = 
2.4 Hz, 1H, 6-H), 7.60 – 7.50 (m, 1H, 4-H), 7.13 – 6.95 (m, 3H, 3-H, 6’-H, 8’-H), 4.77 
(s, 1.3H, 5’-H), 4.67 (s, 0.7H, 5’-H), 4.23 – 4.13 (m, 0.7H, 2’-H), 4.10 – 4.04 (m, 2H, 2’-
H, 3’-H), 4.00 – 3.95 (m, 4.3H, 3’-H, OCH3), 3.90 – 3.86 (m, 6H, OCH3), 1.96 – 1.88 
(m, 0.7H, CH-CH2), 1.73 – 1.67 (m, 0.3H, CH-CH2), 0.91 – 0.80 (m, 2H, CH-CH2), 0.80 
– 0.67 (m, 2H, CH-CH2).  
13C-NMR (mixture of rotamers, 126 MHz, CD2Cl2): δ = 172.9 (C-1’’), 172.3 (C-1’’), 
157.5 (C-2), 152.5 (C-9’), 152.0 (C-9’), 148.2 (C-9a’), 148.0 (C-9a’), 144.74 (N=CH), 
144.65 (N=CH), 136.6 (C-7’), 136.1 (C-7’), 133.7 (C-5), 133.5 (C-5), 133.2 (C-5a’), 
133.1 (C-5a’), 129.9 (C-4), 124.9 (C-6), 124.7 (C-6), 121.4 (C-1), 120.6 (C-6’), 119.3 
(C-6’), 111.9 (C-3), 111.3 (C-8’), 110.7 (C-8’), 73.2 (C-2’), 73.0 (C-2’), 62.2 (OCH3), 
56.7 (OCH3), 56.2 (OCH3), 51.6 (C-3’), 51.4 (C-5’), 49.2 (C-3’), 49.0 (C-5’), 11.8 (CH-
CH2), 11.6 (CH-CH2), 7.7 (CH-CH2), 7.5 (CH-CH2).  
IR (KBr): ṽ (cm-1) = 3447, 3004, 2936, 2838, 2345, 1641, 1587, 1485, 1463, 1431, 
1292, 1256, 1205, 1051, 815. 
MS (ESI+): m/z (%) = 411 (100) [M+ H]+, 412 (16). 
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HRMS (ESI+): m/z calcd for [C23H27N2O5]+ 411.1920, found 411.1912. 
Purity (HPLC): 95 % (210 nm; method 2a). 
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4-({5-[4-(Cyclopropanecarbonyl)-9-methoxy-2,3,4,5-tetrahydro-1,4-
benzoxazepin-7-yl]-2-methoxybenzyl}amino)benzoic acid (49) 
 
 
MF: C29H30N2O6        MW: 502.57 g/mol 
0.25 g (0.67 mmol) 37 and 0.29 g (2.1 mmol) 4-aminobenzoic acid were dissolved in 3 
mL DCM and 3 mL MeOH. 0.15 g (2.4 mmol) NaCNBH3 were added and stirred for 72 
h. To this mixture was added 70 mL of 1 M HCl and it was extracted with DCM (5 x 70 
mL) five times. The combined organic layers were dried over MgSO4 and concentrated 
in vacuo. FCC with EtOAc and hexanes (3:1, Rf 0.2) with 1 % AcOH gave 0.27 g (0.54 
mmol, 80%) of 49 as a white solid.  
mp: 235 °C (decomposition).  
1H NMR (100 °C, 400 MHz, DMSO-d6): δ = 7.73 – 7.65 (m, 2H, 2-H, 6-H), 7.53 – 7.48 
(m, 2H, 3‘-H, 6‘-H), 7.11 – 7.05 (m, 2H, 4‘-H, 6‘‘-H), 7.02 (d, J = 2.1 Hz, 1H, 8‘‘-H), 6.70 
– 6.63 (m, 2H, 3-H, 5-H), 6.45 (br s, 1H, NH), 4.73 (s, 2H, 5’’-H), 4.45 – 4.33 (m, 2H, 
CH2NH), 4.10 – 4.04 (m, 2H, 2’’-H), 4.00 – 3.93 (m, 2H, 3’’-H), 3.90 (s, 3H, 2’-OCH3), 
3.80 (s, 3H, 9’’-OCH3), 1.98 – 1.91 (m, 1H, CH-CH2), 0.72 – 0.67 (m, 4H, CH-CH2).   
13C NMR (100 °C, 101 MHz, DMSO-d6): δ = 171.3 (C-1‘‘‘), 166.7 (O=CO), 156.2 (C-
2‘), 152.1 (C-4), 151.0 (C-9‘‘), 147.0 (C-9a‘‘), 134.8 (C-7‘‘), 131.7 (C-5‘, C-5a‘‘), 130.4 
(C-2, C-6), 126.9 (C-1‘), 126.2 (C-3‘/C-6‘), 125.7 (C-3‘/C-6‘), 118.8 (C-6‘‘), 117.4 (C-1), 
111.1 (C-4‘), 110.9 (C-8‘‘), 110.8 (C-3, C-5), 71.2 (C-2‘‘), 56.0 (2’-OCH3), 55.4 (9’’-
OCH3), 48.6 (C-5‘‘), 48.3 (C-3‘‘), 40.7 (CH2NH), 10.5 (CH-CH2), 6.3 (CH-CH2).  
IR (KBr): ṽ (cm-1) = 3366, 2923, 1641, 1602, 1426, 1291, 1220, 817. 
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MS (EI+): m/z (%) = 225 (59), 255 (69), 296 (72), 364 (34), 366 (58), 388 (80), 456 
(100), 459 (74), 502 (100) [M]+•, 503 (33). 
HRMS (EI+): m/z calcd for C29H30N2O6 502.2104, found 502.2098. 
Purity (HPLC): 98 % (210 nm; method 1c). 
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5-[4-(Cyclopropanecarbonyl)-9-methoxy-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-
yl]-2-methylbenzenaminium chloride (50) 
 
 
MF: C21H24N2O3        MW: 388.89 g/mol  
To a suspension of 6 g Raney nickel in 60 mL water was added 9.2 g NaOH. Upon 
complete activation after 15 minutes this suspension was washed with three 50 mL 
portions water and then with three 50 mL portions EtOH. Seperately 0.45 g (1.2 mmol) 
30 were dissolved in 35 mL EtOH and then 2.2 mL (44 mmol) hydrazine monohydrate 
were added. The activated Raney-nickel suspension was then added to this solution 
and the mixture was refluxed for 40 min. The suspension was filtrated and the filtrate 
dissolved in a mixture of 30 mL 2 M NaOH and 30 mL EtOAc. The mixture was 
extracted with EtOAc (3 x 30 mL) three times. The combined organic layers were dried 
over MgSO4, and concentrated in vacuo. They were redissolved in 40 mL ethyl ether. 
Precipitation with 4 M HCl in 1,4-dioxane gave 0.18 g (0.46 mmol, 38 %) of 50 as a 
purple solid.  
mp: 221 °C (decomposition).  
1H NMR (mixture of rotamers, 500 MHz, DMSO-d6): δ = 10.21 (br s, 3H, NH3+), 7.81 – 
7.63 (m, 1H, 6-H), 7.59 – 7.51 (m, 1H, 4-H), 7.36 (d, J = 7.8 Hz, 1H, 3-H), 7.28 (d, J = 
2.1 Hz, 0.6H, 6’-H), 7.15 – 7.12 (m, 1H, 8’-H), 7.03 (d, J = 2.1 Hz, 0.4H, 6’-H), 4.84 (s, 
1.2H, 5’-H), 4.61 (s, 0.8H, 5’-H), 4.20 – 4.12 (m, 0.8H, 2’-H), 4.12 – 4.07 (m, 0.8H, 3’-
H), 4.05 – 3.96 (m, 1.2H, 2’-H), 3.91 – 3.85 (m, 1.2H, 3’-H), 3.83 (s, 3H, OCH3), 2.37 
(s, 3H, 2-CH3), 2.21 – 2.12 (m, 1H, 0.6H, CH-CH2), 1.99 – 1.90 (m, 0.4H, CH-CH2), 
0.81 – 0.59 (m, 4H, CH-CH2). 
13C NMR (mixture of rotamers, 126 MHz, DMSO-d6): δ = 172.7 (C-1‘‘), 172.0 (C-1‘‘), 
152.0 (C-9‘), 151.8 (C-9‘), 148.2 (C-9a‘), 139.1 (C-5), 138.9 (C-5), 134.7 (C-2), 134.1 
(C-2), 133.2 (C-5a‘), 132.8 (C-5a‘), 132.5 (C-1), 132.2 (C-3), 132.1 (C-3), 130.9 (C-7‘), 
130.7 (C-7‘), 126.1 (C-4), 125.9 (C-4), 121.6 (C-6), 121.4 (C-6), 120.1 (C-6‘), 119.4 
(C-6‘), 110.9 (C-8‘), 110.4 (C-8‘), 72.7 (C-2‘), 72.1 (C-2‘), 56.3 (OCH3), 50.9 (C-3‘), 50.1 
Chapter VII – Experimental Section 
 
144 
 
(C-5‘), 48.7 (C-3‘), 48.3 (C-5‘), 17.3 (2-CH3), 11.2 (CH-CH2), 11.1 (CH-CH2), 7.9 (CH-
CH2), 7.6 (CH-CH2). 
IR (KBr): ṽ (cm-1) = 3425, 3000, 2880, 2757, 2575, 1636, 1583, 1486, 1468, 1208, 
1105, 1091, 1051, 992, 829, 584, 551. 
MS (ESI+): m/z (%) = 223 (20), 285 (25), 331 (73), 353 (100) [M + H]+.  
HRMS (ESI+): m/z calcd for C21H25N2O3 353.1860, found 353.1859. 
Purity (HPLC): 95 % (210 nm; method 1d). 
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N-{5-[4-(cyclopropanecarbonyl)-9-methoxy-2,3,4,5-tetrahydro-1,4-
benzoxazepin-7-yl]-2-methylphenyl}ethanesulfonamide (51) 
 
 
MF: C23H28N2O5S        MW: 444.55 g/mol  
To a solution of 0.058 g (0.15 mmol) 50 and 5 mg (0.04 mmol) DMAP in 2.0 mL pyridine 
were added 0.015 mL (0.16 mmol) ethanesulfonyl chloride at 0 °C. The mixture was 
warmed to rt and stirred for 16 h. To this mixture was added 20 mL 1 M HCl and the 
mixture was extracted with EtOAc (3 x 20 mL) three times. The combined organic 
layers were dried over MgSO4 and concentrated in vacuo. FCC with EtOAc and 
hexanes (2:1, Rf 0.3) gave 0.040 g (0.090 mmol, 60 %) of 51 as a white solid.  
mp: 155 - 156 °C.  
1H NMR (110 °C, 400 MHz, C2D2Cl4): δ = 7.59 (d, J = 1.9 Hz, 1H, 6‘-H), 7.28 (dd, J = 
7.9, 1.9 Hz, 1H, 4‘-H), 7.23 (d, J = 7.9 Hz, 1H, 3‘-H), 7.04 – 6.99 (m, 2H, 6‘‘-H, 8‘‘-H), 
6.00 (br s, 1H, NH), 4.72 (s, 2H, 5‘‘-H), 4.19 – 4.09 (m, 2H, 3’’-H), 4.03 – 3.95 (m, 2H, 
2’’-H), 3.88 (s, 3H, OCH3), 3.14 (q, J = 7.4 Hz, 2H, CH2-CH3), 2.32 (s, 3H, 2‘-CH3), 1.83 
– 1.69 (m, 1H, CH-CH2), 1.37 (t, J = 7.4 Hz, 3H, CH2-CH3), 0.94 – 0.86 (m, 2H, CH-
CH2), 0.78 – 0.68 (m, 2H, CH-CH2).  
13C NMR (ambient temperature, mixture of rotamers, 126 MHz, C2D2Cl4): δ = 172.7 
(C-1‘‘‘), 172.1 (C-1‘‘‘), 151.7 (C-9‘‘), 151.2 (C-9‘‘), 147.8 (C-9a‘‘), 147.6 (C-9a‘‘), 139.7 
(C-5‘), 135.7 (C-7‘‘), 135.3 (C-7‘‘), 135.1 (C-1‘), 135.0 (C-1‘), 132.1 (C-5a‘‘), 131.7 (C-
5a‘‘), 131.5 (C-3‘), 128.5 (C-2‘), 124.3 (C-4‘), 124.2 (C-4‘), 120.4 (C-6‘), 120.2 (C-6‘‘), 
119.0 (C-6‘‘), 111.0 (C-8‘‘), 110.4 (C-8‘‘), 72.4 (C-2‘‘), 72.2 (C-2‘‘), 56.2 (OCH3), 51.6 
(C-5‘‘), 50.8 (C-3‘‘), 48.5 (C-3‘‘), 48.2 (C-5‘‘), 46.7 (CH2-CH3), 46.6 (CH2-CH3), 17.6 (2‘-
CH3), 11.6 (CH-CH2), 11.4 (CH-CH2), 8.2 (CH2-CH3), 7.7 (CH-CH2), 7.5 (CH-CH2).  
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IR (KBr): ṽ (cm-1) = 3438, 3165, 2939, 1617, 1569, 1484, 1315, 1137, 1124, 1046, 993, 
914, 809, 726, 568. 
MS (EI+): m/z (%) = 240 (28), 357 (47), 444 (100) [M]+•. 
HRMS (EI+): m/z calcd for C23H28N2O5S 444.1719, found 444.1727. 
Purity (HPLC): > 99 % (210 nm; method 3a). 
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1-{5-[4-(Cyclopropanecarbonyl)-9-methoxy-2,3,4,5-tetrahydro-1,4-
benzoxazepin-7-yl]-2-methylphenyl}-3-ethylurea (52) 
 
 
MF: C24H29N3O4        MW: 423.51 g/mol  
To a solution of 0.058 g (0.15 mmol) 50 in 1.0 mL DCM were added 0.30 mL (1.7 mmol) 
DIPEA and 0.080 mL (1.3 mmol) ethyl isocyanate and the mixture was stirred for 72 h. 
To this mixture was added 15 mL 0.1 M HCl and the mixture was extracted with EtOAc 
(3 x 15 mL) three times. The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. FCC with EtOAc and hexanes (2:1, Rf 0.3) gave 0.030 g (0.071 
mmol, 47 %) of 52 as a white solid.  
mp: 190 - 191 °C.  
1H NMR (110 °C, 400 MHz, C2D2Cl4): δ = 7.63 (d, J = 1.9 Hz, 1H, 6’-H), 7.31 – 7.16 
(m, 2H, 3’-H, 4’-H), 7.09 – 6.98 (m, 2H, 6’’-H, 8’’-H), 5.99 (br s, 1H, NH), 4.71 (s, 2H, 
5’’-H), 4.59 (br s, 1H, NH), 4.17 – 4.08 (m, 2H, 2’’-H), 4.03 – 3.95 (m, 2H, 3’’-H), 3.87 
(s, 3H, OCH3), 3.24 (q, J = 7.2 Hz, 2H, 4-H), 2.25 (s, 3H, 2’-CH3), 1.81 – 1.69 (m, 1H, 
CH-CH2), 1.12 (t, J = 7.2 Hz, 3H, 5-H), 0.94 – 0.86 (m, 2H, CH-CH2), 0.79 – 0.68 (m, 
2H, CH-CH2).  
13C NMR (110 °C, 101 MHz, C2D2Cl4): δ = 172.4 (C-1’’’), 156.0 (C-2), 152.1 (C-9’’), 
148.5 (C-9a’’), 139.6 (C-5’), 137.1 (C-1’), 136.2 (C-7’’), 132.3 (C-5a’’), 131.2 (C-3’), 
130.8 (C-2’), 123.8 (C-4’), 123.4 (C-6’), 120.2 (C-6’’), 112.6 (C-8’’), 72.4 (C-2’’), 57.1 
(OCH3), 50.2 (C-5’’), 49.7 (C-3’’), 35.5 (C-4), 17.3 (2’-CH3), 15.4 (C-5), 11.8 (CH-CH2), 
7.3 (CH-CH2).  
IR (KBr): ṽ (cm-1) = 3329, 3093, 2969, 2930, 1644, 1560, 1460, 1398, 1293, 1226, 
1171, 1092, 1044, 813, 730, 657. 
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MS (EI+): m/z (%) = 116 (27), 241 (40), 281 (54), 291 (70), 309 (59), 352 (67), 378 
(100), 423 (20) [M]+•.  
HRMS (EI+): m/z calcd for C24H29N3O4 423.2158, found 423.2157. 
  
Chapter VII – Experimental Section 
 
149 
 
1-[7-(2-Aminopyrimidin-4-yl)-9-methoxy-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-
1-(cyclopropyl)methanone (53) 
 
  
MF: C18H20N4O3        MW: 340.39 g/mol 
A solution of 0.20 g (0.69 mmol) 55 in 5 mL anhydrous DMF was heated to 160 °C 
under N2, then 0.52 mL (2.5 mmol) Bredereck’s reagent was added and heating 
continued for 1 h. Then 0.66 g (3.7 mmol) guanidinium carbonate and 0.34 g (2.5 
mmol) K2CO3 were added and the mixture was heated to 160 °C for further 4 h. After 
cooling 40 mL saturated NaHCO3 solution was added and the mixture was extracted 
with DCM (3 x 40 mL) three times. The combined organic layers were dried over 
MgSO4 and concentrated in vacuo. FCC with DCM with 5 % MeOH (Rf 0.1) gave 0.13 
g (0.39 mmol, 57 %) of 53 as a yellow solid.  
mp: 136 – 137 °C.  
1H NMR (mixture of rotamers, 500 MHz, CD2Cl2): δ = 8.34 – 8.26 (m, 1H, 6‘‘-H), 7.63 
– 7.47 (m, 2H, 6‘-H, 8‘-H), 7.06 – 6.98 (m, 1H, 5‘‘-H), 5.25 – 5.13 (m, 2H, NH2), 4.79 
(s, 1.1H, H-5‘), 4.68 (s, 0.9H, H-5‘), 4.24 – 4.18 (m, 0.9H, 2‘-H), 4.13 – 4.06 (m, 2H, 2‘-
H, 3’H), 4.01 – 3.95 (m, 1.1H, 3‘-H), 3.92 – 3.88 (m, 3H, OCH3), 1.92 – 1.83 (m, 0.6H, 
CH-CH2), 1.74 – 1.68 (m, 0.4H, CH-CH2), 0.89 – 0.81 (m, 2H, CH-CH2), 0.77 – 0.69 
(m, 2H, CH-CH2).  
13C NMR (mixture of rotamers, 126 MHz, CD2Cl2): δ = 173.0 (C-1), 172.5 (C-1), 164.62 
(C-4‘‘), 164.57 (C-4‘‘), 163.8 (C-2‘‘), 159.2 (C-6‘‘), 159.1 (C-6‘‘), 152.6 (C-9‘), 152.1 (C-
9‘), 151.1 (C-9a‘), 150.9 (C-9a‘), 132.9 (C-7‘), 132.7 (C-5a‘), 121.3 (C-6‘), 119.8 (C-6‘), 
111.1 (C-8‘), 110.6 (C-8‘), 107.6 (C-5‘‘), 107.5 (C-5‘‘), 73.1 (C-2‘), 72.8 (C-2‘), 56.64 
(OCH3), 56.58 (OCH3), 51.5 (C-3‘), 51.3 (C-5‘), 49.0 (C-3‘), 48.8 (C-5‘), 11.8 (CH-CH2), 
11.6 (CH-CH2), 7.7 (CH-CH2), 7.6 (CH-CH2).  
IR (KBr): ṽ (cm-1) = 3423, 3331, 3173, 3002, 2920, 2873, 1655, 1636, 1562, 1460, 
1446, 1290, 1215, 1104, 1044, 888, 814, 740. 
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MS (EI+): m/z (%) = 242 (26), 253 (45), 271 (46), 340 (100) [M]+•, 341 (22). 
HRMS (EI+): m/z calcd for C18H20N4O3 340.1535, found 340.1538. 
Purity (HPLC): 99 % (210 nm; method 2a). 
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1-[7-(2-Aminothiazol-4-yl)-9-methoxy-2,3-dihydro-1,4-benzoxazepin-4(5H)-yl]-1-
(cyclopropyl)methanone (54) 
 
  
MF: C17H19N3O3S        MW: 345.42 g/mol 
To a solution of 1.0 g (3.1 mmol) 32 and 0.11 g (0.16 mmol) Pd(PPh3)2Cl2 in 12 mL 
anhydrous 1,4-dioxane under N2 were added 1.4 mL (4.0 mmol) tributyl(1-
ethoxyvinyl)tin. The mixture was heated to 140 °C under microwave irradiation with 
300 W for 40 minutes. After cooling 50 mL water was added and the mixture extracted 
with DCM (3 x 50 mL) three times. The combined organic layers were dried over 
MgSO4 and concentrated in vacuo. FCC with EtOAc and hexanes (2:1, Rf 0.3) gave 
1.0 g of the crude enol ether. This intermediate was dissolved in a mixture of 10 mL 
THF and 10 mL water and treated at 0 °C with 0.56 g (2.9 mmol) N-bromosuccinimide. 
After one hour at rt the mixture was extracted with EtOAc (3 x 30 mL) three times. The 
combined organic layers were dried over MgSO4 and concentrated in vacuo to obtain 
0.47 g of the crude α–bromo-ketone. A portion of 0.20 g (0.54 mmol) of this residue 
and 0.20 g (2.6 mmol) thiourea were dissolved in 5 mL anhydrous DMF and stirred for 
16 h. After the addition of 30 mL water the mixture was extracted with DCM (3 x 30 
mL) three times. The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. FCC with DCM with 3 % MeOH (Rf 0.2) gave 0.090 g (0.26 
mmol, 20 %) of 54 as a yellow solid.  
mp: 103 – 104 °C.  
1H NMR (100 °C, 400 MHz, DMSO-d6): δ = 7.41 – 7.30 (m, 2H, 6‘-H, 8’-H), 6.84 (s, 1H, 
5’’-H), 6.65 (s, 2H, NH2), 4.71 (s, 2H, 5‘-H), 4.13 – 4.04 (m, 2H, 2‘-H), 4.04 – 3.91 (m, 
2H, 3‘-H), 3.82 (s, 3H, OCH3), 2.06 – 1.88 (m, 1H, CH-CH2), 0.75 – 0.63 (m, 4H, CH-
CH2).  
13C NMR (100 °C, 101 MHz, DMSO-d6): δ = 171.2 (C-1), 167.5 (C-2‘‘), 150.7 (C-9‘), 
149.2 (C-9a‘), 147.2 (C-4‘‘), 131.3 (C-5a‘), 129.8 (C-7‘), 118.5 (C-6‘), 110.3 (C-8‘), 
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100.5 (C-5‘‘), 71.2 (C-2‘), 55.9 (OCH3), 48.6 (C-5‘), 48.4 (C-3‘), 10.5 (CH-CH2), 6.2 
(CH-CH2).  
IR (KBr): ṽ (cm-1) = 3357, 3155, 3037, 3004, 2962, 2933, 2869, 2361, 2343, 2231, 
2220, 1624, 1590, 1540, 1485, 1461, 1421, 1345, 1222, 1105, 1065, 740. 
MS (ESI+): m/z (%) = 278 (7), 346 (100), [M + H]+, 368 (32). 
HRMS (ESI+): m/z calcd for [C17H20N3O3S]+ 346.1225, found 346.1219. 
Purity (HPLC): 97 % (210 nm; method 1b).  
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1-[4-(Cyclopropanecarbonyl)-9-methoxy-2,3,4,5-tetrahydro-1,4-benzoxazepin-7-
yl]ethan-1-one (55) 
 
  
MF: C16H19NO4        MW: 289.33 g/mol  
To a solution of 0.49 g (1.5 mmol) 32 and 0.053 g (0.075 mmol) Pd(PPh3)2Cl2 in 6.0 
mL anhydrous 1,4-dioxane under N2 were added 0.66 mL (2.0 mmol) tributyl(1-
ethoxyvinyl)tin. The mixture was heated to 140 °C under microwave irradiation with 
300 W for 40 minutes. After cooling 30 mL 10 % aqueous HCl was added and the 
mixture extracted with DCM (3 x 30 mL) three times. The combined organic layers 
were dried over MgSO4 and concentrated in vacuo. FCC with EtOAc and hexanes (4:1, 
Rf 0.5) gave 0.29 g (1.0 mmol, 67 %) of 55 as a white solid.  
mp: 76 - 77 °C.  
1H-NMR (80 °C, 500 MHz, C2D2Cl4): δ = 7.47 – 7.38 (m, 2H, 6’-H, 8’-H), 4.73 (s, 2H, 
5’-H), 4.30 – 4.16 (m, 2H, 2’-H), 4.08 – 3.95 (m, 2H, 3’-H), 3.87 (s, 3H, OCH3), 2.53 (s, 
3H, 2-H), 1.81 – 1.63 (m, 1H, CH-CH2), 0.93 – 0.87 (m, 2H, CH-CH2), 0.79 – 0.70 (m, 
2H, CH-CH2).  
13C-NMR (ambient temperature, mixture of rotamers, 126 MHz, C2D2Cl4): δ = 196.9 
(C-1), 196.7 (C-1), 172.8 (C-1’’), 172.4 (C-1’’), 152.4 (C-9a), 152.1 (C-9a), 151.5 (C-9’), 
151.1 (C-9’), 132.2 (C-7’), 132.1 (C-7’), 130.8 (C-5a), 130.2 (C-5a), 123.5 (C-6’), 121.3 
(C-6’), 111.4 (C-8’), 110.2 (C-8’), 72.1 (C-2’), 71.7 (C-2’), 56.3 (OCH3), 56.2 (OCH3), 
50.4 (C-3’, C-5’), 48.1 (C-3’), 47.6 (C-5’), 26.5 (C-2), 26.4 (C-2), 11.5 (CH-CH2), 11.4 
(CH-CH2), 7.7 (CH-CH2), 7.6 (CH-CH2).  
IR (KBr): ṽ (cm-1) = 3433, 3084, 3009, 2934, 2362, 2345, 2234, 2220, 1666, 1629, 
1583, 1465, 1422, 1370, 1305, 1223, 1202, 1092, 1042, 870, 744. 
MS (ESI+): m/z (%) = 112 (10), 222 (12), 290 (100), [M + H]+, 312 (88). 
HRMS (ESI+): m/z calcd for [C16H20NO4]+ 290.1392, found 290.1386. 
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Purity (HPLC): 98 % (210 nm; method 2a).  
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7-(3-Chloro-4-methoxyphenyl)-9-methoxy-2,3,4,5-tetrahydro-1,4-benzoxazepine 
(56) 
 
 
MF: C17H18ClNO3        MW: 319.79 g/mol  
Standard protocol 2 with 1.5 g (5.8 mmol) 9 and 1.3 g (7.0 mmol) 3-chloro-4-
methoxyphenylboronic acid. FCC with EtOAc with 5 % triethylamine (Rf 0.1) gave 0.90 
g (2.8 mmol, 48 %) of 56 as a white solid.  
mp: 117 – 118 °C.  
1H NMR (500 MHz, CDCl3): δ = 7.56 (d, J = 2.3 Hz, 1H, 2‘-H), 7.40 (dd, J = 8.5, 2.3 
Hz, 1H, 6‘-H), 6.98 (d, J = 8.5 Hz, 1H, 5‘-H), 6.95 (d, J = 2.1 Hz, 1H, 8-H), 6.89 (d, J = 
2.1 Hz, 1H, 6-H), 4.14 – 4.10 (m, 2H, 2-H), 4.02 (s, 2H, 5-H), 3.94 (s, 3H, 4’-OCH3), 
3.93 (s, 3H, 9-OCH3), 3.29 – 3.24 (m, 2H, 3-H).  
13C NMR (101 MHz, CDCl3): δ  = 154.3 (C-4‘), 151.8 (C-9), 148.5 (C-9a), 136.7 (C-5a), 
135.0 (C-7), 134.4 (C-1‘), 128.7 (C-2‘), 126.1 (C-6‘), 122.7 (C-7), 119.5 (C-6), 112.2 
(C-5‘), 109.8 (C-8), 75.5 (C-2), 56.33 (OCH3), 56.27 (OCH3), 53.2 (C-5), 52.3 (C-3).  
IR (KBr): ṽ (cm-1) = 3431, 3290, 3025, 2922, 2904, 2839, 1587, 1493, 1466, 1281, 
1244, 1202, 1182, 1061, 1013, 856, 786, 697, 604. 
MS (EI+): m/z (%) = 139 (11), 198 (11), 261 (22), 263 (9), 276 (58), 278 (21), 319 (100) 
[M]+•, 321 (36). 
HRMS (EI+): m/z calcd for C17H1835ClNO3 319.0975, found 319.0972. 
Purity (HPLC): 97 % (210 nm; method 1c). 
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1-[7-(3-Chloro-4-methoxyphenyl)-9-methoxy-2,3-dihydro-1,4-benzoxazepin-
4(5H)-yl]propan-1-one (57) 
 
  
MF: C20H22ClNO4        MW: 375.85 g/mol  
Standard protocol 1 with 0.16 g (0.50 mmol) 56 and 0.16 mL (0.65 mmol) propionyl 
chloride. FCC with EtOAc and hexanes (3:1, Rf 0.4) gave 0.075 g (0.20 mmol, 40 %) 
of 57 as a white solid.  
mp: 66 – 67 °C.  
1H NMR (110 °C, 400 MHz, C2D2Cl4): δ = 7.52 (d, J = 2.3 Hz, 1H, 2‘‘-H), 7.37 (dd, J = 
8.5, 2.3 Hz, 1H, 6‘‘-H), 7.06 – 6.86 (m, 3H, 6‘-H, 8‘-H, 5‘‘-H), 4.59 (s, 2H, 5‘-H), 4.15 – 
4.06 (m, 2H, 2‘-H), 3.94 – 3.84 (m, 8H, 3‘-H, OCH3), 2.47 – 2.24 (m, 2H, 2-H), 1.10 (t, 
J = 7.4 Hz, 3H, 3-H).  
13C NMR (ambient temperature, mixture of rotamers, 101 MHz, C2D2Cl4): δ = 172.9 
(C-1), 172.3 (C-1), 154.3 (C-4‘‘), 154.1 (C-4‘‘), 151.9 (C-9‘), 151.3 (C-9‘), 147.6 (C-9a‘), 
147.5 (C-9a‘), 135.1 (C-7‘), 134.7 (C-7‘), 133.7 (C-1‘‘), 133.6 (C-1‘‘), 132.1 (C-5a‘), 
131.8 (C-5a‘), 128.5 (C-2‘‘), 128.4 (C-2‘‘), 126.2 (C-6‘‘), 126.1 (C-6‘‘), 122.5 (C-3‘‘), 
122.4 (C-3‘‘), 120.0 (C-6‘), 118.8 (C-6‘), 112.3 (C-5‘‘), 112.2 (C-5‘‘), 110.7 (C-8‘), 110.0 
(C-8‘), 72.4 (C-2‘), 72.3 (C-2‘), 56.29 (OCH3), 56.24 (OCH3), 56.22 (OCH3), 50.8 (C-3‘, 
C-5‘), 48.3 (C-3‘), 47.9 (C-5‘), 26.7 (C-2), 26.4 (C-2), 9.19 (C-3), 9.15 (C-3).  
IR (KBr): ṽ (cm-1) = 3434, 2935, 2839, 1648, 1586, 1486, 1463, 1291, 1256, 1202, 
1063, 1020, 808, 701, 605. 
MS (EI+): m/z (%) = 261 (12), 263 (4), 276 (100), 278 (30), 375 (66) [M]+•, 376 (15), 
377 (23). 
HRMS (EI+): m/z calcd for C20H2235ClNO4 375.1237, found 375.1235. 
Purity (HPLC): 99 % (210 nm; method 1c). 
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1-[7-(3-chloro-4-methoxyphenyl)-9-methoxy-2,3-dihydro-1,4-benzoxazepin-
4(5H)-yl]-2,2,2-trifluoroethan-1-one (58) 
 
  
MF: C19H17ClF3NO4        MW: 415.79 g/mol  
To a solution of 0.040 g (0.13 mmol) 56 and 5 mg (0.04 mmol) DMAP in 1.0 mL DCM 
was added 0.070 mL (0.50 mmol) trifluoroacetic anhydride at 0 °C. The mixture was 
stirred and warmed to rt. 0.70 mL (41 mmol) DIPEA was added and the solution was 
stirred for further 12 h. Then 10 mL saturated NaHCO3 solution was added and this 
mixture was extracted with DCM (3 x 10 mL) three times. The combined organic layers 
were dried over MgSO4 and concentrated in vacuo. FCC with EtOAc and hexanes (1:2, 
Rf 0.2) gave 0.050 g (0.12 mmol, 92 %) of 58 as a white solid.  
mp: 143 - 144 °C.  
1H NMR (110 °C, 400 MHz, C2D2Cl4): δ = 7.52 (d, J = 2.3 Hz, 1H, 2’’-H), 7.36 (dd, J = 
8.6, 2.3 Hz, 1H, 6’’-H), 7.09 – 6.90 (m, 3H, 6’-H, 8’-H, 5’’-H), 4.69 (s, 2H, 5’-H), 4.18 – 
4.13 (m, 2H, 2’-H), 4.03 – 3.93 (m, 2H, 3’-H), 3.90 (s, 3H, 4’’-OCH3), 3.88 (s, 3H, 9’-
OCH3).   
13C NMR (110 °C, 101 MHz, C2D2Cl4): δ = 156.0 (C-1), 155.1 (C-4’’), 152.2 (C-9’), 
148.3 (C-9a’), 136.0 (C-7’), 134.2 (C-1’’), 130.6 (C-5a’), 128.8 (C-2’’), 126.2 (C-6’’), 
123.6 (C-3’’), 120.4 (C-6’), 116.6 (d, 1JCF = 287.9 Hz, C-2), 113.4 (C-8’/C-5’’), 112.9 
(C-8’/C-5’’), 72.4 (C-2’), 57.0 (9’-OCH3), 56.7 (4’’-OCH3), 50.9 (C-3’), 50.4 (C-5’).  
IR (KBr): ṽ (cm-1) = 3433, 3025, 3009, 2970, 2937, 1691, 1488, 1453, 1287, 1237, 
1200, 1174, 1141, 1080, 1046, 815, 705, 580. 
MS (EI+): m/z (%) = 139 (8), 198 (11), 261 (11), 276 (22), 302 (20), 415 (100) [M]+•, 
417 (31). 
HRMS (EI+): m/z calcd for C19H1735ClF3NO4 415.0798, found 415.0792. 
Purity (HPLC): > 99 % (210 nm; method 3a). 
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Methyl 7-(3-chloro-4-methoxyphenyl)-9-methoxy-2,3-dihydro-1,4-
benzoxazepine-4(5H)-carboxylate (59) 
 
 
MF: C19H20ClNO5        MW: 377.82 g/mol  
Standard protocol 1 with 0.10 g (0.31 mmol) 56 and 0.20 mL (2.6 mmol) methyl 
chloroformate. FCC with EtOAc and hexanes (1:1, Rf 0.3) gave 0.11 g (0.29 mmol, 94 
%) of 59 as a white solid.  
mp: 67 – 68 °C.  
1H NMR (110 °C, 400 MHz, C2D2Cl4): δ = 7.53 (d, J = 2.3 Hz, 1H, 2‘-H), 7.37 (dd, J = 
8.5, 2.3 Hz, 1H, 6‘-H), 6.99 – 6.94 (m, 3H, 6-H, 8-H, 5‘-H), 4.53 (s, 2H, 5-H), 4.10 – 
4.06 (m, 2H, 2-H), 3.90 (s, 3H, 4‘-OCH3), 3.87 (s, 3H, 9-OCH3), 3.84 – 3.81 (m, 2H, 3-
H), 3.66 (s, 3H, O=C-OCH3). 
13C NMR (110 °C, 101 MHz, C2D2Cl4): δ = 156.0 (C=O), 154.9 (C-4‘), 152.2 (C-9), 
148.6 (C-9a), 135.2 (C-7), 134.6 (C-1‘), 133.0 (C-5a), 128.8 (C-2‘), 126.2 (C-6‘), 123.6 
(C-3‘), 120.3 (C-6), 113.4 (C-5‘), 112.3 (C-8), 72.6 (C-2), 57.1 (9-OCH3), 56.7 (4‘-
OCH3), 52.7 (O=C-OCH3), 50.2 (C-5), 50.1 (C-3). 
IR (KBr): ṽ (cm-1) = 3433, 2934, 1702, 1637, 1485, 1291, 1235, 1127, 1063, 980, 811, 
700. 
MS (EI+): m/z (%) = 198 (11), 261 (14), 263 (5), 276 (42), 277 (15), 278 (17), 377 (100) 
[M]+•, 378 (21), 379 (34), 380 (7). 
HRMS (EI+): m/z calcd for C19H2035ClNO5 377.1030, found 377.1026. 
Purity (HPLC): 97 % (210 nm; method 1c). 
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7-(3-Chloro-4-methoxyphenyl)-9-methoxy-N,N-dimethyl-2,3-dihydro-1,4-
benzoxazepine-4(5H)-carboxamide (60) 
 
 
MF: C20H23ClN2O4        MW: 390.86 g/mol  
Standard protocol 1 with 0.10 g (0.31 mmol) 56 and 0.24 mL (2.6 mmol) N,N-
dimethylcarbamoyl chloride. FCC with EtOAc and hexanes (5:1, Rf 0.1) gave 0.090 g 
(0.23 mmol, 74 %) of 60 as a white solid.  
mp: 85 - 86 °C.  
1H NMR (500 MHz, CD2Cl2): δ = 7.58 (d, J = 2.3 Hz, 1H, 2‘-H), 7.44 (dd, J = 8.5, 2.3 
Hz, 1H, 6‘-H), 7.05 – 6.94 (m, 3H, 6-H, 8-H, 5‘-H), 4.38 (s, 2H, 5-H), 4.17 – 4.14 (m, 
2H, 2-H), 3.92 (s, 3H, 4‘-OCH3), 3.88 (s, 3H, 9-OCH3), 3.67 – 3.62 (m, 2H, 3-H), 2.80 
(s, 6H, N(CH3)2).  
13C NMR (126 MHz, CD2Cl2): δ = 164.9 (C=O), 154.7 (C-4‘), 152.0 (C-9), 148.7 (C-9a), 
135.0 (C-7), 134.5 (C-1‘), 133.2 (C-5a), 128.9 (C-2‘), 126.6 (C-6‘), 122.8 (C-3‘), 120.2 
(C-6), 112.7 (C-5‘), 110.4 (C-8), 73.0 (C-2), 56.60 (OCH3), 56.57 (OCH3), 52.8 (C-5), 
52.7 (C-3), 39.1 (N(CH3)2).  
IR (Film): ṽ (cm-1) = 3424, 3299, 3002, 2933, 2851, 1644, 1486, 1462, 1391, 1255, 
1202, 1063, 1022, 807, 752, 701. 
MS (EI+): m/z (%) = 72 (100), 276 (56), 277 (20), 278 (22), 317 (83), 318 (60), 319 
(36), 320 (16), 390 (75) [M]+•, 391 (21), 392 (23). 
HRMS (EI+): m/z calcd for C20H2335ClN2O4 390.1346, found 390.1348. 
Purity (HPLC): 96 % (210 nm; method 1c). 
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1-[7-(3-Chloro-4-methoxyphenyl)-9-methoxy-2,3-dihydro-1,4-benzoxazepin-
4(5H)-yl]-3,3,3-trifluoropropan-1-one (61) 
 
 
MF: C20H19ClF3NO4        MW: 429.82 g/mol  
To a solution of 0.066 g (0.21 mmol) 56 and 5 mg (0.04 mmol) DMAP in 2.0 mL DCM 
was added 0.035 mL (0.40 mmol) 3,3,3-trifluoropropionic acid at 0 °C. After five 
minutes 0.058 g (0.30 mmol) EDC-HCl was added, the mixture warmed to rt and stirred 
for further 12 h. To this mixture was added 10 mL saturated NaHCO3 solution and this 
mixture was extracted with DCM (3 x 10 mL) three times. The combined organic layers 
were dried over MgSO4 and concentrated in vacuo. FCC with EtOAc and hexanes (1:1, 
Rf 0.4) gave 0.082 g (0.19 mmol, 94 %) of 61 as a white solid.  
mp: 105 - 106 °C.  
1H NMR (mixture of rotamers, 400 MHz, CDCl3): δ = 7.56 (d, J = 2.3 Hz, 0.4H, 2‘‘-H), 
7.54 (d, J = 2.3 Hz, 0.6H, 2‘‘-H), 7.46 – 7.34 (m, 1H, 6‘‘-H), 7.11 (d, J = 2.1 Hz, 0.4H, 
6‘-H), 7.07 – 6.92 (m, 2H, 8‘-H, 5‘‘-H), 6.88 (d, J = 2.1 Hz, 0.6H, 6‘-H), 4.72 (s, 0.8H, 
5‘-H), 4.57 (s, 1.2H, 5-H), 4.24 – 4.13 (m, 2H, 2‘-H), 4.11 – 4.01 (m, 1.2H, 3‘-H), 4.00 
– 3.84 (m, 6.8H, 3‘-H, OCH3), 3.31 (q, 3JHF = 9.9 Hz, 1.2H, 2-H), 3.23 (q, 3JHF = 9.9 Hz, 
0.8H, 2-H).  
13C NMR (mixture of rotamers, 101 MHz, CDCl3): δ = 162.7 (q, 3JCF = 2.9 Hz, C-1), 
161.9 (q, 3JCF = 2.9 Hz, C-1), 154.7 (C-4‘‘), 154.4 (C-4‘‘), 152.3 (C-9‘), 151.4 (C-9‘), 
147.6 (C-9a‘), 147.4 (C-9a‘), 136.1 (C-7‘), 135.7 (C-7‘), 133.9 (C-1‘‘), 133.7 (C-1‘‘), 
131.2 (C-5a‘), 131.0 (C-5a‘), 128.8 (C-2‘‘), 128.7 (C-2‘‘), 126.2 (C-6‘‘), 125.3 (C-3), 
122.9 (C-3’’), 122.7 (C-3’’), 122.6 (C-3), 120.5 (C-6‘), 118.3 (C-6‘), 112.3 (C-5‘‘), 112.2 
(C-5‘‘), 111.3 (C-8‘), 110.4 (C-8‘), 72.3 (C-2‘), 72.2 (C-2‘), 56.32 (OCH3), 56.31 (OCH3), 
56.27 (OCH3), 56.23 (OCH3), 51.8 (C-3‘), 51.6 (C-5‘), 48.8 (C-3‘), 48.3 (C-5‘), 38.4 (q, 
2JCF = 29.4 Hz, C-2), 38.1 (q, 2JCF = 29.4 Hz, C-2). 
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IR (Film): ṽ (cm-1) = 3387, 2925, 1659, 1486, 1465, 1371, 1290, 1255, 1114, 854, 800. 
MS (EI+): m/z (%) = 111 (18), 198 (15), 247 (13), 261 (17), 276 (72), 278 (29), 318 
(17), 429 (100) [M]+•, 430 (19), 431 (41), 432 (8). 
HRMS (EI+): m/z calcd for C20H1935ClF3NO4 429.0954, found 429.0950. 
Purity (HPLC): 96 % (210 nm; method 1c). 
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(±)-1-[7-(3-Chloro-4-methoxyphenyl)-9-methoxy-2,3-dihydro-1,4-benzoxazepin-
4(5H)-yl]-2-fluoropropan-1-one (62) 
 
 
MF: C20H21ClFNO4        MW: 393.84 g/mol  
To a solution of 0.050 g (0.16 mmol) 56 and 5 mg (0.04 mmol) DMAP in 1.0 mL DCM 
was added 0.019 mL (0.23 mmol) (±)-2-fluoropropionic acid at 0 °C. After five minutes 
0.061 g (0.32 mmol) EDC-HCl was added, then the solution was warmed to rt and 
stirred for further 12 h. To this mixture was added 10 mL saturated NaHCO3 solution 
and this mixture was extracted with DCM (3 x 10 mL) three times. The combined 
organic layers were dried over MgSO4 and concentrated in vacuo. FCC with EtOAc 
and hexanes (1:1, Rf 0.3) gave 0.50 g (0.13 mmol, 81 %) of 62 as a colorless oil.  
1H NMR (110 °C, 400 MHz, C2D2Cl4): δ = 7.53 (d, J = 2.4 Hz, 1H, 2‘‘-H), 7.37 (dd, J = 
8.5, 2.4 Hz, 1H, 6‘‘-H), 7.05 – 6.91 (m, 3H, 6‘-H, 8‘-H, 5‘‘-H), 5.23 (dq, 2JHF = 48.5 Hz, 
3JHH 6.7 Hz, 1H, 2-H), 4.75 – 4.59 (m, 2H, 5‘-H), 4.25 – 4.06 (m, 2H, 2‘-H), 4.02 – 3.91 
(m, 2H, 3’-H), 3.90 (s, 3H, 4’’-OCH3), 3.87 (s, 3H, 9’-OCH3), 1.52 (dd, 3JHF = 24.6, 3JHH 
= 6.7 Hz, 3H).  
13C NMR (110 °C, 101 MHz, C2D2Cl4): δ = 168.1 (d, 2JCF = 18.8 Hz, C-1), 155.0 (C-4‘‘), 
152.1 (C-9‘), 148.5 (C-9a‘), 135.5 (C-7‘), 134.4 (C-1‘‘), 131.8 (C-5a‘), 128.8 (C-2‘‘), 
126.2 (C-6‘‘), 123.6 (C-3‘‘), 120.3 (C-6‘), 113.4 (C-5‘‘), 112.5 (C-8‘), 87.2 (d, 1JCF = 
178.2 Hz, C-2), 72.5 (C-2‘), 57.1 (9’-OCH3), 56.7 (4’’-OCH3), 49.9 (C-3‘, C-5‘), 17.8 (d, 
2JCF = 22.9 Hz).  
IR (KBr): ṽ (cm-1) = 3442, 2936, 2840, 1659, 1587, 1487, 1440, 1378, 1291, 1255, 
1080, 1063, 1033, 854, 807, 701. 
MS (EI+): m/z (%) = 139 (11), 198 (15), 261 (20), 263 (8), 276 (100), 278 (33), 393 
(100) [M]+•, 395 (36).  
HRMS (EI+): m/z calcd for C20H2135ClFNO4 393.1143, found 393.1139. 
Chapter VII – Experimental Section 
 
163 
 
Purity (HPLC): 98 % (210 nm; method 3a). 
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7-(3-Chloro-4-methoxyphenyl)-9-methoxy-N-methyl-2,3-dihydro-1,4-
benzoxazepine-4(5H)-carbothioamide (63) 
 
  
MF: C19H21ClN2O3S       MW: 392.90 g/mol  
To a solution of 0.15 g (0.47 mmol) 56 in 3.0 mL anhydrous THF was added 0.028 g 
(0.71 mmol) of a 60 % suspension of NaH. After 15 minutes a solution of 0.068 g (0.94 
mmol) methyl isothiocyanate in 1.0 mL anhydrous THF was added and the mixture 
was stirred for three hours at rt. To this mixture was added 30 mL saturated NaHCO3 
solution and this mixture was extracted with DCM (3 x 30 mL) three times. The 
combined organic layers were dried over MgSO4 and concentrated in vacuo. FCC with 
EtOAc and hexanes (3:2, Rf 0.3) gave 0.13 g (0.32 mmol, 69 %) of 63 as a white solid.  
mp: 200 - 201 °C.  
1H NMR (mixture of rotamers, 500 MHz, CDCl3): δ = 7.54 (d, J = 2.3 Hz, 1H, 2‘-H), 
7.38 (dd, J = 8.5, 2.3 Hz, 1H, 6‘-H), 7.07 – 6.81 (m, 3H, 6-H, 8-H, 5‘-H), 5.80 – 5.63 
(m, 1H, NH), 4.85 – 4.66 (m, 2H, 5-H), 4.51 – 4.42 (m, 2H, 3-H), 4.28 – 4.15 (m, 2H, 
2-H), 4.01 – 3.79 (m, 6H, OCH3), 3.15 – 3.05 (m, 3H, NCH3).  
13C NMR (mixture of rotamers, 126 MHz, CDCl3): δ = 182.9 (C=S), 154.5 (C-4‘), 152.2 
(C-9), 147.2 (C-9a), 135.6 (C-7), 133.8 (C-1‘), 130.3 (C-5a), 130.1 (C-5a), 128.7 (C-2‘), 
126.2 (C-6‘), 124.0, 122.8 (C-3‘), 120.4 (C-6), 119.0 (C-6), 112.6 (C-8), 112.3 (C-5‘), 
111.0 (C-8), 72.0 (C-2), 71.9 (C-2), 56.3 (OCH3), 56.1 (OCH3), 54.7 (C-3), 54.4 (C-3), 
52.0 (C-5), 51.8 (C-5), 33.2 (NCH3), 33.1 (NCH3). 
IR (KBr): ṽ (cm-1) = 3388, 2936, 2837, 1530, 1485, 1388, 1342, 1255, 1080, 1063, 
1032, 976, 812, 702, 602. 
MS (EI+): m/z (%) = 115 (97), 139 (17), 261 (28), 263 (12), 275 (28), 276 (98), 277 
(31), 278 (36), 319 (100), 321 (34), 392 (51) [M]+•, 393 (12), 394 (20). 
HRMS (EI+): m/z calcd for C19H2135ClN2O3S 392.0961, found 392.0953. 
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Purity (HPLC): 96 % (210 nm; method 1c). 
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7-(3-Chloro-4-methoxyphenyl)-9-methoxy-2,3-dihydro-1,4-benzoxazepine-4(5H)-
carboxamide (64) 
 
 
MF: C18H19ClN2O4        MW: 362.81 g/mol  
To a solution of 0.10 g (0.31 mmol) 56 in 2 mL DCM was added 0.42 mL (3.1 mmol) 
(trimethylsilyl)isocyanate and the mixture was stirred for 2.5 h. The solvent was 
removed in vacuo. The residue was dissolved in 7 mL DCM and 7 mL of a solution of 
4 M HCl in 1,4-dioxane was added, and the mixture stirred for 1 h. After adjustment to 
pH 9 with 1 M NaOH, the mixture was extracted with DCM (3 x 30 mL) three times. 
The combined organic layers were dried over MgSO4 and concentrated in vacuo. FCC 
with EtOAc and 3 % MeOH (Rf 0.2) gave 0.098 g (0.27 mmol, 87 %) of 64 as a white 
solid.  
mp: 153 - 154 °C.  
1H NMR (400 MHz, CDCl3): δ = 7.46 (d, J = 2.3 Hz, 1H, 2‘-H), 7.30 (dd, J = 8.5, 2.3 
Hz, 1H, 6‘-H), 6.92 – 6.87 (m, 3H, 6-H, 8-H, 5‘-H), 4.72 (s, 2H, NH2), 4.41 (s, 2H, 5-H), 
4.10 – 4.05 (m, 2H, 2-H), 3.85 (s, 3H, 4’-OCH3), 3.83 (s, 3H, 9-OCH3), 3.81 – 3.76 (m, 
2H, 3-H).  
13C NMR (101 MHz, CDCl3): δ = 157.0 (C=O), 153.4 (C-4‘), 151.0 (C-9), 146.5 (C-9a), 
134.4 (C-7), 132.9 (C-1‘), 131.1 (C-5a), 127.6 (C-2‘), 125.1 (C-6‘), 121.7 (C-3‘), 118.1 
(C-6), 111.2 (C-5‘), 109.6 (C-8), 71.5 (C-2), 55.3 (OCH3), 49.4 (C-5), 49.0 (C-3). 
IR (KBr): ṽ (cm-1) = 3370, 3216, 2959, 2936, 2839, 1731, 1653, 1601, 1485, 1440, 
1290, 1255, 1237, 1084, 1063, 1020, 809, 702, 607, 580. 
MS (EI+): m/z (%) = 139 (13), 198 (15), 261 (23), 263 (8), 276 (100), 278 (35), 319 
(56), 321 (20), 362 (80) [M]+•, 364 (28). 
HRMS (EI+): m/z calcd for C18H1935ClN2O4 362.1033, found 362.1029. 
Purity (HPLC): 95 % (210 nm; method 1c). 
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1-[7-(3-Chloro-4-methoxyphenyl)-9-methoxy-2,3-dihydro-1,4-benzoxazepin-
4(5H)-yl]-2-hydroxyethan-1-one (65) 
 
  
MF: C19H20ClNO        MW: 377.82 g/mol  
A solution of 0.10 g (0.31 mmol) 56 in 0.95 mL (10 mmol) ethyl glycolate was heated 
to 60 °C. After 24 h and 48 h, EtOH was removed in vacuo. After 84 h purification by 
FCC with EtOAc and hexanes (5:1, Rf 0.2) gave 0.060 g (0.16 mmol, 51 %) of 65 as a 
white solid.  
mp: 160 – 161 °C.  
1H NMR (mixture of rotamers, 500 MHz, CDCl3): δ = 7.57 (d, J = 2.3 Hz, 0.4H, 2’’-H), 
7.54 (d, J = 2.3 Hz, 0.6H, 2’’-H), 7.42 (dd, J = 8.5, 2.3 Hz, 0.4H, 6’’-H), 7.38 (dd, J = 
8.5, 2.3 Hz, 0.6H, 6’’-H), 7.12 (d, J = 2.2 Hz, 0.4H, 6‘-H), 7.02 – 6.96 (m, 2H, 8‘-H, 5‘‘-
H), 6.87 (d, J = 2.2 Hz, 0.6H, 6‘-H), 4.76 (s, 0.8H, 5‘-H), 4.42 (s, 1.2H, 5‘-H), 4.35 – 
4.31 (m, 1.2H, 2-H), 4.21 – 4.06 (m, 4H, 2-H, 2‘-H, 3‘-H), 3.98 – 3.89 (m, 6H, OCH3), 
3.72 – 3.65 (m, 0.8H, 3‘-H), 3.52 (t, J = 4.4 Hz, 0.4H, OH), 3.48 (t, J = 4.4 Hz, 0.6H, 
OH).  
13C NMR (mixture of rotamers, 126 MHz, CDCl3): δ = 171.2 (C-1), 170.6 (C-1), 154.6 
(C-4‘‘), 154.5 (C-4‘‘), 152.2 (C-9‘), 151.6 (C-9‘), 147.6 (C-9a‘), 147.4 (C-9a‘), 136.0 
(C-7‘), 135.8 (C-7‘), 133.9 (C-1‘‘), 133.7 (C-1‘‘), 131.4 (C-5a‘), 131.1 (C-5a‘), 128.72 
(C-2‘‘), 128.71 (C-2‘‘), 126.24 (C-6‘‘), 126.21 (C-6‘‘), 122.9 (C-3‘‘), 122.8 (C-3‘‘), 120.1 
(C-6‘), 119.0 (C-6‘), 112.3 (C-5‘‘), 112.2 (C-5‘‘), 111.1 (C-8‘), 110.4 (C-8‘), 72.5 (C-2‘), 
72.1 (C-2‘), 60.0 (C-2), 60.0 (C-2), 56.31 (OCH3), 56.28 (OCH3), 56.24 (OCH3), 49.4 
(C-5‘), 49.3 (C-3‘), 49.2 (C-3‘), 48.7 (C-5‘).  
IR (KBr): ṽ (cm-1) = 3399, 3001, 2934, 2842, 1638, 1488, 1389, 1289, 1254, 1076, 
1054, 1022, 861, 808, 707, 584, 573. 
MS (EI+): m/z (%) = 198 (10), 261 (14), 276 (67), 277 (29), 278 (30), 318 (23), 320 
(6), 377 (100) [M]+•, 378 (20), 379 (36). 
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HRMS (EI+): m/z calcd for C19H2035ClNO 377.1030, found 377.1021. 
Purity (HPLC): 97 % (210 nm; method 1c). 
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66 and 68 
 
A solution of 1.3 g (4.5 mmol) 14 in 16 mL anhydrous THF and cooled to - 30 °C under 
N2. 45 mL 1 M BH3-THF solution (45 mmol) was added and the mixture refluxed for 40 
h. A mixture of 15 mL MeOH, 15 mL conc. HCl and 30 mL water was added at rt and 
the mixture was refluxed for 1 h. pH was adjusted to 12 with K2CO3 and the mixure 
was extracted with EtOAc three times. The combined organic layers were dried over 
MgSO4 and concentrated in vacuo. A short FCC with DCM with 5 % MeOH and 2 % 
triethylamine gave the secondary amine as crude intermediate. The standard protocol 
for the N-acylation was applied to equal portions of this intermediate with propionyl 
chloride to obtain 66 or with cyclopropanecarbonyl chloride to obtain 68. 
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1-(7-Bromo-9-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)propan-1-one 
(66) 
 
 
MF: C13H16BrNO2S        MW: 330.24 g/mol  
FCC with EtOAc and hexanes (1:3, Rf 0.2) gave 0.36 g (1.1 mmol, 49 %) of 66 as a 
white solid.  
mp: 118 - 119 °C.  
1H NMR (100 °C, 400 MHz, DMSO-d6): δ = 7.20 (d, J = 2.1 Hz, 1H, 6‘-H), 7.08 (d, J = 
2.1 Hz, 1H, 8‘-H), 4.62 (s, 2H, 5‘-H), 3.93 – 3.86 (m, 2H, 3‘-H), 3.82 (s, 3H, OCH3), 
2.98 – 2.91 (m, 2H, 2‘-H), 2.30 (q, J = 7.4 Hz, 2H, 2-H), 0.97 (t, J = 7.4 Hz, 3H, 3-H).  
13C NMR (ambient temperature, mixture of rotamers, 126 MHz, DMSO-d6): δ = 172.8 
(C-1), 171.9 (C-1), 158.5 (C-9‘), 158.2 (C-9‘), 144.3 (C-5a‘), 142.6 (C-5a‘), 125.8 (C-6‘), 
124.6 (C-6‘), 124.0 (C-9a‘), 123.7 (C-9a‘), 119.9 (C-7‘), 119.6 (C-7‘), 113.4 (C-8‘), 113.0 
(C-8‘), 56.5 (OCH3), 56.4 (OCH3) 50.9 (C-3‘), 50.6 (C-5‘), 50.3 (C-5‘), 47.9 (C-3‘), 33.6 
(C-2‘), 31.7 (C-2‘), 25.8 (C-2), 25.6 (C-2), 9.2 (C-3), 9.1 (C-3).  
IR (KBr): ṽ (cm-1) = 2975, 2936, 1647, 1561, 1452, 1436, 1402, 1286, 1266, 1074, 833, 
756. 
MS (ESI+): m/z (%) = 274 (22), 276 (23), 330 (92) [M + H]+, 332 (100). 
HRMS (ESI+): m/z calcd for [C13H1779BrNO2S]+ 330.0163, found 330.0158 
Purity (HPLC): > 99 % (210 nm; method 5a). 
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1-(7-Bromo-9-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-yl)-1-
(cyclopropyl)methanone (68) 
 
 
MF: C14H16BrNO2S        MW: 342.25 g/mol  
FCC with EtOAc and hexanes (1:3, Rf 0.2) gave 0.34 g (1.0 mmol, 45 %) of 68 as a 
white solid.  
mp: 87 – 88 °C.  
1H NMR (100 °C, 400 MHz, DMSO-d6): δ = 7.34 – 7.19 (m, 1H, 6‘-H), 7.08 (d, J = 2.0 
Hz, 1H, 8‘-H), 4.73 (s, 2H, 5‘-H), 4.11 – 3.93 (m, 2H, 3‘-H), 3.83 (s, 3H, OCH3), 2.96 – 
2.90 (m, 2H, 2‘-H), 1.95 – 1.85 (m, 1H, CH-CH2), 0.73 – 0.66 (m, 4H, CH-CH2).  
13C NMR (ambient temperature, mixture of rotamers, 101 MHz, DMSO-d6): δ = 173.1 
(C-1), 172.0 (C-1), 158.9 (C-9‘), 158.8 (C-9‘), 144.7 (C-5a‘), 144.0 (C-5a‘), 126.2 (C-6‘), 
125.1 (C-6‘), 124.4 (C-9a‘), 124.0 (C-9a‘), 120.35 (C-7‘), 120.33 (C-7‘), 113.9 (C-8‘), 
113.5 (C-8‘), 56.94 (OCH3), 56.91 (OCH3), 51.6 (C-3‘), 51.4 (C-5‘), 51.1 (C-5‘), 49.0 
(C-3‘), 34.3 (C-2‘), 32.4 (C-2‘), 11.7 (CH-CH2), 11.1 (CH-CH2), 8.0 (CH-CH2), 7.5 (CH-
CH2).  
IR (film): ṽ (cm-1) = 3005, 2924, 2854, 1639, 1561, 1451, 1436, 1402, 1285, 1266, 
1081, 1058, 834. 
MS (EI+): m/z (%) = 276 (27), 278 (27), 342 (92) [M + H]+, 344 (100), 434 (87), 436 
(84). 
HRMS (ESI+): m/z calcd for [C14H1779BrNO2S]+ 342.0163, found 342.0157. 
Purity (HPLC): 88 % (210 nm; method 5a). 
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1-[7-(3,4-Dimethoxyphenyl)-9-methoxy-2,3-dihydro-1,4-benzothiazepin-4(5H)-
yl]propan-1-one (67) 
 
 
MF: C21H25NO4S        MW: 387.49 g/mol 
Standard protocol 2 with 0.20 g (0.61 mmol) 66 and 0.22 g (1.2 mmol) 3,4-
dimethoxyphenylboronic acid. FCC with EtOAc and hexanes (1:4, Rf 0.3) gave 0.14 g 
(0.36 mmol, 59 %) of 67 as a white solid.  
mp: 82 - 83 °C.  
1H NMR (mixture of rotamers, 500 MHz, CD2Cl2): δ = 7.37 (d, J = 1.9 Hz, 0.6H, 6’-H), 
7.17 (dd, J = 8.3, 2.2 Hz, 0.6H, 6’’-H), 7.14 (dd, J = 8.3, 2.2 Hz, 0.4H, 6’’-H), 7.11 (d, J 
= 2.2 Hz, 0.6H, 2’’-H), 7.10 (d, J = 1.9 Hz, 0.4H, 6’-H), 7.08 (d, J = 2.2 Hz, 0.4H, 2’’-H), 
7.01 (d, J = 1.9 Hz, 0.4H, 8’-H), 6.98 (d, J = 1.9 Hz, 0.6H, 8’-H), 6.98 – 6.93 (m, 1H, 
5’’-H), 4.82 – 4.64 (m, 2H, 5‘-H), 4.08 – 3.89 (m, 8H, 3‘-H, OCH3), 3.89 – 3.86 (m, 3H, 
OCH3), 2.93 – 2.76 (m, 2H, 2‘-H), 2.44 (q, J = 7.4 Hz, 0.8H, 2-H), 2.27 (q, J = 7.4 Hz, 
1.2H, 2-H), 1.2 (t, J = 7.4 Hz, 3H, 3-H).  
13C NMR (mixture of rotamers, 126 MHz, CD2Cl2): δ = 173.6 (C-1), 172.6 (C-1), 159.4 
(C-9’), 159.2 (C-9’), 149.9 (C-3’’), 149.8 (C-3’’), 149.7 (C-4’’), 149.6 (C-4’’), 144.6 
(C-5a’), 143.4 (C-5a’), 141.4 (C-7’), 141.2 (C-7’), 133.6 (C-1’’), 133.5 (C-1’’), 123.8 
(C-9a’), 123.2 (C-9a’), 122.7 (C-6’), 121.2 (C-6’), 119.84 (C-6’’), 119.79 (C-6’’), 112.2 
(C-5’’), 112.1 (C-5’’), 111.1 (C-2’’), 111.0 (C-2’’), 109.4 (C-8’), 108.8 (C-8’), 56.74 
(OCH3), 56.67 (OCH3), 56.4 (OCH3), 56.30 (OCH3), 56.26 (C-5’), 52.33 (C-3’), 52.25 
(C-5’), 49.7 (C-3’), 35.3 (C-2’), 34.0 (C-2’), 27.11 (CH-CH2), 27.06 (CH-CH2), 9.42 (CH-
CH2), 9.40 (CH-CH2).  
IR (KBr): ṽ (cm-1) = 3441, 2934, 2835, 1646, 1557, 1517, 1458, 1256, 1170, 1025, 952, 
846, 806, 763. 
MS (ESI+): m/z (%) = 388 (100) [M + H]+, 410 (18). 
Chapter VII – Experimental Section 
 
173 
 
HRMS (ESI+): m/z calcd for [C21H26NO4S]+ 388.1583, found 388.1575. 
Purity (HPLC): > 99 % (210 nm; method 2b). 
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1-Cyclopropyl-1-[7-(3,4-dimethoxyphenyl)-9-methoxy-2,3-dihydro-1,4-
benzothiazepin-4(5H)-yl]methanone (69) 
 
 
MF: C22H25NO4S        MW: 399.51 g/mol  
Standard protocol 2 with 0.18 g (0.53 mmol) 68 and 0.25 g (1.4 mmol) 3,4-
dimethoxyphenylboronic acid. FCC with EtOAc and hexanes (1:1, Rf 0.1) gave 0.18 g 
(0.45 mmol, 85 %) of 69 as a white solid.  
mp: 92 - 93 °C.  
1H NMR (100 °C, 400 MHz, DMSO-d6): δ = 7.34 – 7.25 (m, 1H, 6’-H), 7.24 – 7.18 (m, 
2H, 2’’-H, 6’’-H), 7.12 (d, J = 1.9 Hz, 1H, 8’-H), 7.07 – 7.01 (m, 1H, 5’’-H), 4.84 (s, 2H, 
5’-H), 4.08 – 3.98 (m, 2H, 3’-H), 3.90 (s, 3H, 9’-OCH3), 3.87 (s, 3H, 3’’-OCH3), 3.83 (s, 
3H, 4’’-OCH3), 2.97 – 2.90 (m, 2H, 2’-H), 2.06 – 1.92 (m, 1H, CH-CH2), 0.73 – 0.64 (m, 
4H, CH-CH2). 
13C NMR (100 °C, 101 MHz, DMSO-d6): δ = 171.5 (C-1), 157.8 (C-9’), 149.1 (C-3’’), 
148.9 (C-4’’), 142.1 (C-5a’), 139.1 (C-7’), 132.4 (C-1’’), 122.7 (C-9a’), 120.5 (C-6’), 
118.9 (C-2’’/C-6’’), 112.9 (C-5’’), 111.6 (C-2’’/C-6’’), 108.7 (C-8’), 56.0 (OCH3), 55.8 
(OCH3), 55.6 (OCH3), 51.2 (C-5’), 49.2 (C-3’), 32.5 (C-2’), 10.7 (CH-CH2), 6.3 (CH-
CH2). 
IR (KBr): ṽ (cm-1) = 3432, 3075, 3001, 2933, 2835, 1639, 1517, 1455, 1439, 1256, 
1170, 1025, 897, 806, 764. 
MS (ESI+): m/z (%) = 400 (100) [M + H]+. 
HRMS (ESI+): m/z calcd for [C22H26NO4S]+ 400.1583, found 400.1577. 
Purity (HPLC): > 99 % (210 nm; method 2b). 
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1-[7-(3-Chloro-4-methoxyphenyl)-9-methoxy-2,3-dihydro-1,4-benzothiazepin-
4(5H)-yl]-1-(cyclopropyl)methanone (70) 
 
 
MF: C21H22ClNO3S        MW: 403.92 g/mol 
Standard protocol 2 with 0.18 g (0.53 mmol) 68 and 0.26 g (1.4 mmol) 3-chloro-4-
methoxyphenylboronic acid. FCC with EtOAc and hexanes (1:1, Rf 0.2) gave 0.15 g 
(0.37 mmol, 70 %) of 70 as a white solid.  
mp: 95 - 96 °C.  
1H NMR (110 °C, 400 MHz, C2D2Cl4): δ = 7.55 (d, J = 2.4 Hz, 1H, 2‘‘-H), 7.40 (dd, J = 
8.5, 2.4 Hz, 1H, 6‘‘-H), 7.22 – 7.09 (m, 1H, 6‘-H), 7.05 – 6.87 (m, 2H, 8‘-H, 5‘‘-H), 4.81 
(s, 2H, 5‘-H), 4.12 – 3.99 (m, 2H, 3‘-H), 3.98 – 3.84 (m, 6H, OCH3), 2.97 – 2.81 (m, 2H, 
2‘-H), 1.81 – 1.64 (m, 1H, CH-CH2), 0.95 – 0.84 (m, 2H, CH-CH2), 0.77 – 0.63 (m, 2H, 
CH-CH2).  
13C NMR (110 °C, 101 MHz, C2D2Cl4): δ = 172.4 (C-1), 159.2 (C-9‘), 155.2 (C-4‘‘), 
143.4 (C-5a‘), 139.4 (C-7‘), 134.2 (C-1‘‘), 128.9 (C-2‘‘), 126.3 (C-6‘‘), 124.7 (C-9a‘), 
123.7 (C-3‘‘), 121.7 (C-6‘), 113.4 (C-8‘/C-5‘‘), 109.8 (C-8‘/C-5‘‘), 56.9 (OCH3), 56.7 
(OCH3), 52.9 (C-5‘), 50.6, (C-3‘) 34.3 (C-2‘), 12.0 (CH-CH2), 7.3 (CH-CH2).  
IR (KBr): ṽ (cm-1) = 3426, 3003, 2932, 2838, 1638, 1552, 1507, 1452, 1439, 1291, 
1258, 1212, 1063, 1020, 944, 853, 810, 706. 
MS (EI+): m/z (%) = 292 (22), 294 (11), 302 (18), 304 (9), 334 (81), 336 (33), 403 (100) 
[M]+•, 405 (40). 
HRMS (EI+): m/z calcd for C21H2235ClNO3S 403.1009, found 403.0998. 
Purity (HPLC): 95 % (210 nm; method 2b). 
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7-bromo-9-methoxy-1,2,3,4-tetrahydro-1,4-benzodiazepin-5H-5-one (71) 
 
MF: C10H11BrN2O2        MW: 271,11 g/mol 
2.0 g (7.1 mmol) 17 was dissolved under nitrogen atmosphere in 75 mL 1 M (75 mmol) 
BH3-THF. The mixture was refluxed for 24 h. Then the mixture was cooled to 0 °C, 
diluted with 20 mL MeOH, and concentrated in vacuo. 30 mL MeOH and 30 mL conc. 
HCl were added and the mixture was refluxed for one hour. The mixture was then 
cooled, and saturated K2CO3 was added until neutral pH. The mixture was extracted 
with ethyl acetate (3 x 50 mL) three times, the combined organic layers were dried over 
MgSO4 and concentrated in vacuo. FCC with DCM with 3 % MeOH (Rf 0.1) gave 1.4 
g (5.2 mmol, 73 %) of 71 as a colorless oil. 
1H NMR (400 MHz, CD2Cl2): δ = 7.67 (d, J = 2.3 Hz, 1H, 6-H), 6.90 (d, J = 2.3 Hz, 1H, 
8-H), 6.77 (br s, 1H, NH), 3.85 (s, 3H, OCH3), 3.64 – 3.55 (m, 2H, 2-H), 3.51 – 3.40 
(m, 2H, 3-H). 
13C NMR (126 MHz, CD2Cl2): δ = 170.1 (C-5), 148.6 (C-9), 136.7 (C-9a), 127.0 (C-6), 
117.3 (C-5a), 114.9 (C-8), 107.1 (C-7), 56.8 (OCH3), 48.4 (C-2), 42.7 (C-3). 
IR (film): ṽ (cm-1) = 3355, 2936, 2793, 1580, 1486, 1257, 1237, 828. 
MS (EI+): m/z (%) = 104 (14), 106 (17), 226 (20), 228 (19), 241 (23), 242 (12), 270 
(100) [M]+•, 272 (80). 
HRMS (EI+): m/z calcd for C10H11Br79N2O2 270.0004, found 270.0004. 
Purity (HPLC): 76 % (210 nm; method 5). 
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tert-Butyl [2-({[N-(2,2-dimethoxyethyl)-2-
nitrophenyl]sulfonylamino}methyl)phenyl]carbamatea (79) 
 
 
MF: C22H29N3O8S        MW: 495.55 g/mol 
To a vigorously stirred solution of 0.68 g (2.6 mmol) triphenylphosphine in 2.0 mL 
anhydrous THF under N2 atmosphere, 0.48 mL (2.5 mmol) DIAD was added. When a 
homogenous white precipitate formed, 0.72 g (2.5 mmol) N-(2,2-dimethoxyethyl)-2-
nitrobenzenesulfonamide[67] was added and the reaction mixture was treated in an 
ultrasonic bath. After 10 min a solution of 0.50 g (2.2 mmol) tert-butyl [2-
(hydroxymethyl)phenyl]carbamate[97] in 0.5 mL anhydrous THF was added and the 
suspension was sonicated until a clear solution was obtained. The solvent was 
evaporated under reduced pressure and FCC with EtOAc and hexanes (1:3, Rf 0.3) 
followed by a second FCC with pure CH2Cl2 gave 0.65 g (1.3 mmol, 50 %) of 79 as a 
colorless oil. 
1H NMR (500 MHz, CD2Cl2) δ = 7.93 (dd, J = 7.9, 1.4 Hz, 1H, Ar-HNosyl), 7.80 – 7.64 
(m, 4H, 6-H, Ar-HNosyl), 7.57 (br s, 1H, NH), 7.28 (ddd, J = 8.5, 7.3, 1.7 Hz, 1H, 5-H), 
7.10 (dd, J = 7.7, 1.7 Hz, 1H, 3-H), 7.03 – 6.98 (m, 1H, 4-H), 4.57 (s, 2H, 2-CH2-N), 
4.30 (t, J = 5.2 Hz, 1H, (N-CH2-CH(OR)2)), 3.31 (s, 6H, OCH3), 3.27 (d, J = 5.2 Hz, 2H, 
(N-CH2-CH(OR)2)), 1.49 (s, 9H, OC(CH3)3). 
13C NMR (126 MHz, CD2Cl2) δ = 153.6 (C=O), 148.4 (quart. CNosyl), 138.3 (C-1), 134.3 
(CHNosyl), 133.7 (CHNosyl), 132.3 (C-3, CHNosyl), 131.3 (quart. CNosyl), 129.5 (C-4/C-5), 
124.9 (C-2), 124.7 (CHNosyl), 124.1 (C-4/C-5), 122.8 (C-6), 104.3 (N-CH2-CH(OR)2), 
80.5 (OC(CH3)3), 55.4 (OCH3), 49.4 (2-CH2-N), 48.4 (N-CH2-CH(OR)2), 28.5 
(OC(CH3)3). 
IR (film): ṽ (cm-1) = 3355, 3095, 2978, 2936, 1726, 1545, 1368, 1236, 1067, 1160. 
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MS (EI+): m/z (%) = 305 (30), 332 (50), 363 (15), 395 (100), 495 (20) [M]+•. 
HRMS (EI+): m/z calcd for C22H29N3O8S 495.1675, found 495.1669. 
Purity (HPLC): 98 % (210 nm; method 1b). 
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4-[(2-Nitrophenyl)sulfonyl]-2,3,4,5-tetrahydro-1H-1,4-benzodiazepinea (80) 
 
 
MF: C15H15N3O4S        MW: 333.36 g/mol 
To a solution of 0.50 g (1.0 mmol) 79 in 2.0 mL CH2Cl2 under N2 atmosphere, 1.0 mL 
trifluoroacetic acid and 0.40 mL (2.5 mmol) triethylsilane were added in rapid 
succession. After 24 h of stirring 2 M NaOH was added and the mixture extracted three 
times with CH2Cl2. The combined organic layers were dried over MgSO4 and 
concentrated in vacuo. FCC with EtOAc and hexanes (1:2, Rf 0.3) gave 0.31 g (0.93 
mmol, 93 %) of 80 as a yellow solid.  
mp: 125 - 127 °C.  
1H NMR (500 MHz, CD2Cl2) δ = 7.91 – 7.85 (m, 1H, Ar-HNosyl), 7.70 – 7.62 (m, 1H, Ar-
HNosyl), 7.65 – 7.55 (m, 2H, Ar-HNosyl), 7.20 (dd, J = 7.4, 1.5 Hz, 1H, 6-H), 7.12 (td, J = 
7.6, 1.5 Hz, 1H, 8-H), 6.87 (td, J = 7.4, 1.2 Hz, 1H, 7-H), 6.73 (dd, J = 7.9, 1.2 Hz, 1H, 
9-H), 4.44 (s, 2H, 5-H), 3.99 (br s, 1H, NH), 3.64 – 3.58 (m, 2H, 3-H), 3.25 – 3.19 (m, 
2H, 2-H). 
13C NMR (126 MHz, CD2Cl2) δ = 150.0 (C-9a), 148.5 (quart. CNosyl), 133.9 (CHNosyl), 
133.5 (quart. CNosyl), 132.0 (CHNosyl), 130.8 (CHNosyl), 130.4 (C-6), 129.1 (C-8), 128.0 
(C-5a), 124.3 (CHNosyl), 121.3 (C-7), 119.5 (C-9), 52.8 (C-5), 51.9 (C-3), 48.8 (C-2). 
IR (KBr): ṽ (cm-1) = 3378, 3367, 3088, 3020, 2929, 1604, 1548, 1372, 1334, 1163, 766. 
MS (EI+): m/z (%) = 147 (100), 333 (20) [M]+•.  
HRMS (EI+): m/z calcd for C15H15N3O4S 333.0783, found 333.0782. 
Purity (HPLC): 98 % (210 nm; method 1b).  
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4-[(2-Nitrophenyl)sulfonyl]-2,3,4,5-tetrahydro-1H-1,4-benzodiazepinea (81) 
 
 
MF: C9H1335ClN2        MW: 184.67 g/mol 
To a solution of 0.20 g (0.60 mmol) 80 in 1.5 mL acetonitrile were added 0.33 g (2.4 
mmol) K2CO3 and 0.18 mL (1.8 mmol) thiophenol. The mixture was stirred at 50 °C for 
24 h. Then 2 M NaOH was added. The mixture was extracted with CH2Cl2 and the 
combined organic layers were dried over Na2SO4. The solvent was evaporated, and 
the residue dissolved in methanol. A 4 M solution of HCl in 1,4-dioxane was added and 
the mixture cooled to -18 °C overnight. The obtained precipitate was washed with 
diethyl ether to give 67 mg (0.36 mmol, 61 %) of 81 as a white solid.  
mp: 232 – 234 °C.  
1H NMR (500 MHz, DMSO-d6) δ = 9.58 (s, 2H, NH), 7.37 (dd, J = 7.7, 1.5 Hz, 1H, 6-
H), 7.27 (td, J = 7.7, 1.5 Hz, 1H, 8-H), 7.18 (d, J = 7.7 Hz, 1H, 9-H), 7.03 – 6.97 (m, 
1H, 7-H), 4.28 – 4.20 (m, 2H, 5-H), 3.35 – 3.26 (m, 4H, 2-H, 3-H). 
13C NMR (126 MHz, DMSO-d6) δ = 147.6 (C-9a), 131.8 (C-6), 129.6 (C-8), 123.6 
(C-5a), 122.3 (C-7), 120.1 (C-9), 49.1 (C-5), 47.5 (C-3), 44.0 (C-2). 
IR (KBr): ṽ (cm-1) = 3433, 3057, 2926, 2617, 2074, 1977, 1416, 778. 
MS (EI+): m/z (%) = 148 (100) [M]+•. 
HRMS (ESI+): m/z calcd for [(C9H13N2)+] 149.1073, found 149.1073. 
Purity (HPLC): > 99 % (210 nm; method 7b). 
 
 
 
aprepared and characterized by Edgar Uhl for his master thesis. 
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tert-Butyl [4-chloro-2-(hydroxymethyl)phenyl]carbamate (84) 
 
 
MF: C12H16ClNO3        MW: 257.71 g/mol 
To a solution of 1.5 g (6.9 mmol) di-tert-butyl dicarbonate in 5 mL anhydrous THF under 
N2 atmosphere, 1.0 g (6.3 mmol) commercial (2-amino-5-chlorophenyl)methanol was 
added and the resulting solution was stirred at 40 °C for 20 h. The solvent was 
evaporated under reduced pressure and FCC with EtOAc and hexanes (1:8, Rf 0.1) 
gave 0.84 g (3.3 mmol, 52 %) of 84 as a white solid.  
mp: 88 - 89 °C.  
1H NMR (400 MHz, CDCl3): δ = 7.85 (d, J = 8.8 Hz, 1H, 6-H), 7.62 (br s, 1H, NH), 7.25 
(dd, J = 8.8, 2.5 Hz, 1H, 5-H), 7.14 (d, J = 2.5 Hz, 1H, 3-H), 4.63 (d, J = 5.7 Hz, 2H, 
CH2), 2.31 (t, J = 5.7 Hz, 1H, OH), 1.51 (s, 9H, OC(CH3)3).  
13C NMR (101 MHz, CDCl3): δ = 153.4 (C=O), 136.7 (C-1), 130.6 (C-2), 129.0 (C-5), 
128.8 (C-3), 128.1 (C-4), 122.5 (C-6), 81.0 (OC(CH3)3), 63.9 (CH2), 28.5 (OC(CH3)3). 
IR (ATR): ṽ (cm-1) = 3423, 3354, 3006, 2984, 1694, 1515, 1163. 
MS (EI+): m/z (%) = 57 (100), 139 (36), 141 (11), 157 (21), 159 (7), 201 (20), 257 (6) 
[M]+•, 259 (2). 
HRMS (EI+): m/z calcd for C12H1635ClNO3 257.0819, found 257.0812. 
Purity (HPLC): 95 % (210 nm; method 7a). 
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tert-Butyl [4-chloro-2-({[N-(2,2-dimethoxyethyl)-2-
nitrophenyl]sulfonylamino}methyl)phenyl]carbamate (85) 
 
 
MF: C22H28ClN3O8S       MW: 529.99 g/mol 
To a vigorously stirred solution of 0.66 g (2.5 mmol) triphenylphosphine in 2.0 mL 
anhydrous THF under N2 atmosphere, 0.51 mL (2.5 mmol) DIAD was added. When a 
homogenous white precipitate formed, 0.73 g (2.5 mmol) N-(2,2-dimethoxyethyl)-2-
nitrobenzenesulfonamide[67] was added and the reaction mixture was treated in an 
ultrasonic bath. After 10 min a solution of 0.55 g (2.1 mmol) 84 in 1.0 mL anhydrous 
THF was added and the suspension was sonicated until a clear solution was obtained. 
The solvent was evaporated under reduced pressure and FCC with EtOAc and 
hexanes (1:2, Rf 0.4) gave 0.46 g (0.86 mmol, 41 %) of 85 as a colorless oil.  
1H NMR (500 MHz, CD2Cl2): δ = 7.96 (dd, J = 7.9, 1.4 Hz, 1H, Ar-HNosyl), 7.77 – 7.63 
(m, 4H, 6-H, Ar-HNosyl), 7.61 (br s, 1H, NH), 7.21 (dd, J = 8.8, 2.5 Hz, 1H, 5-H), 6.97 (d, 
J = 2.5 Hz, 1H, 3-H), 4.55 (s, 2H, 2-CH2-N), 4.40 (t, J = 5.1 Hz, 1H, N-CH2-CH(OR)2), 
3.38 (s, 6H, (OCH3)), 3.32 (d, J = 5.1 Hz, 2H, N-CH2-CH(OR)2), 1.50 (s, 9H, 
(OC(CH3)3)).  
13C NMR (126 MHz, CD2Cl2): δ = 153.2 (C=O), 147.8 (quart. CNosyl), 136.3 (C-1), 133.9 
(CHNosyl), 133.4 (quart. CNosyl), 131.8 (CHNosyl), 131.1 (CHNosyl), 130.5 (C-3), 129.2 
(C-5), 128.7 (C-2/C-4), 126.1 (C-2/C-4), 124.4 (C-6/CHNosyl), 123.8 (C-6/Ns-CHAr), 
104.3 (N-CH2-CH(OR)2), 80.7 (OC(CH3)3), 55.3 (OCH3), 48.6 (2-CH2-N), 48.1 (N-CH2-
CH(OR)2), 28.3 (OC(CH3)3). 
IR (film): ṽ (cm-1) = 3333, 2978, 1725, 1544, 1368, 1159. 
MS (ESI-): m/z (%) = 289 (28), 528 (100) [M - H]-, 530 (35). 
HRMS (ESI-): m/z calcd for C22H2735ClN3O8S 528.1213, found 528.1218. 
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Purity (HPLC): 96 % (210 nm; method 7a). 
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7-Chloro-4-[(2-nitrophenyl)sulfonyl]-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine 
(86) 
 
 
MF: C15H14ClN3O4S       MW: 367.80 g/mol 
To a solution of 0.15 g (0.28 mmol) 85 in 0.50 mL CH2Cl2 under N2 atmosphere, 0.25 
mL trifluoroacetic acid and 0.11 mL (0.71 mmol) triethylsilane were added in rapid 
succession. After 24 h 30 mL of 2 M NaOH was added and the mixture was extracted 
with CH2Cl2 (3 x 30 mL) three times. The combined organic layers were dried over 
MgSO4 and concentrated in vacuo. FCC with EtOAc and hexanes (1:1, Rf 0.3) followed 
by a second FCC with pure CH2Cl2 gave 0.099 g (0.27 mmol, 96 %) of 86 as a yellow 
solid.  
mp: 140 - 141 °C.  
1H NMR (500 MHz, CDCl3): δ = 7.96 (dd, J = 7.8, 1.5 Hz, 1H, Ar-HNosyl), 7.72 – 7.56 
(m, 3H, Ar-HNosyl), 7.21 (d, J = 2.4 Hz, 1H, H-6), 7.06 (dd, J = 8.4, 2.4 Hz, 1H, H-8), 
6.65 (d, J = 8.4 Hz, 1H, H-9), 4.39 (s, 2H, H-5), 3.91 (br s, 1H, NH), 3.66 – 3.58 (m, 
2H, H-3), 3.26 – 3.20 (m, 2H, H-2).  
13C NMR (126 MHz, CDCl3): δ = 148.0 (C-9a, quart. CNosyl), 133.5 (CHNosyl), 133.2 
(quart. CNosyl), 131.5 (CHNosyl), 130.8 (CHNosyl), 129.9 (C-6), 129.2 (C-7), 128.5 (C-8), 
125.9 (C-5a), 124.0 (CHNosyl), 120.5 (C-9), 52.0 (C-5), 51.3 (C-3), 48.5 (C-2). 
IR (ATR): ṽ (cm-1) = 3408, 3097, 2930, 1531, 1495, 1352, 1126. 
MS (ESI+): m/z (%) = 265 (100), 368 (65) [M + H]+, 370 (20). 
HRMS (ESI+): m/z calcd for [C15H1535ClN3O4S]+ 368.0466, found 368.0475. 
Purity (HPLC): 97 % (210 nm; method 7b). 
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tert-Butyl [2-(hydroxymethyl)-6-methylphenyl]carbamate (88) 
 
 
MF: C13H19NO3                                                                                  MW: 237.30 g/mol 
To a solution of 1.7 g (7.7 mmol) di-tert-butyl dicarbonate in 16 mL anhydrous THF 
under N2 atmosphere, 0.96 g (7.0 mmol) commercial (2-amino-3-
methylphenyl)methanol was added and the resulting solution was stirred at 40 °C for 
2 d. The solvent was evaporated under reduced pressure and FCC with EtOAc and 
hexanes (1:5, Rf 0.2) gave 1.0 g (4.2 mmol, 55 %) of 88 as a white solid. 
mp: 122 - 123 °C. 
1H NMR (400 MHz, DMSO-d6): δ = 8.29 (br s, 1H, NH), 7.32 – 7.27 (m, 1H, 3-H), 7.15 
(t, J = 7.5 Hz, 1H, 4-H), 7.13 – 7.06 (m, 1H, 5-H), 5.04 (t, J = 5.6 Hz, 1H, OH), 4.45 (d, 
J = 5.6 Hz, 2H, 2-CH2), 2.16 (s, 3H, 6-CH3), 1.45 (s, 9H, OC(CH3)3).  
13C NMR (101 MHz, DMSO-d6): δ = 153.6 (C=O), 139.7 (C-2), 135.1 (C-6), 133.0 (C-1), 
128.2 (C-5), 126.1 (C-4), 124.0 (C-3), 78.3 (OC(CH3)3), 59.4 (CH2), 28.1 (OC(CH3)3), 
17.7 (6-CH3). 
IR (KBr): ṽ (cm-1) = 3406, 3265, 2980, 1688, 1516, 1279, 1176, 1056, 773. 
MS (EI+): m/z (%) = 59 (100), 119 (73), 137 (35), 181 (40), 237 (5) [M]+•. 
HRMS (EI+): m/z calcd for C13H19NO3 237.1365, found 237.1356. 
Purity (HPLC): 91 % (210 nm; method 7a). 
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tert-Butyl [2-({[N-(2,2-dimethoxyethyl)-2-nitrophenyl]sulfonylamino}methyl)-6-
methylphenyl]carbamate (89) 
 
 
MF: C23H31N3O8S        MW: 509.57 g/mol 
To a vigorously stirred solution of 0.55 g (2.1 mmol) triphenylphosphine in 2.0 mL 
anhydrous THF under N2 atmosphere, 0.41 mL (2.1 mmol) DIAD was added. When a 
homogenous white precipitate formed, 0.60 g (2.1 mmol) N-(2,2-dimethoxyethyl)-2-
nitrobenzenesulfonamide[67] was added and the reaction mixture was treated in an 
ultrasonic bath. After 10 min 0.44 g (1.9 mmol) 88 was added and the suspension was 
sonicated until a clear solution was obtained. The solvent was evaporated under 
reduced pressure and FCC with EtOAc and hexanes (1:1, Rf 0.5) followed by a second 
FCC with pure CH2Cl2 gave 0.61 g (1.2 mmol, 63 %) of 89 as a colorless oil. 
1H NMR (400 MHz, CD2Cl2): δ = 7.92 (dd, J = 7.9, 1.4 Hz, 1H, Ar-HNosyl), 7.73 – 7.56 
(m, 3H, Ar-HNosyl), 7.18 – 7.10 (m, 1H, 5-H), 7.12 – 6.99 (m, 2H, 4-H, 3-H), 6.69 (br s, 
1H, NH), 4.61 (s, 2H, Ar-CH2-N), 4.31 (t, J = 5.2 Hz, 1H, CH(OR)2), 3.33 – 3.24 (m, 
8H, (N-CH2-CH(OCH3)2)), 2.21 (s, 3H, (6-CH3)), 1.49 (s, 9H, OC(CH3)3).  
13C NMR (101 MHz, CD2Cl2): δ = 154.0 (C=O), 148.2 (quart. CNosyl), 137.0 (C-1), 135.2 
(quart. CNosyl), 134.1 (CHNosyl), 133.8 (C-2/C-6), 132.7 (C-2/C-6), 132.1 (CHNosyl), 131.2 
(CHNosyl), 130.7 (C-5), 127.3 (C-4/C-3), 127.2 (C-4/C-3), 124.5 (CHNosyl), 104.3 
(CH(OR)2), 80.2 (OC(CH3)3), 55.3 (OCH3), 49.44 (N-CH2-CH(OR)2), 49.37 (2-CH2-N), 
28.4 (OC(CH3)3), 18.4 (6-CH3). 
IR (ATR): ṽ (cm-1) = 3330, 3019, 2936, 1710, 1543, 1158. 
MS (ESI-): m/z (%) = 289 (20), 508 (100) [M - H]-, 554 (20). 
HRMS (ESI-): m/z calcd for [C23H30N3O8S]- 508.1759, found 508.1764. 
Purity (HPLC):  > 99 % (210 nm; method 7b). 
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9-Methyl-4-[(2-nitrophenyl)sulfonyl]-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine 
(90) 
 
 
MF: C16H17N3O4S        MW: 347.39 g/mol 
To a solution of 0.42 g (0.82 mmol) 89 in 1.6 mL CH2Cl2 under N2 atmosphere, 0.80 
mL trifluoroacetic acid and 0.33 mL (2.1 mmol) triethylsilane were added in rapid 
succession. After 48 h 50 mL of 2 M NaOH was added and the mixture was extracted 
with CH2Cl2 (3 x 50 mL) three times. The combined organic layers were dried over 
MgSO4 and concentrated in vacuo. FCC with EtOAc and hexanes (1:3, Rf 0.4) gave 
0.17 g (0.43 mmol, 53 %) of 90 as a yellow solid. 
mp: 148 - 149 °C. 
1H NMR (500 MHz, CDCl3): δ = 7.77 (dd, J = 7.9, 1.4 Hz, 1H, Ar-HNosyl), 7.58 – 7.50 
(m, 1H, Ar-HNosyl), 7.50 – 7.39 (m, 2H, Ar-HNosyl), 7.02 (dd, J = 7.4, 1.6 Hz, 1H, 6-H), 
6.94 (dd, J = 7.7, 1.6 Hz, 1H, 8-H), 6.70 (dd, J = 7.7, 7.4 Hz, 1H, 7-H), 4.43 (s, 2H, 5-
H), 3.81 (br s, 1H, NH), 3.61 – 3.56 (m, 2H, 3-H), 3.25 – 3.18 (m, 2H, 2-H), 2.05 (s, 3H, 
(9-CH3)).  
13C NMR (126 MHz, CDCl3): δ = 148.2 (quart. CNosyl), 147.6 (C-9a), 133.4 (quart. 
CNosyl), 133.3 (CHNosyl), 131.4 (CHNosyl), 130.8 (CHNosyl), 130.3 (C-8), 128.6 (C-6), 126.8 
(C-5/C-9a), 125.5 (C-5/C-9a), 123.8 (CHNosyl), 120.6 (C-7), 52.4 (C-5), 51.4 (C-3), 47.7 
(C-2), 17.7 (9-CH3). 
IR (KBr): ṽ (cm-1) = 3406, 3087, 2905, 1732, 1535, 1371, 1160, 1026, 938. 
MS (ESI+): m/z (%) = 219 (13), 348 (100) [M + H]+. 
HRMS (ESI+): m/z calcd for [C16H18N3O4S]+ 348.1013, found 348.1015. 
Purity (HPLC):  > 99 % (210 nm; method 7a). 
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tert-Butyl [2-(hydroxymethyl)-6-methoxyphenyl]carbamate (92) 
 
 
MF: C13H19NO4        MW: 253.30 g/mol 
To a solution of 1.3 g (5.9 mmol) di-tert-butyl dicarbonate in 12 mL anhydrous THF 
under N2 atmosphere, 0.83 g (5.4 mmol) (2-amino-3-methoxyphenyl)methanol[102] was 
added and the resulting solution was stirred at 40 °C for 20 h. The solvent was 
evaporated under reduced pressure and FCC with EtOAc and hexanes (1:3, Rf 0.6) 
gave 0.79 g (3.1 mmol, 58 %) of 92 as a white solid. 
mp: 111 - 112 °C. 
1H NMR (500 MHz, CDCl3): δ = 7.18 – 7.12 (m, 1H, 4-H), 7.04 (dd, J = 7.8, 1.3 Hz, 1H, 
3-H), 6.79 (dd, J = 8.3, 1.3 Hz, 1H, 5-H), 6.52 (br s, 1H, NH), 4.50 (d, J = 5.8 Hz, 2H, 
CH2), 4.14 (br s, 1H), 3.77 (s, 3H, OCH3), 1.49 (s, 9H, OC(CH3)3).  
13C NMR (126 MHz, CDCl3): δ = 155.8 (C=O), 153.1 (C-6), 137.9 (C-2), 126.8 (C-4), 
124.0 (C-1), 122.3 (C-3), 110.0 (C-5), 80.7 (OC(CH3)3), 61.8 (CH2), 55.6 (OCH3), 28.1 
(OC(CH3)3). 
IR (ATR): ṽ (cm-1) = 3463, 3361, 3274, 3016, 2924, 1686, 1531, 1158. 
MS (EI+): m/z (%) = 57 (100), 107 (54), 135 (44), 153 (78), 197 (32), 253 (5) [M]+•. 
HRMS (EI+): m/z calcd for C13H19NO4 253.1314, found 253.1327. 
Purity (HPLC): 99 % (210 nm; method 7b). 
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tert-Butyl [2-({[N-(2,2-dimethoxyethyl)-2-nitrophenyl]sulfonylamino}methyl)-6-
methoxyphenyl]carbamate (93) 
 
 
MF: C23H31ClN3O9S       MW: 525.57 g/mol 
To a vigorously stirred solution of 0.66 g (2.5 mmol) triphenylphosphine in 2.0 mL 
anhydrous THF under N2 atmosphere, 0.51 mL (2.5 mmol) DIAD was added. When a 
homogenous white precipitate formed, 0.73 g (2.5 mmol) N-(2,2-dimethoxyethyl)-2-
nitrobenzenesulfonamide[67] was added and the reaction mixture was treated in an 
ultrasonic bath. After 10 min a solution of 0.50 g (2.0 mmol) 92 in 1.0 mL anhydrous 
THF was added and the suspension was sonicated until a clear solution was obtained. 
The solvent was evaporated under reduced pressure and FCC with EtOAc and 
hexanes (1:2, Rf 0.2) followed by a second FCC with pure CH2Cl2 gave 0.39 g (0.74 
mmol, 37 %) of 93 as a colorless oil. 
1H NMR (400 MHz, CD2Cl2): δ = 7.97 – 7.91 (m, 1H, Ar-HNosyl), 7.71 – 7.57 (m, 3H, Ar-
HNosyl), 7.11 (t, J = 8.1 Hz, 1H, 4-H), 6.88 (dd, J = 8.1, 1.2 Hz, 1H, 3-H), 6.81 (dd, J = 
8.1, 1.2 Hz, 1H, 5-H), 6.31 (br s, 1H, NH), 4.64 (s, 2H, 2-CH2-N), 4.32 (t, J = 5.3 Hz, 
1H, (N-CH2-CH(OR)2), 3.81 (s, 3H, 6-OCH3), 3.32 (d, J = 5.3 Hz, 2H, (N-CH2-
CH(OR)2), 3.22 (s, 6H, CH(OCH3)2), 1.48 (s, 9H, OC(CH3)3).  
13C NMR (101 MHz, CD2Cl2): δ = 154.4 (C=O), 154.3 (C-6), 148.2 (quart. CNosyl), 134.1 
(quart. CNosyl), 133.9 (CHNosyl), 133.8 (C-2), 132.0 (CHNosyl), 131.2 (CHNosyl), 127.2 
(C-4), 125.3 (C-1), 124.4 (CHNosyl), 120.5 (C-3), 110.4 (C-5), 103.7 (N-CH2-CH(OR)2), 
80.6 (OC(CH3)3), 56.2 (6-OCH3), 55.0 ((OCH3)2), 49.6 (N-CH2-CH(OR)2, 49.1 (2-CH2-
N), 28.4 (OC(CH3)3). 
IR (ATR): ṽ (cm-1) = 3011, 2936, 1718, 1543, 1366, 1160, 1068. 
MS (ESI-): m/z (%) = 289 (17), 524 (100) [M - H]-, 570 (14). 
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HRMS (ESI-): m/z calcd for [C23H3035ClN3O9S]- 524.1708, found 524.1707. 
Purity (HPLC): > 99 % (210 nm; method 7b). 
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9-Methoxy-4-[(2-nitrophenyl)sulfonyl]-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine 
(94) 
 
 
MF: C16H17N3O5S        MW: 363.39 g/mol 
To a solution of 0.11 g (0.21 mmol) 93 in 0.5 mL CH2Cl2 under N2 atmosphere, 0.25 
mL trifluoroacetic acid and 0.084 mL (0.53 mmol) triethylsilane were added in rapid 
succession. After 24 h 30 mL of 2 M NaOH was added and the mixture was extracted 
with CH2Cl2 (3 x 30 mL) three times. The combined organic layers were dried over 
MgSO4 and concentrated in vacuo. FCC with EtOAc and hexanes (1:3, Rf 0.3) gave 
0.065 g (0.18 mmol, 86 %) of 94 as a yellow solid.  
mp: 132 – 133 °C. 
1H NMR (500 MHz, CD2Cl2): δ = 7.85 (dd, J = 8.2, 1.5 Hz, 1H, Ar-HNosyl), 7.69 – 7.54 
(m, 3H, Ar-HNosyl), 6.91 – 6.68 (m, 3H, 6-H, 7-H, 8-H), 4.74 (br s, 1H, NH), 4.45 (s, 2H, 
5-H), 3.80 (s, 3H, OCH3), 3.65 – 3.59 (m, 2H, 3-H), 3.24 – 3.19 (m, 2H, 2-H).  
13C NMR (126 MHz, CD2Cl2): δ = 149.6 (C-9), 148.5 (quart. CNosyl), 139.6 (C-9a), 133.8 
(CHNosyl), 133.5 (quart. CNosyl), 131.9 (CHNosyl), 130.8 (CHNosyl), 128.0 (C-5a), 124.2 
(CHNosyl), 122.2 (C-6), 120.4 (C-7/C-8), 110.3 (C-7/C-8), 56.2 (OCH3), 52.6 (C-5), 52.0 
(C-3), 48.3 (C-2). 
IR (ATR): ṽ (cm-1) = 3361, 3013, 2920, 1532, 1158, 1074. 
MS (ESI+): m/z (%) = 364 (100) [M + H]+, 365 (13). 
HRMS (ESI+): m/z calcd for [C16H18N3O5S]+ 364.0962, found 364.0959. 
Purity (HPLC): > 99 % (210 nm; method 7a). 
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1-Benzyl-4-[(2-nitrophenyl)sulfonyl]-2,3,4,5-tetrahydro-1H-1,4-benzodiazepinea 
(95) 
 
 
MF: C22H21N3O4S        MW: 423.49 g/mol 
To a solution of 0.15 g (0.30 mmol) 79 in 0.6 mL CH2Cl2, 0.30 mL trifluoroacetic acid 
and 0.17 mL (1.1 mmol) triethylsilane were added in rapid succession and the resulting 
solution was stirred for 20 h at rt. Then 0.061 mL (0.61 mmol) benzaldehyde were 
added. After 1 d another equivalent of each benzaldehyde, TFA and TES were added. 
The reaction mixture was stirred for 2 d, then diluted with CH2Cl2 and washed with 
NaHCO3. The phases were separated and the aqueous layer was extracted with 
CH2Cl2. The combined organic phases were washed with brine (1x 30 mL), dried over 
Na2SO4 and concentrated in vacuo. FCC with EtOAc and hexanes (1:4, Rf 0.2) gave 
0.068 g (0.21 mmol, 68 %) of 80 and 14 mg (33 µmol, 11 %) of 95 as a yellow oil. 
1H NMR (400 MHz, CD2Cl2) δ = 7.75 (dd, J = 8.1, 1.5 Hz, 1H, Ar-HNosyl), 7.62 – 7.47 
(m, 3H, Ar-HNosyl), 7.30 – 7.11 (m, 7H, 6-H, 8-H, 2’-H, 3’-H, 4’-H, 5’-H, 6’-H), 6.90 – 
6.81 (m, 2H, 7-H, 9-H), 4.49 (s, 2H, 5-H), 4.23 (s, 2H, 1’-CH2), 3.41 – 3.31 (m, 2H, 3-
H), 3.05 – 2.97 (m, 2H, 2-H). 
13C NMR (101 MHz, CD2Cl2) δ = 150.9 (C-9a), 147.3 (quart. CNosyl), 138.0 (C-1’), 132.7 
(CHNosyl), 132.2 (quart. CNosyl), 130.8 (CHNosyl), 129.7 (CHNosyl), 129.3 (C-6/C-8), 128.3 
(C-5a), 128.1 (C-6/C-8), 127.7 (C-3’, C-5’), 127.4 (C-2’, C-6’), 126.4 (C-4’), 123.1 
(CHNosyl), 120.7 (C-7/C-9), 117.0 (C-7/C-9), 56.9 (1’-CH2), 52.2 (C-2), 51.2 (C-5), 48.9 
(C-3). 
IR (KBr): ṽ (cm-1) = 3028, 2920, 1599, 1543, 1495, 1371, 1357, 1163, 762. 
MS (EI+): m/z (%) = 194 (100), 237 (50), 423 (20) [M]+•. 
HRMS (EI+): m/z calcd for C22H21N3O4S 423.1253, found 423.1252. 
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Purity (HPLC): 98 % (210 nm; method 1b).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
aprepared and characterized by Edgar Uhl for his master thesis. 
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7-Chloro-1-methyl-4-[(2-nitrophenyl)sulfonyl]-2,3,4,5-tetrahydro-1H-1,4-
benzodiazepine (96) 
 
 
MF: C16H16ClN3O4S       MW: 381.83 g/mol 
To a solution of 0.15 g (0.28 mmol) 85 in 0.50 mL CH2Cl2 under N2 atmosphere, 0.25 
mL trifluoroacetic acid and 0.11 mL (0.71 mmol) triethylsilane were added in rapid 
succession. After 24 h further 0.33 mL (2.1 mmol) triethylsilane and 0.076 g trioxane 
(0.84 mmol) were added and stirred for further 24 h. 30 mL of 2 M NaOH was added 
and the mixture was extracted with CH2Cl2 (3 x 30 mL) three times. The combined 
organic layers were dried over MgSO4 and concentrated in vacuo. FCC with EtOAc 
and hexanes (1:1, Rf 0.6) gave 0.081 g (0.21 mmol, 79 %) of 96 as a yellow oil.  
1H NMR (400 MHz, CD2Cl2): δ = 7.80 – 7.74 (m, 1H, Ar-HNosyl), 7.62 – 7.56 (m, 1H, Ar-
HNosyl), 7.54 – 7.48 (m, 2H, Ar-HNosyl), 7.14 – 7.06 (m, 2H, 6-H, 8-H), 6.69 (d, J = 8.4 
Hz, 1H, 9-H), 4.34 (s, 2H, 5-H), 3.54 – 3.47 (m, 2H, 3-H), 3.07 – 2.99 (m, 2H, 2-H), 
2.74 (s, 3H, NCH3).  
13C NMR (101 MHz, CD2Cl2): δ = 151.2 (C-9a), 148.6 (quart. CNosyl), 134.2 (CHNosyl), 
133.3 (quart. CNosyl), 132.1 (CHNosyl), 131.0 (CHNosyl), 130.24 (C-5a/C-7), 130.21 (C-6), 
128.9 (C-8) , 125.9 (C-5a/C-7), 124.4 (CHNosyl), 118.1 (C-9), 56.7 (C-2), 52.0 (C-5), 
50.0 (C-3), 42.8 (NCH3). 
IR (ATR): ṽ (cm-1) = 3009, 2860, 1737, 1546, 1494, 1355, 1165, 1084. 
MS (ESI+): m/z (%) = 265 (100), 266 (15), 382 (90) [M + H]+, 384 (26). 
HRMS (ESI+): m/z calcd for [C16H1735ClN3O4S]+ 382.0623, found 382.0630. 
Purity (HPLC): 99 % (210 nm; method 7b). 
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7-(3,5-Dimethoxyphenyl)-9-methoxy-4-[(2-nitrophenyl)sulfonyl]-2,3,4,5-
tetrahydro-1H-1,4-benzodiazepine (97) 
 
 
MF: C24H26N3O7S        MW: 499.54 g/mol 
To a solution of 0.30 g (0.68 mmol) 22, 0.18 g (1.0 mmol) 3,5-dimethoxyphenylboronic 
acid, and 0.051 g (0.070 mmol) [1.1′-bis(diphenylphosphino)ferrocene]-
dichloropalladium(II) in a mixture of 1.0 mL H2O and 4.0 mL 1,4-dioxane, were added 
0.47 mL (2.8 mmol) DIPEA. The mixture was heated to 95 °C for 3.5 h. After cooling 
50 mL water was added and the mixture was extracted with CH2Cl2 (3 x 50 mL) three 
times. The combined organic layers were dried over MgSO4, and concentrated in 
vacuo. FCC with with EtOAc and hexanes (1:1, Rf 0.3) gave 0.22 g (0.44 mmol, 65 %) 
of 97 as a yellow oil. 
1H NMR (500 MHz, CDCl3): δ = 7.93 (dd, J = 7.9, 1.5 Hz, 1H, Ar-HNosyl), 7.67 – 7.50 
(m, 3H, Ar-HNosyl), 7.07 (d, J = 1.9 Hz, 1H, 6-H), 6.94 (d, J = 1.9 Hz, 1H, 8-H), 6.68 (d, 
J = 2.2 Hz, 2H, 2‘-H, 6‘-H), 6.44 (t, J = 2.2 Hz, 1H, 4‘-H), 4.75 (br s, 1H, NH), 4.54 (s, 
2H, 5-H), 3.89 – 3.83 (m, 9H, OCH3), 3.73 – 3.65 (m, 2H, 3-H), 3.32 – 3.24 (m, 2H, 2-
H).  
13C NMR (126 MHz, CDCl3): δ = 161.0 (C-3‘, C-5‘), 149.1 (C-9), 148.1 (quart. CNosyl), 
143.2 (C-1‘), 138.7 (C-9a), 133.3 (C-7, CHNosyl), 133.2 (quart. CNosyl), 131.3 (CHNosyl), 
130.8 (CHNosyl), 127.3 (C-5a), 123.9 (CHNosyl), 120.8 (C-6), 108.7 (C-8), 105.2 (C-2‘, C-
6‘), 98.6 (C-4‘), 55.9 (OCH3), 55.5 (OCH3), 52.4 (C-5), 51.5 (C-3), 47.9 (C-2). 
IR (ATR): ṽ (cm-1) = 3380, 3004, 2934, 1589, 1544, 1463, 1342, 1158. 
MS (ESI+): m/z (%) = 223 (14), 500 (100) [M + H]+, 501 (16), 522 (14).  
HRMS (ESI+): m/z calcd for [C24H26N3O7S]+ 500.1486, found 500.1489. 
Purity (HPLC): 98 % (210 nm; method 7b). 
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7-(3,5-Dimethoxyphenyl)-9-methoxy-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine 
(98) 
 
 
MF: C18H22N2O3        MW: 314.39 g/mol 
To a solution of 0.32 g (0.64 mmol) 97 in 1.6 mL MeCN, 0.36 g (2.9 mmol) K2CO3 and 
0.20 mL (1.9 mmol) thiophenol were added and the mixture was warmed under N2 
atmosphere to 50 °C for 12 h. The solvent was evaporated, and the residue dissolved 
in a mixture of EtOAc and 2 M NaOH (70 mL each). This mixture was extracted with 
EtOAc (5 x 35 mL) five times and the combined organic layers were concentrated in 
vacuo. FCC on a short column with CH2Cl2 with 110 % MeOH (Rf 0.1) gave 0.15 g 
(0.48 mmol, 75 %) of 98 as a colorless oil.  
1H NMR (500 MHz, CD2Cl2): δ = 6.99 – 6.95 (m, 2H, 6-H, 8-H), 6.68 (d, J = 2.2 Hz, 2H, 
2‘-H, 6‘-H), 6.40 (t, J = 2.2 Hz, 1H, 4‘-H), 4.84 (br s, 1H, NH), 3.93 (s, 2H, 5-H), 3.89 
(s, 3H, 9-OCH3), 3.82 (s, 6H, 3‘-OCH3, 5‘-OCH3), 3.15 – 3.09 (m, 2H, 2-H), 3.09 – 3.02 
(m, 2H, 3-H).  
13C NMR (126 MHz, CD2Cl2): δ = 161.5 (C-3‘, C-5‘), 149.7 (C-9), 143.7 (C-1‘), 139.9 
(C-9a), 132.8 (C-7), 131.5 (C-5a), 121.0 (C-6), 108.4 (C-8), 105.2 (C-2‘, C-6‘), 98.8 (C-
4‘), 56.4 (9-OCH3), 55.8 (3‘-OCH3, 5‘-OCH3), 54.2 (C-5), 51.8 (C-3), 50.0 (C-2). 
IR (ATR): ṽ (cm-1) = 3377, 2936, 2837, 1586, 1461, 1153. 
MS (ESI+): m/z (%) = 315 (100) [M + H]+, 316 (12). 
HRMS (ESI+): m/z calcd for [C18H23N2O3]+ 315.1703, found 315.1705. 
Purity (HPLC): 90 % (210 nm; method 1a). 
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1-[7-(3,5-Dimethoxyphenyl)-9-methoxy-1,2,3,5-tetrahydro-4H-1,4-benzodiazepin-
4-yl]propan-1-one (99) 
 
 
MF: C21H26N2O4        MW: 370.45 g/mol 
To a solution of 0.050 g (0.16 mmol) 98 in 1.0 mL CH2Cl2 under N2 atmosphere was 
added 0.080 mL (0.47 mmol) DIPEA and the mixture was cooled to - 78 °C. Then 0.014 
mL (0.16 mmol) propionyl chloride were added. After warming to rt, 20 mL of 2 M NaOH 
was added and the mixture was extracted with CH2Cl2 (3 x 20 mL) three times. The 
combined organic layers were dried over MgSO4 and concentrated in vacuo. FCC with 
EtOAc and hexanes (1:1, Rf 0.1) gave 0.030 g (0.09 mmol, 56 %) of 99 as a yellow oil.  
1H NMR (mixture of rotamers, 500 MHz, CDCl3): δ = 7.20 (d, J = 1.9 Hz, 0.3H, 6‘-H), 
6.99 – 6.93 (m, 1.7H, 6‘-H, 8‘-H), 6.70 (d, J = 2.2 Hz, 0.7H, H-2‘‘, H-6‘‘), 6.68 (d, J = 
2.2 Hz, 1.3H, H-2‘‘, H-6‘‘), 6.44 (t, J = 2.2 Hz, 0.7H, H-4‘‘), 6.41 (t, J = 2.2 Hz, 0.3H, H-
4‘‘), 4.90 – 4.77 (m, 1H, NH), 4.64 (s, 0.7H, 5‘-H), 4.51 (s, 1.3H, 5‘-H), 3.92 – 3.82 (m, 
10.3H, 3‘-H, OCH3), 3.76 – 3.69 (m, 0.7H, 3‘-H), 3.29 – 3.19 (m, 2H), 2.46 (q, J = 7.4 
Hz, 1.3H, 2-H), 2.33 (q, J = 7.4 Hz, 0.7H, 2-H), 1.16 – 1.07 (m, 3H, 3-H).  
13C NMR (mixture of rotamers, 126 MHz, CDCl3): δ = 173.2 (C-1), 172.4 (C-1), 161.1 
(C-3‘‘, C-5‘‘), 160.9 (C-3‘‘, C-5‘‘), 149.4 (C-9‘), 149.0 (C-9‘), 143.4 (C-1‘‘), 143.3 (C-1‘‘), 
138.8 (C-9a‘), 138.2 (C-9a‘), 133.1 (C-7‘), 132.7 (C-7‘), 128.8 (C-5a‘), 127.7 (C-5a‘), 
121.5 (C-6‘), 120.2 (C-6‘), 108.6 (C-8‘), 108.2 (C-8‘), 105.3 (C-2‘‘, C-6‘‘), 105.1 (C-2‘‘, 
C-6‘‘), 98.8 (C-4‘‘), 98.3 (C-4‘‘), 56.0 (OCH3), 55.9 (OCH3), 55.47 (OCH3), 55.45 
(OCH3), 52.3 (C-5‘), 51.1 (C-3‘), 49.3 (C-5‘), 48.5 (C-3‘), 48.1 (C-2‘), 47.2 (C-2‘), 27.0 
(C-2), 26.7 (C-2), 9.3 (C-3). 
IR (ATR): ṽ (cm-1) = 3384, 3000, 2937, 1639, 1585, 1461, 1154, 751. 
MS (ESI+): m/z (%) = 371 (100) [M + H]+, 372 (11), 741 [2xM + H]+. 
HRMS (ESI+): m/z calcd for [C21H27N2O4]+ 371.1965, found 371.1969. 
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Purity (HPLC): 97 % (210 nm; method 7a). 
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Methyl 5-bromo-2-hydroxy-3-{[(2-hydroxyethyl)amino]methyl}benzoate (100) 
 
 
MF: C11H14BrNO4        MW: 304.14 g/mol  
To a solution of 1.7 g (6.5 mmol) methyl 5-bromo-3-formyl-2-hydroxybenzoate7 in a 
mixture of 4 mL MeOH and 36 mL anhydrous THF, 0.48 mL (8.1 mmol) 2-aminoethanol 
was added. The solution was stirred for 0.5 h and then 0.22 g (5.8 mmol) NaBH4 was 
added in portions over 15 minutes. After 1 hour of stirring, the solution was 
concentrated and water and EtOAc were added. The product partially precipitated as 
white solid, the remaining product was extracted from the water phase at alkaline pH 
with EtOAc. After drying over MgSO4 and evaporation of the solvent 1.8 g (6.0 mmol, 
93 %) of 100 were obtained.  
mp: 150 – 151 °C.  
1H NMR (500 MHz, DMSO-d6): δ = 7.69 (d, J = 2.7 Hz, 1H, 6-H), 7.57 (d, J = 2.7 Hz, 
1H, 4-H), 3.86 – 3.80 (m, 5H, OCH3, 3-CH2), 3.49 (t, J = 5.7 Hz, 2H, CH2OH), 2.61 (t, 
J = 5.7 Hz, 2H, HNCH2CH2OH).  
13C NMR (126 MHz, DMSO-d6): δ = 167.3 (C=O), 159.1 (C-2), 135.7 (C-4), 130.6 (C-
6), 129.8 (C-3), 116.1 (C-1/C-5), 108.3 (C-1/C-5), 59.7 (CH2OH), 52.4 (OCH3), 50.4 
(HNCH2CH2OH), 48.3 (3-CH2).  
IR (KBr): ṽ (cm-1) = 3418, 3261, 3000, 2953, 2924, 2844, 2629, 1680, 1445, 1429, 
1288, 1230, 1148, 1016, 978, 882, 804, 684. 
MS (EI+): m/z (%) = 131 (100), 169 (96), 181 (92), 219 (49), 281 (41), 303 (4) [M]+•. 
HRMS (EI+): m/z calcd for C11H1479BrNO4 303.0106, found 303.0095. 
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Methyl 5-bromo-3-{[(tert-butoxycarbonyl)(2-hydroxyethyl)amino]methyl}-2-
hydroxybenzoate (101) 
 
 
MF: C16H22BrNO6        MW: 404.26 g/mol  
To a dispersion of 2.8 g (9.2 mmol) 100 in a mixture of 100 mL EtOAc and 60 mL 
saturated NaHCO3 solution, 2.8 g (13 mmol) di-tert-butyl dicarbonate was added and 
the mixture was stirred for 12 h. The organic layer was separated and the aqueous 
phase extracted with EtOAc three times. The combined organic layers were dried over 
MgSO4 and concentrated in vacuo. FCC with EtOAc and hexanes (1:2, Rf 0.5) gave 
2.1 g (5.2 mmol, 56 %) of 101 as a colorless oil.  
1H NMR (70 °C, 400 MHz, DMSO-d6): δ = 7.81 (d, J = 2.6 Hz, 1H, 6-H), 7.45 (d, J = 
2.6 Hz, 1H, 4-H), 4.44 (s, 2H, 1‘-H), 3.94 (s, 3H, OCH3), 3.51 (t, J = 6.1 Hz, 2H, 2‘‘‘-H), 
3.31 (t, J = 6.1 Hz, 2H, 1‘‘‘-H), 3.10 (br s, 1H, OH), 1.38 (s, 9H, 4‘‘-H).  
13C NMR (70 °C, 101 MHz, DMSO-d6): δ = 168.2 (O=CO), 156.8 (C-2), 154.7 (C-1‘‘), 
135.7 (C-4), 129.9 (C-6), 129.7 (C-1/C-3/C-5), 114.0 (C-1/C-3/C-5), 109.6 (C-1/C-3/C-
5), 78.7 (C-3‘‘), 59.0 (C-2‘‘‘), 52.5 (OCH3), 49.5 (C-1‘‘‘), 45.3 (C-1‘), 27.7 (C-4‘‘).  
IR (film): ṽ (cm-1) = 3441, 3160, 2975, 1677, 1609, 1442, 1366, 1326, 1236, 1162, 996, 
880, 794, 699. 
MS (EI+): m/z (%) = 131 (100), 169 (87), 252 (71), 368 (87), 403 (3) [M]+•. 
HRMS (EI+): m/z calcd for C16H2279BrNO6 403.0630, found 403.0637. 
Purity (HPLC): 96 % (210 nm; method 3a). 
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4-(tert-Butyl) 9-methyl 7-bromo-2,3-dihydro-1,4-benzoxazepine-4,9(5H)-
dicarboxylate (102) 
 
 
MF: C16H20BrNO5        MW: 386.24 g/mol  
To a solution of 2.0 g (7.6 mmol) triphenylphosphine in 50 mL anhydrous THF was 
added 1.5 mL (7.6 mmol) DIAD at 0 °C under N2. After 20 minutes a solution of 2.0 g 
(5.0 mmol) 101 in 80 mL anhydrous THF was added and the mixture was stirred for 16 
h. After concentration in vacuo FCC with EtOAc and hexanes (1:4, Rf 0.3) gave 1.7 g 
(4.3 mmol, 85 %) of 102 as a white solid.  
mp: 89 - 90 °C.  
1H NMR (70 °C, 400 MHz, DMSO-d6): δ = 7.65 (d, J = 2.6 Hz, 1H, 8-H), 7.60 (d, J = 
2.6 Hz, 1H, 6-H), 4.44 (s, 2H, 5-H), 4.09 – 4.03 (m, 2H, 2-H), 3.82 (s, 3H, OCH3), 3.78 
– 3.71 (m, 2H, 3-H), 1.35 (s, 9H, C(CH3)3).  
13C NMR (70 °C, 101 MHz, DMSO-d6): δ = 164.5 (O=CO), 156.5 (C-9a), 153.8 (NC=O), 
135.5 (C-5a/C-7/C-9), 134.9 (C-6), 130.6 (C-8), 126.6 (C-5a/C-7/C-9), 113.8 (C-5a/C-
7/C-9), 79.2 (C(CH3)3), 71.9 (C-2), 51.9 (OCH3), 48.8 (C-3), 48.4 (C-5), 27.6 (C(CH3)3).  
IR (KBr): ṽ (cm-1) = 3420, 3075, 2981, 2962, 2924, 1716, 1691, 1438, 1395, 1292, 
1214, 1170, 1014, 794, 657. 
MS (EI+): m/z (%) = 131 (100), 169 (97), 252 (66), 331 (37), 385 (3) [M]+•. 
HRMS (EI+): m/z calcd for C16H2079BrNO5 385.0525, found 385.0503. 
Purity (HPLC): > 99 % (210 nm; method 3a). 
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Methyl 7-bromo-4-propionyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-9-
carboxylate (103) 
 
 
MF: C14H16BrNO4        MW: 342.19 g/mol  
To a solution of 0.89 g (2.3 mmol) 102 in 5 mL 1,4-dioxane, 10 mL of a 4 M solution of 
HCl in 1,4-dioxane was added. After 5 h the supernatant was removed and the white 
precipitate washed with 5 mL diethyl ether. The solid was dissolved in 10 mL DCM and 
cooled to 0 °C. 1.6 mL (9.2 mmol) DIPEA and 0.40 mL (4.6 mmol) propionyl chloride 
were added. The mixture was warmed to rt and stirred for 12 h. Then 20 mL NaHCO3 
solution was added and the mixture extracted with DCM (3 x 20 mL) three times. The 
combined organic layers were dried over MgSO4 and concentrated in vacuo. FCC with 
EtOAc and hexanes (1:1, Rf 0.3) gave 0.58 g (1.7 mmol, 74 %) of 103 as a white solid.  
mp: 112 - 113 °C.  
1H NMR (100 °C, 400 MHz, DMSO-d6): δ = 7.80 – 7.57 (m, 2H, 6-H, 8-H), 4.62 (s, 2H, 
5-H), 4.17 – 4.11 (m, 2H, 2-H), 3.90 – 3.86 (m, 2H, 3-H), 3.83 (s, 3H, OCH3), 2.34 (q, 
J = 7.4 Hz, 2H, 2‘-H), 0.99 (t, J = 7.4 Hz, 3H, 3‘-H).  
13C NMR (100 °C, 126 MHz, DMSO-d6): δ = 171.8 (C-1’), 164.3 (O=CO), 156.2 (C-9a), 
134.6 (C-6), 134.5 (C-5a), 130.5 (C-8), 126.3 (C-7/C-9), 113.6 (C-7/C-9), 71.7 (C-2), 
51.6 (OCH3), 47.9 (C-3), 47.2 (C-5), 25.1 (C-2’), 8.5 (C-3’). 
IR (KBr): ṽ (cm-1) = 3084, 3023, 2993, 2948, 1733, 1647, 1462, 1443, 1286, 1221, 
1187, 1155, 1024, 889, 798, 681, 640. 
MS (EI+): m/z (%) = 206 (89), 252 (97), 286 (76), 310 (26), 312 (26), 341 (100) [M]+•. 
HRMS (EI+): m/z calcd for C14H1679BrNO4 341.0263, found 341.0260. 
Purity (HPLC): 98 % (210 nm; method 4a). 
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Methyl 7-(3,5-dimethoxyphenyl)-4-propionyl-2,3,4,5-tetrahydro-1,4-
benzoxazepine-9-carboxylate (104) 
 
 
MF: C22H25NO6        MW: 399.44 g/mol  
Standard protocol 2 with 1.0 g (2.9 mmol) 103 and 1.1 g (6.0 mmol) 3,5-
dimethoxyphenylboronic acid. FCC with EtOAc and hexanes (2:1, Rf 0.3) gave 0.84 g 
(2.1 mmol, 72 %) of 104 as a colorless oil.  
1H NMR (100 °C, 400 MHz, DMSO-d6): δ = 7.84 – 7.66 (m, 2H, 6-H, 8-H), 6.76 (d, J = 
2.2 Hz, 2H, 3‘‘-H, 5‘‘-H), 6.53 (t, J = 2.2 Hz, 1H, 4‘‘-H), 4.71 (s, 2H, 5-H), 4.20 – 4.13 
(m, 2H, 2-H), 3.95 – 3.86 (m, 2H, 3-H), 3.85 (s, 3H, O=COCH3), 3.83 (s, 6H, 3’’-OCH3, 
5’’-OCH3), 2.38 (q, J = 7.3 Hz, 2H, 2‘-H), 1.00 (t, J = 7.3 Hz, 3H, 3‘-H).  
13C NMR (100 °C, 101 MHz, DMSO-d6): δ = 171.8 (C-1’), 165.7 (O=CO), 160.7 (C-3’’, 
C-5’’), 156.3 (C-9a), 140.4 (C-1’’), 134.5 (C-7), 132.2 (C-5a/C-9), 130.5 (C-6/C-8), 
126.3 (C-6/C-8), 124.9 (C-5a/C-9), 104.8 (C-2’’, C-6’’), 99.5 (C-4’’), 71.6 (C-2), 55.0 
(3’’-OCH3, 5’’-OCH3), 51.3 (O=COCH3), 48.3 (C-5/C-3), 47.5 (C-5/C-3), 25.2 (C-2’), 8.5 
(C-3’).  
IR (film): ṽ (cm-1) = 2938, 1728, 1648, 1596, 1462, 1295, 1209, 1155, 1041, 816. 
MS (EI+): m/z (%) = 154 (100), 399 (5) [M]+•. 
HRMS (EI+): m/z calcd for C22H25NO6 399.1682, found 399.1662. 
Purity (HPLC): 99 % (210 nm; method 3a). 
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Methyl 7-(3,4-dimethoxyphenyl)-4-propionyl-2,3,4,5-tetrahydro-1,4-
benzoxazepine-9-carboxylate (105) 
 
 
MF: C22H25NO6        MW: 399.44 g/mol  
Standard protocol 2 with 0.30 g (0.88 mmol) 103 and 0.32 g (1.8 mmol) 3,4-
dimethoxyphenylboronic acid. FCC with EtOAc and hexanes (3:1, Rf 0.3) gave 0.28 g 
(0.70 mmol, 80 %) of 105 as a white solid.  
mp: 107 - 108 °C.  
1H NMR (mixture of rotamers, 400 MHz, CDCl3): δ = 7.83 (d, J = 2.5 Hz, 0.5H, 8-H), 
7.81 (d, J = 2.5 Hz, 0.5H, 8-H), 7.72 (d, J = 2.5 Hz, 0.5H, 6-H), 7.49 (d, J = 2.5 Hz, 
0.5H, 6-H), 7.19 – 7.00 (m, 2H, 2‘‘-H, 6‘‘-H), 7.00 – 6.86 (m, 1H, 5‘‘-H), 4.71 (s, 1H, 5-
H), 4.61 (s, 1H, 5-H), 4.23 – 4.14 (m, 2H, 2-H), 4.09 – 4.03 (m, 1H, 3-H), 3.98 – 3.87 
(m, 10H, 3-H, OCH3), 2.46 (q, J = 7.4 Hz, 1H, 2‘-H), 2.32 (q, J = 7.4 Hz, 1H, 2‘-H), 1.18 
– 1.08 (m, 3H, 3‘-H).  
13C NMR (mixture of rotamers, 101 MHz, CDCl3): δ = 172.9 (C-1‘), 172.4 (C-1‘), 166.72 
(O=CO), 166.70 (O=CO), 157.5 (C-9a), 157.4 (C-9a), 149.3 (C-3‘‘/C-4‘‘), 149.2 (C-
3‘‘/C-4‘‘), 149.0 (C-3‘‘/C-4‘‘), 148.8 (C-3‘‘/C-4‘‘), 136.64 (C-7), 136.57 (C-7), 133.6 (C-
5a), 133.20 (C-5a), 132.28 (C-1‘‘), 132.25 (C-1‘‘), 132.18 (C-6), 130.5 (C-6), 128.5 (C-
8), 127.9 (C-8), 125.8 (C-9), 124.7 (C-9), 119.5 (C-6‘‘), 119.4 (C-6‘‘), 111.6 (C-5‘‘), 
111.4 (C-5‘‘), 110.3 (C-2‘‘), 110.2 (C-2‘‘), 73.12 (C-2), 73.06 (C-2), 56.1 (OCH3), 56.0 
(OCH3), 52.4 (OCH3), 52.3 (OCH3), 51.1 (C-3/C-5), 50.9 (C-3/C-5), 48.3 (C-5), 48.3 
(C-3), 26.8 (C-2‘), 26.5 (C-2‘), 9.2 (C-3‘).  
IR (film): ṽ (cm-1) = 2939, 1730, 1651, 1519, 1476, 1256, 1222, 1142, 1025. 
MS (EI+): m/z (%) = 300 (37), 399 (100) [M]+•. 
HRMS (EI+): m/z calcd for C22H25NO6 399.1682, found 399.1682. 
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Purity (HPLC): > 99 % (210 nm; method 1c). 
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7-(3,5-Dimethoxyphenyl)-4-propionyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-9-
carboxylic acid (106) 
 
 
MF: C21H23NO6        MW: 385.42 g/mol 
A solution of 0.30 g (0.75 mmol) 105 in a mixture of 5 mL MeOH, 5 mL THF and 10 mL 
1 M NaOH was heated to 70 °C for 45 min. Then the mixture was acidified with 20 mL 
2 M HCl and extracted with EtOAc (3 x 20 mL) three times. The combined organic 
layers were dried over MgSO4 and concentrated in vacuo. FCC with EtOAc with 2 % 
AcOH (Rf 0.5) gave 0.27 g (0.70 mmol, 93 %) of 106 as a colorless oil.  
1H NMR (90 °C, 400 MHz, DMSO-d6): δ = 7.80 – 7.68 (m, 2H, 6-H, 8-H), 6.76 (d, J = 
2.2 Hz, 2H, 2‘‘-H, 6‘‘-H), 6.52 (t, J = 2.2 Hz, 1H, 4‘‘-H), 4.70 (s, 2H, 5-H), 4.24 – 4.12 
(m, 2H, 2-H), 3.96 – 3.87 (m, 2H, 3-H), 3.83 (s, 6H, OCH3), 2.44 – 2.32 (m, 2H, 2‘-H), 
0.99 (t, J = 7.4 Hz, 3H, 3‘-H).  
13C NMR (90 °C, 101 MHz, DMSO-d6): δ = 171.8 (C-1’), 166.6 (O=COH), 160.7 (C-3’’, 
C-5’’), 156.2 (C-9a), 140.6 (C-1’’), 134.4 (C-7), 132.1 (C-5a), 130.1 (C-6), 130.0 (C-9), 
126.3 (C-8), 104.7 (C-2’’, C-6’’), 99.4 (C-4’’), 71.6 (C-2), 55.0 (OCH3), 49.1 (C-5), 47.1 
(C-3), 25.3 (C-2’), 8.6 (C-3’). 
IR (KBr): ṽ (cm-1) = 3431, 2938, 2839, 1719, 1647, 1597, 1466, 1205, 1155, 839, 729. 
MS (EI+): m/z (%) = 162 (100), 186 (95), 319 (84), 385 (21) [M]+•. 
HRMS (EI+): m/z calcd for C21H23NO6 385.1525, found 385.1519. 
Purity (HPLC): 96 % (210 nm; method 4a). 
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7-(3,4-Dimethoxyphenyl)-4-propionyl-2,3,4,5-tetrahydro-1,4-benzoxazepine-9-
carboxylic acid (107) 
 
 
MF: C21H23NO6        MW: 385.42 g/mol  
A solution of 0.30 g (0.75 mmol) 105 in a mixture of 5 mL MeOH, 5 mL THF and 10 mL 
1 M NaOH was heated to 70 °C for 45 min. Then the mixture was acidified with 20 mL 
2 M HCl and extracted with EtOAc (3 x 20 mL) three times. The combined organic 
layers were dried over MgSO4 and concentrated in vacuo. FCC with EtOAc with 2 % 
AcOH (Rf 0.5) gave 0.25 g (0.65 mmol, 87 %) of 107 as a white solid.  
mp: 97 - 98 °C.  
1H NMR (mixture of rotamers, 400 MHz, C2D2Cl4): δ = 8.28 – 8.16 (m, 1H, 8-H), 7.79 
(d, J = 2.5 Hz, 0.5H, 6-H), 7.59 (d, J = 2.5 Hz, 0.5H, 6-H), 7.16 (dd, J = 8.4, 2.1 Hz, 
0.5H, 6’’-H), 7.13 (dd, J = 8.4, 2.1 Hz, 0.5H, 6’’-H), 7.08 (d, J = 2.1 Hz, 0.5H, 2’’-H), 
7.05 (d, J = 2.1 Hz, 0.5H, 2’’-H), 6.99 – 6.90 (m, 1H, 5’’-H), 4.73 (s, 1H, 5-H), 4.65 (s, 
1H, 5-H), 4.42 – 4.31 (m, 2H, 2-H), 4.14 – 4.06 (m, 1H, 3-H), 4.00 – 3.92 (m, 4H, 3-H, 
OCH3), 3.92 – 3.87 (m, 3H, OCH3), 2.45 (q, J = 7.4 Hz, 1H, 2’-H), 2.31 (q, J = 7.4 Hz, 
1H, 2’-H), 1.15 – 1.05 (m, 3H, 3’-H). 
13C NMR (mixture of rotamers, 101 MHz, C2D2Cl4): δ = 173.0 (C-1‘), 172.7 (C-1‘), 165.2 
(O=COH), 165.1 (O=COH), 156.8 (C-9a), 149.4 (C-3‘‘/C-4‘‘), 149.2 (C-3‘‘/C-4‘‘), 137.9 
(C-7), 137.7 (C-7), 134.1 (C-6), 132.7 (C-6), 132.0 (C-5a), 131.6 (C-5a), 131.4 (C-1‘‘), 
131.3 (C-1‘‘), 130.5 (C-8), 129.8 (C-8), 121.8 (C-9), 121.0 (C-9), 119.7 (C-6‘‘), 111.9 
(C-5‘‘), 111.8 (C-5‘‘), 110.5 (C-2‘‘), 110.3 (C-2‘‘), 74.6 (C-2), 56.3 (OCH3), 56.1 (OCH3), 
50.7 (C-5), 50.0 (C-3), 47.9 (C-5), 47.4 (C-3), 26.8 (C-2‘), 26.6 (C-2‘), 9.32 (C-3‘), 9.28 
(C-3‘).  
IR (KBr): ṽ (cm-1) = 3429, 2975, 2937, 2836, 1724, 1646, 1520, 1475, 1255, 1219, 
1145, 1203, 814, 763, 673. 
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MS (EI+): m/z (%) = 307 (13), 330 (13), 368 (11), 385 (100) [M]+•. 
HRMS (EI+): m/z calcd for C21H23NO6 385.1525, found 385.1518. 
Purity (HPLC): > 99 % (210 nm; method 4a). 
 
 
 
  
Chapter VII – Experimental Section 
 
209 
 
7-(3,5-Dimethoxyphenyl)-N-[2-(piperidin-1-yl)ethyl]-4-propionyl-2,3,4,5-
tetrahydro-1,4-benzoxazepine-9-carboxamide (108) 
 
 
MF: C28H37N3O5        MW: 495.62 g/mol  
Standard protocol 3 with 0.11 g (0.29 mmol) 106 and 0.050 mL (0.35 mmol) 1-(2-
aminoethyl)piperidine. FCC with DCM with 0.6 % MeOH and 3 % triethylamine (Rf 0.3) 
gave 0.055 g (0.11 mmol, 31 %) of 108 as a white solid.  
mp: 88 – 89 °C.  
1H NMR (mixture of rotamers, 400 MHz, CDCl3): δ = 8.55 – 8.48 (m, 0.7H, NH), 8.45 
– 8.39 (m, 0.3H, NH), 8.38 (d, J = 2.5 Hz, 0.7H, 8-H), 8.29 (d, J = 2.5 Hz, 0.3H, 8-H), 
7.71 (d, J = 2.5 Hz, 0.3H, 6-H), 7.49 (d, J = 2.5 Hz, 0.7H, 6-H), 6.74 (d, J = 2.2 Hz, 
0.7H, 2’’-H, 6’’-H), 6.72 (d, J = 2.2 Hz, 1.3H, 2’’-H, 6’’-H), 6.48 (t, J = 2.2 Hz, 0.7H, 4’’-
H), 6.45 (t, J = 2.2 Hz, 0.3H, 4’’-H), 4.73 (s, 0.7H, 5-H), 4.63 (s, 1.3H, 5-H), 4.30 – 4.23 
(m, 2H, 2-H), 4.13 – 4.07 (m, 1.3H, 3-H), 3.96 – 3.92 (m, 0.7H, 3-H), 3.87 – 3.82 (m, 
6H, OCH3), 3.62 – 3.55 (m, 2H, OCHN-CH2), 2.62 – 2.38 (m, 7.3H, 2’-H, N(CH2)3), 
2.33 (q, J = 7.4 Hz, 0.7H, 2’-H), 1.65 – 1.55 (m, 4H, 3’’’-H, 5’’’-H), 1.55 – 1.44 (m, 2H, 
4’’’-H), 1.16 – 1.10 (m, 3H, 3’-H). 
13C NMR (mixture of rotamers, 126 MHz, CDCl3): δ = 173.0 (C-1‘), 172.3 (C-1‘), 164.8 
(O=CNH), 164.4 (O=CNH), 161.2 (C-3‘‘, C-5‘‘), 161.0 (C-3‘‘, C-5‘‘), 157.1 (C-9a), 156.9 
(C-9a), 141.7 (C-1‘‘), 141.6 (C-1‘‘), 137.1 (C-7), 136.9 (C-7), 132.2 (C-6), 132.1 (C-
5a/C-9), 131.7 (C-5a/C-9), 130.6 (C-6), 130.0 (C-8), 129.2 (C-8), 126.0 (C-5a/C-9), 
125.4 (C-5a/C-9), 105.3 (C-2‘‘, C-6‘‘), 105.1 (C-2‘‘, C-6‘‘), 100.0 (C-4‘‘), 99.5 (C-4‘‘), 
73.3 (C-2), 73.2 (C-2), 57.3 (N(CH2)3), 57.2 (N(CH2)3), 55.5 (OCH3), 54.3 (N(CH2)3), 
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51.0 (C-5), 50.4 (C-3), 48.1 (C-5), 47.7 (C-3), 36.62 (OCHN-CH2), 36.56 (OCHN-CH2), 
26.8 (C-2‘), 26.5 (C-2‘), 26.1 (C-3‘‘‘, C-5‘‘‘), 24.4 (C-4‘‘‘), 9.21 (C-3‘), 9.18 (C-3‘). 
IR (film): ṽ (cm-1) = 3381, 2936, 2850, 2807, 1649, 1597, 1518, 1464, 1205, 1155, 
1041, 843, 753. 
MS (EI+): m/z (%) = 162 (24), 269 (100), 353 (26), 410 (34), 495 (14) [M]+•. 
HRMS (EI+): m/z calcd for C28H37N3O5 495.2733, found 495.2734. 
Purity (HPLC): 97 % (210 nm; method 1c). 
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1-{2-[7-(3,4-Dimethoxyphenyl)-4-propionyl-2,3,4,5-tetrahydro-1,4-
benzoxazepine-9-carboxamido]ethyl}piperidin-1-ium chloride (109) 
 
 
MF: C28H38ClN3O5        MW: 532.08 g/mol  
Standard protocol 3 with 0.090 g (0.23 mmol) 107 and 0.033 mL (0.27 mmol) 1-(2-
aminoethyl)piperidine. FCC with DCM with 10 % MeOH (Rf 0.46) gave a colourless oil. 
109 was then precipitated from a solution in 1,4-dioxane as hydrochloride by addition 
of 4 N solution of HCl in 1,4-dioxane. The precipitate was washed with diethyl ether to 
obtain 0.043 g (0.10 mmol, 43 %) of 109 as a white solid.  
mp: 98 – 99 °C.  
1H NMR (mixture of rotamers, 400 MHz, C2D2Cl4): δ = 11.93 (br s, 1H, N+H), 8.78 (br 
s, 1H, OCNH), 8.29 – 8.10 (m, 1H, 8’’-H), 7.75 – 7.61 (m, 0.5H, 6’’-H), 7.55 – 7.44 (m, 
0.5H, 6’’-H), 7.23 – 7.03 (m, 2H, 2’’’’-H, 6’’’’-H), 7.04 – 6.92 (m, 1H, 5’’’’-H), 4.84 – 4.31 
(m, 4H, 2’’-H, 5’’-H), 4.18 – 3.78 (m, 10H, 1’-H/2’-H, 3’’-H, OCH3), 3.66 – 3.44 (m, 2H, 
2-H/6-H), 3.38 – 3.03 (m, 2H, 1’-H/2’-H), 2.90 – 2.55 (m, 2H, 2-H, 6-H), 2.55 – 2.14 (m, 
3H, 3-H/5-H, 2’’’-H), 2.05 – 1.72 (m, 4H, 3-H, 5-H, 4-H), 1.53 – 1.31 (m, 1H, 4-H), 1.19 
– 1.01 (m, 3H, 3’’’-H). 
13C NMR (mixture of rotamers, 101 MHz, C2D2Cl4): δ = 172.9 (C-1’’’), 172.6 (C-1’’’), 
165.8 (OCNH), 165.7 (OCNH), 156.5 (C-9a’’), 156.5 (C-9a’’), 149.04 (C-3’’’’), 148.95 
(C-3’’’’), 148.8 (C-4’’’’), 148.6 (C-4’’’’), 136.4 (C-7’’), 136.1 (C-7’’), 132.2 (C-6’’), 131.9 
(C-1’’’’), 131.8 (C-1’’’’), 131.4 (C-5a’’), 131.3 (C-5a’’), 130.8 (C-6’’), 129.0 (C-8’’), 128.4 
(C-8’’), 124.9 (C-9’’), 123.9 (C-9’’), 119.3 (C-2’’’’/C-6’’’’), 111.54 (C-5’’’’), 111.50 
(C-5’’’’), 110.3 (C-2’’’’/C-6’’’’), 110.1 (C-2’’’’/C-6’’’’), 73.0 (C-2’’), 57.5 (C-1’/C-2’), 57.3 
(C-1’/C-2’), 56.1 (OCH3), 55.9 (OCH3), 54.9 (C-2, C-6), 50.6 (C-5’’), 50.0 (C-3’’), 47.6 
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(C-5’’), 47.5 (C-3’’), 35.6 (C-1’/C-2’), 35.5 (C-1’/C-2’), 26.7 (C-2’’’), 26.4 (C-2’’’), 22.5 
(C-4, C-3, C-5), 21.7 (C-4), 9.2 (C-3’’’), 9.1 (C-3’’’). 
IR (KBr): ṽ (cm-1) = 3432, 2939, 2639, 2535, 1642, 1519, 1470, 1253, 1218, 1022, 872, 
764. 
MS (ESI+): m/z (%) = 496 (100) [M + H]+, 497 (16). 
HRMS (ESI+): m/z calcd for [C28H38N3O5]+ 496.2811, found 496.2804. 
Purity (HPLC): > 99 % (210 nm; method 1c). 
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N-[2-(Diethylamino)ethyl]-7-(3,5-dimethoxyphenyl)-4-propionyl-2,3,4,5-
tetrahydro-1,4-benzoxazepine-9-carboxamide (110) 
 
 
MF: C27H37N3O5        MW: 483.61 g/mol  
Standard protocol 3 with 0.050 g (0.13 mmol) 106 and 0.028 mL (0.20 mmol) N,N-
diethylethylenediamine. FCC with DCM with 0.6 % MeOH and 3 % triethylamine (Rf 
0.3) gave 0.029 g (0.060 mmol, 46 %) of 110 as a colourless oil.  
1H NMR (mixture of rotamers, 400 MHz, CDCl3): δ = 8.50 (s, 0.6H, NH), 8.40 (s, 0.4H, 
NH), 8.37 (d, J = 2.5 Hz, 0.6H, 8-H), 8.29 (d, J = 2.5 Hz, 0.4H, 8-H), 7.70 (d, J = 2.5 
Hz, 0.4H, 6-H), 7.49 (d, J = 2.5 Hz, 0.6H, 6-H), 6.74 (d, J = 2.3 Hz, 0.8H, 2’’-H, 6’’-H), 
6.72 (d, J = 2.3 Hz, 1.2H, 2’’-H, 6’’-H), 6.48 (t, J = 2.3 Hz, 0.6H, 4’’-H), 6.45 (t, J = 2.3 
Hz, 0.4H, 4’’-H), 4.73 (s, 0.8H, 5-H), 4.62 (s, 1.2H, 5-H), 4.29 – 4.19 (m, 2H, 2-H), 4.11 
– 4.05 (m, 1.4H, 3-H), 3.95 – 3.90 (m, 0.6H, 3-H), 3.87 – 3.81 (m, 6H, OCH3), 3.61 – 
3.52 (m, 2H, HNCH2), 2.75 – 2.56 (m, 6H, N(CH2)3), 2.47 (q, J = 7.4 Hz, 1.2H, 2’-H), 
2.33 (q, J = 7.4 Hz, 0.8H, 2’-H), 1.18 – 1.02 (m, 9H, CH2CH3). 
13C NMR (mixture of rotamers, 101 MHz, CDCl3): δ = 173.0 (C-1‘), 172.3 (C-1‘), 164.9 
(O=CNH), 164.5 (O=CNH), 161.2 (C-3‘‘, C-5‘‘), 161.1 (C-3‘‘, C-5‘‘), 157.1 (C-9a), 156.9 
(C-9a), 141.7 (C-1‘‘), 141.6 (C-1‘‘), 137.0 (C-7), 136.9 (C-7), 132.2 (C-6), 132.1 (C-5a), 
131.7 (C-5a), 130.6 (C-6), 130.0 (C-8), 129.2 (C-8), 126.1 (C-9), 125.4 (C-9), 105.3 
(C-2‘‘, C-6‘‘), 105.1 (C-2‘‘, C-6‘‘), 100.0 (C-4‘‘), 99.6 (C-4‘‘), 73.3 (C-2), 73.1 (C-2), 55.5 
(OCH3), 51.5 (N(CH2)3), 51.4 (N(CH2)3), 51.0 (C-5), 50.4 (C-3), 48.1 (C-5), 47.7 (C-3), 
46.8 (N(CH2)3), 46.6 (N(CH2)3), 37.5 (HNCH2), 37.4 (HNCH2), 26.8 (C-2‘), 26.5 (C-2‘), 
11.7 (NCH2CH3), 9.2 (C-3‘). 
IR (film): ṽ (cm-1) = 3375, 2969, 2936, 2838, 1649, 1597, 1517, 1462, 1205, 1153, 
1066, 1042, 985. 
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MS (EI+): m/z (%) = 269 (100), 483 (17) [M]+•. 
HRMS (EI+): m/z calcd for C27H37N3O5 483.2733, found 483.2720. 
Purity (HPLC): 98 % (210 nm; method 1c). 
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7-(3,5-Dimethoxyphenyl)-N-[2-(dimethylamino)ethyl]-4-propionyl-2,3,4,5-
tetrahydro-1,4-benzoxazepine-9-carboxamide (111) 
 
 
MF: C25H33N3O5        MW: 455.56 g/mol  
Standard protocol 3 with 0.11 g (0.29 mmol) 106 and 0.039 mL (0.35 mmol) N,N-
dimethylethylenediamine. FCC with DCM with 1 % MeOH and 1 % triethylamine (Rf 
0.3) gave 0.09 g (0.20 mmol, 69 %) of 111 as a colourless oil.  
1H NMR (mixture of rotamers, 400 MHz, CDCl3): δ = 8.53 – 8.46 (m, 0.7H, NH), 8.40 
– 8.34 (m, 1H, NH, 8-H), 8.28 (d, J = 2.5 Hz, 0.3H, 8-H), 7.71 (d, J = 2.5 Hz, 0.3H, 6-
H), 7.49 (d, J = 2.5 Hz, 0.7H, 6-H), 6.74 (d, J = 2.3 Hz, 0.6H, 2’’-H, 6’’-H), 6.72 (d, J = 
2.3 Hz, 1.4H, 2’’-H, 6’’-H), 6.48 (t, J = 2.3 Hz, 0.7H, 4’’-H), 6.45 (t, J = 2.3 Hz, 0.3H, 4’’-
H), 4.72 (s, 0.7H, 5-H), 4.62 (s, 1.3H, 5-H), 4.23 – 4.16 (m, 2H, 2-H), 4.13 – 4.07 (m, 
1.3H, 3-H), 3.96 – 3.91 (m, 0.7H, 3-H), 3.87 – 3.82 (m, 6H, OCH3), 3.61 – 3.52 (m, 2H, 
HNCH2), 2.57 – 2.50 (m, 2H, (CH2N(CH3)2)), 2.46 (q, J = 7.4 Hz, 1.4H, 2’-H), 2.36 – 
2.25 (m, 6.6H, 2’-H, (N(CH3)2)), 1.18 – 1.09 (m, 3H). 
13C NMR (mixture of rotamers, 101 MHz, CDCl3): δ = 173.0 (C-1‘), 172.2 (C-1‘), 164.8 
(O=CNH), 164.5 (O=CNH), 161.2 (C-3‘‘, C-5‘‘), 161.0 (C-3‘‘, C-5‘‘), 157.0 (C-9a), 156.8 
(C-9a), 141.7 (C-1‘‘), 141.6 (C-1‘‘), 137.2 (C-7), 137.0 (C-7), 132.4 (C-5a), 132.2 (C-6), 
131.9 (C-5a), 130.6 (C-6), 129.9 (C-8), 129.2 (C-8), 126.2 (C-9), 125.5 (C-9), 105.3 
(C-2‘‘, C-6‘‘), 105.2 (C-2‘‘, C-6‘‘), 100.0 (C-4‘‘), 99.6 (C-4‘‘), 73.3 (C-2), 73.2 (C-2), 57.8 
(CH2N(CH3)2), 57.7 (CH2N(CH3)2), 55.5 (OCH3), 51.1 (C-5), 50.5 (C-3), 48.2 (C-5), 
47.8 (C-3), 45.23 (N(CH3)2), 45.19 (N(CH3)2), 37.3 (HNCH2), 26.8 (C-2‘), 26.5 (C-2‘), 
9.2 (C-3‘).  
IR (film): ṽ (cm-1) = 3376, 2939, 2821, 2771, 1650, 1596, 1521, 1461, 1254, 1205, 
1155, 1065, 1041, 1019, 943, 844. 
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MS (EI+): m/z (%) = 269 (74), 385 (100), 455 (10) [M]+•. 
HRMS (EI+): m/z calcd for C25H33N3O5 455.2420, found 455.2426. 
Purity (HPLC): 95 % (210 nm; method 1c). 
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(S)-7-(3,5-Dimethoxyphenyl)-N-(piperidin-3-yl)-4-propionyl-2,3,4,5-tetrahydro-
1,4-benzoxazepine-9-carboxamide (112) 
 
 
MF: C26H33N3O5        MW: 467.57 g/mol 
Standard protocol 3 with 0.75 g (2.0 mmol) 106 and 0.50 g (2.5 mmol) (S)-(+)-3-amino-
1-boc-piperidine. FCC with EtOAc and hexanes (5:1, Rf 0.2) gave a white solid, which 
was dissolved in 3 mL 1,4-dioxane. Then 3 mL of a 4 N solution of HCl in 1,4-dioxane 
was added and the mixture stirred for 16 h. Then 100 mL 1 M NaOH was added and 
the mixture was extracted with DCM (3 x 100mL) three times. The combined organic 
layers were dried over MgSO4. After concentration in vacuo purification by FCC with 
DCM with 5 % MeOH and 2 % triethylamine (Rf 0.2) gave 0.29 g (0.62 mmol, 31 %) of 
112 as a white solid.  
mp: 91 - 92 °C.  
[α]20D = -4.5 (c 0.16, MeOH).  
1H NMR (mixture of rotamers, 500 MHz, C2D2Cl4): δ = 8.40 (br s, 0.6H, O=CNH), 8.35 
– 8.27 (m, 1H, O=CNH, 8-H), 8.27 – 8.22 (m, 0.4H, 8-H), 7.69 (d, J = 2.6 Hz, 0.4H, 6-
H), 7.51 (d, J = 2.6 Hz, 0.6H, 6-H), 6.76 – 6.70 (m, 2H, 2‘‘-H, 6‘‘-H), 6.50 – 6.43 (m, 
1H, 4‘‘-H), 4.77 – 4.56 (m, 2H, 5-H), 4.31 – 3.87 (m, 5H, 2-H, 3-H, 3‘‘‘-H), 3.87 – 3.82 
(m, 6H, OCH3), 3.21 – 3.05 (m, 1H, 2‘‘‘-H), 2.92 – 2.69 (m, 3H, 2‘‘‘-H, 6‘‘‘-H), 2.46 – 
2.39 (m, 1.2H, 2‘-H), 2.32 – 2.26 (m, 0.8H, 2‘-H), 1.91 – 1.55 (m, 4H, 4‘‘‘-H, 5‘‘‘-H), 1.13 
– 1.05 (m, 3H, 3‘-H).  
13C NMR (mixture of rotamers, 126 MHz, C2D2Cl4): δ = 172.8 (C-1‘), 172.2 (C-1‘), 163.7 
(O=CNH), 163.5 (O=CNH), 160.9 (C-3‘‘, C-5‘‘), 156.8 (C-9a), 156.7 (C-9a), 141.2 (C-
1‘‘), 136.5 (C-7), 132.2 (C-5a), 131.9 (C-5a), 131.8 (C-6), 130.5 (C-6), 129.5 (C-8), 
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128.8 (C-8), 125.9 (C-9), 125.3 (C-9), 105.2 (C-2‘‘), 104.9 (C-6‘‘), 99.8 (C-4‘‘), 99.4 (C-
4‘‘), 73.1 (C-2), 55.5 (OCH3), 50.9 (C-5, C-2‘‘‘), 50.7 (C-3‘‘‘), 50.1 (C-3‘‘‘), 47.9 (C-5), 
47.5 (C-3), 46.1 (C-6‘‘‘), 46.0 (C-6‘‘‘), 45.5 (C-3), 29.8 (C-4‘‘‘), 26.6 (C-2‘), 26.4 (C-2‘), 
23.2 (C-5‘‘‘), 23.1 (C-5‘‘‘), 9.1 (C-3‘).  
IR (KBr): ṽ (cm-1) = 3381, 2937, 2839, 2734, 1648, 1597, 1523, 1463, 1205, 1154, 
1040, 831, 811, 756. 
MS (EI+): m/z (%) = 252 (100), 269 (58), 368 (32), 404 (13), 467 (9) [M]+•. 
HRMS (EI+): m/z calcd for C26H33N3O5 467.2420, found 467.2419. 
Purity (HPLC): 98 % (210 nm; method 1c). 
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(R)-7-(3,5-Dimethoxyphenyl)-N-(piperidin-3-yl)-4-propionyl-2,3,4,5-tetrahydro-
1,4-benzoxazepine-9-carboxamide (113) 
 
 
MF: C26H33N3O5        MW: 467.57 g/mol 
Standard protocol 3 with 0.75 g (2.0 mmol) 106 and 0.50 g (2.5 mmol) (R)-(-)-3-amino-
1-boc-piperidine. FCC with EtOAc and hexanes (5:1, Rf 0.2) gave a white solid, which 
was dissolved in 3 mL 1,4-dioxane. 3 mL of a 4 N solution of HCl in 1,4-dioxane was 
added and the mixture stirred for 16 h. Then 100 mL of 1 M NaOH was added and the 
mixture was extracted with DCM (3 x 100 mL) three times. The combined organic 
layers were dried over MgSO4. It was concentrated in vacuo and purification by FCC 
with DCM with 5 % MeOH and 2 % triethylamine (Rf 0.2) gave 0.50 g (1.1 mmol, 55 
%) of 113 as a white solid.  
mp: 91 – 92 °C.  
[α]20D = +4.4 (c 0.16, MeOH).  
1H NMR (mixture of rotamers, 500 MHz, C2D2Cl4): δ = 8.44 (br s, 0.6H, O=CNH), 8.35 
(br s, 0.4H, O=CNH), 8.32 (d, J = 2.5 Hz, 0.6H, 8-H), 8.27 (d, J = 2.5 Hz, 0.4H, 8-H), 
7.69 (d, J = 2.5 Hz, 0.4H, 6-H), 7.51 (d, J = 2.5 Hz, 0.6H, 6-H), 6.75 (d, J = 2.3 Hz, 
0.8H, 2’’-H, 6’’-H), 6.73 (d, J = 2.3 Hz, 1.2H, 2’’-H, 6’’-H), 6.48 (t, J = 2.3 Hz, 0.6H, 4’’-
H), 6.46 (t, J = 2.3 Hz, 0.4H, 4’’-H), 4.79 – 4.57 (m, 2H, 5-H), 4.30 – 3.89 (m, 5H, 2-H, 
3-H, 3’’’-H), 3.87 – 3.82 (m, 6H, OCH3), 3.10 – 3.03 (m, 1H, 2’’’-H), 2.83 – 2.67 (m, 3H, 
2‘‘‘-H, 6‘‘‘-H), 2.47 – 2.38 (m, 1.2H, 2’-H), 2.35 – 2.24 (m, 0.8H, 2’-H), 1.91 – 1.55 (m, 
4H, 4‘‘‘-H, 5‘‘‘-H), 1.12 – 1.07 (m, 3H, 1’-H).  
13C NMR (mixture of rotamers, 126 MHz, C2D2Cl4): δ = 172.8 (C-1’), 172.2 (C-1’), 163.7 
(O=CNH), 163.4 (O=CNH), 160.88 (C-3’’, C-5’’), 160.85 (C-3’’, C-5’’), 156.8 (C-9a), 
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156.7 (C-9a), 141.2 (C-1’’), 136.5 (C-7), 132.3 (C-5a), 131.9 (C-5a), 131.8 (C-6), 130.5 
(C-6), 129.5 (C-8), 128.8 (C-8), 125.9 (C-9), 125.3 (C-9), 105.2 (C-2’’, C-6’’), 104.9 
(C-2’’, C-6’’), 99.8 (C-4’’), 99.4 (C-4’’), 73.1 (C-2), 55.5 (OCH3), 50.7 (C-5, C-2’’’), 50.1 
(C-3’’’), 47.9 (C-5), 47.5 (C-3), 46.1 (C-6’’’), 45.7 (C-6’’’), 45.5 (C-3), 29.8 (C-4’’’), 26.6 
(C-2’), 26.4 (C-2’), 23.2 (C-5’’’), 9.2 (C-3’), 9.1 (C-3’).  
IR (film): ṽ (cm-1) = 3374, 2938, 1651, 1597, 1525, 1463, 1205, 1155. 
MS (EI+): m/z (%) = 83 (100), 269 (10), 368 (2), 467 (0.3) [M]+•. 
HRMS (EI+): m/z calcd for C26H33N3O5 467.2420, found 467.2420. 
Purity (HPLC): 97 % (210 nm; method 1c). 
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(S)-7-(3,5-Dimethoxyphenyl)-N-(1-methylpiperidin-3-yl)-4-propionyl-2,3,4,5-
tetrahydro-1,4-benzoxazepine-9-carboxamide (114) 
 
 
MF: C27H35N3O5        MW: 481.59 g/mol 
To a solution of 0.16 g (0.34 mmol) 112 in 1.0 mL acetonitrile 0.14 mL (1.7 mmol) of a 
35 % solution of formaldehyde in water and 34 mg (0.54 mmol) NaCNBH3 were added. 
The mixture was stirred for 1 h, then 20 mL 2 M NaOH was added and the mixture was 
extracted with DCM (3 x 20 mL) three times. The combined organic layers were dried 
over MgSO4. FCC with DCM with 5 % MeOH (Rf 0.2) gave 0.060 g (0.12 mmol, 35 %) 
of 114 as a white solid.  
mp: 75 – 76 °C.  
[α]20D = -1.7 (c 0.41, MeOH).  
1H NMR (mixture of rotamers, 500 MHz, CDCl3): δ = 8.56 (br s, 0.7H, NH), 8.43 (br s, 
0.3H, NH), 8.36 (d, J = 2.5 Hz, 0.7H, 8-H), 8.28 (d, J = 2.5 Hz, 0.3H, 8-H), 7.71 (d, J = 
2.5 Hz, 0.3H, 6-H), 7.49 (d, J = 2.5 Hz, 0.7H, 6-H), 6.74 (d, J = 2.3 Hz, 0.6H, 2’’-H, 6’’-
H), 6.72 (d, J = 2.3 Hz, 1.4H, 2’’-H, 6’’-H), 6.48 (t, J = 2.2 Hz, 0.7H, 4’’-H), 6.45 (t, J = 
2.2 Hz, 0.3H, 4’’-H), 4.72 (s, 0.6H, 5-H), 4.62 (s, 1.4H, 5-H), 4.34 – 4.28 (m, 1H, 3‘‘‘-
H), 4.24 – 4.19 (m, 2H, 2-H), 4.14 – 4.08 (m, 1.4H, 3-H), 3.97 – 3.91 (m, 0.6H, 3-H), 
3.87 – 3.83 (m, 6H, OCH3), 2.65 – 2.30 (m, 5H, 2‘-H, 2‘‘‘-H, 6‘‘‘-H), 2.29 – 2.26 (s, 3H, 
NCH3), 2.23 – 2.13 (m, 1H, 6‘‘‘-H), 1.78 – 1.71 (m, 2H, 4‘‘‘-H, 5‘‘‘-H), 1.67 – 1.58 (m, 
2H, 4‘‘‘-H, 5‘‘‘-H), 1.15 – 1.11 (m, 3H, 3‘-H).  
13C NMR (mixture of rotamers, 101 MHz, CDCl3): δ = 173.0 (C-1‘), 172.2 (C-1‘), 163.8 
(O=CNH), 163.4 (O=CNH), 161.2 (C-3‘‘, C-5‘‘), 161.0 (C-3‘‘, C-5‘‘), 157.0 (C-9a), 156.8 
(C-9a), 141.7 (C-1‘‘), 141.6 (C-1‘‘), 137.2 (C-7), 137.1 (C-7), 132.5 (C-5a), 132.1 (C-
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6), 132.0 (C-5a), 130.5 (C-6), 129.9 (C-8), 129.2 (C-8), 126.4 (C-9), 125.8 (C-9), 105.3 
(C-2‘‘, C-6‘‘), 105.2 (C-2‘‘, C-6‘‘), 100.0 (C-4‘‘), 99.6 (C-4‘‘), 73.3 (C-2), 60.5 (C-2‘‘‘), 
60.4 (C-2‘‘‘), 56.0 (C-6‘‘‘), 55.5 (OCH3), 51.1 (C-5), 50.5 (C-3), 48.3 (C-5), 47.9 (C-3), 
46.7 (NCH3), 45.5 (C-3‘‘‘), 45.4 (C-3‘‘‘), 28.5 (C-4‘‘‘), 28.4 (C-4‘‘‘), 26.8 (C-2‘), 26.5 (C-
2‘), 22.1 (C-5‘‘‘), 22.0 (C-5‘‘‘), 9.20 (C-3‘), 9.18 (C-3‘). 
IR (KBr): ṽ (cm-1) = 3429, 2937, 2842, 2786, 1654, 1599, 1521, 1463, 1205, 1154, 
1041, 1019, 843, 816. 
MS (EI+): m/z (%) = 269 (100), 385 (47), 481 (5) [M]+•. 
HRMS (EI+): m/z calcd for C27H35N3O5 481.2577, found 481.2591. 
Purity (HPLC): 96 % (210 nm; method 1c). 
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(R)-7-(3,5-Dimethoxyphenyl)-N-(1-methylpiperidin-3-yl)-4-propionyl-2,3,4,5-
tetrahydro-1,4-benzoxazepine-9-carboxamide (115) 
 
 
MF: C27H35N3O5        MW: 481.59 g/mol  
To a solution of 0.27 g (0.58 mmol) 113 in 1.7 mL acetonitrile 0.23 mL (2.9 mmol) of a 
35 % solution of formaldehyde in water and 58 mg (0.92 mmol) NaCNBH3 was added. 
The mixture was stirred for 1 h, then 50 mL 2 M NaOH was added and the mixture was 
extracted with DCM (3 x 50 mL) three times. The combined organic layers were dried 
over MgSO4. FCC with DCM with 5 % MeOH (Rf 0.2) gave 0.10 g (0.21 mmol, 36 %) 
of 115 as a white solid.  
mp: 75 – 76 °C.  
[α]20D = +1.6 (c 0.40, MeOH)  
1H NMR (mixture of rotamers, 400 MHz, CDCl3): δ = 8.56 (br s, 0.7H, NH), 8.43 (br s, 
0.3H, NH), 8.35 (d, J = 2.5 Hz, 0.7H, 8-H), 8.27 (d, J = 2.5 Hz, 0.3H, 8-H), 7.71 (d, J = 
2.5 Hz, 0.3H, 6-H), 7.49 (d, J = 2.5 Hz, 0.7H, 6-H), 6.74 (d, J = 2.3 Hz, 0.6H, 2’’-H, 6’’-
H), 6.71 (d, J = 2.3 Hz, 1.4H, 2’’-H, 6’’-H), 6.48 (t, J = 2.2 Hz, 0.7H, 4’’-H), 6.45 (t, J = 
2.3 Hz, 0.3H, 4’’-H), 4.72 (s, 0.6H, 5-H), 4.62 (s, 1.4H, 5-H), 4.34 – 4.28 (m, 1H, 3’’’-
H), 4.25 – 4.18 (m, 2H, 2-H), 4.13 – 4.08 (m, 1.4H, 3-H), 3.98 – 3.90 (m, 0.6H, 3-H), 
3.86 – 3.82 (m, 6H, OCH3), 2.62 – 2.30 (m, 5H, 2‘-H, 2‘‘‘-H, 6‘‘‘-H), 2.28 (s, 3H, NCH3), 
2.23 – 2.13 (m, 1H, 6‘‘‘-H), 1.78 – 1.70 (m, 2H, 4‘‘‘-H, 5‘‘‘-H), 1.67 – 1.57 (m, 2H, 4‘‘‘-
H, 5‘‘‘-H), 1.16 – 1.09 (m, 3H, 3‘-H).  
13C NMR (mixture of rotamers, 101 MHz, CDCl3): δ = 173.1 (C-1’), 172.2 (C-1’), 163.8 
(O=CNH), 163.4 (O=CNH), 161.2 (C-3‘‘, C-5‘‘), 161.1 (C-3‘‘, C-5‘‘), 157.0 (C-9a), 156.8 
(C-9a), 141.7 (C-1‘‘), 141.6 (C-1‘‘), 137.2 (C-7), 137.1 (C-7), 132.5 (C-5a), 132.1 (C-
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6), 132.0 (C-5a), 130.5 (C-6), 129.9 (C-8), 129.2 (C-8), 126.4 (C-9), 125.8 (C-9), 105.3 
(C-2‘‘, C-6‘‘), 105.2 (C-2‘‘, C-6‘‘), 100.0 (C-4‘‘), 99.6 (C-4‘‘), 73.3 (C-2), 60.4 (C-2‘‘‘), 
56.0 (C-6‘‘‘), 55.5 (OCH3), 51.1 (C-5), 50.5 (C-3), 48.3 (C-5), 47.9 (C-3), 46.7 (NCH3), 
45.5 (C-3‘‘‘), 45.4 (C-3‘‘‘), 28.4 (C-4‘‘‘), 26.8 (C-2‘), 26.5 (C-2‘), 22.1 (C-5‘‘‘), 9.2 (C-3‘).  
IR (KBr): ṽ (cm-1) = 3376, 2938, 2842, 2789, 1652, 1600, 1523, 1465, 1206, 1156. 
MS (ESI+): m/z (%) = 482 (100) [M + H]+, 483 (12). 
HRMS (ESI+): m/z calcd for [C27H36N3O5]+ 482.2649, found 482.2650. 
Purity (HPLC): > 99 % (210 nm; method 1a). 
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Standard protocol for the N-methylation of aromatic amines and N-heterocycles 
 
Under nitrogen atmosphere 1.0 mmol of N-containing substance and 3.0 mmol of 
trioxane were dissolved in 1.5 mL CH2Cl2. To this solution 0.75 mL TFA and 1.45 mL 
(10 mmol) triethylsilane were added. Reaction was monitored by tlc. After 24 or 48 
hours (in case of incomplete conversion after 24 hours), 20 mL of 2 N NaOH solution 
were carefully added and the mixture was extracted three times with 20 mL of CH2Cl2. 
The combined organic layers were dried over MgSO4 and concentrated in vacuo. FCC 
was used for purification. 
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1-Methyl-1,2,3,4-tetrahydroquinoline* (118) 
 
 
MF: C10H13N         MW: 147.22 g/mol 
 
Standard TTT protocol with 0.45 g (3.4 mmol) 1,2,3,4-tetrahydroquinoline. Standard 
protocol workup after 48 h and purification by FCC with hexanes and EtOAc (20:1, Rf 
0.5) gave 0.32 g (2.2 mmol, 64 %) of 118 as a colorless oil. 
 
1H NMR (500 MHz, CDCl3): δ = 7.15 – 7.11 (m, 1H, 7-H), 7.02 – 6.99 (m, 1H, 5-H), 
6.68 – 6.63 (m, 2H, 8-H, 6-H), 3.28 – 3.25 (m, 2H, 2-H), 2.93 (s, 3H, CH3), 2.84 – 2.80 
(m, 2H, 4-H), 2.07 – 2.00 (m, 2H, 3-H). 
 
13C NMR (126 MHz, CDCl3): δ = 146.9 (8a), 128.9 (C-5), 127.1 (C-7), 123.0 (C-4a), 
116.3 (C-6), 111.1 (C-8), 51.4 (C-2), 39.2 (CH3), 27.9 (C-4), 22.6 (C-3). 
 
IR (film): ṽ (cm-1) = 3065, 2927, 2862, 1602, 1507, 1321, 1208. 
 
MS (EI+): m/z (%) = 91 (21), 131 (23), 146 (100) [M – H]+, 147 (87) [M]+•. 
 
HRMS (EI+): m/z calcd for C10H13N: 147.1048; found: 147.1031. 
 
Purity (HPLC): > 99 % (210 nm; method 6a). 
 
 
 
 
 
 
*Known compound, novel synthesis. 
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N-Methyl-N-phenylaniline* (120) 
 
 
MF: C13H13N         MW: 183.25 g/mol 
 
Standard TTT protocol with 0.36 g (2.2 mmol) diphenylamine. Standard protocol 
workup after 24 h and purification by FCC with hexanes and EtOAc (10:1, Rf 0.5) gave 
0.35 g (1.9 mmol, 89 %) of 120 as a colorless oil.  
 
1H NMR (400 MHz, CDCl3): δ = 7.28 – 7.22 (m, 4H, 3-H, 5-H), 7.03 – 6.98 (m, 4H, 2-H, 
6-H), 6.93 (tt, J = 7.3, 1.1 Hz, 2H, 4-H), 3.29 (s, 3H, CH3). 
 
13C NMR (126 MHz, CDCl3): δ = 149.1 (C-1), 129.3 (C-3, C-5), 121.4 (C-4), 120.5 (C-2, 
C-6), 40.3 (CH3). 
 
IR (film): ṽ (cm-1) = 3060, 3035, 2939, 2878, 1591, 1496, 1342, 1252, 1131. 
 
MS (EI+): m/z (%) = 77 (32), 104 (17), 168 (11), 183 (100) [M]+•. 
 
HRMS (EI+): m/z calcd for C13H13N: 183.1048; found: 183.1036. 
 
Purity (HPLC): > 99 % (210 nm; method 6a). 
 
 
 
 
 
 
 
 
 
*Known compound, novel synthesis. 
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N-Benzyl-N-methylaniline* (121) 
 
  
MF: C14H15N         MW: 197.28 g/mol 
 
Standard TTT protocol with 0.35 g (1.9 mmol) N-benzylaniline. Standard protocol 
workup after 48 h and purification by FCC with hexanes and EtOAc (10:1, Rf 0.6) gave 
0.19 g (0.96 mmol, 51 %) of 121 as a yellow oil. 
 
1H NMR (500 MHz, CDCl3): δ = 7.33 – 7.27 (m, 2H, 3‘-H, 5‘-H), 7.25 – 7.18 (m, 5H, 3-
H, 5-H, 2‘-H, 4‘-H, 6‘-H), 6.77 – 6.72 (m, 2H, 2-H, 6-H), 6.72 – 6.68 (m, 1H, 4-H), 4.51 
(s, 2H, CH2), 2.99 (s, 3H, CH3). 
 
13C NMR (126 MHz, CDCl3): δ = 149.9 (C-1), 139.1 (C-1‘), 129.3 (C-3, C-5), 128.7 
(C-3‘, C-5‘), 127.0 (C-4‘), 126.8 (C-2‘, C-6‘), 116.6 (C-4), 112.5 (C-2, C-6), 56.7 (CH2), 
38.6 (CH3). 
 
IR (film): ṽ (cm-1) = 3061, 3026, 2894, 1599, 1506, 1451, 1354. 
 
MS (EI+): m/z (%) = 91 (100), 120 (59), 197 (71) [M]+•. 
 
HRMS (EI+): m/z calcd for C14H15N: 197.1204; found: 197.1198. 
 
Purity (HPLC): 96 % (210 nm; method 6a). 
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Ethyl 4-(N-methylamino)benzoate (123) and ethyl 4-(N,N-
dimethylamino)benzoate (124) 
 
Standard TTT protocol with 0.31 g (1.9 mmol) ethyl 4-aminobenzoate (benzocaine). 
Standard protocol workup after 48 h and purification by FCC with hexanes and EtOAc 
(5:1, Rf 0.5 and 0.3) gave 0.13 g (0.73 mmol, 38 %) of ethyl 4-(methylamino)benzoate 
(123) and 0.21 g (1.1 mmol, 57 %) of ethyl 4-(dimethylamino)benzoate (124) as white 
solids. 
 
Ethyl 4-(N-methylamino)benzoate* (123) 
 
 
MF: C10H13NO2        MW: 179.22 g/mol 
 
mp: 62 - 63 °C [Lit[128].: 59 – 62 °C]. 
 
1H NMR (500 MHz, CDCl3): δ = 7.90 – 7.86 (m, 2H, 2-H, 6-H), 6.57 – 6.53 (m, 2H, 3-
H, 5-H), 4.31 (q, J = 7.1 Hz, 2H, CH2CH3), 4.19 (br s, 1H, NH), 2.88 (s, 3H, NCH3), 
1.36 (t, J = 7.1 Hz, 3H, CH2CH3). 
 
13C NMR (126 MHz, CDCl3): δ = 167.0 (C=O), 152.9 (C-4), 131.6 (C-2, C-6), 118.7 
(C-1), 111.2 (C-3, C-5), 60.3 (CH2CH3), 30.3 (NCH3), 14.6 (CH2CH3). 
 
IR (KBr): ṽ (cm-1) = 3383, 2962, 2936, 2903, 1680, 1602, 1538, 1276, 1174, 835. 
 
MS (EI+): m/z (%) = 106 (10), 134 (100), 151 (19), 179 (68) [M]+•. 
 
HRMS (EI+): m/z calcd for C10H13NO2: 179.0946; found: 179.0947. 
 
Purity (HPLC): > 99 % (210 nm; method 6a). 
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Ethyl 4-(N,N-dimethylamino)benzoate* (124) 
 
 
MF: C11H15NO2        MW: 193.25 g/mol 
 
mp: 61 - 62 °C [Lit[129].: 65 – 66 °C]. 
 
1H NMR (500 MHz, CDCl3): δ = 7.93 – 7.89 (m, 2H, 2-H, 6-H), 6.64 – 6.60 (m, 2H, 3-
H, 5-H), 4.31 (q, J = 7.1 Hz, 2H, OCH2), 3.00 (s, 6H, N(CH3)2), 1.36 (t, J = 7.1 Hz, 3H, 
CH2CH3). 
 
13C NMR (126 MHz, CDCl3): δ = 167.0 (C=O), 153.2 (C-4), 131.2 (C-2, C-6), 117.3 
(C-1), 110.7 (C-3, C-5), 60.1 (OCH2), 40.0 (N(CH3)2), 14.5 (CH2CH3). 
 
IR (KBr): ṽ (cm-1) = 2982, 2903, 2820, 1695, 1611, 1365, 1283, 1186, 1106. 
 
MS (EI+): m/z (%) = 148 (100), 164 (41), 193 (68) [M]+•. 
 
HRMS (EI+): m/z calcd for C11H15NO2: 193.1103; found: 193.1088. 
 
Purity (HPLC): > 99 % (210 nm; method 6a). 
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2-(Dimethylamino)ethyl 4-(N-butyl-N-methylamino)benzoate (122) 
 
 
MF: C16H26N2O2        MW: 278.40 g/mol 
 
Standard TTT protocol with 0.57 g (1.9 mmol) 2-(dimethylamino)ethyl 4-(N-
butylamino)benzoate (tetracaine) hydrochloride. Standard protocol workup after 48 h 
and purification by FCC with CH2Cl2 with 10 % MeOH (Rf 0.2) gave 0.27 g (0.97 mmol, 
51 %) of 122 as a colorless oil.  
 
1H NMR (500 MHz, CD2Cl2): δ = 7.76 – 7.73 (m, 2H, 2-H, 6-H), 6.54 – 6.51 (m, 2H, 3-
H, 5-H), 4.21 (t, J = 5.9 Hz, 2H, 1‘-H), 3.28 – 3.24 (m, 2H, 1‘‘-H), 2.88 (s, 3 H, 4-N-
CH3), 2.54 (t, J = 5.9 Hz, 2H, 2‘-H), 2.19 (s, 6H, N(CH3)2), 1.50 – 1.43 (m, 2H, 2‘‘-H), 
1.29 – 1.20 (m, 2H, 3‘‘-H), 0.85 (t, J = 7.3 Hz, 3H, 4‘‘-H). 
 
13C NMR (126 MHz, CD2Cl2): δ = 167.1 (C=O), 153.0 (C-4), 131.7 (C-2, C-6), 117.0 
(C-1), 110.9 (C-3, C-5), 62.7 (C-1‘), 58.6 (C-2‘), 52.6 (C-1‘‘), 46.1 (N(CH3)2), 38.7 (4-N-
CH3), 29.5 (C-2‘‘), 20.8 (C-3‘‘), 14.3 (C-4‘‘). 
 
IR (film): ṽ (cm-1) = 2956, 2873, 2770, 1703, 1607, 1525, 1278, 1184, 1111. 
 
MS (EI+): m/z (%) = 58 (100), 164 (53), 207 (38), 278 (0.2) [M]+•. 
 
HRMS (EI+): m/z calcd for C16H26N2O2: 278.1994; found: 278.1997. 
 
Purity (HPLC): > 99 % (210 nm; method 6b). 
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N,N-Dimethyl-4-nitroaniline* (125) 
 
 
MF: C8H10N2O2        MW: 166.18 g/mol 
 
Standard TTT protocol with 0.26 g (1.9 mmol) 4-nitroaniline. Standard protocol workup 
after 48 h and purification by FCC with hexanes and EtOAc (5:1, Rf 0.3) gave 0.31 g 
(1.9 mmol, 98 %) of 125 as a yellow solid. 
 
mp: 162 - 163 °C [Lit[130].: 162 – 165 °C]. 
 
1H NMR (500 MHz, CD2Cl2): δ = 8.12 – 8.05 (m, 2H, 3-H, 5-H), 6.65 – 6.60 (m, 2H, 2-
H, 6-H), 3.09 (s, 6H, N(CH3)2). 
 
13C NMR (126 MHz, CD2Cl2): δ = 154.7 (C-1), 137.1 (C-4), 126.3 (C-3, C-5), 110.6 
(C-2, C-6), 40.5 (N(CH3)2). 
 
IR (KBr): ṽ (cm-1) = 3424, 2924, 1735, 1601, 1582, 1485, 1457, 1310, 1116. 
 
MS (EI+): m/z (%) = 105 (18), 119 (26), 136 (28), 166 (100) [M]+•. 
 
HRMS (EI+): m/z calcd for C8H10N2O2: 166.0742; found: 166.0738. 
 
Purity (HPLC): 96 % (210 nm; method 6a). 
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N,N-Dimethyl-2,4,6-trichloroaniline* (126) 
 
 
MF: C8H8Cl3N        MW: 224.51 g/mol 
 
Standard TTT protocol with 0.37 g (1.9 mmol) 2,4,6-trichloroaniline. Standard protocol 
workup after 48 h and purification by FCC with hexanes (Rf 0.7) gave 0.40 g (1.8 mmol, 
94 %) of 126 as a colorless oil.  
 
1H NMR (500 MHz, CD2Cl2): δ = 7.29 (s, 2H, 3-H, 5-H), 2.85 (s, 6H, N(CH3)2). 
 
13C NMR (126 MHz, CD2Cl2): δ = 145.8 (C-1), 136.3 (C-2, C-6), 130.4 (C-4), 129.2  
(C-3, C-5), 42.2 (N(CH3)2). 
 
IR (film): ṽ (cm-1) = 3054, 2986, 1421, 1265, 739, 705. 
 
MS (EI+): m/z (%) = 222 (100) [M – H]+, 223 (49) [M]+•, 224 (94), 225 (53), 226 (30), 
227 (15). 
 
HRMS (EI+): m/z calcd for (C8H8Cl3N): 222.9722; found: 222.9722. 
 
Purity (HPLC): > 99 % (210 nm; method 6a). 
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10-Methyl-10H-phenoxazine* (127) 
 
  
MF: C13H11NO        MW: 197.24 g/mol 
 
Standard TTT protocol with 0.35 g (1.9 mmol) 10H-phenoxazine. Standard protocol 
workup after 24 h and purification by FCC with hexanes and EtOAc (20:1, Rf 0.6) gave 
0.37 g (1.9 mmol, 98 %) of 127 as a white to pale violet solid.  
 
mp: 27 °C. 
 
1H NMR (500 MHz, CDCl3): δ = 6.90 – 6.84 (m, 2H, 4-H, 6-H), 6.75 – 6.70 (m, 4H, 2-
H, 3-H, 7-H, 8-H), 6.54 (d, J = 7.9 Hz, 2H, 1-H, 9-H), 3.05 (s, 3H, CH3). 
 
13C NMR (126 MHz, CDCl3): δ = 145.7 (C-4a, C-5a), 135.1 (C-9a, C-10a), 123.9 (C-4, 
C-6), 121.0 (C-3, C-7), 115.4 (C-2, C-10), 111.5 (C-1, C-9), 31.0 (CH3). 
 
IR (KBr): ṽ (cm-1) = 3063, 2882, 1592, 1486, 1362, 1268, 1217. 
 
MS (EI+): m/z (%) = 127 (6), 182 (100), 197 (63) [M]+•. 
 
HRMS (EI+): m/z calcd for C13H11NO: 197.0841; found: 197.0831. 
 
Purity (HPLC): > 99 % (210 nm; method 6a). 
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10-Methyl-10H-phenothiazine* (128) 
 
 
MF: C13H11NS        MW: 213.30 g/mol 
 
Standard TTT protocol with 0.40 g (2.0 mmol) 10H-phenothiazine. Standard protocol 
workup after 24 h and purification by FCC with hexanes and EtOAc (20:1, Rf 0.6) 
gave 0.41 g (1.9 mmol, 96 %) of 128 as a white solid.  
 
mp: 101 - 102 °C [Lit[131].: 99 – 100 °C]. 
 
1H NMR (500 MHz, CDCl3): δ = 7.21 – 7.14 (m, 4H, 2-H, 4-H, 6-H, 8-H), 6.97 – 6.92 
(m, 2H, 3-H, 7-H), 6.82 (dd, J = 8.1, 1.1 Hz, 2H, 1-H, 9-H), 3.38 (s, 3H, CH3). 
 
13C NMR (126 MHz, CDCl3): δ = 145.9 (C-9a, C-10a), 127.5 (C-2/C-4, C-6/C-8), 
127.3 (C-2/C-4, C-6/C-8), 123.5 (C-4a, C-5a), 122.6 (C-3, C-7), 114.2 (C-1, C-9), 
35.4 (CH3). 
 
IR (KBr): ṽ (cm-1) = 3058, 2968, 2888, 1592, 1568, 1457, 1331, 1258, 1137. 
 
MS (EI+): m/z (%) = 198 (73), 213 (100) [M]+•. 
 
HRMS (EI+): m/z calcd for C13H11NS: 213.0612; found: 213.0601. 
 
Purity (HPLC): 99 % (210 nm; method 6a). 
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9-Methyl-9H-carbazole* (129) 
 
 
MF: C13H11N         MW: 181.24 g/mol 
 
Standard TTT protocol with 0.33 g (1.9 mmol) 9H-carbazole. Standard protocol workup 
after 24 h and purification by FCC with hexanes and EtOAc (20:1, Rf 0.3) gave 0.21 g 
(1.2 mmol, 61 %) of 129 as a white solid. Starting with 0.25 g (0.95 mmol) N-Boc-
carbazole (135), the same product was obtained with slightly lower yield (0.084 g, 0.46 
mmol, 49 %).  
 
mp: 84 - 85 °C [Lit[132].: 88 – 90 °C]. 
 
1H NMR (500 MHz, CDCl3): δ = 8.06 (d, J = 8.0 Hz, 2H, 4-H, 5-H), 7.45 – 7.40 (m, 2H, 
2-H, 7-H), 7.30 (d, J = 8.2 Hz, 2H, 1-H, 8-H), 7.22 – 7.18 (m, 2H, 3-H, 6-H), 3.70 (s, 
3H, CH3). 
 
13C NMR (126 MHz, CDCl3): δ = 141.1 (C-8a, C-9a), 125.7 (C-2, C-7), 122.8 (C-4a, 
C-4b), 120.4 (C-4, C-5), 118.9 (C-3, C-6), 108.5 (C-1, C-8), 29.0 (CH3). 
 
IR (KBr): ṽ (cm-1) = 3433, 3049, 2926, 1598, 1467, 1323, 1246. 
 
MS (EI+): m/z (%) = 152 (20), 166 (9), 181 (100) [M]+•. 
 
HRMS (EI+): m/z calcd for C13H11N: 181.0891; found: 181.0884. 
 
Purity (HPLC): 97 % (210 nm; method 6a). 
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9-Methyl-2,3,4,9-tetrahydro-1H-carbazol-1-one* (130) 
 
 
MF: C13H13NO        MW: 199.25 g/mol 
 
Standard TTT protocol with 0.35 g (1.9 mmol) 2,3,4,9-tetrahydro-1H-carbazol-1-one. 
Standard protocol workup after 48 h and purification by FCC with hexanes and EtOAc 
(10:1, Rf 0.3) gave 0.11 g (0.55 mmol, 29 %) of 130 as a yellow solid. 
 
mp: 95 - 97 °C. 
 
1H NMR (500 MHz, CDCl3): δ = 7.62 (d, J = 8.1 Hz, 1H, 7-H), 7.39 – 7.35 (m, 1H, 5-
H), 7.30 (d, J = 8.5 Hz, 1H, 8-H), 7.14 – 7.10 (m, 1H, 6-H), 4.03 (s, 3H, CH3), 2.97 (t, 
J = 6.1 Hz, 2H, 4-H), 2.63 – 2.59 (m, 2H, 2-H), 2.21 – 2.15 (m, 2H, 3-H). 
 
13C NMR (126 MHz, CDCl3): δ = 192.3 (C-1), 139.7 (C-8a), 130.4 (C-9a), 129.2 (C-4a), 
126.7 (C-5), 124.7 (C-4b), 121.3 (C-7), 120.0 (C-6), 110.3 (C-8), 40.1 (C-2), 31.6 (CH3), 
24.8 (C-3), 21.9 (C-4). 
 
IR (KBr): ṽ (cm-1) = 3428, 2927, 2838, 1643, 1408, 1230, 935, 760. 
 
MS (EI+): m/z (%) = 128 (20), 143 (63), 170 (40), 199 (100) [M]+•. 
 
HRMS (EI+): m/z calcd for C13H13NO: 199.0997; found: 199.0988. 
 
Purity (HPLC): 98 % (210 nm; method 6a). 
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9-Methyl-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole* (131) 
 
 
MF: C12H14N2        MW: 186.26 g/mol 
 
Standard TTT protocol with 0.33 g (1.9 mmol) 2,3,4,9-tetrahydro-1H-pyrido[3,4-
b]indole. Standard protocol workup after 48 h and purification by FCC with CH2Cl2 with 
10 % MeOH (Rf 0.3) gave 0.24 g (1.3 mmol, 68 %) of 131 as a yellow oil. 
 
1H NMR (400 MHz, CDCl3): δ = 7.48 (ddd, J = 7.9, 1.1, 0.8 Hz, 1H, 5-H), 7.27 – 7.24 
(m, 1H, 8-H), 7.17 (ddd, J = 8.2, 7.0, 1.1 Hz, 1H, 7-H), 7.08 (ddd, J = 7.9, 7.0, 1.1 Hz, 
1H, 6-H), 4.01 (t, J = 1.7 Hz, 2H, 1-H), 3.56 (s, 3H, CH3), 3.15 (t, J = 5.7 Hz, 2H, 3-H), 
2.75 (tt, J = 5.7, 1.7 Hz, 2H, 4-H), 1.80 (br s, 1H, NH). 
 
13C NMR (101 MHz, CDCl3): δ = 136.8 (C-8a), 134.4 (C-9a), 127.2 (C-4b), 121.0 (C-7), 
118.9 (C-6), 117.9 (C-5), 108.7 (C-8), 107.7 (C-4a), 44.0 (C-3), 42.5 (C-1), 29.3 (CH3), 
22.7 (C-4). 
 
IR (film): ṽ (cm-1) = 3306, 3049, 2918, 2838, 1615, 1471, 1380, 1183, 739. 
 
MS (EI+): m/z (%) = 142 (11), 157 (100), 186 (36) [M]+•. 
 
HRMS (EI+): m/z calcd for C12H14N2: 186.1157; found: 186.1152. 
 
Purity (HPLC): 96 % (210 nm; method 6b). 
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2-(1-Methyl-1H-indol-3-yl)ethan-1-amine* (132) 
 
 
MF: C11H15N2        MW: 174.25 g/mol 
 
Standard TTT protocol with 0.30 g (1.9 mmol) 2-(1H-indol-3-yl)ethan-1-amine 
(tryptamine). Standard protocol workup after 48 h and purification by FCC with CH2Cl2 
with 10 % MeOH (Rf 0.1) gave 0.10 g (0.57 mmol, 30 %) of 132 as a colorless oil. 
 
1H NMR (500 MHz, CD2Cl2): δ = 7.55 (d, J = 7.9 Hz, 1H, 4‘-H), 7.26 (d, J = 8.2 Hz, 1H, 
7‘-H), 7.17 (ddd, J = 8.2, 7.0, 1.2 Hz, 1H, 6‘-H), 7.04 (ddd, J = 7.9, 7.0, 1.1 Hz, 1H, 5‘-
H), 6.89 (s, 1H, 2‘-H), 3.69 (s, 3H, CH3), 3.13 (br s, 2H, NH2), 2.97 (t, J = 6.8 Hz, 2H, 
1-H), 2.89 (t, J = 6.8 Hz, 2H, 2-H). 
 
13C NMR (126 MHz, CD2Cl2): δ = 137.6 (C-7a‘), 128.2 (C-3a‘), 127.5 (C-2‘), 121.8 
(C-6‘), 119.1 (C-4‘), 119.0 (C-5‘), 111.9 (C-3‘), 109.6 (C-7‘), 42.4 (C-1), 32.8 (CH3), 
28.5 (C-2). 
 
IR (film): ṽ (cm-1) = 3347, 3050, 2926, 1578, 1473, 1328, 739. 
 
MS (ESI+): m/z (%) = 158 (100), 175 (78, [M + H]+). 
 
HRMS (ESI+): m/z calcd for C11H15N2: 175.1230; found: 175.1231. 
 
Purity (HPLC): 96 % (210 nm; method 6a). 
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Abbreviations 
 
Ac   acetyl 
ATP   adenosine triphosphate 
cAMP   cyclic adenosine monophosphate 
BET   Bromodomain and extraterminal  
CBP, CREBBP CREB (cAMP responsive element binding protein) binding protein 
CI   chemical ionization 
CMMP  (cyanomethylene)trimethylphosphorane 
CpG   cytosine-phosphate-guanine 
DCM   dichloromethane 
DIAD   diisopropyl azodicarboxylate 
DIPEA  N,N-diisopropylethylamine 
DTBAD  di-tert-butylazodicarboxylate 
DMAP  4-(dimethylamino)pyridine 
DMF   N,N-dimethylformamide 
DMSO  dimethylsulfoxide 
DNA   deoxyribonucleic acid 
DSF   differential scanning fluorimetry 
DSMZ Deutsche Sammlung von Mikroorganismen und Zellkulturen 
GmbH 
EDC   1-ethyl-3-(3-dimethylaminopropyl)carbodiimide 
EI   electronic ionization 
EMA   European Medicines Agency 
ESI   electron spray ionization 
EtOAc  ethyl acetate 
EtOH   ethanol 
FDA   Food and Drug Administration 
FRAP   fluorescence recovery after photobleach 
GFP   green fluorescent protein 
H [number]  histone [number] 
HAT   histone acetyltransferase 
Abbreviations 
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HDAC   histone deacetylase 
HPLC   high-performance liquid chromatography 
HR   high resolution 
IC   inhibitory concentration 
ITC   isothermal titration calorimetry 
K   lysine 
Kac    acetylated lysine 
Kd   dissociation constant 
MeCN   acetonitrile 
MF   molecular formula 
MeOH  methanol 
MLL   mixed lineage leukemia 
MOZ   monocytic leukaemia zinc finger protein 
mp   melting point 
MS   mass spectrometry 
mTOR  mechanistic Target of Rapamycin 
MTT   3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
MW   molecular weight 
N   asparagine 
NAD(P)  Nicotinamide adenine dinucleotide (phosphate) 
NFκB   nuclear factor kappa-light-chain-enhancer of activated B cells 
NMR   nuclear magnetic resonance 
Ns-   nosyl-, 4-nitrophenylsulfonyl- 
PCR   polymerase chain reaction 
PDB   protein data bank 
PPh3   triphenylphosphine 
ppm   part per million 
R   arginine 
RNA   ribonucleic acid 
rt   room temperature 
SAR   structure-activity relationship 
SGC   Structural Genomics Consortium 
TBDMS-  tert-butyl-dimethylsilyl- 
THF   tetrahydrofuran 
Abbreviations 
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TFA   trifluoroacetic acid 
TES   triethylsilane 
tlc   thin layer chromatography  
TTT   1,3,5-trioxane-triethylsilane-trifluoroacetic acid 
Y   tyrosine 
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